ADCIRCA	549	34068-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	18
After at least one week following the initiation of ritonavir , resume ADCIRCA at 20 mg once daily .
1	0	4	O	After
2	6	7	O	at
3	9	13	O	least
4	15	17	O	one
5	19	22	O	week
6	24	32	O	following
7	34	36	O	the
8	38	47	O	initiation
9	49	50	O	of
10	52	60	O	ritonavir
11	62	62	O	,
12	64	69	O	resume
13	71	77	O	XXXXXXXX
14	79	80	O	at
15	82	83	O	20
16	85	86	O	mg
17	88	91	O	once
18	93	97	O	daily
NULL

ADCIRCA	550	34068-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	9
Avoid use of ADCIRCA during the initiation of ritonavir .
1	0	4	B-TRI	Avoid
2	6	8	L-TRI	use
3	10	11	O	of
4	13	19	O	XXXXXXXX
5	21	26	O	during
6	28	30	O	the
7	32	41	O	initiation
8	43	44	O	of
9	46	54	U-UNK	ritonavir
NULL

ADCIRCA	551	34068-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	8
Co-administration of ADCIRCA in Patients on Ritonavir .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	27	O	XXXXXXXX
5	29	30	O	in
6	32	39	O	Patients
7	41	42	O	on
8	44	52	O	Ritonavir
NULL

ADCIRCA	552	34068-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	8
Co-administration of Ritonavir in Patients on ADCIRCA .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	29	O	Ritonavir
5	31	32	O	in
6	34	41	O	Patients
7	43	44	O	on
8	46	52	O	XXXXXXXX
NULL

ADCIRCA	553	34068-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	17
In patients receiving ritonavir for at least one week , start ADCIRCA at 20 mg once daily .
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	30	O	ritonavir
5	32	34	O	for
6	36	37	O	at
7	39	43	O	least
8	45	47	O	one
9	49	52	O	week
10	54	54	O	,
11	56	60	O	start
12	62	68	O	XXXXXXXX
13	70	71	O	at
14	73	74	O	20
15	76	77	O	mg
16	79	82	O	once
17	84	88	O	daily
NULL

ADCIRCA	554	34068-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	10
Stop ADCIRCA at least 24 hours prior to starting ritonavir .
1	0	3	U-TRI	Stop
2	5	11	O	XXXXXXXX
3	13	14	O	at
4	16	20	O	least
5	22	23	O	24
6	25	29	O	hours
7	31	35	O	prior
8	37	38	O	to
9	40	47	O	starting
10	49	57	U-UNK	ritonavir
NULL

ADCIRCA	555	34070-3	ff61b237-be8e-461b-8114-78c52a8ad0ae	15
ADCIRCA is contraindicated in patients with a known serious hypersensitivity to tadalafil ( ADCIRCA or CIALIS ) .
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	25	O	contraindicated
4	27	28	O	in
5	30	37	O	patients
6	39	42	O	with
7	44	44	O	a
8	46	50	O	known
9	52	58	O	serious
10	60	75	O	hypersensitivity
11	77	78	O	to
12	80	88	O	XXXXXXXX
13	92	98	O	XXXXXXXX
14	100	101	O	or
15	103	108	O	CIALIS
NULL

ADCIRCA	556	34070-3	ff61b237-be8e-461b-8114-78c52a8ad0ae	16
Do not use ADCIRCA in patients who are using a GC stimulator , such as riociguat .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	9	L-TRI	use
4	11	17	O	XXXXXXXX
5	19	20	O	in
6	22	29	O	patients
7	31	33	O	who
8	35	37	O	are
9	39	43	O	using
10	45	45	O	a
11	47	48	B-UNK	GC
12	50	59	L-UNK	stimulator
13	61	61	O	,
14	63	66	O	such
15	68	69	O	as
16	71	79	U-UNK	riociguat
NULL

ADCIRCA	557	34070-3	ff61b237-be8e-461b-8114-78c52a8ad0ae	11
History of known serious hypersensitivity reaction to ADCIRCA or CIALIS ( 4.3 ) .
1	0	6	O	History
2	8	9	O	of
3	11	15	O	known
4	17	23	O	serious
5	25	40	O	hypersensitivity
6	42	49	O	reaction
7	51	52	O	to
8	54	60	O	XXXXXXXX
9	62	63	O	or
10	65	70	O	CIALIS
11	74	76	O	4.3
NULL

ADCIRCA	558	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	9
[See Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)].
1	1	3	O	See
2	5	12	O	Warnings
3	14	16	O	and
4	18	28	O	Precautions
5	31	33	O	5.1
6	36	38	O	and
7	40	47	O	Clinical
8	49	60	O	Pharmacology
9	63	66	O	12.2
NULL

ADCIRCA	559	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	14
Alcohol Both alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators.
1	0	6	O	Alcohol
2	8	11	O	Both
3	13	19	U-DYN	alcohol
4	21	23	O	and
5	25	33	O	XXXXXXXX
6	34	34	O	,
7	36	36	O	a
8	38	41	O	PDE5
9	43	51	O	inhibitor
10	52	52	O	,
11	54	56	O	act
12	58	59	O	as
13	61	64	O	mild
14	66	77	O	GGGGGGGG
NULL

ADCIRCA	560	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	20
Alpha-Blockers PDE5 inhibitors, including ADCIRCA, and alphaadrenergic blocking agents are both vasodilators with blood-pressure-lowering effects.
1	0	4	B-DYN	Alpha
2	6	13	L-DYN	Blockers
3	15	18	B-DYN	PDE5
4	20	29	L-DYN	inhibitors
5	30	30	O	,
6	32	40	O	including
7	42	48	O	XXXXXXXX
8	49	49	O	,
9	51	53	O	and
10	55	69	B-DYN	alphaadrenergic
11	71	78	I-DYN	blocking
12	80	85	L-DYN	agents
13	87	89	O	are
14	91	94	O	both
15	96	107	O	GGGGGGGG
16	109	112	O	with
17	114	118	B-EFF	blood
18	120	127	I-EFF	pressure
19	129	136	L-EFF	lowering
20	138	144	O	effects
D/1:17:1 D/10:17:1 D/3:17:1

ADCIRCA	561	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	10
Antihypertensives PDE5inhibitors, including ADCIRCA, are mild systemic vasodilators.
1	0	16	O	Antihypertensives
2	18	31	O	PDE5inhibitors
3	32	32	O	,
4	34	42	O	including
5	44	50	O	XXXXXXXX
6	51	51	O	,
7	53	55	O	are
8	57	60	O	mild
9	62	69	O	systemic
10	71	82	O	GGGGGGGG
NULL

ADCIRCA	562	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	24
Aspirin Tadalafil (10 mg and 20 mg once daily) does not potentiate the increase in bleeding time caused by aspirin [see Clinical Pharmacology (12.3)].
1	0	6	O	Aspirin
2	8	16	O	XXXXXXXX
3	19	20	O	10
4	22	23	O	mg
5	25	27	O	and
6	29	30	O	20
7	32	33	O	mg
8	35	38	O	once
9	40	44	O	daily
10	47	50	O	does
11	52	54	O	not
12	56	65	O	potentiate
13	67	69	O	the
14	71	78	O	increase
15	80	81	O	in
16	83	90	O	bleeding
17	92	95	O	time
18	97	102	O	caused
19	104	105	O	by
20	107	113	O	aspirin
21	116	118	O	see
22	120	127	O	Clinical
23	129	140	O	Pharmacology
24	143	146	O	12.3
NULL

ADCIRCA	563	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	36
At steady state of ritonavir ( about 1 week ) , the exposure to tadalafil is similar as in the absence of ritonavir see Dosage and Administration ( 2.3 ) , Warnings and Precautions ( 5.2 ) , and Clinical Pharmacology ( 12.3 ) .
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	16	17	O	of
5	19	27	O	ritonavir
6	31	35	O	about
7	37	37	O	1
8	39	42	O	week
9	46	46	O	,
10	48	50	O	the
11	52	59	O	exposure
12	61	62	O	to
13	64	72	O	XXXXXXXX
14	74	75	O	is
15	77	83	O	similar
16	85	86	O	as
17	88	89	O	in
18	91	93	O	the
19	95	101	O	absence
20	103	104	O	of
21	106	114	O	ritonavir
22	116	118	O	see
23	120	125	O	Dosage
24	127	129	O	and
25	131	144	O	Administration
26	148	150	O	2.3
27	154	154	O	,
28	156	163	O	Warnings
29	165	167	O	and
30	169	179	O	Precautions
31	183	185	O	5.2
32	189	189	O	,
33	191	193	O	and
34	195	202	O	Clinical
35	204	215	O	Pharmacology
36	219	222	O	12.3
NULL

ADCIRCA	564	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	36
At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration (2.3), Warnings and Precautions (5.2), and Clinical Pharmacology (12.3)].
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	16	17	O	of
5	19	27	O	ritonavir
6	30	34	O	about
7	36	36	O	1
8	38	41	O	week
9	43	43	O	,
10	45	47	O	the
11	49	56	O	exposure
12	58	59	O	to
13	61	69	O	XXXXXXXX
14	71	72	O	is
15	74	80	O	similar
16	82	83	O	as
17	85	86	O	in
18	88	90	O	the
19	92	98	O	absence
20	100	101	O	of
21	103	111	O	ritonavir
22	114	116	O	see
23	118	123	O	Dosage
24	125	127	O	and
25	129	142	O	Administration
26	145	147	O	2.3
27	149	149	O	,
28	151	158	O	Warnings
29	160	162	O	and
30	164	174	O	Precautions
31	177	179	O	5.2
32	181	181	O	,
33	183	185	O	and
34	187	194	O	Clinical
35	196	207	O	Pharmacology
36	210	213	O	12.3
NULL

ADCIRCA	565	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	13
Both alcohol and tadalafil , a PDE5 inhibitor , act as mild vasodilators .
1	0	3	O	Both
2	5	11	U-DYN	alcohol
3	13	15	O	and
4	17	25	O	XXXXXXXX
5	27	27	O	,
6	29	29	O	a
7	31	34	O	PDE5
8	36	44	O	inhibitor
9	46	46	O	,
10	48	50	O	act
11	52	53	O	as
12	55	58	O	mild
13	60	71	O	GGGGGGGG
NULL

ADCIRCA	566	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	25
Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin , alfuzosin or tamsulosin see Warnings and Precautions ( 5.1 ) and Clinical Pharmacology ( 12.2 ) .
1	0	7	O	Clinical
2	9	20	O	pharmacology
3	22	28	O	studies
4	30	33	O	have
5	35	38	O	been
6	40	48	O	conducted
7	50	53	O	with
8	55	70	O	coadministration
9	72	73	O	of
10	75	83	O	XXXXXXXX
11	85	88	O	with
12	90	98	O	doxazosin
13	100	100	O	,
14	102	110	O	alfuzosin
15	112	113	O	or
16	115	124	O	tamsulosin
17	126	128	O	see
18	130	137	O	Warnings
19	139	141	O	and
20	143	153	O	Precautions
21	157	159	O	5.1
22	163	165	O	and
23	167	174	O	Clinical
24	176	187	O	Pharmacology
25	191	194	O	12.2
NULL

ADCIRCA	567	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	37
Clinical pharmacology studies were conducted to assess the effect of tadalafil on the potentiation of the blood pressure lowering effects of selected antihypertensive medications ( amlodipine , angiotensin II receptor blockers , bendroflumethiazide , enalapril , and metoprolol ) .
1	0	7	O	Clinical
2	9	20	O	pharmacology
3	22	28	O	studies
4	30	33	O	were
5	35	43	O	conducted
6	45	46	O	to
7	48	53	O	assess
8	55	57	O	the
9	59	64	O	effect
10	66	67	O	of
11	69	77	O	XXXXXXXX
12	79	80	O	on
13	82	84	O	the
14	86	97	O	potentiation
15	99	100	O	of
16	102	104	O	the
17	106	110	O	blood
18	112	119	O	pressure
19	121	128	O	lowering
20	130	136	O	effects
21	138	139	O	of
22	141	148	O	selected
23	150	165	O	antihypertensive
24	167	177	O	medications
25	181	190	O	amlodipine
26	192	192	O	,
27	194	204	O	angiotensin
28	206	207	O	II
29	209	216	O	receptor
30	218	225	O	blockers
31	227	227	O	,
32	229	247	O	bendroflumethiazide
33	249	249	O	,
34	251	259	O	enalapril
35	261	261	O	,
36	263	265	O	and
37	267	276	O	metoprolol
NULL

ADCIRCA	568	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	23
Coadministration of tadalafil ( 40 mg once daily ) for 10 days did not significantly alter digoxin pharmacokinetics in healthy subjects see Clinical Pharmacology ( 12.3 ) .
1	0	15	O	Coadministration
2	17	18	O	of
3	20	28	O	XXXXXXXX
4	32	33	O	40
5	35	36	O	mg
6	38	41	O	once
7	43	47	O	daily
8	51	53	O	for
9	55	56	O	10
10	58	61	O	days
11	63	65	O	did
12	67	69	O	not
13	71	83	O	significantly
14	85	89	O	alter
15	91	97	O	digoxin
16	99	114	O	pharmacokinetics
17	116	117	O	in
18	119	125	O	healthy
19	127	134	O	subjects
20	136	138	O	see
21	140	147	O	Clinical
22	149	160	O	Pharmacology
23	164	167	O	12.3
NULL

ADCIRCA	569	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	40
Cytochrome P450 Substrates Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 (CYP) isoforms (e.g., theophylline, warfarin, midazolam, lovastatin, bosentan) [see Clinical Pharmacology (12.3)].
1	0	9	O	Cytochrome
2	11	14	O	P450
3	16	25	O	Substrates
4	27	35	O	XXXXXXXX
5	37	38	O	is
6	40	42	O	not
7	44	51	O	expected
8	53	54	O	to
9	56	60	O	cause
10	62	71	O	clinically
11	73	83	O	significant
12	85	94	O	inhibition
13	96	97	O	or
14	99	107	O	induction
15	109	110	O	of
16	112	114	O	the
17	116	124	O	clearance
18	126	127	O	of
19	129	133	O	drugs
20	135	145	O	metabolized
21	147	148	O	by
22	150	159	O	cytochrome
23	161	164	O	P450
24	167	169	O	CYP
25	172	179	O	isoforms
26	182	184	O	e.g
27	186	186	O	,
28	188	199	O	theophylline
29	200	200	O	,
30	202	209	O	warfarin
31	210	210	O	,
32	212	220	O	midazolam
33	221	221	O	,
34	223	232	O	lovastatin
35	233	233	O	,
36	235	242	O	bosentan
37	246	248	O	see
38	250	257	O	Clinical
39	259	270	O	Pharmacology
40	273	276	O	12.3
NULL

ADCIRCA	570	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	26
For patients chronically taking potent inducers of CYP3A , such as rifampin , avoid use of ADCIRCA see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 ) .
1	0	2	O	For
2	4	11	O	patients
3	13	23	O	chronically
4	25	30	O	taking
5	32	37	O	potent
6	39	46	B-UNK	inducers
7	48	49	I-UNK	of
8	51	55	L-UNK	CYP3A
9	57	57	O	,
10	59	62	O	such
11	64	65	O	as
12	67	74	U-UNK	rifampin
13	76	76	O	,
14	78	82	B-TRI	avoid
15	84	86	L-TRI	use
16	88	89	O	of
17	91	97	O	XXXXXXXX
18	99	101	O	see
19	103	110	O	Warnings
20	112	114	O	and
21	116	126	O	Precautions
22	130	132	O	5.2
23	136	138	O	and
24	140	147	O	Clinical
25	149	160	O	Pharmacology
26	164	167	O	12.3
NULL

ADCIRCA	571	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	37
In a patient who has taken ADCIRCA, where nitrate administration is deemed medically necessary in a lifethreatening situation, at least 48 hours should elapse after the last dose of ADCIRCA before nitrate administration is considered.
1	0	1	O	In
2	3	3	O	a
3	5	11	O	patient
4	13	15	O	who
5	17	19	O	has
6	21	25	O	taken
7	27	33	O	XXXXXXXX
8	34	34	O	,
9	36	40	O	where
10	42	48	U-UNK	nitrate
11	50	63	O	administration
12	65	66	O	is
13	68	73	O	deemed
14	75	83	O	medically
15	85	93	O	necessary
16	95	96	O	in
17	98	98	O	a
18	100	114	O	lifethreatening
19	116	124	O	situation
20	125	125	O	,
21	127	128	O	at
22	130	134	O	least
23	136	137	B-TRI	48
24	139	143	I-TRI	hours
25	145	150	I-TRI	should
26	152	157	I-TRI	elapse
27	159	163	I-TRI	after
28	165	167	I-TRI	the
29	169	172	I-TRI	last
30	174	177	L-TRI	dose
31	179	180	O	of
32	182	188	O	XXXXXXXX
33	190	195	O	before
34	197	203	O	nitrate
35	205	218	O	administration
36	220	221	O	is
37	223	232	O	considered
NULL

ADCIRCA	572	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	15
In clinical pharmacology studies ADCIRCA potentiated the hypotensive effect of nitrates [see Clinical Pharmacology (12.2)].
1	0	1	O	In
2	3	10	O	clinical
3	12	23	O	pharmacology
4	25	31	O	studies
5	33	39	O	XXXXXXXX
6	41	51	B-EFF	potentiated
7	53	55	I-EFF	the
8	57	67	I-EFF	hypotensive
9	69	74	L-EFF	effect
10	76	77	O	of
11	79	86	U-DYN	nitrates
12	89	91	O	see
13	93	100	O	Clinical
14	102	113	O	Pharmacology
15	116	119	O	12.2
D/11:6:1

ADCIRCA	573	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	27
In patients taking potent inhibitors of CYP3A such as ketoconazole , and itraconazole , avoid use of ADCIRCA see Warnings and Precautions ( 5.2 ) and Clinical Pharmacology ( 12.3 ) .
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	24	O	potent
5	26	35	B-UNK	inhibitors
6	37	38	I-UNK	of
7	40	44	L-UNK	CYP3A
8	46	49	O	such
9	51	52	O	as
10	54	65	U-UNK	ketoconazole
11	67	67	O	,
12	69	71	O	and
13	73	84	U-UNK	itraconazole
14	86	86	O	,
15	88	92	B-TRI	avoid
16	94	96	L-TRI	use
17	98	99	O	of
18	101	107	O	XXXXXXXX
19	109	111	O	see
20	113	120	O	Warnings
21	122	124	O	and
22	126	136	O	Precautions
23	140	142	O	5.2
24	146	148	O	and
25	150	157	O	Clinical
26	159	170	O	Pharmacology
27	174	177	O	12.3
NULL

ADCIRCA	574	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	18
In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring.
1	0	1	O	In
2	3	6	O	such
3	8	20	O	circumstances
4	21	21	O	,
5	23	30	U-UNK	nitrates
6	32	37	O	should
7	39	43	O	still
8	45	48	O	only
9	50	51	O	be
10	53	64	O	administered
11	66	70	O	under
12	72	76	O	close
13	78	84	O	medical
14	86	96	O	supervision
15	98	101	O	with
16	103	113	O	appropriate
17	115	125	O	hemodynamic
18	127	136	O	monitoring
NULL

ADCIRCA	575	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	18
Nitrates Do not use ADCIRCA in patients who are using any form of organic nitrate [see Contraindications (4.1)].
1	0	7	O	Nitrates
2	9	10	B-TRI	Do
3	12	14	I-TRI	not
4	16	18	L-TRI	use
5	20	26	O	XXXXXXXX
6	28	29	O	in
7	31	38	O	patients
8	40	42	O	who
9	44	46	O	are
10	48	52	O	using
11	54	56	O	any
12	58	61	O	form
13	63	64	O	of
14	66	72	B-UNK	organic
15	74	80	L-UNK	nitrate
16	83	85	O	see
17	87	103	O	Contraindications
18	106	108	O	4.1
NULL

ADCIRCA	576	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	14
Other Potent Inhibitors of CYP3A Tadalafil is metabolized predominantly by CYP3A in the liver.
1	0	4	O	Other
2	6	11	O	Potent
3	13	22	O	Inhibitors
4	24	25	O	of
5	27	31	O	CYP3A
6	33	41	O	XXXXXXXX
7	43	44	O	is
8	46	56	O	metabolized
9	58	70	O	predominantly
10	72	73	O	by
11	75	79	O	CYP3A
12	81	82	O	in
13	84	86	O	the
14	88	92	O	liver
NULL

ADCIRCA	577	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	28
P-glycoprotein (e.g., digoxin) Coadministration of tadalafil (40 mg once daily) for 10 days did not significantly alter digoxin pharmacokinetics in healthy subjects [see Clinical Pharmacology (12.3)].
1	0	0	O	P
2	2	13	O	glycoprotein
3	16	18	O	e.g
4	20	20	O	,
5	22	28	O	digoxin
6	31	46	O	Coadministration
7	48	49	O	of
8	51	59	O	XXXXXXXX
9	62	63	O	40
10	65	66	O	mg
11	68	71	O	once
12	73	77	O	daily
13	80	82	O	for
14	84	85	O	10
15	87	90	O	days
16	92	94	O	did
17	96	98	O	not
18	100	112	O	significantly
19	114	118	O	alter
20	120	126	O	digoxin
21	128	143	O	pharmacokinetics
22	145	146	O	in
23	148	154	O	healthy
24	156	163	O	subjects
25	166	168	O	see
26	170	177	O	Clinical
27	179	190	O	Pharmacology
28	193	196	O	12.3
NULL

ADCIRCA	578	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	19
PDE5 inhibitors , including ADCIRCA , and alpha adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects .
1	0	3	B-DYN	PDE5
2	5	14	L-DYN	inhibitors
3	16	16	O	,
4	18	26	O	including
5	28	34	O	XXXXXXXX
6	36	36	O	,
7	38	40	O	and
8	42	46	B-DYN	alpha
9	48	57	I-DYN	adrenergic
10	59	66	I-DYN	blocking
11	68	73	L-DYN	agents
12	75	77	O	are
13	79	82	O	both
14	84	95	O	GGGGGGGG
15	97	100	O	with
16	102	106	B-EFF	blood
17	108	115	I-EFF	pressure
18	117	124	L-EFF	lowering
19	126	132	O	effects
D/1:16:1 D/8:16:1

ADCIRCA	579	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	10
PDE5 inhibitors , including ADCIRCA , are mild systemic vasodilators .
1	0	3	O	PDE5
2	5	14	O	inhibitors
3	16	16	O	,
4	18	26	O	including
5	28	34	O	XXXXXXXX
6	36	36	O	,
7	38	40	O	are
8	42	45	O	mild
9	47	54	O	systemic
10	56	67	O	GGGGGGGG
NULL

ADCIRCA	580	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	30
Potent Inducers of CYP3A For patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of ADCIRCA [see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3)].
1	0	5	O	Potent
2	7	14	O	Inducers
3	16	17	O	of
4	19	23	O	CYP3A
5	25	27	O	For
6	29	36	O	patients
7	38	48	O	chronically
8	50	55	O	taking
9	57	62	O	potent
10	64	71	B-UNK	inducers
11	73	74	I-UNK	of
12	76	80	L-UNK	CYP3A
13	81	81	O	,
14	83	86	O	such
15	88	89	O	as
16	91	98	U-UNK	rifampin
17	99	99	O	,
18	101	105	B-TRI	avoid
19	107	109	L-TRI	use
20	111	112	O	of
21	114	120	O	XXXXXXXX
22	123	125	O	see
23	127	134	O	Warnings
24	136	138	O	and
25	140	150	O	Precautions
26	153	155	O	5.2
27	158	160	O	and
28	162	169	O	Clinical
29	171	182	O	Pharmacology
30	185	188	O	12.3
NULL

ADCIRCA	581	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	16
Ritonavir initially inhibits and later induces CYP3A , the enzyme involved in the metabolism of tadalafil .
1	0	8	U-UNK	Ritonavir
2	10	18	O	initially
3	20	27	O	inhibits
4	29	31	O	and
5	33	37	O	later
6	39	45	B-TRI	induces
7	47	51	L-TRI	CYP3A
8	53	53	O	,
9	55	57	O	the
10	59	64	O	enzyme
11	66	73	O	involved
12	75	76	O	in
13	78	80	O	the
14	82	91	O	metabolism
15	93	94	O	of
16	96	104	O	XXXXXXXX
NULL

ADCIRCA	582	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	17
Ritonavir Ritonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil.
1	0	8	U-UNK	Ritonavir
2	10	18	O	Ritonavir
3	20	28	O	initially
4	30	37	O	inhibits
5	39	41	O	and
6	43	47	O	later
7	49	55	B-TRI	induces
8	57	61	L-TRI	CYP3A
9	62	62	O	,
10	64	66	O	the
11	68	73	O	enzyme
12	75	82	O	involved
13	84	85	O	in
14	87	89	O	the
15	91	100	O	metabolism
16	102	103	O	of
17	105	113	O	XXXXXXXX
NULL

ADCIRCA	583	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	25
Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.2)].
1	0	4	O	Small
2	6	15	O	reductions
3	17	18	O	in
4	20	24	O	blood
5	26	33	O	pressure
6	35	42	O	occurred
7	44	52	O	following
8	54	69	O	coadministration
9	71	72	O	of
10	74	82	O	XXXXXXXX
11	84	87	O	with
12	89	93	O	these
13	95	100	O	agents
14	102	109	O	compared
15	111	114	O	with
16	116	122	O	placebo
17	125	127	O	see
18	129	136	O	Warnings
19	138	140	O	and
20	142	152	O	Precautions
21	155	157	O	5.1
22	160	162	O	and
23	164	171	O	Clinical
24	173	184	O	Pharmacology
25	187	190	O	12.2
NULL

ADCIRCA	584	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	40
Substantial consumption of alcohol (e.g., 5 units or greater) in combination with ADCIRCA can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.
1	0	10	O	Substantial
2	12	22	O	consumption
3	24	25	O	of
4	27	33	U-DYN	alcohol
5	36	38	O	e.g
6	40	40	O	,
7	42	42	O	5
8	44	48	O	units
9	50	51	O	or
10	53	59	O	greater
11	62	63	O	in
12	65	75	O	combination
13	77	80	O	with
14	82	88	O	XXXXXXXX
15	90	92	O	can
16	94	101	O	increase
17	103	105	O	the
18	107	115	O	potential
19	117	119	O	for
20	121	131	O	orthostatic
21	133	137	O	signs
22	139	141	O	and
23	143	150	O	symptoms
24	151	151	O	,
25	153	161	O	including
26	163	170	B-EFF	increase
27	172	173	I-EFF	in
28	175	179	I-EFF	heart
29	181	184	L-EFF	rate
30	185	185	O	,
31	187	194	B-EFF	decrease
32	196	197	I-EFF	in
33	199	206	I-EFF	standing
34	208	212	I-EFF	blood
35	214	221	L-EFF	pressure
36	222	222	O	,
37	224	232	U-EFF	dizziness
38	233	233	O	,
39	235	237	O	and
40	239	246	U-EFF	headache
D/4:26:1 D/4:31:1 D/4:37:1 D/4:40:1

ADCIRCA	585	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	23
Tadalafil ( 10 mg and 20 mg once daily ) does not potentiate the increase in bleeding time caused by aspirin see Clinical Pharmacology ( 12.3 ) .
1	0	8	O	XXXXXXXX
2	12	13	O	10
3	15	16	O	mg
4	18	20	O	and
5	22	23	O	20
6	25	26	O	mg
7	28	31	O	once
8	33	37	O	daily
9	41	44	O	does
10	46	48	O	not
11	50	59	O	potentiate
12	61	63	O	the
13	65	72	O	increase
14	74	75	O	in
15	77	84	O	bleeding
16	86	89	O	time
17	91	96	O	caused
18	98	99	O	by
19	101	107	O	aspirin
20	109	111	O	see
21	113	120	O	Clinical
22	122	133	O	Pharmacology
23	137	140	O	12.3
NULL

ADCIRCA	586	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	20
Tadalafil ( 10 mg or 20 mg ) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations .
1	0	8	O	XXXXXXXX
2	12	13	O	10
3	15	16	O	mg
4	18	19	O	or
5	21	22	O	20
6	24	25	O	mg
7	29	31	O	did
8	33	35	O	not
9	37	42	O	affect
10	44	50	O	alcohol
11	52	57	O	plasma
12	59	72	O	concentrations
13	74	76	O	and
14	78	84	O	alcohol
15	86	88	O	did
16	90	92	O	not
17	94	99	O	affect
18	101	109	O	XXXXXXXX
19	111	116	O	plasma
20	118	131	O	concentrations
NULL

ADCIRCA	587	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	20
Tadalafil (10 mg or 20 mg) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations.
1	0	8	O	XXXXXXXX
2	11	12	O	10
3	14	15	O	mg
4	17	18	O	or
5	20	21	O	20
6	23	24	O	mg
7	27	29	O	did
8	31	33	O	not
9	35	40	O	affect
10	42	48	O	alcohol
11	50	55	O	plasma
12	57	70	O	concentrations
13	72	74	O	and
14	76	82	O	alcohol
15	84	86	O	did
16	88	90	O	not
17	92	97	O	affect
18	99	107	O	XXXXXXXX
19	109	114	O	plasma
20	116	129	O	concentrations
NULL

ADCIRCA	588	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	37
Tadalafil is not expected to cause clinically significant inhibition or induction of the clearance of drugs metabolized by cytochrome P450 ( CYP ) isoforms ( e.g. , theophylline , warfarin , midazolam , lovastatin , bosentan ) see Clinical Pharmacology ( 12.3 ) .
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	15	O	not
4	17	24	O	expected
5	26	27	O	to
6	29	33	O	cause
7	35	44	O	clinically
8	46	56	O	significant
9	58	67	O	inhibition
10	69	70	O	or
11	72	80	O	induction
12	82	83	O	of
13	85	87	O	the
14	89	97	O	clearance
15	99	100	O	of
16	102	106	O	drugs
17	108	118	O	metabolized
18	120	121	O	by
19	123	132	O	cytochrome
20	134	137	O	P450
21	141	143	O	CYP
22	147	154	O	isoforms
23	158	160	O	e.g
24	163	163	O	,
25	165	176	O	theophylline
26	178	178	O	,
27	180	187	O	warfarin
28	189	189	O	,
29	191	199	O	midazolam
30	201	201	O	,
31	203	212	O	lovastatin
32	214	214	O	,
33	216	223	O	bosentan
34	227	229	O	see
35	231	238	O	Clinical
36	240	251	O	Pharmacology
37	255	258	O	12.3
NULL

ADCIRCA	589	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	18
When mild vasodilators are taken in combination, blood pressurelowering effects of each individual compound may be increased.
1	0	3	O	When
2	5	8	O	mild
3	10	21	U-DYN	GGGGGGGG
4	23	25	O	are
5	27	31	O	taken
6	33	34	O	in
7	36	46	O	combination
8	47	47	O	,
9	49	53	B-EFF	blood
10	55	70	L-EFF	pressurelowering
11	72	78	O	effects
12	80	81	O	of
13	83	86	O	each
14	88	97	O	individual
15	99	106	O	compound
16	108	110	O	may
17	112	113	O	be
18	115	123	O	increased
D/3:9:1

ADCIRCA	590	34073-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	16
When vasodilators are used in combination, an additive effect on blood pressure may be anticipated.
1	0	3	O	When
2	5	16	U-DYN	GGGGGGGG
3	18	20	O	are
4	22	25	O	used
5	27	28	O	in
6	30	40	O	combination
7	41	41	O	,
8	43	44	O	an
9	46	53	B-EFF	additive
10	55	60	I-EFF	effect
11	62	63	I-EFF	on
12	65	69	I-EFF	blood
13	71	78	L-EFF	pressure
14	80	82	O	may
15	84	85	O	be
16	87	97	O	anticipated
D/2:9:1

ADCIRCA	591	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	7
Both alcohol and tadalafil are mild vasodilators .
1	0	3	O	Both
2	5	11	U-DYN	alcohol
3	13	15	O	and
4	17	25	O	XXXXXXXX
5	27	29	O	are
6	31	34	O	mild
7	36	47	O	GGGGGGGG
NULL

ADCIRCA	592	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	23
Discuss with patients the appropriate action to take in the event that they experience anginal chest pain requiring nitroglycerin following intake of ADCIRCA .
1	0	6	O	Discuss
2	8	11	O	with
3	13	20	O	patients
4	22	24	O	the
5	26	36	O	appropriate
6	38	43	O	action
7	45	46	O	to
8	48	51	O	take
9	53	54	O	in
10	56	58	O	the
11	60	64	O	event
12	66	69	O	that
13	71	74	O	they
14	76	85	O	experience
15	87	93	O	anginal
16	95	99	O	chest
17	101	104	O	pain
18	106	114	O	requiring
19	116	128	O	nitroglycerin
20	130	138	O	following
21	140	145	O	intake
22	147	148	O	of
23	150	156	O	XXXXXXXX
NULL

ADCIRCA	593	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	25
For patients chronically taking potent inducers of CYP3A , such as rifampin , avoid use of ADCIRCA see Drug Interactions ( 7.2 ) and Clinical Pharmacology ( 12.3 ) .
1	0	2	O	For
2	4	11	O	patients
3	13	23	O	chronically
4	25	30	O	taking
5	32	37	O	potent
6	39	46	B-UNK	inducers
7	48	49	I-UNK	of
8	51	55	L-UNK	CYP3A
9	57	57	O	,
10	59	62	O	such
11	64	65	O	as
12	67	74	U-UNK	rifampin
13	76	76	O	,
14	78	82	B-TRI	avoid
15	84	86	L-TRI	use
16	88	89	O	of
17	91	97	O	XXXXXXXX
18	99	101	O	see
19	103	106	O	Drug
20	108	119	O	Interactions
21	123	125	O	7.2
22	129	131	O	and
23	133	140	O	Clinical
24	142	153	O	Pharmacology
25	157	160	O	12.3
NULL

ADCIRCA	594	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	25
In patients taking potent inhibitors of CYP3A such as ketoconazole and itraconazole , avoid use of ADCIRCA see Drug Interactions ( 7.2 ) and Clinical Pharmacology ( 12.3 ) .
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	24	O	potent
5	26	35	B-UNK	inhibitors
6	37	38	I-UNK	of
7	40	44	L-UNK	CYP3A
8	46	49	O	such
9	51	52	O	as
10	54	65	U-UNK	ketoconazole
11	67	69	O	and
12	71	82	U-UNK	itraconazole
13	84	84	O	,
14	86	90	B-TRI	avoid
15	92	94	L-TRI	use
16	96	97	O	of
17	99	105	O	XXXXXXXX
18	107	109	O	see
19	111	114	O	Drug
20	116	127	O	Interactions
21	131	133	O	7.2
22	137	139	O	and
23	141	148	O	Clinical
24	150	161	O	Pharmacology
25	165	168	O	12.3
NULL

ADCIRCA	595	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	12
Inform patients taking ADCIRCA not to take CIALIS or other PDE5 inhibitors .
1	0	5	O	Inform
2	7	14	O	patients
3	16	21	O	taking
4	23	29	O	XXXXXXXX
5	31	33	O	not
6	35	36	O	to
7	38	41	O	take
8	43	48	U-UNK	CIALIS
9	50	51	O	or
10	53	57	O	other
11	59	62	B-UNK	PDE5
12	64	73	L-UNK	inhibitors
NULL

ADCIRCA	596	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	10
Other concomitant potent CYP3A inhibitors : Avoid use with ADCIRCA .
1	0	4	O	Other
2	6	16	O	concomitant
3	18	23	O	potent
4	25	29	B-UNK	CYP3A
5	31	40	L-UNK	inhibitors
6	42	42	O	:
7	44	48	B-TRI	Avoid
8	50	52	L-TRI	use
9	54	57	O	with
10	59	65	O	XXXXXXXX
NULL

ADCIRCA	597	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	18
PDE5 inhibitors , including ADCIRCA , and alpha adrenergic blocking agents are vasodilators with blood pressure lowering effects .
1	0	3	B-DYN	PDE5
2	5	14	L-DYN	inhibitors
3	16	16	O	,
4	18	26	O	including
5	28	34	O	XXXXXXXX
6	36	36	O	,
7	38	40	O	and
8	42	46	B-DYN	alpha
9	48	57	I-DYN	adrenergic
10	59	66	I-DYN	blocking
11	68	73	L-DYN	agents
12	75	77	O	are
13	79	90	O	GGGGGGGG
14	92	95	O	with
15	97	101	B-EFF	blood
16	103	110	I-EFF	pressure
17	112	119	L-EFF	lowering
18	121	127	O	effects
D/1:15:1 D/8:15:1

ADCIRCA	598	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	20
PDE5 inhibitors , including tadalafil , have mild systemic vasodilatory properties that may result in transient decreases in blood pressure .
1	0	3	O	PDE5
2	5	14	O	inhibitors
3	16	16	O	,
4	18	26	O	including
5	28	36	O	XXXXXXXX
6	38	38	O	,
7	40	43	O	have
8	45	48	O	mild
9	50	57	O	systemic
10	59	70	O	vasodilatory
11	72	81	O	properties
12	83	86	O	that
13	88	90	O	may
14	92	97	O	result
15	99	100	O	in
16	102	110	O	transient
17	112	120	O	decreases
18	122	123	O	in
19	125	129	O	blood
20	131	138	O	pressure
NULL

ADCIRCA	599	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	20
Potent Inducers of CYP3A : Avoid use of ADCIRCA in patients chronically taking potent inducers of CYP3A ( e.g. , rifampin ) .
1	0	5	O	Potent
2	7	14	O	Inducers
3	16	17	O	of
4	19	23	O	CYP3A
5	25	25	O	:
6	27	31	B-TRI	Avoid
7	33	35	L-TRI	use
8	37	38	O	of
9	40	46	O	XXXXXXXX
10	48	49	O	in
11	51	58	O	patients
12	60	70	O	chronically
13	72	77	O	taking
14	79	84	O	potent
15	86	93	B-UNK	inducers
16	95	96	I-UNK	of
17	98	102	L-UNK	CYP3A
18	106	108	O	e.g
19	111	111	O	,
20	113	120	U-UNK	rifampin
NULL

ADCIRCA	600	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	6
Tadalafil is also marketed as CIALIS .
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	16	O	also
4	18	25	O	marketed
5	27	28	O	as
6	30	35	O	CIALIS
NULL

ADCIRCA	601	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	18
The safety and efficacy of taking ADCIRCA together with CIALIS or other PDE5 inhibitors have not been studied .
1	0	2	O	The
2	4	9	O	safety
3	11	13	O	and
4	15	22	O	efficacy
5	24	25	O	of
6	27	32	O	taking
7	34	40	O	XXXXXXXX
8	42	49	O	together
9	51	54	O	with
10	56	61	O	CIALIS
11	63	64	O	or
12	66	70	O	other
13	72	75	O	PDE5
14	77	86	O	inhibitors
15	88	91	O	have
16	93	95	O	not
17	97	100	O	been
18	102	108	O	studied
NULL

ADCIRCA	602	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	27
These events , which may be accompanied by tinnitus and dizziness , have been reported in temporal association to the intake of PDE5 inhibitors , including ADCIRCA .
1	0	4	O	These
2	6	11	O	events
3	13	13	O	,
4	15	19	O	which
5	21	23	O	may
6	25	26	O	be
7	28	38	O	accompanied
8	40	41	O	by
9	43	50	O	tinnitus
10	52	54	O	and
11	56	64	O	dizziness
12	66	66	O	,
13	68	71	O	have
14	73	76	O	been
15	78	85	O	reported
16	87	88	O	in
17	90	97	O	temporal
18	99	109	O	association
19	111	112	O	to
20	114	116	O	the
21	118	123	O	intake
22	125	126	O	of
23	128	131	O	PDE5
24	133	142	O	inhibitors
25	144	144	O	,
26	146	154	O	including
27	156	162	O	XXXXXXXX
NULL

ADCIRCA	603	43685-7	ff61b237-be8e-461b-8114-78c52a8ad0ae	20
When administered in combination with aspirin , tadalafil 20 mg did not prolong bleeding time , relative to aspirin alone .
1	0	3	O	When
2	5	16	O	administered
3	18	19	O	in
4	21	31	O	combination
5	33	36	O	with
6	38	44	O	aspirin
7	46	46	O	,
8	48	56	O	XXXXXXXX
9	58	59	O	20
10	61	62	O	mg
11	64	66	O	did
12	68	70	O	not
13	72	78	O	prolong
14	80	87	O	bleeding
15	89	92	O	time
16	94	94	O	,
17	96	103	O	relative
18	105	106	O	to
19	108	114	O	aspirin
20	116	120	O	alone
NULL

Adenocard	511	34071-1	f0e32589-dad9-4887-8481-bcf7f6618466	34
Adenocard ( adenosine injection ) is a respiratory stimulant ( probably through activation of carotid body chemoreceptors ) and intravenous administration in man has been shown to increase minute ventilation ( Ve ) and reduce arterial PCO2 causing respiratory alkalosis .
1	0	8	O	XXXXXXXX
2	12	20	O	XXXXXXXX
3	22	30	O	injection
4	34	35	O	is
5	37	37	O	a
6	39	49	O	respiratory
7	51	59	O	stimulant
8	63	70	O	probably
9	72	78	O	through
10	80	89	O	activation
11	91	92	O	of
12	94	100	O	carotid
13	102	105	O	body
14	107	120	O	chemoreceptors
15	124	126	O	and
16	128	138	O	intravenous
17	140	153	O	administration
18	155	156	O	in
19	158	160	O	man
20	162	164	O	has
21	166	169	O	been
22	171	175	O	shown
23	177	178	O	to
24	180	187	O	increase
25	189	194	O	minute
26	196	206	O	ventilation
27	210	211	O	Ve
28	215	217	O	and
29	219	224	O	reduce
30	226	233	O	arterial
31	235	238	O	PCO2
32	240	246	O	causing
33	248	258	O	respiratory
34	260	268	O	alkalosis
NULL

Adenocard	512	34073-7	f0e32589-dad9-4887-8481-bcf7f6618466	31
Because of the potential for additive or synergistic depressant effects on the SA and AV nodes, however, Adenocard should be used with caution in the presence of these agents.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	23	O	potential
5	25	27	O	for
6	29	36	O	additive
7	38	39	O	or
8	41	51	O	synergistic
9	53	62	O	depressant
10	64	70	O	effects
11	72	73	O	on
12	75	77	O	the
13	79	80	O	SA
14	82	84	O	and
15	86	87	O	AV
16	89	93	O	nodes
17	94	94	O	,
18	96	102	O	however
19	103	103	O	,
20	105	113	O	XXXXXXXX
21	115	120	O	should
22	122	123	O	be
23	125	128	O	used
24	130	133	O	with
25	135	141	O	caution
26	143	144	O	in
27	146	148	O	the
28	150	157	O	presence
29	159	160	O	of
30	162	166	O	these
31	168	173	O	agents
NULL

Adenocard	513	34073-7	f0e32589-dad9-4887-8481-bcf7f6618466	15
Carbamazepine has been reported to increase the degree of heart block produced by other agents.
1	0	12	U-DYN	Carbamazepine
2	14	16	O	has
3	18	21	O	been
4	23	30	O	reported
5	32	33	O	to
6	35	42	O	increase
7	44	46	O	the
8	48	53	O	degree
9	55	56	O	of
10	58	62	B-EFF	heart
11	64	68	L-EFF	block
12	70	77	O	produced
13	79	80	O	by
14	82	86	O	other
15	88	93	O	agents
D/1:10:1

Adenocard	514	34073-7	f0e32589-dad9-4887-8481-bcf7f6618466	17
Digoxin and verapamil use may be rarely associated with ventricular fibrillation when combined with Adenocard (see Warnings ).
1	0	6	U-DYN	Digoxin
2	8	10	O	and
3	12	20	U-DYN	verapamil
4	22	24	O	use
5	26	28	O	may
6	30	31	O	be
7	33	38	O	rarely
8	40	49	O	associated
9	51	54	O	with
10	56	66	B-EFF	ventricular
11	68	79	L-EFF	fibrillation
12	81	84	O	when
13	86	93	O	combined
14	95	98	O	with
15	100	108	O	XXXXXXXX
16	111	113	O	see
17	115	122	O	Warnings
D/1:10:1 D/3:10:1

Adenocard	515	34073-7	f0e32589-dad9-4887-8481-bcf7f6618466	44
Intravenous Adenocard (adenosine injection) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.
1	0	10	O	Intravenous
2	12	20	O	XXXXXXXX
3	23	31	O	XXXXXXXX
4	33	41	O	injection
5	44	46	O	has
6	48	51	O	been
7	53	63	O	effectively
8	65	76	O	administered
9	78	79	O	in
10	81	83	O	the
11	85	92	O	presence
12	94	95	O	of
13	97	101	O	other
14	103	114	O	cardioactive
15	116	120	O	drugs
16	121	121	O	,
17	123	126	O	such
18	128	129	O	as
19	131	139	O	quinidine
20	140	140	O	,
21	142	145	O	beta
22	147	156	O	adrenergic
23	158	165	O	blocking
24	167	172	O	agents
25	173	173	O	,
26	175	181	O	calcium
27	183	189	O	channel
28	191	198	O	blocking
29	200	205	O	agents
30	206	206	O	,
31	208	210	O	and
32	212	222	O	angiotensin
33	224	233	O	converting
34	235	240	O	enzyme
35	242	251	O	inhibitors
36	252	252	O	,
37	254	260	O	without
38	262	264	O	any
39	266	271	O	change
40	273	274	O	in
41	276	278	O	the
42	280	286	O	adverse
43	288	295	O	reaction
44	297	303	O	profile
NULL

Adenocard	516	34073-7	f0e32589-dad9-4887-8481-bcf7f6618466	17
The use of Adenocard in patients receiving digitalis may be rarely associated with ventricular fibrillation (see Warnings ).
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	19	O	XXXXXXXX
5	21	22	O	in
6	24	31	O	patients
7	33	41	O	receiving
8	43	51	U-DYN	digitalis
9	53	55	O	may
10	57	58	O	be
11	60	65	O	rarely
12	67	76	O	associated
13	78	81	O	with
14	83	93	B-EFF	ventricular
15	95	106	L-EFF	fibrillation
16	109	111	O	see
17	113	120	O	Warnings
D/8:14:1

Adenocard	517	42232-9	f0e32589-dad9-4887-8481-bcf7f6618466	6
Adenosine effects are potentiated by dipyridamole .
1	0	8	B-EFF	XXXXXXXX
2	10	16	I-EFF	effects
3	18	20	I-EFF	are
4	22	32	L-EFF	potentiated
5	34	35	O	by
6	37	48	U-DYN	dipyridamole
D/6:1:1

Adenocard	518	42232-9	f0e32589-dad9-4887-8481-bcf7f6618466	29
As the primary effect of adenosine is to decrease conduction through the A-V node , higher degrees of heart block may be produced in the presence of carbamazepine .
1	0	1	O	As
2	3	5	O	the
3	7	13	O	primary
4	15	20	O	effect
5	22	23	O	of
6	25	33	O	XXXXXXXX
7	35	36	O	is
8	38	39	O	to
9	41	48	O	decrease
10	50	59	O	conduction
11	61	67	O	through
12	69	71	O	the
13	73	73	O	A
14	75	75	O	V
15	77	80	O	node
16	82	82	O	,
17	84	89	O	higher
18	91	97	O	degrees
19	99	100	O	of
20	102	106	B-EFF	heart
21	108	112	L-EFF	block
22	114	116	O	may
23	118	119	O	be
24	121	128	O	produced
25	130	131	O	in
26	133	135	O	the
27	137	144	O	presence
28	146	147	O	of
29	149	161	U-DYN	carbamazepine
D/29:20:1

Adenocard	519	42232-9	f0e32589-dad9-4887-8481-bcf7f6618466	20
In the presence of these methylxanthines , larger doses of adenosine may be required or adenosine may not be effective .
1	0	1	O	In
2	3	5	O	the
3	7	14	O	presence
4	16	17	O	of
5	19	23	O	these
6	25	39	U-DYN	methylxanthines
7	41	41	O	,
8	43	48	O	larger
9	50	54	O	doses
10	56	57	O	of
11	59	67	O	XXXXXXXX
12	69	71	O	may
13	73	74	O	be
14	76	83	O	required
15	85	86	O	or
16	88	96	B-EFF	XXXXXXXX
17	98	100	I-EFF	may
18	102	104	I-EFF	not
19	106	107	I-EFF	be
20	109	117	L-EFF	effective
D/6:16:1

Adenocard	520	42232-9	f0e32589-dad9-4887-8481-bcf7f6618466	44
Intravenous Adenocard ( adenosine injection ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , beta-adrenergic blocking agents , calcium channel blocking agents , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile .
1	0	10	O	Intravenous
2	12	20	O	XXXXXXXX
3	24	32	O	XXXXXXXX
4	34	42	O	injection
5	46	48	O	has
6	50	53	O	been
7	55	65	O	effectively
8	67	78	O	administered
9	80	81	O	in
10	83	85	O	the
11	87	94	O	presence
12	96	97	O	of
13	99	103	O	other
14	105	116	O	cardioactive
15	118	122	O	drugs
16	124	124	O	,
17	126	129	O	such
18	131	132	O	as
19	134	142	O	quinidine
20	144	144	O	,
21	146	149	O	beta
22	151	160	O	adrenergic
23	162	169	O	blocking
24	171	176	O	agents
25	178	178	O	,
26	180	186	O	calcium
27	188	194	O	channel
28	196	203	O	blocking
29	205	210	O	agents
30	212	212	O	,
31	214	216	O	and
32	218	228	O	angiotensin
33	230	239	O	converting
34	241	246	O	enzyme
35	248	257	O	inhibitors
36	259	259	O	,
37	261	267	O	without
38	269	271	O	any
39	273	278	O	change
40	280	281	O	in
41	283	285	O	the
42	287	293	O	adverse
43	295	302	O	reaction
44	304	310	O	profile
NULL

Adenocard	521	42232-9	f0e32589-dad9-4887-8481-bcf7f6618466	13
The effects of adenosine are antagonized by methylxanthines such as caffeine and theophylline .
1	0	2	O	The
2	4	10	B-EFF	effects
3	12	13	I-EFF	of
4	15	23	I-EFF	XXXXXXXX
5	25	27	I-EFF	are
6	29	39	L-EFF	antagonized
7	41	42	O	by
8	44	58	U-DYN	methylxanthines
9	60	63	O	such
10	65	66	O	as
11	68	75	U-DYN	caffeine
12	77	79	O	and
13	81	92	U-DYN	theophylline
D/11:2:1 D/13:2:1 D/8:2:1

Adenocard	522	42232-9	f0e32589-dad9-4887-8481-bcf7f6618466	14
Thus , smaller doses of adenosine may be effective in the presence of dipyridamole .
1	0	3	O	Thus
2	5	5	O	,
3	7	13	O	smaller
4	15	19	O	doses
5	21	22	O	of
6	24	32	O	XXXXXXXX
7	34	36	O	may
8	38	39	O	be
9	41	49	O	effective
10	51	52	O	in
11	54	56	O	the
12	58	65	O	presence
13	67	68	O	of
14	70	81	O	dipyridamole
NULL

Aldactone	1	34068-7	0fed2822-3a03-4b64-9857-c682fcd462bc	33
ALDACTONE in a dosage ranging from 25 mg to 100 mg daily is useful in treating a diuretic-induced hypokalemia , when oral potassium supplements or other potassium-sparing regimens are considered inappropriate .
1	0	8	O	XXXXXXXX
2	10	11	O	in
3	13	13	O	a
4	15	20	O	dosage
5	22	28	O	ranging
6	30	33	O	from
7	35	36	O	25
8	38	39	O	mg
9	41	42	O	to
10	44	46	O	100
11	48	49	O	mg
12	51	55	O	daily
13	57	58	O	is
14	60	65	O	useful
15	67	68	O	in
16	70	77	O	treating
17	79	79	O	a
18	81	88	O	diuretic
19	90	96	O	induced
20	98	108	O	hypokalemia
21	110	110	O	,
22	112	115	O	when
23	117	120	O	oral
24	122	130	O	potassium
25	132	142	O	supplements
26	144	145	O	or
27	147	151	O	other
28	153	161	O	potassium
29	163	169	O	sparing
30	171	178	O	regimens
31	180	182	O	are
32	184	193	O	considered
33	195	207	O	inappropriate
NULL

Aldactone	2	34068-7	0fed2822-3a03-4b64-9857-c682fcd462bc	20
ALDACTONE may also be given with diuretics that act more proximally in the renal tubule or with other antihypertensive agents .
1	0	8	O	XXXXXXXX
2	10	12	O	may
3	14	17	O	also
4	19	20	O	be
5	22	26	O	given
6	28	31	O	with
7	33	41	O	GGGGGGGG
8	43	46	O	that
9	48	50	O	act
10	52	55	O	more
11	57	66	O	proximally
12	68	69	O	in
13	71	73	O	the
14	75	79	O	renal
15	81	86	O	tubule
16	88	89	O	or
17	91	94	O	with
18	96	100	O	other
19	102	117	O	antihypertensive
20	119	124	O	agents
NULL

Aldactone	3	34068-7	0fed2822-3a03-4b64-9857-c682fcd462bc	37
Because of the additive effect of ALDACTONE when administered concurrently with such diuretics , an enhanced diuresis usually begins on the first day of combined treatment , combined therapy is indicated when more rapid diuresis is desired .
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	22	O	additive
5	24	29	O	effect
6	31	32	O	of
7	34	42	O	XXXXXXXX
8	44	47	O	when
9	49	60	O	administered
10	62	73	O	concurrently
11	75	78	O	with
12	80	83	O	such
13	85	93	U-DYN	GGGGGGGG
14	95	95	O	,
15	97	98	O	an
16	100	107	B-EFF	enhanced
17	109	116	L-EFF	diuresis
18	118	124	O	usually
19	126	131	O	begins
20	133	134	O	on
21	136	138	O	the
22	140	144	O	first
23	146	148	O	day
24	150	151	O	of
25	153	160	O	combined
26	162	170	O	treatment
27	172	172	O	,
28	174	181	O	combined
29	183	189	O	therapy
30	191	192	O	is
31	194	202	O	indicated
32	204	207	O	when
33	209	212	O	more
34	214	218	O	rapid
35	220	227	O	diuresis
36	229	230	O	is
37	232	238	O	desired
D/13:16:1

Aldactone	4	34068-7	0fed2822-3a03-4b64-9857-c682fcd462bc	33
If , after five days , an adequate diuretic response to ALDACTONE has not occurred , a second diuretic that acts more proximally in the renal tubule may be added to the regimen .
1	0	1	O	If
2	3	3	O	,
3	5	9	O	after
4	11	14	O	five
5	16	19	O	days
6	21	21	O	,
7	23	24	O	an
8	26	33	O	adequate
9	35	42	O	diuretic
10	44	51	O	response
11	53	54	O	to
12	56	64	O	XXXXXXXX
13	66	68	O	has
14	70	72	O	not
15	74	81	O	occurred
16	83	83	O	,
17	85	85	O	a
18	87	92	O	second
19	94	101	O	diuretic
20	103	106	O	that
21	108	111	O	acts
22	113	116	O	more
23	118	127	O	proximally
24	129	130	O	in
25	132	134	O	the
26	136	140	O	renal
27	142	147	O	tubule
28	149	151	O	may
29	153	154	O	be
30	156	160	O	added
31	162	163	O	to
32	165	167	O	the
33	169	175	O	regimen
NULL

Aldactone	5	34070-3	0fed2822-3a03-4b64-9857-c682fcd462bc	31
ALDACTONE is contraindicated for patients with anuria , acute renal insufficiency , significant impairment of renal excretory function , hyperkalemia , Addison 's disease , and with concomitant use of eplerenone .
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	27	U-TRI	contraindicated
4	29	31	O	for
5	33	40	O	patients
6	42	45	O	with
7	47	52	O	anuria
8	54	54	O	,
9	56	60	O	acute
10	62	66	O	renal
11	68	80	O	insufficiency
12	82	82	O	,
13	84	94	O	significant
14	96	105	O	impairment
15	107	108	O	of
16	110	114	O	renal
17	116	124	O	excretory
18	126	133	O	function
19	135	135	O	,
20	137	148	O	hyperkalemia
21	150	150	O	,
22	152	158	O	Addison
23	160	161	O	's
24	163	169	O	disease
25	171	171	O	,
26	173	175	O	and
27	177	180	O	with
28	182	192	O	concomitant
29	194	196	O	use
30	198	199	O	of
31	201	210	U-UNK	eplerenone
NULL

Aldactone	6	34071-1	0fed2822-3a03-4b64-9857-c682fcd462bc	24
ALDACTONE , when used with ACE inhibitors or indomethacin , even in the presence of a diuretic , has been associated with severe hyperkalemia .
1	0	8	O	XXXXXXXX
2	10	10	O	,
3	12	15	O	when
4	17	20	O	used
5	22	25	O	with
6	27	29	B-DYN	ACE
7	31	40	L-DYN	inhibitors
8	42	43	O	or
9	45	56	U-DYN	indomethacin
10	58	58	O	,
11	60	63	O	even
12	65	66	O	in
13	68	70	O	the
14	72	79	O	presence
15	81	82	O	of
16	84	84	O	a
17	86	93	O	diuretic
18	95	95	O	,
19	97	99	O	has
20	101	104	O	been
21	106	115	O	associated
22	117	120	O	with
23	122	127	B-EFF	severe
24	129	140	L-EFF	hyperkalemia
D/6:23:1 D/9:23:1

Aldactone	7	34071-1	0fed2822-3a03-4b64-9857-c682fcd462bc	11
ALDACTONE should not be administered concurrently with other potassium-sparing diuretics .
1	0	8	O	XXXXXXXX
2	10	15	B-TRI	should
3	17	19	I-TRI	not
4	21	22	I-TRI	be
5	24	35	L-TRI	administered
6	37	48	O	concurrently
7	50	53	O	with
8	55	59	O	other
9	61	69	B-UNK	potassium
10	71	77	I-UNK	sparing
11	79	87	L-UNK	GGGGGGGG
NULL

Aldactone	8	34071-1	0fed2822-3a03-4b64-9857-c682fcd462bc	17
Concomitant administration of ALDACTONE with the following drugs or potassium sources may lead to severe hyperkalemia : .
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	38	O	XXXXXXXX
5	40	43	O	with
6	45	47	O	the
7	49	57	O	following
8	59	63	O	drugs
9	65	66	O	or
10	68	76	O	potassium
11	78	84	O	sources
12	86	88	O	may
13	90	93	O	lead
14	95	96	O	to
15	98	103	O	severe
16	105	116	O	hyperkalemia
17	118	118	O	:
NULL

Aldactone	9	34071-1	0fed2822-3a03-4b64-9857-c682fcd462bc	27
Potassium supplementation , either in the form of medication or as a diet rich in potassium , should not ordinarily be given in association with ALDACTONE therapy .
1	0	8	O	Potassium
2	10	24	O	supplementation
3	26	26	O	,
4	28	33	O	either
5	35	36	O	in
6	38	40	O	the
7	42	45	O	form
8	47	48	O	of
9	50	59	O	medication
10	61	62	O	or
11	64	65	O	as
12	67	67	O	a
13	69	72	O	diet
14	74	77	O	rich
15	79	80	O	in
16	82	90	U-UNK	potassium
17	92	92	O	,
18	94	99	O	should
19	101	103	O	not
20	105	114	O	ordinarily
21	116	117	O	be
22	119	123	O	given
23	125	126	O	in
24	128	138	O	association
25	140	143	O	with
26	145	153	O	XXXXXXXX
27	155	161	O	therapy
NULL

Aldactone	10	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	18
Combination of NSAIDs, e.g., indomethacin, with potassium-sparing diuretics has been associated with severe hyperkalemia.
1	0	10	O	Combination
2	12	13	O	of
3	15	20	U-DYN	NSAIDs
4	21	21	O	,
5	23	25	O	e.g
6	27	27	O	,
7	29	40	U-DYN	indomethacin
8	41	41	O	,
9	43	46	O	with
10	48	56	O	potassium
11	58	64	O	sparing
12	66	74	O	GGGGGGGG
13	76	78	O	has
14	80	83	O	been
15	85	94	O	associated
16	96	99	O	with
17	101	106	B-EFF	severe
18	108	119	L-EFF	hyperkalemia
D/3:17:1 D/7:17:1

Aldactone	11	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	7
Concomitant administration may lead to severe hyperkalemia.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	29	O	may
4	31	34	O	lead
5	36	37	O	to
6	39	44	O	severe
7	46	57	O	hyperkalemia
NULL

Aldactone	12	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	15
Concomitant administration of ACE inhibitors with potassium-sparing diuretics has been associated with severe hyperkalemia.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	32	B-DYN	ACE
5	34	43	L-DYN	inhibitors
6	45	48	O	with
7	50	58	O	potassium
8	60	66	O	sparing
9	68	76	O	GGGGGGGG
10	78	80	O	has
11	82	85	O	been
12	87	96	O	associated
13	98	101	O	with
14	103	108	B-EFF	severe
15	110	121	L-EFF	hyperkalemia
D/4:14:1

Aldactone	13	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	15
Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
1	0	14	O	GGGGGGGG
2	16	21	O	reduce
3	23	25	O	the
4	27	31	O	renal
5	33	41	O	clearance
6	43	44	O	of
7	46	52	U-KIN	lithium
8	54	56	O	and
9	58	60	O	add
10	62	62	O	a
11	64	67	O	high
12	69	72	O	risk
13	74	75	O	of
14	77	83	O	lithium
15	85	92	O	toxicity
K/7:C54357

Aldactone	14	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	28
In some patients, the administration of an NSAID can reduce the diuretic, natriuretic, and antihypertensive effect of loop, potassium-sparing, and thiazide diuretics.
1	0	1	O	In
2	3	6	O	some
3	8	15	O	patients
4	16	16	O	,
5	18	20	O	the
6	22	35	O	administration
7	37	38	O	of
8	40	41	O	an
9	43	47	U-DYN	NSAID
10	49	51	O	can
11	53	58	O	reduce
12	60	62	O	the
13	64	71	O	diuretic
14	72	72	O	,
15	74	84	O	natriuretic
16	85	85	O	,
17	87	89	O	and
18	91	106	O	antihypertensive
19	108	113	O	effect
20	115	116	O	of
21	118	121	O	loop
22	122	122	O	,
23	124	132	O	potassium
24	134	140	O	sparing
25	141	141	O	,
26	143	145	O	and
27	147	154	O	thiazide
28	156	164	O	GGGGGGGG
NULL

Aldactone	15	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	9
Intensified electrolyte depletion, particularly hypokalemia, may occur.
1	0	10	O	Intensified
2	12	22	O	electrolyte
3	24	32	O	depletion
4	33	33	O	,
5	35	46	O	particularly
6	48	58	O	hypokalemia
7	59	59	O	,
8	61	63	O	may
9	65	69	O	occur
NULL

Aldactone	16	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	29
It may be necessary to reduce the maintenance and digitalization doses when ALDACTONE is administered, and the patient should be carefully monitored to avoid over- or under-digitalization.
1	0	1	O	It
2	3	5	O	may
3	7	8	O	be
4	10	18	O	necessary
5	20	21	O	to
6	23	28	O	reduce
7	30	32	O	the
8	34	44	O	maintenance
9	46	48	O	and
10	50	63	O	digitalization
11	65	69	O	doses
12	71	74	O	when
13	76	84	O	XXXXXXXX
14	86	87	O	is
15	89	100	O	administered
16	101	101	O	,
17	103	105	O	and
18	107	109	O	the
19	111	117	O	patient
20	119	124	O	should
21	126	127	O	be
22	129	137	O	carefully
23	139	147	O	monitored
24	149	150	O	to
25	152	156	O	avoid
26	158	161	O	over
27	164	165	O	or
28	167	171	O	under
29	173	186	O	digitalization
NULL

Aldactone	17	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	8
Lithium generally should not be given with diuretics.
1	0	6	U-UNK	Lithium
2	8	16	O	generally
3	18	23	B-TRI	should
4	25	27	I-TRI	not
5	29	30	I-TRI	be
6	32	36	L-TRI	given
7	38	41	O	with
8	43	51	O	GGGGGGGG
NULL

Aldactone	18	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	9
Possible increased responsiveness to the muscle relaxant may result.
1	0	7	O	Possible
2	9	17	O	increased
3	19	32	O	responsiveness
4	34	35	O	to
5	37	39	O	the
6	41	46	O	muscle
7	48	55	O	relaxant
8	57	59	O	may
9	61	66	O	result
NULL

Aldactone	19	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	6
Potentiation of orthostatic hypotension may occur.
1	0	11	O	Potentiation
2	13	14	O	of
3	16	26	O	orthostatic
4	28	38	O	hypotension
5	40	42	O	may
6	44	48	O	occur
NULL

Aldactone	20	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	24
Therefore, caution should be exercised in the management of patients subjected to regional or general anesthesia while they are being treated with ALDACTONE.
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	O	caution
4	19	24	O	should
5	26	27	O	be
6	29	37	O	exercised
7	39	40	O	in
8	42	44	O	the
9	46	55	O	management
10	57	58	O	of
11	60	67	O	patients
12	69	77	O	subjected
13	79	80	O	to
14	82	89	O	regional
15	91	92	O	or
16	94	100	O	general
17	102	111	O	anesthesia
18	113	117	O	while
19	119	122	O	they
20	124	126	O	are
21	128	132	O	being
22	134	140	O	treated
23	142	145	O	with
24	147	155	O	XXXXXXXX
NULL

Aldactone	21	34073-7	0fed2822-3a03-4b64-9857-c682fcd462bc	12
This may result in increased serum digoxin levels and subsequent digitalis toxicity.
1	0	3	O	This
2	5	7	O	may
3	9	14	O	result
4	16	17	O	in
5	19	27	O	increased
6	29	33	O	serum
7	35	41	O	digoxin
8	43	48	O	levels
9	50	52	O	and
10	54	63	O	subsequent
11	65	73	O	digitalis
12	75	82	O	toxicity
NULL

Aldactone	22	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	52
A dose-related ( above 20 mg/kg/day ) incidence of myelocytic leukemia was observed in rats fed daily doses of potassium canrenoate ( a compound chemically similar to ALDACTONE and whose primary metabolite , canrenone , is also a major product of ALDACTONE in man ) for a period of one year .
1	0	0	O	A
2	2	5	O	dose
3	7	13	O	related
4	17	21	O	above
5	23	24	O	20
6	26	27	O	mg
7	28	28	O	/
8	29	30	O	kg
9	31	31	O	/
10	32	34	O	day
11	38	46	O	incidence
12	48	49	O	of
13	51	60	O	myelocytic
14	62	69	O	leukemia
15	71	73	O	was
16	75	82	O	observed
17	84	85	O	in
18	87	90	O	rats
19	92	94	O	fed
20	96	100	O	daily
21	102	106	O	doses
22	108	109	O	of
23	111	119	O	potassium
24	121	130	O	canrenoate
25	134	134	O	a
26	136	143	O	compound
27	145	154	O	chemically
28	156	162	O	similar
29	164	165	O	to
30	167	175	O	XXXXXXXX
31	177	179	O	and
32	181	185	O	whose
33	187	193	O	primary
34	195	204	O	metabolite
35	206	206	O	,
36	208	216	O	canrenone
37	218	218	O	,
38	220	221	O	is
39	223	226	O	also
40	228	228	O	a
41	230	234	O	major
42	236	242	O	product
43	244	245	O	of
44	247	255	O	XXXXXXXX
45	257	258	O	in
46	260	262	O	man
47	266	268	O	for
48	270	270	O	a
49	272	277	O	period
50	279	280	O	of
51	282	284	O	one
52	286	289	O	year
NULL

Aldactone	23	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	78
ALDACTONE ( 100 mg/kg/day ) , administered i.p. to female mice during a two-week cohabitation period with untreated males , decreased the number of mated mice that conceived ( effect shown to be caused by an inhibition of ovulation ) and decreased the number of implanted embryos in those that became pregnant ( effect shown to be caused by an inhibition of implantation ) , and at 200 mg/kg , also increased the latency period to mating .
1	0	8	O	XXXXXXXX
2	12	14	O	100
3	16	17	O	mg
4	18	18	O	/
5	19	20	O	kg
6	21	21	O	/
7	22	24	O	day
8	28	28	O	,
9	30	41	O	administered
10	43	45	O	i.p
11	48	49	O	to
12	51	56	O	female
13	58	61	O	mice
14	63	68	O	during
15	70	70	O	a
16	72	74	O	two
17	76	79	O	week
18	81	92	O	cohabitation
19	94	99	O	period
20	101	104	O	with
21	106	114	O	untreated
22	116	120	O	males
23	122	122	O	,
24	124	132	O	decreased
25	134	136	O	the
26	138	143	O	number
27	145	146	O	of
28	148	152	O	mated
29	154	157	O	mice
30	159	162	O	that
31	164	172	O	conceived
32	176	181	O	effect
33	183	187	O	shown
34	189	190	O	to
35	192	193	O	be
36	195	200	O	caused
37	202	203	O	by
38	205	206	O	an
39	208	217	O	inhibition
40	219	220	O	of
41	222	230	O	ovulation
42	234	236	O	and
43	238	246	O	decreased
44	248	250	O	the
45	252	257	O	number
46	259	260	O	of
47	262	270	O	implanted
48	272	278	O	embryos
49	280	281	O	in
50	283	287	O	those
51	289	292	O	that
52	294	299	O	became
53	301	308	O	pregnant
54	312	317	O	effect
55	319	323	O	shown
56	325	326	O	to
57	328	329	O	be
58	331	336	O	caused
59	338	339	O	by
60	341	342	O	an
61	344	353	O	inhibition
62	355	356	O	of
63	358	369	O	implantation
64	373	373	O	,
65	375	377	O	and
66	379	380	O	at
67	382	384	O	200
68	386	387	O	mg
69	388	388	O	/
70	389	390	O	kg
71	392	392	O	,
72	394	397	O	also
73	399	407	O	increased
74	409	411	O	the
75	413	419	O	latency
76	421	426	O	period
77	428	429	O	to
78	431	436	O	mating
NULL

Aldactone	24	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	11
ALDACTONE has been shown to increase the half-life of digoxin .
1	0	8	O	XXXXXXXX
2	10	12	O	has
3	14	17	O	been
4	19	23	O	shown
5	25	26	O	to
6	28	35	O	increase
7	37	39	O	the
8	41	44	O	half
9	46	49	O	life
10	51	52	O	of
11	54	60	U-KIN	digoxin
K/11:C54611

Aldactone	25	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	7
ALDACTONE reduces the vascular responsiveness to norepinephrine .
1	0	8	O	XXXXXXXX
2	10	16	B-EFF	reduces
3	18	20	I-EFF	the
4	22	29	I-EFF	vascular
5	31	44	L-EFF	responsiveness
6	46	47	O	to
7	49	62	U-DYN	norepinephrine
D/7:2:1

Aldactone	26	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	29
Because of its antiandrogenic activity and the requirement of testosterone for male morphogenesis , ALDACTONE may have the potential for adversely affecting sex differentiation of the male during embryogenesis .
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	its
4	15	28	O	antiandrogenic
5	30	37	O	activity
6	39	41	O	and
7	43	45	O	the
8	47	57	O	requirement
9	59	60	O	of
10	62	73	O	testosterone
11	75	77	O	for
12	79	82	O	male
13	84	96	O	morphogenesis
14	98	98	O	,
15	100	108	O	XXXXXXXX
16	110	112	O	may
17	114	117	O	have
18	119	121	O	the
19	123	131	O	potential
20	133	135	O	for
21	137	145	O	adversely
22	147	155	O	affecting
23	157	159	O	sex
24	161	175	O	differentiation
25	177	178	O	of
26	180	182	O	the
27	184	187	O	male
28	189	194	O	during
29	196	208	O	embryogenesis
NULL

Aldactone	27	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	15
Canrenone , a major ( and active ) metabolite of ALDACTONE , appears in human breast milk .
1	0	8	O	Canrenone
2	10	10	O	,
3	12	12	O	a
4	14	18	O	major
5	22	24	O	and
6	26	31	O	active
7	35	44	O	metabolite
8	46	47	O	of
9	49	57	O	XXXXXXXX
10	59	59	O	,
11	61	67	O	appears
12	69	70	O	in
13	72	76	O	human
14	78	83	O	breast
15	85	88	O	milk
NULL

Aldactone	28	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	11
Consequently , no potassium supplement should ordinarily be given with ALDACTONE .
1	0	11	O	Consequently
2	13	13	O	,
3	15	16	O	no
4	18	26	B-UNK	potassium
5	28	37	L-UNK	supplement
6	39	44	O	should
7	46	55	O	ordinarily
8	57	58	O	be
9	60	64	O	given
10	66	69	O	with
11	71	79	O	XXXXXXXX
NULL

Aldactone	29	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	76
Dilutional hyponatremia , manifested by dryness of the mouth , thirst , lethargy , and drowsiness , and confirmed by a low serum sodium level , may be caused or aggravated , especially when ALDACTONE is administered in combination with other diuretics , and dilutional hyponatremia may occur in edematous patients in hot weather , appropriate therapy is water restriction rather than administration of sodium , except in rare instances when the hyponatremia is life-threatening .
1	0	9	B-EFF	Dilutional
2	11	22	L-EFF	hyponatremia
3	24	24	O	,
4	26	35	O	manifested
5	37	38	O	by
6	40	46	B-EFF	dryness
7	48	49	I-EFF	of
8	51	53	I-EFF	the
9	55	59	L-EFF	mouth
10	61	61	O	,
11	63	68	U-EFF	thirst
12	70	70	O	,
13	72	79	U-EFF	lethargy
14	81	81	O	,
15	83	85	O	and
16	87	96	U-EFF	drowsiness
17	98	98	O	,
18	100	102	O	and
19	104	112	O	confirmed
20	114	115	O	by
21	117	117	O	a
22	119	121	B-EFF	low
23	123	127	I-EFF	serum
24	129	134	I-EFF	sodium
25	136	140	L-EFF	level
26	142	142	O	,
27	144	146	O	may
28	148	149	O	be
29	151	156	O	caused
30	158	159	O	or
31	161	170	O	aggravated
32	172	172	O	,
33	174	183	O	especially
34	185	188	O	when
35	190	198	O	XXXXXXXX
36	200	201	O	is
37	203	214	O	administered
38	216	217	O	in
39	219	229	O	combination
40	231	234	O	with
41	236	240	O	other
42	242	250	U-DYN	GGGGGGGG
43	252	252	O	,
44	254	256	O	and
45	258	267	O	dilutional
46	269	280	O	hyponatremia
47	282	284	O	may
48	286	290	O	occur
49	292	293	O	in
50	295	303	O	edematous
51	305	312	O	patients
52	314	315	O	in
53	317	319	O	hot
54	321	327	O	weather
55	329	329	O	,
56	331	341	O	appropriate
57	343	349	O	therapy
58	351	352	O	is
59	354	358	O	water
60	360	370	O	restriction
61	372	377	O	rather
62	379	382	O	than
63	384	397	O	administration
64	399	400	O	of
65	402	407	O	sodium
66	409	409	O	,
67	411	416	O	except
68	418	419	O	in
69	421	424	O	rare
70	426	434	O	instances
71	436	439	O	when
72	441	443	O	the
73	445	456	O	hyponatremia
74	458	459	O	is
75	461	464	O	life
76	466	476	O	threatening
D/42:1:1 D/42:11:1 D/42:13:1 D/42:16:1 D/42:22:1 D/42:6:1

Aldactone	30	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	13
Hyperkalemic metabolic acidosis has been reported in patients given ALDACTONE concurrently with cholestyramine .
1	0	11	B-EFF	Hyperkalemic
2	13	21	I-EFF	metabolic
3	23	30	L-EFF	acidosis
4	32	34	O	has
5	36	39	O	been
6	41	48	O	reported
7	50	51	O	in
8	53	60	O	patients
9	62	66	O	given
10	68	76	O	XXXXXXXX
11	78	89	O	concurrently
12	91	94	O	with
13	96	109	U-DYN	cholestyramine
D/13:1:1

Aldactone	31	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	23
In the absence of metabolic activation , neither ALDACTONE nor potassium canrenoate has been shown to be mutagenic in mammalian tests in vitro .
1	0	1	O	In
2	3	5	O	the
3	7	13	O	absence
4	15	16	O	of
5	18	26	O	metabolic
6	28	37	O	activation
7	39	39	O	,
8	41	47	O	neither
9	49	57	O	XXXXXXXX
10	59	61	O	nor
11	63	71	O	potassium
12	73	82	O	canrenoate
13	84	86	O	has
14	88	91	O	been
15	93	97	O	shown
16	99	100	O	to
17	102	103	O	be
18	105	113	O	mutagenic
19	115	116	O	in
20	118	126	O	mammalian
21	128	132	O	tests
22	134	135	O	in
23	137	141	O	vitro
NULL

Aldactone	32	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	14
Neither ALDACTONE nor potassium canrenoate produced mutagenic effects in tests using bacteria or yeast .
1	0	6	O	Neither
2	8	16	O	XXXXXXXX
3	18	20	O	nor
4	22	30	O	potassium
5	32	41	O	canrenoate
6	43	50	O	produced
7	52	60	O	mutagenic
8	62	68	O	effects
9	70	71	O	in
10	73	77	O	tests
11	79	83	O	using
12	85	92	O	bacteria
13	94	95	O	or
14	97	101	O	yeast
NULL

Aldactone	33	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	22
Patients who receive ALDACTONE should be advised to avoid potassium supplements and foods containing high levels of potassium , including salt substitutes .
1	0	7	O	Patients
2	9	11	O	who
3	13	19	O	receive
4	21	29	O	XXXXXXXX
5	31	36	O	should
6	38	39	O	be
7	41	47	O	advised
8	49	50	O	to
9	52	56	U-TRI	avoid
10	58	66	U-UNK	potassium
11	68	78	O	supplements
12	80	82	O	and
13	84	88	O	foods
14	90	99	O	containing
15	101	104	O	high
16	106	111	O	levels
17	113	114	O	of
18	116	124	O	potassium
19	126	126	O	,
20	128	136	O	including
21	138	141	O	salt
22	143	153	O	substitutes
NULL

Aldactone	34	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	20
Several reports of possible interference with digoxin radioimmunoassay by ALDACTONE , or its metabolites , have appeared in the literature .
1	0	6	O	Several
2	8	14	O	reports
3	16	17	O	of
4	19	26	O	possible
5	28	39	O	interference
6	41	44	O	with
7	46	52	O	digoxin
8	54	69	O	radioimmunoassay
9	71	72	O	by
10	74	82	O	XXXXXXXX
11	84	84	O	,
12	86	87	O	or
13	89	91	O	its
14	93	103	O	metabolites
15	105	105	O	,
16	107	110	O	have
17	112	119	O	appeared
18	121	122	O	in
19	124	126	O	the
20	128	137	O	literature
NULL

Aldactone	35	42232-9	0fed2822-3a03-4b64-9857-c682fcd462bc	27
Therefore , when ALDACTONE and NSAIDs are used concomitantly , the patient should be observed closely to determine if the desired effect of the diuretic is obtained .
1	0	8	O	Therefore
2	10	10	O	,
3	12	15	O	when
4	17	25	O	XXXXXXXX
5	27	29	O	and
6	31	36	U-UNK	NSAIDs
7	38	40	O	are
8	42	45	O	used
9	47	59	O	concomitantly
10	61	61	O	,
11	63	65	O	the
12	67	73	O	patient
13	75	80	B-TRI	should
14	82	83	I-TRI	be
15	85	92	L-TRI	observed
16	94	100	O	closely
17	102	103	O	to
18	105	113	O	determine
19	115	116	O	if
20	118	120	O	the
21	122	128	O	desired
22	130	135	O	effect
23	137	138	O	of
24	140	142	O	the
25	144	151	O	diuretic
26	153	154	O	is
27	156	163	O	obtained
NULL

BRILINTA	523	34066-1	f7b3f443-e83d-4bf2-0e96-023448fed9a8	5
ASPIRIN DOSE AND BRILINTA EFFECTIVENESS .
1	0	6	O	ASPIRIN
2	8	11	O	DOSE
3	13	15	O	AND
4	17	24	O	XXXXXXXX
5	26	38	O	EFFECTIVENESS
NULL

BRILINTA	524	34066-1	f7b3f443-e83d-4bf2-0e96-023448fed9a8	16
BRILINTA , like other antiplatelet agents , can cause significant , sometimes fatal bleeding ( 5.1 , 6.1 ) .
1	0	7	O	XXXXXXXX
2	9	9	O	,
3	11	14	O	like
4	16	20	O	other
5	22	40	O	GGGGGGGG
6	42	42	O	,
7	44	46	O	can
8	48	52	O	cause
9	54	64	O	significant
10	66	66	O	,
11	68	76	O	sometimes
12	78	82	O	fatal
13	84	91	O	bleeding
14	95	97	O	5.1
15	99	99	O	,
16	101	103	O	6.1
NULL

BRILINTA	525	34066-1	f7b3f443-e83d-4bf2-0e96-023448fed9a8	21
Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided ( 2.1 , 5.2 , 14.1 ) .
1	0	10	O	Maintenance
2	12	16	O	doses
3	18	19	O	of
4	21	27	U-DYN	aspirin
5	29	33	O	above
6	35	37	O	100
7	39	40	O	mg
8	42	47	B-EFF	reduce
9	49	51	I-EFF	the
10	53	65	I-EFF	effectiveness
11	67	68	I-EFF	of
12	70	77	L-EFF	XXXXXXXX
13	79	81	O	and
14	83	88	O	should
15	90	91	O	be
16	93	99	O	avoided
17	103	105	O	2.1
18	107	107	O	,
19	109	111	O	5.2
20	113	113	O	,
21	115	118	O	14.1
D/4:8:1

BRILINTA	526	34066-1	f7b3f443-e83d-4bf2-0e96-023448fed9a8	16
Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided .
1	0	10	O	Maintenance
2	12	16	O	doses
3	18	19	O	of
4	21	27	U-DYN	aspirin
5	29	33	O	above
6	35	37	O	100
7	39	40	O	mg
8	42	47	B-EFF	reduce
9	49	51	I-EFF	the
10	53	65	I-EFF	effectiveness
11	67	68	I-EFF	of
12	70	77	L-EFF	XXXXXXXX
13	79	81	O	and
14	83	88	O	should
15	90	91	O	be
16	93	99	O	avoided
D/4:8:1

BRILINTA	527	34066-1	f7b3f443-e83d-4bf2-0e96-023448fed9a8	12
WARNING : ( A ) BLEEDING RISK , ( B ) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS .
1	0	6	O	WARNING
2	8	8	O	:
3	12	12	O	A
4	16	23	O	BLEEDING
5	25	28	O	RISK
6	30	30	O	,
7	34	34	O	B
8	38	44	O	ASPIRIN
9	46	49	O	DOSE
10	51	53	O	AND
11	55	62	O	XXXXXXXX
12	64	76	O	EFFECTIVENESS
NULL

BRILINTA	528	34066-1	f7b3f443-e83d-4bf2-0e96-023448fed9a8	13
WARNING : ( A ) BLEEDING RISK , and ( B ) ASPIRIN DOSE AND BRILINTA EFFECTIVENESS .
1	0	6	O	WARNING
2	8	8	O	:
3	12	12	O	A
4	16	23	O	BLEEDING
5	25	28	O	RISK
6	30	30	O	,
7	32	34	O	and
8	38	38	O	B
9	42	48	O	ASPIRIN
10	50	53	O	DOSE
11	55	57	O	AND
12	59	66	O	XXXXXXXX
13	68	80	O	EFFECTIVENESS
NULL

BRILINTA	529	34068-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	10
Do not administer BRILINTA with another oral P2Y12 platelet inhibitor .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	16	L-TRI	administer
4	18	25	O	XXXXXXXX
5	27	30	O	with
6	32	38	O	another
7	40	43	O	oral
8	45	49	B-UNK	P2Y12
9	51	58	I-UNK	platelet
10	60	68	L-UNK	inhibitor
NULL

BRILINTA	530	34068-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	13
Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg .
1	0	2	O	Use
2	4	11	O	XXXXXXXX
3	13	16	O	with
4	18	18	O	a
5	20	24	O	daily
6	26	36	O	maintenance
7	38	41	O	dose
8	43	44	O	of
9	46	52	O	aspirin
10	54	55	O	of
11	57	58	O	75
12	60	62	O	100
13	64	65	O	mg
NULL

BRILINTA	531	34068-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	22
Use BRILINTA with a daily maintenance dose of aspirin of 75-100 mg see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.1 ) .
1	0	2	O	Use
2	4	11	O	XXXXXXXX
3	13	16	O	with
4	18	18	O	a
5	20	24	O	daily
6	26	36	O	maintenance
7	38	41	O	dose
8	43	44	O	of
9	46	52	O	aspirin
10	54	55	O	of
11	57	58	O	75
12	60	62	O	100
13	64	65	O	mg
14	67	69	O	see
15	71	78	O	Warnings
16	80	82	O	and
17	84	94	O	Precautions
18	98	100	O	5.2
19	104	106	O	and
20	108	115	O	Clinical
21	117	123	O	Studies
22	127	130	O	14.1
NULL

BRILINTA	532	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	25
(7.1, 7.2) Patients receiving more than 40 mg per day of simvastatin or lovastatin may be at increased risk of statin-related adverse effects.
1	1	3	O	7.1
2	4	4	O	,
3	6	8	O	7.2
4	11	18	O	Patients
5	20	28	O	receiving
6	30	33	O	more
7	35	38	O	than
8	40	41	O	40
9	43	44	O	mg
10	46	48	O	per
11	50	52	O	day
12	54	55	O	of
13	57	67	U-DYN	simvastatin
14	69	70	O	or
15	72	81	U-DYN	lovastatin
16	83	85	O	may
17	87	88	O	be
18	90	91	O	at
19	93	101	O	increased
20	103	106	O	risk
21	108	109	O	of
22	111	116	B-EFF	statin
23	118	124	I-EFF	related
24	126	132	I-EFF	adverse
25	134	140	L-EFF	effects
D/13:22:1 D/15:22:1

BRILINTA	533	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	12
(7.4) Monitor digoxin levels with initiation of or any change in BRILINTA.
1	1	3	O	7.4
2	6	12	U-TRI	Monitor
3	14	20	U-UNK	digoxin
4	22	27	O	levels
5	29	32	O	with
6	34	43	O	initiation
7	45	46	O	of
8	48	49	O	or
9	51	53	O	any
10	55	60	O	change
11	62	63	O	in
12	65	72	O	XXXXXXXX
NULL

BRILINTA	534	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	22
(7.5) Strong CYP3A inhibitors substantially increase ticagrelor exposure and so increase the risk of dyspnea, bleeding, and other adverse events.
1	1	3	O	7.5
2	6	11	O	Strong
3	13	17	B-DYN	CYP3A
4	19	28	L-DYN	inhibitors
5	30	42	O	substantially
6	44	51	B-TRI	increase
7	53	62	I-TRI	XXXXXXXX
8	64	71	L-TRI	exposure
9	73	75	O	and
10	77	78	O	so
11	80	87	O	increase
12	89	91	O	the
13	93	96	O	risk
14	98	99	O	of
15	101	107	U-EFF	dyspnea
16	108	108	O	,
17	110	117	U-EFF	bleeding
18	118	118	O	,
19	120	122	O	and
20	124	128	O	other
21	130	136	O	adverse
22	138	143	O	events
D/3:15:1 D/3:17:1

BRILINTA	535	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	13
Avoid simvastatin and lovastatin doses greater than 40 mg [see Clinical Pharmacology (12.3) ].
1	0	4	U-TRI	Avoid
2	6	16	U-UNK	simvastatin
3	18	20	O	and
4	22	31	U-UNK	lovastatin
5	33	37	O	doses
6	39	45	O	greater
7	47	50	O	than
8	52	53	O	40
9	55	56	O	mg
10	59	61	O	see
11	63	70	O	Clinical
12	72	83	O	Pharmacology
13	86	89	O	12.3
NULL

BRILINTA	536	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	34
Avoid use of strong inhibitors of CYP3A (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir and telithromycin) [see Clinical Pharmacology (12.3) ].
1	0	4	B-TRI	Avoid
2	6	8	L-TRI	use
3	10	11	O	of
4	13	18	O	strong
5	20	29	B-UNK	inhibitors
6	31	32	I-UNK	of
7	34	38	L-UNK	CYP3A
8	41	43	O	e.g
9	45	45	O	,
10	47	58	U-UNK	ketoconazole
11	59	59	O	,
12	61	72	U-UNK	itraconazole
13	73	73	O	,
14	75	86	U-UNK	voriconazole
15	87	87	O	,
16	89	102	U-UNK	clarithromycin
17	103	103	O	,
18	105	114	U-UNK	nefazodone
19	115	115	O	,
20	117	125	U-UNK	ritonavir
21	126	126	O	,
22	128	137	U-UNK	saquinavir
23	138	138	O	,
24	140	149	U-UNK	nelfinavir
25	150	150	O	,
26	152	160	U-UNK	indinavir
27	161	161	O	,
28	163	172	U-UNK	atazanavir
29	174	176	O	and
30	178	190	U-UNK	telithromycin
31	194	196	O	see
32	198	205	O	Clinical
33	207	218	O	Pharmacology
34	221	224	O	12.3
NULL

BRILINTA	537	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	9
Avoid use with strong CYP3A inhibitors or CYP3A inducers.
1	0	4	B-TRI	Avoid
2	6	8	L-TRI	use
3	10	13	O	with
4	15	20	O	strong
5	22	26	B-UNK	CYP3A
6	28	37	L-UNK	inhibitors
7	39	40	O	or
8	42	46	B-UNK	CYP3A
9	48	55	L-UNK	inducers
NULL

BRILINTA	538	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	20
Avoid use with strong inducers of CYP3A (e.g., rifampin, phenytoin, carbamazepine and phenobarbital) [see Clinical Pharmacology (12.3) ].
1	0	4	B-TRI	Avoid
2	6	8	L-TRI	use
3	10	13	O	with
4	15	20	O	strong
5	22	29	B-UNK	inducers
6	31	32	I-UNK	of
7	34	38	L-UNK	CYP3A
8	41	43	O	e.g
9	45	45	O	,
10	47	54	U-UNK	rifampin
11	55	55	O	,
12	57	65	U-UNK	phenytoin
13	66	66	O	,
14	68	80	U-UNK	carbamazepine
15	82	84	O	and
16	86	98	U-UNK	phenobarbital
17	102	104	O	see
18	106	113	O	Clinical
19	115	126	O	Pharmacology
20	129	132	O	12.3
NULL

BRILINTA	539	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	15
BRILINTA increases serum concentrations of simvastatin and lovastatin because these drugs are metabolized by CYP3A4 .
1	0	7	O	XXXXXXXX
2	9	17	B-TRI	increases
3	19	23	I-TRI	serum
4	25	38	L-TRI	concentrations
5	40	41	O	of
6	43	53	U-KIN	simvastatin
7	55	57	O	and
8	59	68	U-KIN	lovastatin
9	70	76	O	because
10	78	82	O	these
11	84	88	O	drugs
12	90	92	O	are
13	94	104	O	metabolized
14	106	107	O	by
15	109	114	O	CYP3A4
K/6:C54357 K/8:C54357

BRILINTA	540	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	21
BRILINTA inhibits the P-glycoprotein transporter; monitor digoxin levels with initiation of or change in BRILINTA therapy [see Clinical Pharmacology (12.3) ].
1	0	7	O	XXXXXXXX
2	9	16	O	inhibits
3	18	20	O	the
4	22	22	O	P
5	24	35	O	glycoprotein
6	37	47	O	transporter
7	50	56	U-TRI	monitor
8	58	64	U-UNK	digoxin
9	66	71	O	levels
10	73	76	O	with
11	78	87	O	initiation
12	89	90	O	of
13	92	93	O	or
14	95	100	O	change
15	102	103	O	in
16	105	112	O	XXXXXXXX
17	114	120	O	therapy
18	123	125	O	see
19	127	134	O	Clinical
20	136	147	O	Pharmacology
21	150	153	O	12.3
NULL

BRILINTA	541	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	14
Strong CYP3A inducers substantially reduce ticagrelor exposure and so decrease the efficacy of ticagrelor .
1	0	5	O	Strong
2	7	11	B-KIN	CYP3A
3	13	20	L-KIN	inducers
4	22	34	O	substantially
5	36	41	B-TRI	reduce
6	43	52	I-TRI	XXXXXXXX
7	54	61	L-TRI	exposure
8	63	65	O	and
9	67	68	O	so
10	70	77	O	decrease
11	79	81	O	the
12	83	90	O	efficacy
13	92	93	O	of
14	95	104	O	XXXXXXXX
K/2:C54356

BRILINTA	542	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	21
Strong CYP3A inhibitors substantially increase ticagrelor exposure and so increase the risk of dyspnea , bleeding , and other adverse events .
1	0	5	O	Strong
2	7	11	B-KIN	CYP3A
3	13	22	L-KIN	inhibitors
4	24	36	O	substantially
5	38	45	B-TRI	increase
6	47	56	I-TRI	XXXXXXXX
7	58	65	L-TRI	exposure
8	67	69	O	and
9	71	72	O	so
10	74	81	O	increase
11	83	85	O	the
12	87	90	O	risk
13	92	93	O	of
14	95	101	O	dyspnea
15	103	103	O	,
16	105	112	O	bleeding
17	114	114	O	,
18	116	118	O	and
19	120	124	O	other
20	126	132	O	adverse
21	134	139	O	events
K/2:C54355

BRILINTA	543	34073-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	24
Use of BRILINTA with aspirin maintenance doses above 100 mg reduced the effectiveness of BRILINTA see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.1 ) .
1	0	2	O	Use
2	4	5	O	of
3	7	14	O	XXXXXXXX
4	16	19	O	with
5	21	27	U-DYN	aspirin
6	29	39	O	maintenance
7	41	45	O	doses
8	47	51	O	above
9	53	55	O	100
10	57	58	O	mg
11	60	66	B-EFF	reduced
12	68	70	I-EFF	the
13	72	84	I-EFF	effectiveness
14	86	87	I-EFF	of
15	89	96	L-EFF	XXXXXXXX
16	98	100	O	see
17	102	109	O	Warnings
18	111	113	O	and
19	115	125	O	Precautions
20	129	131	O	5.2
21	135	137	O	and
22	139	146	O	Clinical
23	148	154	O	Studies
24	158	161	O	14.1
D/5:11:1

BRILINTA	544	43685-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	50
Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment , but led to study drug discontinuation in 0.9 % of BRILINTA and 0.1 % of clopidogrel patients in PLATO and 4.3 % of BRILINTA 60 mg and 0.7 % on aspirin alone patients in PEGASUS .
1	0	6	O	Dyspnea
2	8	10	O	was
3	12	18	O	usually
4	20	23	O	mild
5	25	26	O	to
6	28	35	O	moderate
7	37	38	O	in
8	40	48	O	intensity
9	50	52	O	and
10	54	58	O	often
11	60	67	O	resolved
12	69	74	O	during
13	76	84	O	continued
14	86	94	O	treatment
15	96	96	O	,
16	98	100	O	but
17	102	104	O	led
18	106	107	O	to
19	109	113	O	study
20	115	118	O	drug
21	120	134	O	discontinuation
22	136	137	O	in
23	139	141	O	0.9
24	143	143	O	%
25	145	146	O	of
26	148	155	O	XXXXXXXX
27	157	159	O	and
28	161	163	O	0.1
29	165	165	O	%
30	167	168	O	of
31	170	180	O	clopidogrel
32	182	189	O	patients
33	191	192	O	in
34	194	198	O	PLATO
35	200	202	O	and
36	204	206	O	4.3
37	208	208	O	%
38	210	211	O	of
39	213	220	O	XXXXXXXX
40	222	223	O	60
41	225	226	O	mg
42	228	230	O	and
43	232	234	O	0.7
44	236	236	O	%
45	238	239	O	on
46	241	247	O	aspirin
47	249	253	O	alone
48	255	262	O	patients
49	264	265	O	in
50	267	273	O	PEGASUS
NULL

BRILINTA	545	43685-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	19
In PLATO the use of BRILINTA with maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA .
1	0	1	O	In
2	3	7	O	PLATO
3	9	11	O	the
4	13	15	O	use
5	17	18	O	of
6	20	27	O	XXXXXXXX
7	29	32	O	with
8	34	44	O	maintenance
9	46	50	O	doses
10	52	53	O	of
11	55	61	U-DYN	aspirin
12	63	67	O	above
13	69	71	O	100
14	73	74	O	mg
15	76	84	B-EFF	decreased
16	86	88	I-EFF	the
17	90	102	I-EFF	effectiveness
18	104	105	I-EFF	of
19	107	114	L-EFF	XXXXXXXX
D/11:15:1

BRILINTA	546	43685-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	16
In the case of intolerable dyspnea requiring discontinuation of BRILINTA , consider prescribing another antiplatelet agent .
1	0	1	O	In
2	3	5	O	the
3	7	10	O	case
4	12	13	O	of
5	15	25	O	intolerable
6	27	33	O	dyspnea
7	35	43	O	requiring
8	45	59	O	discontinuation
9	61	62	O	of
10	64	71	O	XXXXXXXX
11	73	73	O	,
12	75	82	O	consider
13	84	94	O	prescribing
14	96	102	O	another
15	104	115	O	antiplatelet
16	117	121	O	agent
NULL

BRILINTA	547	43685-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	41
Patients with a history of sick sinus syndrome , 2nd or 3rd degree AV block or bradycardia-related syncope not protected by a pacemaker were excluded from PLATO and PEGASUS and may be at increased risk of developing bradyarrhythmias with ticagrelor .
1	0	7	O	Patients
2	9	12	O	with
3	14	14	O	a
4	16	22	O	history
5	24	25	O	of
6	27	30	O	sick
7	32	36	O	sinus
8	38	45	O	syndrome
9	47	47	O	,
10	49	51	O	2nd
11	53	54	O	or
12	56	58	O	3rd
13	60	65	O	degree
14	67	68	O	AV
15	70	74	O	block
16	76	77	O	or
17	79	89	O	bradycardia
18	91	97	O	related
19	99	105	O	syncope
20	107	109	O	not
21	111	119	O	protected
22	121	122	O	by
23	124	124	O	a
24	126	134	O	pacemaker
25	136	139	O	were
26	141	148	O	excluded
27	150	153	O	from
28	155	159	O	PLATO
29	161	163	O	and
30	165	171	O	PEGASUS
31	173	175	O	and
32	177	179	O	may
33	181	182	O	be
34	184	185	O	at
35	187	195	O	increased
36	197	200	O	risk
37	202	203	O	of
38	205	214	O	developing
39	216	231	O	bradyarrhythmias
40	233	236	O	with
41	238	247	O	XXXXXXXX
NULL

BRILINTA	548	43685-7	f7b3f443-e83d-4bf2-0e96-023448fed9a8	31
Therefore , after the initial loading dose of aspirin , use BRILINTA with a maintenance dose of aspirin of 75-100 mg see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14.1 ) .
1	0	8	O	Therefore
2	10	10	O	,
3	12	16	O	after
4	18	20	O	the
5	22	28	O	initial
6	30	36	O	loading
7	38	41	O	dose
8	43	44	O	of
9	46	52	O	aspirin
10	54	54	O	,
11	56	58	O	use
12	60	67	O	XXXXXXXX
13	69	72	O	with
14	74	74	O	a
15	76	86	O	maintenance
16	88	91	O	dose
17	93	94	O	of
18	96	102	O	aspirin
19	104	105	O	of
20	107	108	O	75
21	110	112	O	100
22	114	115	O	mg
23	117	119	O	see
24	121	126	O	Dosage
25	128	130	O	and
26	132	145	O	Administration
27	149	151	O	2.1
28	155	157	O	and
29	159	166	O	Clinical
30	168	174	O	Studies
31	178	181	O	14.1
NULL

Brevibloc	206	34068-7	595cc3d5-1306-4828-aefa-5595219ffd62	15
BREVIBLOC is not compatible with Sodium Bicarbonate ( 5 % ) solution ( limited stability ) or furosemide ( precipitation ) .
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	15	O	not
4	17	26	O	compatible
5	28	31	O	with
6	33	38	O	Sodium
7	40	50	O	Bicarbonate
8	54	54	O	5
9	56	56	O	%
10	60	67	O	solution
11	71	77	O	limited
12	79	87	O	stability
13	91	92	O	or
14	94	103	O	furosemide
15	107	119	O	precipitation
NULL

Brevibloc	207	34070-3	595cc3d5-1306-4828-aefa-5595219ffd62	18
Coadministration of IV cardiodepressant calcium-channel antagonists ( e.g. verapamil ) in close proximity to BREVIBLOC injection ( 4 , 7 ) .
1	0	15	O	Coadministration
2	17	18	O	of
3	20	21	O	IV
4	23	38	O	cardiodepressant
5	40	46	O	calcium
6	48	54	O	channel
7	56	66	O	antagonists
8	70	72	O	e.g
9	75	83	O	verapamil
10	87	88	O	in
11	90	94	O	close
12	96	104	O	proximity
13	106	107	O	to
14	109	117	O	XXXXXXXX
15	119	127	O	injection
16	131	131	O	4
17	133	133	O	,
18	135	135	O	7
NULL

Brevibloc	208	34070-3	595cc3d5-1306-4828-aefa-5595219ffd62	24
Hypersensitivity reactions , including anaphylaxis , to esmolol or any of the inactive ingredients of the product ( cross-sensitivity between beta blockers is possible ) .
1	0	15	O	Hypersensitivity
2	17	25	O	reactions
3	27	27	O	,
4	29	37	O	including
5	39	49	O	anaphylaxis
6	51	51	O	,
7	53	54	O	to
8	56	62	O	XXXXXXXX
9	64	65	O	or
10	67	69	O	any
11	71	72	O	of
12	74	76	O	the
13	78	85	O	inactive
14	87	97	O	ingredients
15	99	100	O	of
16	102	104	O	the
17	106	112	O	product
18	116	120	O	cross
19	122	132	O	sensitivity
20	134	140	O	between
21	142	145	O	beta
22	147	154	O	blockers
23	156	157	O	is
24	159	166	O	possible
NULL

Brevibloc	209	34070-3	595cc3d5-1306-4828-aefa-5595219ffd62	39
IV administration of cardiodepressant calcium-channel antagonists ( e.g. , verapamil ) and BREVIBLOC in close proximity ( i.e. , while cardiac effects from the other are still present ) , fatal cardiac arrests have occurred in patients receiving BREVIBLOC and intravenous verapamil .
1	0	1	O	IV
2	3	16	O	administration
3	18	19	O	of
4	21	36	O	cardiodepressant
5	38	44	B-DYN	calcium
6	46	52	I-DYN	channel
7	54	64	L-DYN	antagonists
8	68	70	O	e.g
9	73	73	O	,
10	75	83	U-DYN	verapamil
11	87	89	O	and
12	91	99	O	XXXXXXXX
13	101	102	O	in
14	104	108	O	close
15	110	118	O	proximity
16	122	124	O	i.e
17	127	127	O	,
18	129	133	O	while
19	135	141	O	cardiac
20	143	149	O	effects
21	151	154	O	from
22	156	158	O	the
23	160	164	O	other
24	166	168	O	are
25	170	174	O	still
26	176	182	O	present
27	186	186	O	,
28	188	192	O	fatal
29	194	200	U-EFF	cardiac
30	202	208	O	arrests
31	210	213	O	have
32	215	222	O	occurred
33	224	225	O	in
34	227	234	O	patients
35	236	244	O	receiving
36	246	254	O	XXXXXXXX
37	256	258	O	and
38	260	270	O	intravenous
39	272	280	O	verapamil
D/10:29:1 D/5:29:1

Brevibloc	210	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	8
(See clonidine, guanfacine, and moxonidine below.)
1	1	3	O	See
2	5	13	O	clonidine
3	14	14	O	,
4	16	25	O	guanfacine
5	26	26	O	,
6	28	30	O	and
7	32	41	O	moxonidine
8	43	47	O	below
NULL

Brevibloc	211	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	21
Anticholinesterases : BREVIBLOC prolonged the duration of succinylcholine-induced neuromuscular blockade and moderately prolonged clinical duration and recovery index of mivacurium .
1	0	18	O	Anticholinesterases
2	20	20	O	:
3	22	30	O	XXXXXXXX
4	32	40	O	prolonged
5	42	44	O	the
6	46	53	O	duration
7	55	56	O	of
8	58	72	O	succinylcholine
9	74	80	O	induced
10	82	94	O	neuromuscular
11	96	103	O	blockade
12	105	107	O	and
13	109	118	O	moderately
14	120	128	O	prolonged
15	130	137	O	clinical
16	139	146	O	duration
17	148	150	O	and
18	152	159	O	recovery
19	161	165	O	index
20	167	168	O	of
21	170	179	O	mivacurium
NULL

Brevibloc	212	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	25
Antihypertensive agents clonidine, guanfacine, or moxonidine: Beta blockers also increase the risk of clonidine-, guanfacine-, or moxonidine-withdrawal rebound hypertension.
1	0	15	O	Antihypertensive
2	17	22	O	agents
3	24	32	U-DYN	clonidine
4	33	33	O	,
5	35	44	U-DYN	guanfacine
6	45	45	O	,
7	47	48	O	or
8	50	59	U-DYN	moxonidine
9	60	60	O	:
10	62	65	O	Beta
11	67	74	O	blockers
12	76	79	O	also
13	81	88	O	increase
14	90	92	O	the
15	94	97	O	risk
16	99	100	O	of
17	102	110	O	clonidine
18	112	112	O	,
19	114	123	O	guanfacine
20	125	125	O	,
21	127	128	O	or
22	130	139	O	moxonidine
23	141	150	O	withdrawal
24	152	158	B-EFF	rebound
25	160	171	L-EFF	hypertension
D/3:24:1 D/5:24:1 D/8:24:1

Brevibloc	213	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	12
Both digoxin and beta blockers slow atrioventricular conduction and decrease heart rate.
1	0	3	O	Both
2	5	11	O	digoxin
3	13	15	O	and
4	17	20	O	beta
5	22	29	O	blockers
6	31	34	O	slow
7	36	51	O	atrioventricular
8	53	62	O	conduction
9	64	66	O	and
10	68	75	O	decrease
11	77	81	O	heart
12	83	86	O	rate
NULL

Brevibloc	214	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	35
BREVIBLOC should therefore be used only after careful individual assessment of the risks and expected benefits in patients receiving drugs that can cause these types of pharmacodynamic interactions , including but not limited to : .
1	0	8	O	XXXXXXXX
2	10	15	O	should
3	17	25	O	therefore
4	27	28	O	be
5	30	33	O	used
6	35	38	O	only
7	40	44	O	after
8	46	52	O	careful
9	54	63	O	individual
10	65	74	O	assessment
11	76	77	O	of
12	79	81	O	the
13	83	87	O	risks
14	89	91	O	and
15	93	100	O	expected
16	102	109	O	benefits
17	111	112	O	in
18	114	121	O	patients
19	123	131	O	receiving
20	133	137	O	drugs
21	139	142	O	that
22	144	146	O	can
23	148	152	O	cause
24	154	158	O	these
25	160	164	O	types
26	166	167	O	of
27	169	183	O	pharmacodynamic
28	185	196	O	interactions
29	198	198	O	,
30	200	208	O	including
31	210	212	O	but
32	214	216	O	not
33	218	224	O	limited
34	226	227	O	to
35	229	229	O	:
NULL

Brevibloc	215	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	28
Calcium channel antagonists : In patients with depressed myocardial function , use of BREVIBLOC with cardiodepressant calcium channel antagonists ( e.g. , verapamil ) can lead to fatal cardiac arrests .
1	0	6	O	Calcium
2	8	14	O	channel
3	16	26	O	antagonists
4	28	28	O	:
5	30	31	O	In
6	33	40	O	patients
7	42	45	O	with
8	47	55	O	depressed
9	57	66	O	myocardial
10	68	75	O	function
11	77	77	O	,
12	79	81	O	use
13	83	84	O	of
14	86	94	O	XXXXXXXX
15	96	99	O	with
16	101	116	O	cardiodepressant
17	118	124	B-DYN	calcium
18	126	132	I-DYN	channel
19	134	144	L-DYN	antagonists
20	148	150	O	e.g
21	153	153	O	,
22	155	163	U-DYN	verapamil
23	167	169	O	can
24	171	174	O	lead
25	176	177	O	to
26	179	183	B-EFF	fatal
27	185	191	I-EFF	cardiac
28	193	199	L-EFF	arrests
D/17:26:1 D/22:26:1

Brevibloc	216	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	7
Concomitant use increases the risk of bradycardia.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	24	O	increases
4	26	28	O	the
5	30	33	O	risk
6	35	36	O	of
7	38	48	O	bradycardia
NULL

Brevibloc	217	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	45
Concomitant use of BREVIBLOC injection with other drugs that can lower blood pressure , reduce myocardial contractility , or interfere with sinus node function or electrical impulse propagation in the myocardium can exaggerate BREVIBLOC s effects on blood pressure , contractility , and impulse propagation .
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	O	XXXXXXXX
5	29	37	O	injection
6	39	42	O	with
7	44	48	O	other
8	50	54	O	drugs
9	56	59	O	that
10	61	63	O	can
11	65	69	B-EFF	lower
12	71	75	I-EFF	blood
13	77	84	L-EFF	pressure
14	86	86	O	,
15	88	93	B-EFF	reduce
16	95	104	I-EFF	myocardial
17	106	118	L-EFF	contractility
18	120	120	O	,
19	122	123	O	or
20	125	133	O	interfere
21	135	138	O	with
22	140	144	O	sinus
23	146	149	O	node
24	151	158	O	function
25	160	161	O	or
26	163	172	O	electrical
27	174	180	O	impulse
28	182	192	O	propagation
29	194	195	O	in
30	197	199	O	the
31	201	210	O	myocardium
32	212	214	O	can
33	216	225	O	exaggerate
34	227	235	O	XXXXXXXX
35	237	237	O	s
36	239	245	O	effects
37	247	248	O	on
38	250	254	O	blood
39	256	263	O	pressure
40	265	265	O	,
41	267	279	O	contractility
42	281	281	O	,
43	283	285	O	and
44	287	293	O	impulse
45	295	305	O	propagation
NULL

Brevibloc	218	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	27
Digitalis glycosides : Concomitant administration of digoxin and BREVIBLOC leads to an approximate 10 % to 20 % increase of digoxin blood levels at some time points .
1	0	8	O	Digitalis
2	10	19	O	glycosides
3	21	21	O	:
4	23	33	O	Concomitant
5	35	48	O	administration
6	50	51	O	of
7	53	59	U-KIN	digoxin
8	61	63	O	and
9	65	73	O	XXXXXXXX
10	75	79	O	leads
11	81	82	O	to
12	84	85	O	an
13	87	97	O	approximate
14	99	100	O	10
15	102	102	O	%
16	104	105	O	to
17	107	108	O	20
18	110	110	O	%
19	112	119	O	increase
20	121	122	O	of
21	124	130	O	digoxin
22	132	136	O	blood
23	138	143	O	levels
24	145	146	O	at
25	148	151	O	some
26	153	156	O	time
27	158	163	O	points
K/7:C54357

Brevibloc	219	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	39
Digitalis glycosides: Risk of bradycardia (7) Anticholinesterases: Prolongs neuromuscular blockade (7) Antihypertensive agents: Risk of rebound hypertension (7) Sympathomimetic drugs: Dose adjustment needed (7) Vasoconstrictive and positive inotropic effect substances: Avoid concomitant use (7)
1	0	8	B-DYN	Digitalis
2	10	19	L-DYN	glycosides
3	20	20	O	:
4	22	25	O	Risk
5	27	28	O	of
6	30	40	U-EFF	bradycardia
7	43	43	O	7
8	46	64	U-DYN	Anticholinesterases
9	65	65	O	:
10	67	74	B-EFF	Prolongs
11	76	88	I-EFF	neuromuscular
12	90	97	L-EFF	blockade
13	100	100	O	7
14	103	118	B-DYN	Antihypertensive
15	120	125	L-DYN	agents
16	126	126	O	:
17	128	131	O	Risk
18	133	134	O	of
19	136	142	B-EFF	rebound
20	144	155	L-EFF	hypertension
21	158	158	O	7
22	161	175	B-UNK	Sympathomimetic
23	177	181	L-UNK	drugs
24	182	182	O	:
25	184	187	B-TRI	Dose
26	189	198	I-TRI	adjustment
27	200	205	L-TRI	needed
28	208	208	O	7
29	211	226	O	Vasoconstrictive
30	228	230	O	and
31	232	239	B-UNK	positive
32	241	249	I-UNK	inotropic
33	251	256	I-UNK	effect
34	258	267	L-UNK	substances
35	268	268	O	:
36	270	274	U-TRI	Avoid
37	276	286	O	concomitant
38	288	290	O	use
39	293	293	O	7
D/1:10:0 D/1:19:0 D/1:6:1 D/14:10:0 D/14:19:1 D/14:6:0 D/8:10:1 D/8:19:0 D/8:6:0

Brevibloc	220	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	6
Digoxin does not affect BREVIBLOC pharmacokinetics .
1	0	6	O	Digoxin
2	8	11	O	does
3	13	15	O	not
4	17	22	O	affect
5	24	32	O	XXXXXXXX
6	34	49	O	pharmacokinetics
NULL

Brevibloc	221	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	31
If, during concomitant use of a beta blocker, antihypertensive therapy needs to be interrupted or discontinued, discontinue the beta blocker first, and the discontinuation should be gradual.
1	0	1	O	If
2	2	2	O	,
3	4	9	O	during
4	11	21	O	concomitant
5	23	25	O	use
6	27	28	O	of
7	30	30	O	a
8	32	35	O	beta
9	37	43	O	blocker
10	44	44	O	,
11	46	61	O	antihypertensive
12	63	69	O	therapy
13	71	75	O	needs
14	77	78	O	to
15	80	81	O	be
16	83	93	O	interrupted
17	95	96	O	or
18	98	109	O	discontinued
19	110	110	O	,
20	112	122	O	discontinue
21	124	126	O	the
22	128	131	O	beta
23	133	139	O	blocker
24	141	145	O	first
25	146	146	O	,
26	148	150	O	and
27	152	154	O	the
28	156	170	O	discontinuation
29	172	177	O	should
30	179	180	O	be
31	182	188	O	gradual
NULL

Brevibloc	222	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	14
In addition, with some drugs, beta blockade may precipitate increased withdrawal effects.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	16	O	with
5	18	21	O	some
6	23	27	O	drugs
7	28	28	O	,
8	30	33	B-DYN	beta
9	35	42	L-DYN	blockade
10	44	46	O	may
11	48	58	O	precipitate
12	60	68	O	increased
13	70	79	B-EFF	withdrawal
14	81	87	L-EFF	effects
D/8:13:1

Brevibloc	223	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	35
Severe interactions with such drugs can result in, for example, severe hypotension, cardiac failure, severe bradycardia, sinus pause, sinoatrial block, atrioventricular block, and/or cardiac arrest.
1	0	5	O	Severe
2	7	18	O	interactions
3	20	23	O	with
4	25	28	O	such
5	30	34	O	drugs
6	36	38	O	can
7	40	45	O	result
8	47	48	O	in
9	49	49	O	,
10	51	53	O	for
11	55	61	O	example
12	62	62	O	,
13	64	69	O	severe
14	71	81	O	hypotension
15	82	82	O	,
16	84	90	O	cardiac
17	92	98	O	failure
18	99	99	O	,
19	101	106	O	severe
20	108	118	O	bradycardia
21	119	119	O	,
22	121	125	O	sinus
23	127	131	O	pause
24	132	132	O	,
25	134	143	O	sinoatrial
26	145	149	O	block
27	150	150	O	,
28	152	167	O	atrioventricular
29	169	173	O	block
30	174	174	O	,
31	176	178	O	and
32	179	179	O	/
33	180	181	O	or
34	183	189	O	cardiac
35	191	196	O	arrest
NULL

Brevibloc	224	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	15
Sympathomimetic drugs : Sympathomimetic drugs having beta-adrenergic agonist activity will counteract effects of BREVIBLOC .
1	0	14	B-DYN	Sympathomimetic
2	16	20	L-DYN	drugs
3	22	22	O	:
4	24	38	O	Sympathomimetic
5	40	44	O	drugs
6	46	51	O	having
7	53	56	O	beta
8	58	67	O	adrenergic
9	69	75	O	agonist
10	77	84	O	activity
11	86	89	O	will
12	91	100	B-EFF	counteract
13	102	108	I-EFF	effects
14	110	111	I-EFF	of
15	113	121	L-EFF	XXXXXXXX
D/1:12:1

Brevibloc	225	34073-7	595cc3d5-1306-4828-aefa-5595219ffd62	50
Vasoconstrictive and positive inotropic agents : Because of the risk of reducing cardiac contractility in presence of high systemic vascular resistance , do not use BREVIBLOC to control tachycardia in patients receiving drugs that are vasoconstrictive and have positive inotropic effects , such as epinephrine , norepinephrine , and dopamine .
1	0	15	O	Vasoconstrictive
2	17	19	O	and
3	21	28	B-DYN	positive
4	30	38	I-DYN	inotropic
5	40	45	L-DYN	agents
6	47	47	O	:
7	49	55	O	Because
8	57	58	O	of
9	60	62	O	the
10	64	67	O	risk
11	69	70	O	of
12	72	79	B-EFF	reducing
13	81	87	I-EFF	cardiac
14	89	101	L-EFF	contractility
15	103	104	O	in
16	106	113	O	presence
17	115	116	O	of
18	118	121	O	high
19	123	130	O	systemic
20	132	139	O	vascular
21	141	150	O	resistance
22	152	152	O	,
23	154	155	O	do
24	157	159	O	not
25	161	163	O	use
26	165	173	O	XXXXXXXX
27	175	176	O	to
28	178	184	O	control
29	186	196	O	tachycardia
30	198	199	O	in
31	201	208	O	patients
32	210	218	O	receiving
33	220	224	O	drugs
34	226	229	O	that
35	231	233	O	are
36	235	250	O	vasoconstrictive
37	252	254	O	and
38	256	259	O	have
39	261	268	O	positive
40	270	278	O	inotropic
41	280	286	O	effects
42	288	288	O	,
43	290	293	O	such
44	295	296	O	as
45	298	308	U-DYN	epinephrine
46	310	310	O	,
47	312	325	U-DYN	norepinephrine
48	327	327	O	,
49	329	331	O	and
50	333	340	U-DYN	dopamine
D/3:12:1 D/45:12:1 D/47:12:1 D/50:12:1

Brevibloc	226	43685-7	595cc3d5-1306-4828-aefa-5595219ffd62	17
Beta blockers , including BREVIBLOC , have been associated with increases in serum potassium levels and hyperkalemia .
1	0	3	O	Beta
2	5	12	O	blockers
3	14	14	O	,
4	16	24	O	including
5	26	34	O	XXXXXXXX
6	36	36	O	,
7	38	41	O	have
8	43	46	O	been
9	48	57	O	associated
10	59	62	O	with
11	64	72	O	increases
12	74	75	O	in
13	77	81	O	serum
14	83	91	O	potassium
15	93	98	O	levels
16	100	102	O	and
17	104	115	O	hyperkalemia
NULL

Brevibloc	227	43685-7	595cc3d5-1306-4828-aefa-5595219ffd62	15
Beta blockers , including BREVIBLOC , have been reported to cause hyperkalemic renal tubular acidosis .
1	0	3	O	Beta
2	5	12	O	blockers
3	14	14	O	,
4	16	24	O	including
5	26	34	O	XXXXXXXX
6	36	36	O	,
7	38	41	O	have
8	43	46	O	been
9	48	55	O	reported
10	57	58	O	to
11	60	64	O	cause
12	66	77	O	hyperkalemic
13	79	83	O	renal
14	85	91	O	tubular
15	93	100	O	acidosis
NULL

Brevibloc	228	43685-7	595cc3d5-1306-4828-aefa-5595219ffd62	21
Beta blockers , like BREVIBLOC injection , can cause depression of myocardial contractility and may precipitate heart failure and cardiogenic shock .
1	0	3	O	Beta
2	5	12	O	blockers
3	14	14	O	,
4	16	19	O	like
5	21	29	O	XXXXXXXX
6	31	39	O	injection
7	41	41	O	,
8	43	45	O	can
9	47	51	O	cause
10	53	62	O	depression
11	64	65	O	of
12	67	76	O	myocardial
13	78	90	O	contractility
14	92	94	O	and
15	96	98	O	may
16	100	110	O	precipitate
17	112	116	O	heart
18	118	124	O	failure
19	126	128	O	and
20	130	140	O	cardiogenic
21	142	146	O	shock
NULL

Brevibloc	229	43685-7	595cc3d5-1306-4828-aefa-5595219ffd62	28
If BREVIBLOC is used in the setting of pheochromocytoma , give it in combination with an alpha-blocker , and only after the alpha-blocker has been initiated .
1	0	1	O	If
2	3	11	O	XXXXXXXX
3	13	14	O	is
4	16	19	O	used
5	21	22	O	in
6	24	26	O	the
7	28	34	O	setting
8	36	37	O	of
9	39	54	O	pheochromocytoma
10	56	56	O	,
11	58	61	O	give
12	63	64	O	it
13	66	67	O	in
14	69	79	O	combination
15	81	84	O	with
16	86	87	O	an
17	89	93	O	alpha
18	95	101	O	blocker
19	103	103	O	,
20	105	107	O	and
21	109	112	O	only
22	114	118	O	after
23	120	122	O	the
24	124	128	O	alpha
25	130	136	O	blocker
26	138	140	O	has
27	142	145	O	been
28	147	155	O	initiated
NULL

Brevibloc	230	43685-7	595cc3d5-1306-4828-aefa-5595219ffd62	7
Monitor serum electrolytes during therapy with BREVIBLOC .
1	0	6	O	Monitor
2	8	12	O	serum
3	14	25	O	electrolytes
4	27	32	O	during
5	34	40	O	therapy
6	42	45	O	with
7	47	55	O	XXXXXXXX
NULL

DIURIL	400	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	12
Alcohol, Barbiturates, or Narcotics- potentiation of orthostatic hypotension may occur.
1	0	6	O	Alcohol
2	7	7	O	,
3	9	20	O	Barbiturates
4	21	21	O	,
5	23	24	O	or
6	26	34	O	Narcotics
7	37	48	O	potentiation
8	50	51	O	of
9	53	63	O	orthostatic
10	65	75	O	hypotension
11	77	79	O	may
12	81	85	O	occur
NULL

DIURIL	401	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	15
Antidiabetic Drugs (Oral Agents and Insulin)- dosage adjustment of the antidiabetic drug may be required.
1	0	11	O	Antidiabetic
2	13	17	O	Drugs
3	20	23	O	Oral
4	25	30	O	Agents
5	32	34	O	and
6	36	42	O	Insulin
7	46	51	O	dosage
8	53	62	O	adjustment
9	64	65	O	of
10	67	69	O	the
11	71	82	O	antidiabetic
12	84	87	O	drug
13	89	91	O	may
14	93	94	O	be
15	96	103	O	required
NULL

DIURIL	402	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	24
Cholestyramine and Colestipol Resins- Both cholestyramine and colestipol resins have the potential of binding thiazide diuretics and reducing diuretic absorption from the gastrointestinal tract.
1	0	13	U-KIN	Cholestyramine
2	15	17	O	and
3	19	28	O	Colestipol
4	30	35	O	Resins
5	38	41	O	Both
6	43	56	O	cholestyramine
7	58	60	O	and
8	62	71	B-KIN	colestipol
9	73	78	L-KIN	resins
10	80	83	O	have
11	85	87	O	the
12	89	97	O	potential
13	99	100	O	of
14	102	108	O	binding
15	110	117	O	thiazide
16	119	127	O	GGGGGGGG
17	129	131	O	and
18	133	140	O	reducing
19	142	149	O	diuretic
20	151	160	O	absorption
21	162	165	O	from
22	167	169	O	the
23	171	186	O	gastrointestinal
24	188	192	O	tract
K/1:C54356 K/8:C54356

DIURIL	403	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	9
Corticosteroids, ACTH- intensified electrolyte depletion, particularly hypokalemia.
1	0	14	O	Corticosteroids
2	15	15	O	,
3	17	20	O	ACTH
4	23	33	O	intensified
5	35	45	O	electrolyte
6	47	55	O	depletion
7	56	56	O	,
8	58	69	O	particularly
9	71	81	O	hypokalemia
NULL

DIURIL	404	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	15
Diuretic agents reduce the renal clearance of lithium and add a high risk of lithium toxicity.
1	0	14	O	GGGGGGGG
2	16	21	O	reduce
3	23	25	O	the
4	27	31	O	renal
5	33	41	O	clearance
6	43	44	O	of
7	46	52	U-KIN	lithium
8	54	56	O	and
9	58	60	O	add
10	62	62	O	a
11	64	67	O	high
12	69	72	O	risk
13	74	75	O	of
14	77	83	O	lithium
15	85	92	O	toxicity
K/7:C54357

DIURIL	405	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	13
Drug Interactions When given concurrently the following drugs may interact with thiazide diuretics.
1	0	3	O	Drug
2	5	16	O	Interactions
3	18	21	O	When
4	23	27	O	given
5	29	40	O	concurrently
6	42	44	O	the
7	46	54	O	following
8	56	60	O	drugs
9	62	64	O	may
10	66	73	O	interact
11	75	78	O	with
12	80	87	O	thiazide
13	89	97	O	GGGGGGGG
NULL

DIURIL	406	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	66
In some patients with compromised renal function (e.g., elderly patients or patients who are volume-depleted, including those on diuretic therapy) who are being treated with non-steroidal anti-inflammatory drugs, including selective COX-2 inhibitors, the co-administration of angiotensin II receptor antagonists or ACE inhibitors may result in a further deterioration of renal function, including possible acute renal failure.
1	0	1	O	In
2	3	6	O	some
3	8	15	O	patients
4	17	20	O	with
5	22	32	O	compromised
6	34	38	O	renal
7	40	47	O	function
8	50	52	O	e.g
9	54	54	O	,
10	56	62	O	elderly
11	64	71	O	patients
12	73	74	O	or
13	76	83	O	patients
14	85	87	O	who
15	89	91	O	are
16	93	98	O	volume
17	100	107	O	depleted
18	108	108	O	,
19	110	118	O	including
20	120	124	O	those
21	126	127	O	on
22	129	136	O	diuretic
23	138	144	O	therapy
24	147	149	O	who
25	151	153	O	are
26	155	159	O	being
27	161	167	O	treated
28	169	172	O	with
29	174	176	O	non
30	178	186	O	steroidal
31	188	191	O	anti
32	193	204	O	inflammatory
33	206	210	O	drugs
34	211	211	O	,
35	213	221	O	including
36	223	231	O	selective
37	233	235	O	COX
38	237	237	O	2
39	239	248	O	inhibitors
40	249	249	O	,
41	251	253	O	the
42	255	256	O	co
43	258	271	O	administration
44	273	274	O	of
45	276	286	B-DYN	angiotensin
46	288	289	I-DYN	II
47	291	298	I-DYN	receptor
48	300	310	L-DYN	antagonists
49	312	313	O	or
50	315	317	B-DYN	ACE
51	319	328	L-DYN	inhibitors
52	330	332	O	may
53	334	339	O	result
54	341	342	O	in
55	344	344	O	a
56	346	352	O	further
57	354	366	B-EFF	deterioration
58	368	369	I-EFF	of
59	371	375	I-EFF	renal
60	377	384	L-EFF	function
61	385	385	O	,
62	387	395	O	including
63	397	404	O	possible
64	406	410	B-EFF	acute
65	412	416	I-EFF	renal
66	418	424	L-EFF	failure
D/45:57:1 D/45:64:1 D/50:57:1 D/50:64:1

DIURIL	407	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	8
Lithium - generally should not be given with diuretics.
1	0	6	U-UNK	Lithium
2	10	18	O	generally
3	20	25	B-TRI	should
4	27	29	I-TRI	not
5	31	32	I-TRI	be
6	34	38	L-TRI	given
7	40	43	O	with
8	45	53	O	GGGGGGGG
NULL

DIURIL	408	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	49
Non-steroidal Anti-inflammatory Drugs Including Selective Cyclooxygenase-2 (COX-2) Inhibitors- In some patients, the administration of a non-steroidal anti-inflammatory agent including a selective COX-2 inhibitor can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
1	0	2	O	Non
2	4	12	O	steroidal
3	14	17	O	Anti
4	19	30	O	inflammatory
5	32	36	O	Drugs
6	38	46	O	Including
7	48	56	O	Selective
8	58	71	O	Cyclooxygenase
9	73	73	O	2
10	76	78	O	COX
11	80	80	O	2
12	83	92	O	Inhibitors
13	95	96	O	In
14	98	101	O	some
15	103	110	O	patients
16	111	111	O	,
17	113	115	O	the
18	117	130	O	administration
19	132	133	O	of
20	135	135	O	a
21	137	139	B-DYN	non
22	141	149	I-DYN	steroidal
23	151	154	I-DYN	anti
24	156	167	I-DYN	inflammatory
25	169	173	L-DYN	agent
26	175	183	O	including
27	185	185	O	a
28	187	195	B-DYN	selective
29	197	199	I-DYN	COX
30	201	201	I-DYN	2
31	203	211	L-DYN	inhibitor
32	213	215	O	can
33	217	222	O	reduce
34	224	226	O	the
35	228	235	O	diuretic
36	236	236	O	,
37	238	248	O	natriuretic
38	249	249	O	,
39	251	253	O	and
40	255	270	O	antihypertensive
41	272	278	O	effects
42	280	281	O	of
43	283	286	O	loop
44	287	287	O	,
45	289	297	O	potassium
46	299	305	O	sparing
47	307	309	O	and
48	311	318	O	thiazide
49	320	328	O	GGGGGGGG
NULL

DIURIL	409	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	6
Other Antihypertensive Drugs- additive effect or potentiation.
1	0	4	O	Other
2	6	27	O	GGGGGGGG
3	30	37	O	additive
4	39	44	O	effect
5	46	47	O	or
6	49	60	O	potentiation
NULL

DIURIL	410	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	18
Pressor Amines (e.g., Norepinephrine)- possible decreased response to pressor amines but not sufficient to preclude their use.
1	0	6	B-UNK	Pressor
2	8	13	L-UNK	Amines
3	16	18	O	e.g
4	20	20	O	,
5	22	35	U-UNK	Norepinephrine
6	39	46	O	possible
7	48	56	B-TRI	decreased
8	58	65	L-TRI	response
9	67	68	O	to
10	70	76	O	pressor
11	78	83	O	amines
12	85	87	O	but
13	89	91	O	not
14	93	102	O	sufficient
15	104	105	O	to
16	107	114	O	preclude
17	116	120	O	their
18	122	124	O	use
NULL

DIURIL	411	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	15
Refer to the package insert for lithium preparations before use of such preparations with DIURIL.
1	0	4	O	Refer
2	6	7	O	to
3	9	11	O	the
4	13	19	O	package
5	21	26	O	insert
6	28	30	O	for
7	32	38	O	lithium
8	40	51	O	preparations
9	53	58	O	before
10	60	62	O	use
11	64	65	O	of
12	67	70	O	such
13	72	83	O	preparations
14	85	88	O	with
15	90	95	O	XXXXXXXX
NULL

DIURIL	412	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	15
Skeletal Muscle Relaxants, Nondepolarizing (e.g., Tubocurarine)- possible increased responsiveness to the muscle relaxant.
1	0	7	O	Skeletal
2	9	14	O	Muscle
3	16	24	O	Relaxants
4	25	25	O	,
5	27	41	O	Nondepolarizing
6	44	46	O	e.g
7	48	48	O	,
8	50	61	U-DYN	Tubocurarine
9	65	72	O	possible
10	74	82	B-EFF	increased
11	84	97	I-EFF	responsiveness
12	99	100	I-EFF	to
13	102	104	I-EFF	the
14	106	111	I-EFF	muscle
15	113	120	L-EFF	relaxant
D/8:10:1

DIURIL	413	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	14
Therefore, the combination should be administered with caution, especially in the elderly.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	25	O	combination
5	27	32	O	should
6	34	35	O	be
7	37	48	O	administered
8	50	53	O	with
9	55	61	O	caution
10	62	62	O	,
11	64	73	O	especially
12	75	76	O	in
13	78	80	O	the
14	82	88	O	elderly
NULL

DIURIL	414	34073-7	bd936e35-1af8-42da-bcc0-f22489d68574	24
These interactions should be considered in patients taking NSAIDs including selective COX-2 inhibitors concomitantly with diuretics and angiotensin II antagonists or ACE inhibitors.
1	0	4	O	These
2	6	17	B-TRI	interactions
3	19	24	I-TRI	should
4	26	27	I-TRI	be
5	29	38	L-TRI	considered
6	40	41	O	in
7	43	50	O	patients
8	52	57	O	taking
9	59	64	U-UNK	NSAIDs
10	66	74	O	including
11	76	84	B-UNK	selective
12	86	88	I-UNK	COX
13	90	90	I-UNK	2
14	92	101	L-UNK	inhibitors
15	103	115	O	concomitantly
16	117	120	O	with
17	122	130	O	GGGGGGGG
18	132	134	O	and
19	136	146	O	angiotensin
20	148	149	O	II
21	151	161	O	antagonists
22	163	164	O	or
23	166	168	O	ACE
24	170	179	O	inhibitors
NULL

DIURIL	415	42232-9	bd936e35-1af8-42da-bcc0-f22489d68574	29
It is not known whether chlorothiazide can cause fetal harm when administered to a pregnant woman , however , thiazides cross the placental barrier and appear in cord blood .
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	22	O	whether
6	24	37	O	XXXXXXXX
7	39	41	O	can
8	43	47	O	cause
9	49	53	O	fetal
10	55	58	O	harm
11	60	63	O	when
12	65	76	O	administered
13	78	79	O	to
14	81	81	O	a
15	83	90	O	pregnant
16	92	96	O	woman
17	98	98	O	,
18	100	106	O	however
19	108	108	O	,
20	110	118	O	GGGGGGGG
21	120	124	O	cross
22	126	128	O	the
23	130	138	O	placental
24	140	146	O	barrier
25	148	150	O	and
26	152	157	O	appear
27	159	160	O	in
28	162	165	O	cord
29	167	171	O	blood
NULL

DIURIL	416	42232-9	bd936e35-1af8-42da-bcc0-f22489d68574	36
Therefore , when DIURIL and non-steroidal anti-inflammatory agents or selective COX-2 inhibitors are used concomitantly , the patient should be observed closely to determine if the desired effect of the diuretic is obtained .
1	0	8	O	Therefore
2	10	10	O	,
3	12	15	O	when
4	17	22	O	XXXXXXXX
5	24	26	O	and
6	28	30	O	non
7	32	40	O	steroidal
8	42	45	O	anti
9	47	58	O	inflammatory
10	60	65	O	agents
11	67	68	O	or
12	70	78	O	selective
13	80	82	O	COX
14	84	84	O	2
15	86	95	O	inhibitors
16	97	99	O	are
17	101	104	O	used
18	106	118	O	concomitantly
19	120	120	O	,
20	122	124	O	the
21	126	132	O	patient
22	134	139	O	should
23	141	142	O	be
24	144	151	O	observed
25	153	159	O	closely
26	161	162	O	to
27	164	172	O	determine
28	174	175	O	if
29	177	179	O	the
30	181	187	O	desired
31	189	194	O	effect
32	196	197	O	of
33	199	201	O	the
34	203	210	O	diuretic
35	212	213	O	is
36	215	222	O	obtained
NULL

Demser	93	34068-7	32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92	21
If patients are not adequately controlled by the use of DEMSER , an alpha-adrenergic blocking agent ( phenoxybenzamine ) should be added .
1	0	1	O	If
2	3	10	O	patients
3	12	14	O	are
4	16	18	O	not
5	20	29	O	adequately
6	31	40	O	controlled
7	42	43	O	by
8	45	47	O	the
9	49	51	O	use
10	53	54	O	of
11	56	61	O	XXXXXXXX
12	63	63	O	,
13	65	66	O	an
14	68	72	O	alpha
15	74	83	O	adrenergic
16	85	92	O	blocking
17	94	98	O	agent
18	102	117	O	phenoxybenzamine
19	121	126	O	should
20	128	129	O	be
21	131	135	O	added
NULL

Demser	94	34068-7	32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92	28
Optimally effective dosages of DEMSER usually are between 2.0 and 3.0 g/day , and the dose should be titrated by monitoring clinical symptoms and catecholamine excretion .
1	0	8	O	Optimally
2	10	18	O	effective
3	20	26	O	dosages
4	28	29	O	of
5	31	36	O	XXXXXXXX
6	38	44	O	usually
7	46	48	O	are
8	50	56	O	between
9	58	60	O	2.0
10	62	64	O	and
11	66	68	O	3.0
12	70	70	O	g
13	71	71	O	/
14	72	74	O	day
15	76	76	O	,
16	78	80	O	and
17	82	84	O	the
18	86	89	O	dose
19	91	96	O	should
20	98	99	O	be
21	101	108	O	titrated
22	110	111	O	by
23	113	122	O	monitoring
24	124	131	O	clinical
25	133	140	O	symptoms
26	142	144	O	and
27	146	158	O	catecholamine
28	160	168	O	excretion
NULL

Demser	95	34071-1	32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92	22
DEMSER may add to the sedative effects of alcohol and other CNS depressants , e.g. , hypnotics , sedatives , and tranquilizers .
1	0	5	O	XXXXXXXX
2	7	9	O	may
3	11	13	O	add
4	15	16	O	to
5	18	20	O	the
6	22	29	B-EFF	sedative
7	31	37	L-EFF	effects
8	39	40	O	of
9	42	48	U-DYN	alcohol
10	50	52	O	and
11	54	58	O	other
12	60	62	B-DYN	CNS
13	64	74	L-DYN	depressants
14	76	76	O	,
15	78	80	O	e.g
16	83	83	O	,
17	85	93	U-DYN	hypnotics
18	95	95	O	,
19	97	105	U-DYN	sedatives
20	107	107	O	,
21	109	111	O	and
22	113	125	U-DYN	tranquilizers
D/12:6:1 D/17:6:1 D/19:6:1 D/22:6:1 D/9:6:1

Demser	96	34071-1	32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92	46
When DEMSER is used preoperatively , alone or especially in combination with alpha-adrenergic blocking drugs , adequate intravascular volume must be maintained intraoperatively ( especially after tumor removal ) and postoperatively to avoid hypotension and decreased perfusion of vital organs resulting from vasodilatation and expanded volume capacity .
1	0	3	O	When
2	5	10	O	XXXXXXXX
3	12	13	O	is
4	15	18	O	used
5	20	33	O	preoperatively
6	35	35	O	,
7	37	41	O	alone
8	43	44	O	or
9	46	55	O	especially
10	57	58	O	in
11	60	70	O	combination
12	72	75	O	with
13	77	81	B-DYN	alpha
14	83	92	I-DYN	adrenergic
15	94	101	I-DYN	blocking
16	103	107	L-DYN	drugs
17	109	109	O	,
18	111	118	O	adequate
19	120	132	O	intravascular
20	134	139	O	volume
21	141	144	O	must
22	146	147	O	be
23	149	158	O	maintained
24	160	175	O	intraoperatively
25	179	188	O	especially
26	190	194	O	after
27	196	200	O	tumor
28	202	208	O	removal
29	212	214	O	and
30	216	230	O	postoperatively
31	232	233	O	to
32	235	239	O	avoid
33	241	251	U-EFF	hypotension
34	253	255	O	and
35	257	265	B-EFF	decreased
36	267	275	I-EFF	perfusion
37	277	278	I-EFF	of
38	280	284	I-EFF	vital
39	286	291	L-EFF	organs
40	293	301	O	resulting
41	303	306	O	from
42	308	321	U-EFF	vasodilatation
43	323	325	O	and
44	327	334	B-EFF	expanded
45	336	341	I-EFF	volume
46	343	350	L-EFF	capacity
D/13:33:1 D/13:35:1 D/13:42:1 D/13:44:1

Demser	97	34071-1	32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92	50
While the preoperative use of DEMSER in patients with pheochromocytoma is thought to decrease intraoperative problems with blood pressure control , DEMSER does not eliminate the danger of hypertensive crises or arrhythmias during manipulation of the tumor , and the alpha-adrenergic blocking drug , phentolamine , may be needed .
1	0	4	O	While
2	6	8	O	the
3	10	21	O	preoperative
4	23	25	O	use
5	27	28	O	of
6	30	35	O	XXXXXXXX
7	37	38	O	in
8	40	47	O	patients
9	49	52	O	with
10	54	69	O	pheochromocytoma
11	71	72	O	is
12	74	80	O	thought
13	82	83	O	to
14	85	92	O	decrease
15	94	107	O	intraoperative
16	109	116	O	problems
17	118	121	O	with
18	123	127	O	blood
19	129	136	O	pressure
20	138	144	O	control
21	146	146	O	,
22	148	153	O	XXXXXXXX
23	155	158	O	does
24	160	162	O	not
25	164	172	O	eliminate
26	174	176	O	the
27	178	183	O	danger
28	185	186	O	of
29	188	199	O	hypertensive
30	201	206	O	crises
31	208	209	O	or
32	211	221	O	arrhythmias
33	223	228	O	during
34	230	241	O	manipulation
35	243	244	O	of
36	246	248	O	the
37	250	254	O	tumor
38	256	256	O	,
39	258	260	O	and
40	262	264	O	the
41	266	270	O	alpha
42	272	281	O	adrenergic
43	283	290	O	blocking
44	292	295	O	drug
45	297	297	O	,
46	299	310	O	phentolamine
47	312	312	O	,
48	314	316	O	may
49	318	319	O	be
50	321	326	O	needed
NULL

Demser	98	34073-7	32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92	8
(See WARNINGS and PRECAUTIONS, Information for Patients .)
1	1	3	O	See
2	5	12	O	WARNINGS
3	14	16	O	and
4	18	28	O	PRECAUTIONS
5	29	29	O	,
6	31	41	O	Information
7	43	45	O	for
8	47	54	O	Patients
NULL

Demser	99	42232-9	32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92	31
Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis .
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	25	O	observed
5	27	28	O	in
6	30	42	O	administering
7	44	49	O	XXXXXXXX
8	51	52	O	to
9	54	61	O	patients
10	63	71	O	receiving
11	73	86	U-DYN	phenothiazines
12	88	89	O	or
13	91	101	U-DYN	haloperidol
14	103	109	O	because
15	111	113	O	the
16	115	128	B-EFF	extrapyramidal
17	130	136	L-EFF	effects
18	138	139	O	of
19	141	145	O	these
20	147	151	O	drugs
21	153	155	O	can
22	157	158	O	be
23	160	167	O	expected
24	169	170	O	to
25	172	173	O	be
26	175	185	O	potentiated
27	187	188	O	by
28	190	199	O	inhibition
29	201	202	O	of
30	204	216	O	catecholamine
31	218	226	O	synthesis
D/11:16:1 D/13:16:1

Demser	100	42232-9	32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92	15
Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects .
1	0	9	O	Concurrent
2	11	13	O	use
3	15	16	O	of
4	18	23	O	XXXXXXXX
5	25	28	O	with
6	30	36	U-DYN	alcohol
7	38	39	O	or
8	41	45	O	other
9	47	49	B-DYN	CNS
10	51	61	L-DYN	depressants
11	63	65	O	can
12	67	74	O	increase
13	76	80	O	their
14	82	89	B-EFF	sedative
15	91	97	L-EFF	effects
D/6:14:1 D/9:14:1

Demser	101	42232-9	32fb2f2f-34b5-4cd5-9145-c3ab37c5ca92	21
DEMSER may have additive sedative effects with alcohol and other CNS depressants , e.g. , hypnotics , sedatives , and tranquilizers .
1	0	5	O	XXXXXXXX
2	7	9	O	may
3	11	14	O	have
4	16	23	O	additive
5	25	32	B-EFF	sedative
6	34	40	L-EFF	effects
7	42	45	O	with
8	47	53	U-DYN	alcohol
9	55	57	O	and
10	59	63	O	other
11	65	67	B-DYN	CNS
12	69	79	L-DYN	depressants
13	81	81	O	,
14	83	85	O	e.g
15	88	88	O	,
16	90	98	U-DYN	hypnotics
17	100	100	O	,
18	102	110	U-DYN	sedatives
19	112	112	O	,
20	114	116	O	and
21	118	130	U-DYN	tranquilizers
D/11:5:1 D/16:5:1 D/18:5:1 D/21:5:1 D/8:5:1

Diovan	245	34068-7	5ddba454-f3e6-43c2-a7a6-58365d297213	7
Diovan may be administered with other antihypertensive agents .
1	0	5	O	XXXXXXXX
2	7	9	O	may
3	11	12	O	be
4	14	25	O	administered
5	27	30	O	with
6	32	36	O	other
7	38	60	O	GGGGGGGG
NULL

Diovan	246	34068-7	5ddba454-f3e6-43c2-a7a6-58365d297213	22
Diovan may be given with other standard post-myocardial infarction treatment , including thrombolytics , aspirin , beta-blockers , and statins .
1	0	5	O	XXXXXXXX
2	7	9	O	may
3	11	12	O	be
4	14	18	O	given
5	20	23	O	with
6	25	29	O	other
7	31	38	O	standard
8	40	43	O	post
9	45	54	O	myocardial
10	56	65	O	infarction
11	67	75	O	treatment
12	77	77	O	,
13	79	87	O	including
14	89	101	O	thrombolytics
15	103	103	O	,
16	105	111	O	aspirin
17	113	113	O	,
18	115	118	O	beta
19	120	127	O	blockers
20	129	129	O	,
21	131	133	O	and
22	135	141	O	statins
NULL

Diovan	247	34070-3	5ddba454-f3e6-43c2-a7a6-58365d297213	14
Do not coadminister aliskiren with Diovan in patients with diabetes see Drug Interactions ( 7 ) .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	18	L-TRI	coadminister
4	20	28	U-UNK	aliskiren
5	30	33	O	with
6	35	40	O	XXXXXXXX
7	42	43	O	in
8	45	52	O	patients
9	54	57	O	with
10	59	66	O	diabetes
11	68	70	O	see
12	72	75	O	Drug
13	77	88	O	Interactions
14	92	92	O	7
NULL

Diovan	248	34070-3	5ddba454-f3e6-43c2-a7a6-58365d297213	17
Known hypersensitivity to any component , Do not coadminister aliskiren with Diovan in patients with diabetes ( 4 ) .
1	0	4	O	Known
2	6	21	O	hypersensitivity
3	23	24	O	to
4	26	28	O	any
5	30	38	O	component
6	40	40	O	,
7	42	43	B-TRI	Do
8	45	47	I-TRI	not
9	49	60	L-TRI	coadminister
10	62	70	U-UNK	aliskiren
11	72	75	O	with
12	77	82	O	XXXXXXXX
13	84	85	O	in
14	87	94	O	patients
15	96	99	O	with
16	101	108	O	diabetes
17	112	112	O	4
NULL

Diovan	249	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	16
Avoid use of aliskiren with Diovan in patients with renal impairment ( GFR 60 mL/min ) .
1	0	4	O	Avoid
2	6	8	O	use
3	10	11	O	of
4	13	21	O	aliskiren
5	23	26	O	with
6	28	33	O	XXXXXXXX
7	35	36	O	in
8	38	45	O	patients
9	47	50	O	with
10	52	56	O	renal
11	58	67	O	impairment
12	71	73	O	GFR
13	75	76	O	60
14	78	79	O	mL
15	80	80	O	/
16	81	83	O	min
NULL

Diovan	250	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	31
Blood Urea Nitrogen (BUN): In heart failure trials, greater than 50% increases in BUN were observed in 16.6% of Diovan-treated patients compared to 6.3% of placebo-treated patients.
1	0	4	O	Blood
2	6	9	O	Urea
3	11	18	O	Nitrogen
4	21	23	O	BUN
5	25	25	O	:
6	27	28	O	In
7	30	34	O	heart
8	36	42	O	failure
9	44	49	O	trials
10	50	50	O	,
11	52	58	O	greater
12	60	63	O	than
13	65	67	O	50%
14	69	77	O	increases
15	79	80	O	in
16	82	84	O	BUN
17	86	89	O	were
18	91	98	O	observed
19	100	101	O	in
20	103	107	O	16.6%
21	109	110	O	of
22	112	117	O	XXXXXXXX
23	119	125	O	treated
24	127	134	O	patients
25	136	143	O	compared
26	145	146	O	to
27	148	151	O	6.3%
28	153	154	O	of
29	156	162	O	placebo
30	164	170	O	treated
31	172	179	O	patients
NULL

Diovan	251	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	20
Closely monitor blood pressure , renal function and electrolytes in patients on Diovan and other agents that affect the RAS .
1	0	6	O	Closely
2	8	14	U-TRI	monitor
3	16	20	O	blood
4	22	29	O	pressure
5	31	31	O	,
6	33	37	O	renal
7	39	46	O	function
8	48	50	O	and
9	52	63	O	electrolytes
10	65	66	O	in
11	68	75	O	patients
12	77	78	O	on
13	80	85	O	XXXXXXXX
14	87	89	O	and
15	91	95	O	other
16	97	102	B-UNK	agents
17	104	107	I-UNK	that
18	109	114	I-UNK	affect
19	116	118	I-UNK	the
20	120	122	L-UNK	RAS
NULL

Diovan	252	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	21
Coadministration of inhibitors of the uptake transporter ( rifampin , cyclosporine ) or efflux transporter ( ritonavir ) may increase the systemic exposure to valsartan .
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	B-KIN	inhibitors
4	31	32	I-KIN	of
5	34	36	I-KIN	the
6	38	43	I-KIN	uptake
7	45	55	L-KIN	transporter
8	59	66	U-KIN	rifampin
9	68	68	O	,
10	70	81	U-KIN	cyclosporine
11	85	86	O	or
12	88	93	O	efflux
13	95	105	O	transporter
14	109	117	U-KIN	ritonavir
15	121	123	O	may
16	125	132	O	increase
17	134	136	O	the
18	138	145	O	systemic
19	147	154	O	exposure
20	156	157	O	to
21	159	167	O	XXXXXXXX
K/10:C54355 K/14:C54355 K/3:C54355 K/8:C54355

Diovan	253	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	22
Coadministration of valsartan and warfarin did not change the pharmacokinetics of valsartan or the time-course of the anticoagulant properties of warfarin .
1	0	15	O	Coadministration
2	17	18	O	of
3	20	28	O	XXXXXXXX
4	30	32	O	and
5	34	41	O	warfarin
6	43	45	O	did
7	47	49	O	not
8	51	56	O	change
9	58	60	O	the
10	62	77	O	pharmacokinetics
11	79	80	O	of
12	82	90	O	XXXXXXXX
13	92	93	O	or
14	95	97	O	the
15	99	102	O	time
16	104	109	O	course
17	111	112	O	of
18	114	116	O	the
19	118	130	O	anticoagulant
20	132	141	O	properties
21	143	144	O	of
22	146	153	O	warfarin
NULL

Diovan	254	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	24
Creatinine: Minor elevations in creatinine occurred in 0.8% of patients taking Diovan and 0.6% given placebo in controlled clinical trials of hypertensive patients.
1	0	9	O	Creatinine
2	10	10	O	:
3	12	16	O	Minor
4	18	27	O	elevations
5	29	30	O	in
6	32	41	O	creatinine
7	43	50	O	occurred
8	52	53	O	in
9	55	58	O	0.8%
10	60	61	O	of
11	63	70	O	patients
12	72	77	O	taking
13	79	84	O	XXXXXXXX
14	86	88	O	and
15	90	93	O	0.6%
16	95	99	O	given
17	101	107	O	placebo
18	109	110	O	in
19	112	121	O	controlled
20	123	130	O	clinical
21	132	137	O	trials
22	139	140	O	of
23	142	153	O	hypertensive
24	155	162	O	patients
NULL

Diovan	255	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	33
CYP 450 Interactions: In vitro metabolism studies indicate that CYP 450 mediated drug interactions between valsartan and coadministered drugs are unlikely because of the low extent of metabolism [see Clinical Pharmacology (12.3)].
1	0	2	O	CYP
2	4	6	O	450
3	8	19	O	Interactions
4	20	20	O	:
5	22	23	O	In
6	25	29	O	vitro
7	31	40	O	metabolism
8	42	48	O	studies
9	50	57	O	indicate
10	59	62	O	that
11	64	66	O	CYP
12	68	70	O	450
13	72	79	O	mediated
14	81	84	O	drug
15	86	97	O	interactions
16	99	105	O	between
17	107	115	O	XXXXXXXX
18	117	119	O	and
19	121	134	O	coadministered
20	136	140	O	drugs
21	142	144	O	are
22	146	153	O	unlikely
23	155	161	O	because
24	163	164	O	of
25	166	168	O	the
26	170	172	O	low
27	174	179	O	extent
28	181	182	O	of
29	184	193	O	metabolism
30	196	198	O	see
31	200	207	O	Clinical
32	209	220	O	Pharmacology
33	223	226	O	12.3
NULL

Diovan	256	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	10
Do not coadminister aliskiren with Diovan in patients with diabetes .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	18	L-TRI	coadminister
4	20	28	U-UNK	aliskiren
5	30	33	O	with
6	35	40	O	XXXXXXXX
7	42	43	O	in
8	45	52	O	patients
9	54	57	O	with
10	59	66	O	diabetes
NULL

Diovan	257	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	46
Dual Blockade of the Renin-Angiotensin System (RAS): Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
1	0	3	O	Dual
2	5	12	O	Blockade
3	14	15	O	of
4	17	19	O	the
5	21	25	O	Renin
6	27	37	O	Angiotensin
7	39	44	O	System
8	47	49	O	RAS
9	51	51	O	:
10	53	56	O	Dual
11	58	65	O	blockade
12	67	68	O	of
13	70	72	O	the
14	74	76	O	RAS
15	78	81	O	with
16	83	93	B-DYN	angiotensin
17	95	102	I-DYN	receptor
18	104	111	L-DYN	blockers
19	112	112	O	,
20	114	116	B-DYN	ACE
21	118	127	L-DYN	inhibitors
22	128	128	O	,
23	130	131	O	or
24	133	141	U-DYN	aliskiren
25	143	144	O	is
26	146	155	O	associated
27	157	160	O	with
28	162	170	O	increased
29	172	176	O	risks
30	178	179	O	of
31	181	191	U-EFF	hypotension
32	192	192	O	,
33	194	205	U-EFF	hyperkalemia
34	206	206	O	,
35	208	210	O	and
36	212	218	B-EFF	changes
37	220	221	I-EFF	in
38	223	227	I-EFF	renal
39	229	236	L-EFF	function
40	239	247	O	including
41	249	253	O	acute
42	255	259	O	renal
43	261	267	O	failure
44	270	277	O	compared
45	279	280	O	to
46	282	292	O	monotherapy
D/16:31:1 D/16:33:1 D/16:36:1 D/20:31:1 D/20:33:1 D/20:36:1 D/24:31:1 D/24:33:1 D/24:36:1

Diovan	258	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	34
Hemoglobin and Hematocrit: Greater than 20% decreases in hemoglobin and hematocrit were observed in 0.4% and 0.8%, respectively, of Diovan patients, compared with 0.1% and 0.1% in placebo-treated patients.
1	0	9	O	Hemoglobin
2	11	13	O	and
3	15	24	O	Hematocrit
4	25	25	O	:
5	27	33	O	Greater
6	35	38	O	than
7	40	42	O	20%
8	44	52	O	decreases
9	54	55	O	in
10	57	66	O	hemoglobin
11	68	70	O	and
12	72	81	O	hematocrit
13	83	86	O	were
14	88	95	O	observed
15	97	98	O	in
16	100	103	O	0.4%
17	105	107	O	and
18	109	112	O	0.8%
19	113	113	O	,
20	115	126	O	respectively
21	127	127	O	,
22	129	130	O	of
23	132	137	O	XXXXXXXX
24	139	146	O	patients
25	147	147	O	,
26	149	156	O	compared
27	158	161	O	with
28	163	166	O	0.1%
29	168	170	O	and
30	172	175	O	0.1%
31	177	178	O	in
32	180	186	O	placebo
33	188	194	O	treated
34	196	203	O	patients
NULL

Diovan	259	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	13
If co-medication is considered necessary, monitoring of serum potassium is advisable.
1	0	1	O	If
2	3	4	O	co
3	6	15	O	medication
4	17	18	O	is
5	20	29	O	considered
6	31	39	O	necessary
7	40	40	O	,
8	42	51	O	monitoring
9	53	54	O	of
10	56	60	O	serum
11	62	70	O	potassium
12	72	73	O	is
13	75	83	O	advisable
NULL

Diovan	260	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	9
In general, avoid combined use of RAS inhibitors.
1	0	1	O	In
2	3	9	O	general
3	10	10	O	,
4	12	16	O	avoid
5	18	25	O	combined
6	27	29	O	use
7	31	32	O	of
8	34	36	B-UNK	RAS
9	38	47	L-UNK	inhibitors
NULL

Diovan	261	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	27
In heart failure patients, greater than 20% increases in serum potassium were observed in 10.0% of Diovan-treated patients compared to 5.1% of placebo-treated patients.
1	0	1	O	In
2	3	7	O	heart
3	9	15	O	failure
4	17	24	O	patients
5	25	25	O	,
6	27	33	O	greater
7	35	38	O	than
8	40	42	O	20%
9	44	52	O	increases
10	54	55	O	in
11	57	61	O	serum
12	63	71	O	potassium
13	73	76	O	were
14	78	85	O	observed
15	87	88	O	in
16	90	94	O	10.0%
17	96	97	O	of
18	99	104	O	XXXXXXXX
19	106	112	O	treated
20	114	121	O	patients
21	123	130	O	compared
22	132	133	O	to
23	135	138	O	5.1%
24	140	141	O	of
25	143	149	O	placebo
26	151	157	O	treated
27	159	166	O	patients
NULL

Diovan	262	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	26
In heart failure trials, greater than 50% increases in creatinine were observed in 3.9% of Diovan-treated patients compared to 0.9% of placebo-treated patients.
1	0	1	O	In
2	3	7	O	heart
3	9	15	O	failure
4	17	22	O	trials
5	23	23	O	,
6	25	31	O	greater
7	33	36	O	than
8	38	40	O	50%
9	42	50	O	increases
10	52	53	O	in
11	55	64	O	creatinine
12	66	69	O	were
13	71	78	O	observed
14	80	81	O	in
15	83	86	O	3.9%
16	88	89	O	of
17	91	96	O	XXXXXXXX
18	98	104	O	treated
19	106	113	O	patients
20	115	122	O	compared
21	124	125	O	to
22	127	130	O	0.9%
23	132	133	O	of
24	135	141	O	placebo
25	143	149	O	treated
26	151	158	O	patients
NULL

Diovan	263	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	26
In post-myocardial infarction patients , doubling of serum creatinine was observed in 4.2 % of valsartan-treated patients and 3.4 % of captopril-treated patients .
1	0	1	O	In
2	3	6	O	post
3	8	17	O	myocardial
4	19	28	O	infarction
5	30	37	O	patients
6	39	39	O	,
7	41	48	O	doubling
8	50	51	O	of
9	53	57	O	serum
10	59	68	O	creatinine
11	70	72	O	was
12	74	81	O	observed
13	83	84	O	in
14	86	88	O	4.2
15	90	90	O	%
16	92	93	O	of
17	95	103	O	XXXXXXXX
18	105	111	O	treated
19	113	120	O	patients
20	122	124	O	and
21	126	128	O	3.4
22	130	130	O	%
23	132	133	O	of
24	135	143	O	captopril
25	145	151	O	treated
26	153	160	O	patients
NULL

Diovan	264	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	26
Lithium : Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists , including Diovan .
1	0	6	O	Lithium
2	8	8	O	:
3	10	18	O	Increases
4	20	21	O	in
5	23	27	O	serum
6	29	35	U-KIN	lithium
7	37	50	O	concentrations
8	52	54	O	and
9	56	62	O	lithium
10	64	71	O	toxicity
11	73	76	O	have
12	78	81	O	been
13	83	90	O	reported
14	92	97	O	during
15	99	109	O	concomitant
16	111	124	O	administration
17	126	127	O	of
18	129	135	O	lithium
19	137	140	O	with
20	142	152	O	angiotensin
21	154	155	O	II
22	157	164	O	receptor
23	166	176	O	antagonists
24	178	178	O	,
25	180	188	O	including
26	190	195	O	XXXXXXXX
K/6:C54357

Diovan	265	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	17
Liver Function Tests: Occasional elevations (greater than 150%) of liver chemistries occurred in Diovan-treated patients.
1	0	4	O	Liver
2	6	13	O	Function
3	15	19	O	Tests
4	20	20	O	:
5	22	31	O	Occasional
6	33	42	O	elevations
7	45	51	O	greater
8	53	56	O	than
9	58	61	O	150%
10	64	65	O	of
11	67	71	O	liver
12	73	83	O	chemistries
13	85	92	O	occurred
14	94	95	O	in
15	97	102	O	XXXXXXXX
16	104	110	O	treated
17	112	119	O	patients
NULL

Diovan	266	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	11
Monitor renal function periodically in patients receiving valsartan and NSAID therapy .
1	0	6	U-TRI	Monitor
2	8	12	O	renal
3	14	21	O	function
4	23	34	O	periodically
5	36	37	O	in
6	39	46	O	patients
7	48	56	O	receiving
8	58	66	O	XXXXXXXX
9	68	70	O	and
10	72	76	U-UNK	NSAID
11	78	84	O	therapy
NULL

Diovan	267	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	7
Monitor serum lithium levels during concomitant use.
1	0	6	O	Monitor
2	8	12	O	serum
3	14	20	O	lithium
4	22	27	O	levels
5	29	34	O	during
6	36	46	O	concomitant
7	48	50	O	use
NULL

Diovan	268	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	22
Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy [see Clinical Studies (14.3)].
1	0	3	O	Most
2	5	12	O	patients
3	14	22	O	receiving
4	24	26	O	the
5	28	38	O	combination
6	40	41	O	of
7	43	45	O	two
8	47	49	O	RAS
9	51	60	O	inhibitors
10	62	63	O	do
11	65	67	O	not
12	69	74	O	obtain
13	76	78	O	any
14	80	89	O	additional
15	91	97	O	benefit
16	99	106	O	compared
17	108	109	O	to
18	111	121	O	monotherapy
19	124	126	O	see
20	128	135	O	Clinical
21	137	143	O	Studies
22	146	149	O	14.3
NULL

Diovan	269	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	19
Neutropenia: Neutropenia was observed in 1.9% of patients treated with Diovan and 0.8% of patients treated with placebo.
1	0	10	O	Neutropenia
2	11	11	O	:
3	13	23	O	Neutropenia
4	25	27	O	was
5	29	36	O	observed
6	38	39	O	in
7	41	44	O	1.9%
8	46	47	O	of
9	49	56	O	patients
10	58	64	O	treated
11	66	69	O	with
12	71	76	O	XXXXXXXX
13	78	80	O	and
14	82	85	O	0.8%
15	87	88	O	of
16	90	97	O	patients
17	99	105	O	treated
18	107	110	O	with
19	112	118	O	placebo
NULL

Diovan	270	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	29
No clinically significant pharmacokinetic interactions were observed when Diovan ( valsartan ) was coadministered with amlodipine , atenolol , cimetidine , digoxin , furosemide , glyburide , hydrochlorothiazide , or indomethacin .
1	0	1	O	No
2	3	12	O	clinically
3	14	24	O	significant
4	26	40	O	pharmacokinetic
5	42	53	O	interactions
6	55	58	O	were
7	60	67	O	observed
8	69	72	O	when
9	74	79	O	XXXXXXXX
10	83	91	O	XXXXXXXX
11	95	97	O	was
12	99	112	O	coadministered
13	114	117	O	with
14	119	128	O	amlodipine
15	130	130	O	,
16	132	139	O	atenolol
17	141	141	O	,
18	143	152	O	cimetidine
19	154	154	O	,
20	156	162	O	digoxin
21	164	164	O	,
22	166	175	O	furosemide
23	177	177	O	,
24	179	187	O	glyburide
25	189	189	O	,
26	191	209	O	hydrochlorothiazide
27	211	211	O	,
28	213	214	O	or
29	216	227	O	indomethacin
NULL

Diovan	271	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	66
Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors ( COX-2 Inhibitors ) : In patients who are elderly , volume-depleted ( including those on diuretic therapy ) , or with compromised renal function , coadministration of NSAIDs , including selective COX-2 inhibitors , with angiotensin II receptor antagonists , including valsartan , may result in deterioration of renal function , including possible acute renal failure .
1	0	2	O	Non
2	4	12	O	Steroidal
3	14	17	O	Anti
4	19	30	O	Inflammatory
5	32	37	O	Agents
6	39	47	O	including
7	49	57	O	Selective
8	59	72	O	Cyclooxygenase
9	74	74	O	2
10	76	85	O	Inhibitors
11	89	91	O	COX
12	93	93	O	2
13	95	104	O	Inhibitors
14	108	108	O	:
15	110	111	O	In
16	113	120	O	patients
17	122	124	O	who
18	126	128	O	are
19	130	136	O	elderly
20	138	138	O	,
21	140	145	O	volume
22	147	154	O	depleted
23	158	166	O	including
24	168	172	O	those
25	174	175	O	on
26	177	184	O	diuretic
27	186	192	O	therapy
28	196	196	O	,
29	198	199	O	or
30	201	204	O	with
31	206	216	O	compromised
32	218	222	O	renal
33	224	231	O	function
34	233	233	O	,
35	235	250	O	coadministration
36	252	253	O	of
37	255	260	U-DYN	NSAIDs
38	262	262	O	,
39	264	272	O	including
40	274	282	O	selective
41	284	286	B-DYN	COX
42	288	288	I-DYN	2
43	290	299	L-DYN	inhibitors
44	301	301	O	,
45	303	306	O	with
46	308	318	O	angiotensin
47	320	321	O	II
48	323	330	O	receptor
49	332	342	O	antagonists
50	344	344	O	,
51	346	354	O	including
52	356	364	O	XXXXXXXX
53	366	366	O	,
54	368	370	O	may
55	372	377	O	result
56	379	380	O	in
57	382	394	B-EFF	deterioration
58	396	397	I-EFF	of
59	399	403	I-EFF	renal
60	405	412	L-EFF	function
61	414	414	O	,
62	416	424	O	including
63	426	433	O	possible
64	435	439	B-EFF	acute
65	441	445	I-EFF	renal
66	447	453	L-EFF	failure
D/37:57:1 D/37:64:1 D/41:57:1 D/41:64:1

Diovan	272	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	8
One valsartan patient discontinued treatment for microcytic anemia.
1	0	2	O	One
2	4	12	O	XXXXXXXX
3	14	20	O	patient
4	22	33	O	discontinued
5	35	43	O	treatment
6	45	47	O	for
7	49	58	O	microcytic
8	60	65	O	anemia
NULL

Diovan	273	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	62
Potassium : Concomitant use of valsartan with other agents that block the renin-angiotensin system , potassium-sparing diuretics ( e.g. , spironolactone , triamterene , amiloride ) , potassium supplements , salt substitutes containing potassium or other drugs that may increase potassium levels ( e.g. , heparin ) may lead to increases in serum potassium and in heart failure patients to increases in serum creatinine .
1	0	8	O	Potassium
2	10	10	O	:
3	12	22	O	Concomitant
4	24	26	O	use
5	28	29	O	of
6	31	39	O	XXXXXXXX
7	41	44	O	with
8	46	50	O	other
9	52	57	B-DYN	agents
10	59	62	I-DYN	that
11	64	68	I-DYN	block
12	70	72	I-DYN	the
13	74	78	I-DYN	renin
14	80	90	I-DYN	angiotensin
15	92	97	L-DYN	system
16	99	99	O	,
17	101	109	B-DYN	potassium
18	111	117	I-DYN	sparing
19	119	127	L-DYN	diuretics
20	131	133	O	e.g
21	136	136	O	,
22	138	151	U-DYN	spironolactone
23	153	153	O	,
24	155	165	U-DYN	triamterene
25	167	167	O	,
26	169	177	U-DYN	amiloride
27	181	181	O	,
28	183	191	B-DYN	potassium
29	193	203	L-DYN	supplements
30	205	205	O	,
31	207	210	B-DYN	salt
32	212	222	I-DYN	substitutes
33	224	233	I-DYN	containing
34	235	243	L-DYN	potassium
35	245	246	O	or
36	248	252	O	other
37	254	258	B-DYN	drugs
38	260	263	I-DYN	that
39	265	267	I-DYN	may
40	269	276	I-DYN	increase
41	278	286	I-DYN	potassium
42	288	293	L-DYN	levels
43	297	299	O	e.g
44	302	302	O	,
45	304	310	U-DYN	heparin
46	314	316	O	may
47	318	321	O	lead
48	323	324	O	to
49	326	334	B-EFF	increases
50	336	337	I-EFF	in
51	339	343	I-EFF	serum
52	345	353	L-EFF	potassium
53	355	357	O	and
54	359	360	O	in
55	362	366	O	heart
56	368	374	O	failure
57	376	383	O	patients
58	385	386	O	to
59	388	396	B-EFF	increases
60	398	399	I-EFF	in
61	401	405	I-EFF	serum
62	407	416	L-EFF	creatinine
D/17:49:1 D/17:59:1 D/22:49:1 D/22:59:1 D/24:49:1 D/24:59:1 D/26:49:1 D/26:59:1 D/28:49:1 D/28:59:1 D/31:49:1 D/31:59:1 D/37:49:1 D/37:59:1 D/45:49:1 D/45:59:1 D/9:49:1 D/9:59:1

Diovan	274	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	93
Potassium-sparing diuretics, potassium supplements or salt substitutes may lead to increases in serum potassium, and in heart failure patients, increases in serum creatinine (7) NSAID use may lead to increased risk of renal impairment and loss of antihypertensive effect (7) Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7) Lithium: Increases in serum lithium concentrations and lithium toxicity (7) In controlled clinical trials, clinically important changes in standard laboratory parameters were rarely associated with administration of Diovan.
1	0	8	B-DYN	Potassium
2	10	16	I-DYN	sparing
3	18	26	L-DYN	diuretics
4	27	27	O	,
5	29	37	B-DYN	potassium
6	39	49	L-DYN	supplements
7	51	52	O	or
8	54	57	B-DYN	salt
9	59	69	L-DYN	substitutes
10	71	73	O	may
11	75	78	O	lead
12	80	81	O	to
13	83	91	B-EFF	increases
14	93	94	I-EFF	in
15	96	100	I-EFF	serum
16	102	110	L-EFF	potassium
17	111	111	O	,
18	113	115	O	and
19	117	118	O	in
20	120	124	O	heart
21	126	132	O	failure
22	134	141	O	patients
23	142	142	O	,
24	144	152	B-EFF	increases
25	154	155	I-EFF	in
26	157	161	I-EFF	serum
27	163	172	L-EFF	creatinine
28	175	175	O	7
29	178	182	U-DYN	NSAID
30	184	186	O	use
31	188	190	O	may
32	192	195	O	lead
33	197	198	O	to
34	200	208	O	increased
35	210	213	O	risk
36	215	216	O	of
37	218	222	B-EFF	renal
38	224	233	L-EFF	impairment
39	235	237	O	and
40	239	242	B-EFF	loss
41	244	245	I-EFF	of
42	247	262	I-EFF	antihypertensive
43	264	269	L-EFF	effect
44	272	272	O	7
45	275	278	O	Dual
46	280	289	O	inhibition
47	291	292	O	of
48	294	296	O	the
49	298	302	O	renin
50	304	314	O	angiotensin
51	316	321	O	system
52	322	322	O	:
53	324	332	O	Increased
54	334	337	O	risk
55	339	340	O	of
56	342	346	O	renal
57	348	357	O	impairment
58	358	358	O	,
59	360	370	O	hypotension
60	371	371	O	,
61	373	375	O	and
62	377	388	O	hyperkalemia
63	391	391	O	7
64	394	400	O	Lithium
65	401	401	O	:
66	403	411	O	Increases
67	413	414	O	in
68	416	420	O	serum
69	422	428	U-KIN	lithium
70	430	443	O	concentrations
71	445	447	O	and
72	449	455	O	lithium
73	457	464	O	toxicity
74	467	467	O	7
75	470	471	O	In
76	473	482	O	controlled
77	484	491	O	clinical
78	493	498	O	trials
79	499	499	O	,
80	501	510	O	clinically
81	512	520	O	important
82	522	528	O	changes
83	530	531	O	in
84	533	540	O	standard
85	542	551	O	laboratory
86	553	562	O	parameters
87	564	567	O	were
88	569	574	O	rarely
89	576	585	O	associated
90	587	590	O	with
91	592	605	O	administration
92	607	608	O	of
93	610	615	O	XXXXXXXX
D/1:13:1 D/1:24:1 D/1:37:0 D/1:40:0 D/29:13:0 D/29:24:0 D/29:37:1 D/29:40:1 D/5:13:1 D/5:24:1 D/5:37:0 D/5:40:0 D/8:13:1 D/8:24:1 D/8:37:0 D/8:40:0K/69:C54357

Diovan	275	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	29
Serum Potassium: In hypertensive patients, greater than 20% increases in serum potassium were observed in 4.4% of Diovan-treated patients compared to 2.9% of placebo-treated patients.
1	0	4	O	Serum
2	6	14	O	Potassium
3	15	15	O	:
4	17	18	O	In
5	20	31	O	hypertensive
6	33	40	O	patients
7	41	41	O	,
8	43	49	O	greater
9	51	54	O	than
10	56	58	O	20%
11	60	68	O	increases
12	70	71	O	in
13	73	77	O	serum
14	79	87	O	potassium
15	89	92	O	were
16	94	101	O	observed
17	103	104	O	in
18	106	109	O	4.4%
19	111	112	O	of
20	114	119	O	XXXXXXXX
21	121	127	O	treated
22	129	136	O	patients
23	138	145	O	compared
24	147	148	O	to
25	150	153	O	2.9%
26	155	156	O	of
27	158	164	O	placebo
28	166	172	O	treated
29	174	181	O	patients
NULL

Diovan	276	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	22
The antihypertensive effect of angiotensin II receptor antagonists , including valsartan , may be attenuated by NSAIDs including selective COX-2 inhibitors .
1	0	2	O	The
2	4	19	O	antihypertensive
3	21	26	O	effect
4	28	29	O	of
5	31	41	O	angiotensin
6	43	44	O	II
7	46	53	O	receptor
8	55	65	O	antagonists
9	67	67	O	,
10	69	77	O	including
11	79	87	O	XXXXXXXX
12	89	89	O	,
13	91	93	O	may
14	95	96	O	be
15	98	107	O	attenuated
16	109	110	O	by
17	112	117	U-DYN	NSAIDs
18	119	127	O	including
19	129	137	B-DYN	selective
20	139	141	I-DYN	COX
21	143	143	I-DYN	2
22	145	154	L-DYN	inhibitors
NULL

Diovan	277	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	23
The valsartan-atenolol combination was more antihypertensive than either component , but it did not lower the heart rate more than atenolol alone .
1	0	2	O	The
2	4	12	O	XXXXXXXX
3	14	21	O	atenolol
4	23	33	O	combination
5	35	37	O	was
6	39	42	O	more
7	44	59	O	antihypertensive
8	61	64	O	than
9	66	71	O	either
10	73	81	O	component
11	83	83	O	,
12	85	87	O	but
13	89	90	O	it
14	92	94	O	did
15	96	98	O	not
16	100	104	O	lower
17	106	108	O	the
18	110	114	O	heart
19	116	119	O	rate
20	121	124	O	more
21	126	129	O	than
22	131	138	O	atenolol
23	140	144	O	alone
NULL

Diovan	278	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	12
Three patients (<0.1%) treated with valsartan discontinued treatment for elevated liver chemistries.
1	0	4	O	Three
2	6	13	O	patients
3	16	20	O	<0.1%
4	23	29	O	treated
5	31	34	O	with
6	36	44	O	XXXXXXXX
7	46	57	O	discontinued
8	59	67	O	treatment
9	69	71	O	for
10	73	80	O	elevated
11	82	86	O	liver
12	88	98	O	chemistries
NULL

Diovan	279	34073-7	5ddba454-f3e6-43c2-a7a6-58365d297213	31
Transporters: The results from an in vitro study with human liver tissue indicate that valsartan is a substrate of the hepatic uptake transporter OATP1B1 and the hepatic efflux transporter MRP2.
1	0	11	O	Transporters
2	12	12	O	:
3	14	16	O	The
4	18	24	O	results
5	26	29	O	from
6	31	32	O	an
7	34	35	O	in
8	37	41	O	vitro
9	43	47	O	study
10	49	52	O	with
11	54	58	O	human
12	60	64	O	liver
13	66	71	O	tissue
14	73	80	O	indicate
15	82	85	O	that
16	87	95	O	XXXXXXXX
17	97	98	O	is
18	100	100	O	a
19	102	110	O	substrate
20	112	113	O	of
21	115	117	O	the
22	119	125	O	hepatic
23	127	132	O	uptake
24	134	144	O	transporter
25	146	152	O	OATP1B1
26	154	156	O	and
27	158	160	O	the
28	162	168	O	hepatic
29	170	175	O	efflux
30	177	187	O	transporter
31	189	192	O	MRP2
NULL

Diovan	280	43685-7	5ddba454-f3e6-43c2-a7a6-58365d297213	36
In the VALsartan In Acute myocardial iNfarcTion trial ( VALIANT ) , hypotension in post-myocardial infarction patients led to permanent discontinuation of therapy in 1.4 % of valsartan-treated patients and 0.8 % of captopril-treated patients .
1	0	1	O	In
2	3	5	O	the
3	7	15	O	XXXXXXXX
4	17	18	O	In
5	20	24	O	Acute
6	26	35	O	myocardial
7	37	46	O	iNfarcTion
8	48	52	O	trial
9	56	62	O	VALIANT
10	66	66	O	,
11	68	78	O	hypotension
12	80	81	O	in
13	83	86	O	post
14	88	97	O	myocardial
15	99	108	O	infarction
16	110	117	O	patients
17	119	121	O	led
18	123	124	O	to
19	126	134	O	permanent
20	136	150	O	discontinuation
21	152	153	O	of
22	155	161	O	therapy
23	163	164	O	in
24	166	168	O	1.4
25	170	170	O	%
26	172	173	O	of
27	175	183	O	XXXXXXXX
28	185	191	O	treated
29	193	200	O	patients
30	202	204	O	and
31	206	208	O	0.8
32	210	210	O	%
33	212	213	O	of
34	215	223	O	captopril
35	225	231	O	treated
36	233	240	O	patients
NULL

Dobutamine Hydrochloride in Dextrose	281	34068-7	6b17b98b-e06d-42ed-925f-69aa2699dead	19
Do not administer Dobutamine Hydrochloride in 5 %   Dextrose Injection simultaneously with solutions containing sodium bicarbonate or strong alkaline solutions .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	16	L-TRI	administer
4	18	41	O	XXXXXXXX
5	43	44	O	in
6	46	46	O	5
7	48	48	O	%
8	52	59	O	Dextrose
9	61	69	O	Injection
10	71	84	O	simultaneously
11	86	89	O	with
12	91	99	O	solutions
13	101	110	O	containing
14	112	117	B-UNK	sodium
15	119	129	L-UNK	bicarbonate
16	131	132	O	or
17	134	139	B-UNK	strong
18	141	148	I-UNK	alkaline
19	150	158	L-UNK	solutions
NULL

Dobutamine Hydrochloride in Dextrose	282	34068-7	6b17b98b-e06d-42ed-925f-69aa2699dead	21
Dobutamine Hydrochloride in 5 %   Dextrose Injection solutions may exhibit a pink color that , if present , will increase with time .
1	0	23	O	XXXXXXXX
2	25	26	O	in
3	28	28	O	5
4	30	30	O	%
5	34	41	O	Dextrose
6	43	51	O	Injection
7	53	61	O	solutions
8	63	65	O	may
9	67	73	O	exhibit
10	75	75	O	a
11	77	80	O	pink
12	82	86	O	color
13	88	91	O	that
14	93	93	O	,
15	95	96	O	if
16	98	104	O	present
17	106	106	O	,
18	108	111	O	will
19	113	120	O	increase
20	122	125	O	with
21	127	130	O	time
NULL

Dobutamine Hydrochloride in Dextrose	283	34071-1	6b17b98b-e06d-42ed-925f-69aa2699dead	35
Dobutamine Hydrochloride in 5 %   Dextrose Injection contains sodium bisulfite , a sulfite that may cause allergic-type reactions , including anaphylactic symptoms and life-threatening or less severe asthmatic episodes , in certain susceptible people .
1	0	23	O	XXXXXXXX
2	25	26	O	in
3	28	28	O	5
4	30	30	O	%
5	34	41	O	Dextrose
6	43	51	O	Injection
7	53	60	O	contains
8	62	67	O	sodium
9	69	77	O	bisulfite
10	79	79	O	,
11	81	81	O	a
12	83	89	O	sulfite
13	91	94	O	that
14	96	98	O	may
15	100	104	O	cause
16	106	113	O	allergic
17	115	118	O	type
18	120	128	O	reactions
19	130	130	O	,
20	132	140	O	including
21	142	153	O	anaphylactic
22	155	162	O	symptoms
23	164	166	O	and
24	168	171	O	life
25	173	183	O	threatening
26	185	186	O	or
27	188	191	O	less
28	193	198	O	severe
29	200	208	O	asthmatic
30	210	217	O	episodes
31	219	219	O	,
32	221	222	O	in
33	224	230	O	certain
34	232	242	O	susceptible
35	244	249	O	people
NULL

Dobutamine Hydrochloride in Dextrose	284	34071-1	6b17b98b-e06d-42ed-925f-69aa2699dead	26
In patients who have atrial fibrillation with rapid ventricular response , a digitalis preparation should be used prior to institution of therapy with Dobutamine in D5W .
1	0	1	O	In
2	3	10	O	patients
3	12	14	O	who
4	16	19	O	have
5	21	26	O	atrial
6	28	39	O	fibrillation
7	41	44	O	with
8	46	50	O	rapid
9	52	62	O	ventricular
10	64	71	O	response
11	73	73	O	,
12	75	75	O	a
13	77	85	O	digitalis
14	87	97	O	preparation
15	99	104	O	should
16	106	107	O	be
17	109	112	O	used
18	114	118	O	prior
19	120	121	O	to
20	123	133	O	institution
21	135	136	O	of
22	138	144	O	therapy
23	146	149	O	with
24	151	160	O	XXXXXXXX
25	162	163	O	in
26	165	167	O	D5W
NULL

Dobutamine Hydrochloride in Dextrose	285	42232-9	6b17b98b-e06d-42ed-925f-69aa2699dead	25
During the administration of Dobutamine Hydrochloride in 5 %   Dextrose Injection , as with any adrenergic agent , ECG and blood pressure should be continuously monitored .
1	0	5	O	During
2	7	9	O	the
3	11	24	O	administration
4	26	27	O	of
5	29	52	O	XXXXXXXX
6	54	55	O	in
7	57	57	O	5
8	59	59	O	%
9	63	70	O	Dextrose
10	72	80	O	Injection
11	82	82	O	,
12	84	85	O	as
13	87	90	O	with
14	92	94	O	any
15	96	105	O	adrenergic
16	107	111	O	agent
17	113	113	O	,
18	115	117	O	ECG
19	119	121	O	and
20	123	127	O	blood
21	129	136	O	pressure
22	138	143	O	should
23	145	146	O	be
24	148	159	O	continuously
25	161	169	O	monitored
NULL

Dobutamine Hydrochloride in Dextrose	286	42232-9	6b17b98b-e06d-42ed-925f-69aa2699dead	14
Hypovolemia should be corrected with suitable volume expanders before treatment with dobutamine is instituted .
1	0	10	O	Hypovolemia
2	12	17	O	should
3	19	20	O	be
4	22	30	O	corrected
5	32	35	O	with
6	37	44	O	suitable
7	46	51	O	volume
8	53	61	O	expanders
9	63	68	O	before
10	70	78	O	treatment
11	80	83	O	with
12	85	94	O	XXXXXXXX
13	96	97	O	is
14	99	108	O	instituted
NULL

Dobutamine Hydrochloride in Dextrose	287	42232-9	6b17b98b-e06d-42ed-925f-69aa2699dead	44
In premature neonates , however , dobutamine is less effective than dopamine in raising systemic blood pressure without causing undue tachycardia , and dobutamine has not been shown to provide any added benefit when given to such infants already receiving optimal infusions of dopamine .
1	0	1	O	In
2	3	11	O	premature
3	13	20	O	neonates
4	22	22	O	,
5	24	30	O	however
6	32	32	O	,
7	34	43	O	XXXXXXXX
8	45	46	O	is
9	48	51	O	less
10	53	61	O	effective
11	63	66	O	than
12	68	75	O	dopamine
13	77	78	O	in
14	80	86	O	raising
15	88	95	O	systemic
16	97	101	O	blood
17	103	110	O	pressure
18	112	118	O	without
19	120	126	O	causing
20	128	132	O	undue
21	134	144	O	tachycardia
22	146	146	O	,
23	148	150	O	and
24	152	161	O	XXXXXXXX
25	163	165	O	has
26	167	169	O	not
27	171	174	O	been
28	176	180	O	shown
29	182	183	O	to
30	185	191	O	provide
31	193	195	O	any
32	197	201	O	added
33	203	209	O	benefit
34	211	214	O	when
35	216	220	O	given
36	222	223	O	to
37	225	228	O	such
38	230	236	O	infants
39	238	244	O	already
40	246	254	O	receiving
41	256	262	O	optimal
42	264	272	O	infusions
43	274	275	O	of
44	277	284	O	dopamine
NULL

Dobutamine Hydrochloride in Dextrose	288	42232-9	6b17b98b-e06d-42ed-925f-69aa2699dead	33
Preliminary studies indicate that the concomitant use of dobutamine and nitroprusside results in a higher cardiac output and , usually , a lower pulmonary wedge pressure than when either drug is used alone .
1	0	10	O	Preliminary
2	12	18	O	studies
3	20	27	O	indicate
4	29	32	O	that
5	34	36	O	the
6	38	48	O	concomitant
7	50	52	O	use
8	54	55	O	of
9	57	66	O	XXXXXXXX
10	68	70	O	and
11	72	84	U-DYN	nitroprusside
12	86	92	O	results
13	94	95	O	in
14	97	97	O	a
15	99	104	B-EFF	higher
16	106	112	I-EFF	cardiac
17	114	119	L-EFF	output
18	121	123	O	and
19	125	125	O	,
20	127	133	O	usually
21	135	135	O	,
22	137	137	O	a
23	139	143	B-EFF	lower
24	145	153	I-EFF	pulmonary
25	155	159	I-EFF	wedge
26	161	168	L-EFF	pressure
27	170	173	O	than
28	175	178	O	when
29	180	185	O	either
30	187	190	O	drug
31	192	193	O	is
32	195	198	O	used
33	200	204	O	alone
D/11:15:1 D/11:23:1

Dobutamine Hydrochloride in Dextrose	289	42232-9	6b17b98b-e06d-42ed-925f-69aa2699dead	52
There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs , including digitalis preparations , furosemide , spironolactone , lidocaine , glyceryl trinitrate , isosorbide dinitrate , morphine , atropine , heparin , protamine , potassium chloride , folic acid , and acetaminophen .
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	20	O	evidence
5	22	23	O	of
6	25	28	O	drug
7	30	41	O	interactions
8	43	44	O	in
9	46	53	O	clinical
10	55	61	O	studies
11	63	64	O	in
12	66	70	O	which
13	72	81	O	XXXXXXXX
14	83	85	O	was
15	87	98	O	administered
16	100	111	O	concurrently
17	113	116	O	with
18	118	122	O	other
19	124	128	O	drugs
20	130	130	O	,
21	132	140	O	including
22	142	150	O	digitalis
23	152	163	O	preparations
24	165	165	O	,
25	167	176	O	furosemide
26	178	178	O	,
27	180	193	O	spironolactone
28	195	195	O	,
29	197	205	O	lidocaine
30	207	207	O	,
31	209	216	O	glyceryl
32	218	227	O	trinitrate
33	229	229	O	,
34	231	240	O	isosorbide
35	242	250	O	dinitrate
36	252	252	O	,
37	254	261	O	morphine
38	263	263	O	,
39	265	272	O	atropine
40	274	274	O	,
41	276	282	O	heparin
42	284	284	O	,
43	286	294	O	protamine
44	296	296	O	,
45	298	306	O	potassium
46	308	315	O	chloride
47	317	317	O	,
48	319	323	O	folic
49	325	328	O	acid
50	330	330	O	,
51	332	334	O	and
52	336	348	O	acetaminophen
NULL

Integrilin	231	34068-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	33
Before infusion of INTEGRILIN , the following laboratory tests should be performed to identify pre-existing hemostatic abnormalities : hematocrit or hemoglobin , platelet count , serum creatinine , and PT/aPTT .
1	0	5	O	Before
2	7	14	O	infusion
3	16	17	O	of
4	19	28	O	XXXXXXXX
5	30	30	O	,
6	32	34	O	the
7	36	44	O	following
8	46	55	O	laboratory
9	57	61	O	tests
10	63	68	O	should
11	70	71	O	be
12	73	81	O	performed
13	83	84	O	to
14	86	93	O	identify
15	95	97	O	pre
16	99	106	O	existing
17	108	117	O	hemostatic
18	119	131	O	abnormalities
19	133	133	O	:
20	135	144	O	hematocrit
21	146	147	O	or
22	149	158	O	hemoglobin
23	160	160	O	,
24	162	169	O	platelet
25	171	175	O	count
26	177	177	O	,
27	179	183	O	serum
28	185	194	O	creatinine
29	196	196	O	,
30	198	200	O	and
31	202	203	O	PT
32	204	204	O	/
33	205	208	O	aPTT
NULL

Integrilin	232	34068-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	11
Do not administer INTEGRILIN through the same intravenous line as furosemide .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	16	L-TRI	administer
4	18	27	O	XXXXXXXX
5	29	35	O	through
6	37	39	O	the
7	41	44	O	same
8	46	56	O	intravenous
9	58	61	O	line
10	63	64	O	as
11	66	75	U-UNK	furosemide
NULL

Integrilin	233	34068-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	14
INTEGRILIN should be given concomitantly with heparin dosed to achieve the following parameters : .
1	0	9	O	XXXXXXXX
2	11	16	O	should
3	18	19	O	be
4	21	25	O	given
5	27	39	O	concomitantly
6	41	44	O	with
7	46	52	O	heparin
8	54	58	O	dosed
9	60	61	O	to
10	63	69	O	achieve
11	71	73	O	the
12	75	83	O	following
13	85	94	O	parameters
14	96	96	O	:
NULL

Integrilin	234	34068-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	17
INTEGRILIN should be given concomitantly with heparin to achieve a target ACT of 200 to 300 seconds .
1	0	9	O	XXXXXXXX
2	11	16	O	should
3	18	19	O	be
4	21	25	O	given
5	27	39	O	concomitantly
6	41	44	O	with
7	46	52	O	heparin
8	54	55	O	to
9	57	63	O	achieve
10	65	65	O	a
11	67	72	O	target
12	74	76	O	ACT
13	78	79	O	of
14	81	83	O	200
15	85	86	O	to
16	88	90	O	300
17	92	98	O	seconds
NULL

Integrilin	235	34068-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	31
May administer INTEGRILIN in the same intravenous line as alteplase , atropine , dobutamine , heparin , lidocaine , meperidine , metoprolol , midazolam , morphine , nitroglycerin , or verapamil .
1	0	2	O	May
2	4	13	O	administer
3	15	24	O	XXXXXXXX
4	26	27	O	in
5	29	31	O	the
6	33	36	O	same
7	38	48	O	intravenous
8	50	53	O	line
9	55	56	O	as
10	58	66	O	alteplase
11	68	68	O	,
12	70	77	O	atropine
13	79	79	O	,
14	81	90	O	dobutamine
15	92	92	O	,
16	94	100	O	heparin
17	102	102	O	,
18	104	112	O	lidocaine
19	114	114	O	,
20	116	125	O	meperidine
21	127	127	O	,
22	129	138	O	metoprolol
23	140	140	O	,
24	142	150	O	midazolam
25	152	152	O	,
26	154	161	O	morphine
27	163	163	O	,
28	165	177	O	nitroglycerin
29	179	179	O	,
30	181	182	O	or
31	184	192	O	verapamil
NULL

Integrilin	236	34068-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	20
May administer INTEGRILIN in the same IV line with 0.9 % NaCl or 0.9 % NaCl/5 % dextrose .
1	0	2	O	May
2	4	13	O	administer
3	15	24	O	XXXXXXXX
4	26	27	O	in
5	29	31	O	the
6	33	36	O	same
7	38	39	O	IV
8	41	44	O	line
9	46	49	O	with
10	51	53	O	0.9
11	55	55	O	%
12	57	60	O	NaCl
13	62	63	O	or
14	65	67	O	0.9
15	69	69	O	%
16	71	74	O	NaCl
17	75	75	O	/
18	76	76	O	5
19	78	78	O	%
20	80	87	O	dextrose
NULL

Integrilin	237	34073-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	20
(7.1) Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding.
1	1	3	O	7.1
2	6	21	O	Coadministration
3	23	24	O	of
4	26	44	U-DYN	GGGGGGGG
5	45	45	O	,
6	47	59	U-DYN	thrombolytics
7	60	60	O	,
8	62	68	U-DYN	heparin
9	69	69	O	,
10	71	77	U-DYN	aspirin
11	78	78	O	,
12	80	82	O	and
13	84	90	O	chronic
14	92	96	U-DYN	NSAID
15	98	100	O	use
16	102	110	B-EFF	increases
17	112	114	I-EFF	the
18	116	119	I-EFF	risk
19	121	122	I-EFF	of
20	124	131	L-EFF	bleeding
D/10:16:0 D/14:16:0 D/4:16:1 D/6:16:0 D/8:16:0

Integrilin	238	34073-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	11
Avoid concomitant use with other glycoprotein (GP) IIb/IIIa inhibitors.
1	0	4	O	Avoid
2	6	16	O	concomitant
3	18	20	O	use
4	22	25	O	with
5	27	31	O	other
6	33	44	O	glycoprotein
7	47	48	O	GP
8	51	53	O	IIb
9	54	54	O	/
10	55	58	O	IIIa
11	60	69	O	inhibitors
NULL

Integrilin	239	34073-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	19
Coadministration of antiplatelet agents, thrombolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	38	U-DYN	GGGGGGGG
4	39	39	O	,
5	41	53	U-DYN	thrombolytics
6	54	54	O	,
7	56	62	U-DYN	heparin
8	63	63	O	,
9	65	71	O	aspirin
10	72	72	O	,
11	74	76	O	and
12	78	84	O	chronic
13	86	90	U-DYN	NSAID
14	92	94	O	use
15	96	104	O	increases
16	106	108	O	the
17	110	113	O	risk
18	115	116	O	of
19	118	125	U-EFF	bleeding
D/13:19:1 D/3:19:1 D/5:19:1 D/7:19:1

Integrilin	240	34073-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	15
Concomitant treatment with other inhibitors of platelet receptor GP IIb/IIIa should be avoided.
1	0	10	O	Concomitant
2	12	20	O	treatment
3	22	25	O	with
4	27	31	O	other
5	33	42	O	inhibitors
6	44	45	O	of
7	47	54	O	platelet
8	56	63	O	receptor
9	65	66	O	GP
10	68	70	O	IIb
11	71	71	O	/
12	72	75	O	IIIa
13	77	82	O	should
14	84	85	O	be
15	87	93	O	avoided
NULL

Integrilin	241	43685-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	21
If bleeding at access site can not be controlled with pressure , infusion of INTEGRILIN and heparin should be discontinued immediately .
1	0	1	O	If
2	3	10	O	bleeding
3	12	13	O	at
4	15	20	O	access
5	22	25	O	site
6	27	29	O	can
7	31	33	O	not
8	35	36	O	be
9	38	47	O	controlled
10	49	52	O	with
11	54	61	O	pressure
12	63	63	O	,
13	65	72	O	infusion
14	74	75	O	of
15	77	86	O	XXXXXXXX
16	88	90	O	and
17	92	98	O	heparin
18	100	105	O	should
19	107	108	O	be
20	110	121	O	discontinued
21	123	133	O	immediately
NULL

Integrilin	242	43685-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	26
In any case , both heparin and INTEGRILIN should be discontinued and sheath hemostasis should be achieved at least 2 to 4 hours before hospital discharge .
1	0	1	O	In
2	3	5	O	any
3	7	10	O	case
4	12	12	O	,
5	14	17	O	both
6	19	25	O	heparin
7	27	29	O	and
8	31	40	O	XXXXXXXX
9	42	47	O	should
10	49	50	O	be
11	52	63	O	discontinued
12	65	67	O	and
13	69	74	O	sheath
14	76	85	O	hemostasis
15	87	92	O	should
16	94	95	O	be
17	97	104	O	achieved
18	106	107	O	at
19	109	113	O	least
20	115	115	O	2
21	117	118	O	to
22	120	120	O	4
23	122	126	O	hours
24	128	133	O	before
25	135	142	O	hospital
26	144	152	O	discharge
NULL

Integrilin	243	43685-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	26
In the event of acute profound thrombocytopenia or a confirmed platelet decrease to 100,000 / mm3 , discontinue INTEGRILIN and heparin ( unfractionated or low-molecular weight ) .
1	0	1	O	In
2	3	5	O	the
3	7	11	O	event
4	13	14	O	of
5	16	20	O	acute
6	22	29	O	profound
7	31	46	O	thrombocytopenia
8	48	49	O	or
9	51	51	O	a
10	53	61	O	confirmed
11	63	70	O	platelet
12	72	79	O	decrease
13	81	82	O	to
14	84	90	O	100,000
15	92	92	O	/
16	94	96	O	mm3
17	98	98	O	,
18	100	110	O	discontinue
19	112	121	O	XXXXXXXX
20	123	125	O	and
21	127	133	O	heparin
22	137	150	O	unfractionated
23	152	153	O	or
24	155	157	O	low
25	159	167	O	molecular
26	169	174	O	weight
NULL

Integrilin	244	43685-7	5ad82e30-50d8-450c-8a2a-b4b507ed1ce2	6
Thrombocytopenia : Discontinue INTEGRILIN and heparin .
1	0	15	O	Thrombocytopenia
2	17	17	O	:
3	19	29	O	Discontinue
4	31	40	O	XXXXXXXX
5	42	44	O	and
6	46	52	O	heparin
NULL

Lasix	471	34068-7	eadfe464-720b-4dcd-a0d8-45dba706bd33	27
As the blood pressure falls under the potentiating effect of LASIX , a further reduction in dosage or even discontinuation of other antihypertensive drugs may be necessary .
1	0	1	O	As
2	3	5	O	the
3	7	11	B-EFF	blood
4	13	20	I-EFF	pressure
5	22	26	L-EFF	falls
6	28	32	O	under
7	34	36	O	the
8	38	49	O	potentiating
9	51	56	O	effect
10	58	59	O	of
11	61	65	O	XXXXXXXX
12	67	67	O	,
13	69	69	O	a
14	71	77	O	further
15	79	87	O	reduction
16	89	90	O	in
17	92	97	O	dosage
18	99	100	O	or
19	102	105	O	even
20	107	121	O	discontinuation
21	123	124	O	of
22	126	130	O	other
23	132	147	B-DYN	antihypertensive
24	149	153	L-DYN	drugs
25	155	157	O	may
26	159	160	O	be
27	162	170	O	necessary
D/23:3:1

Lasix	472	34068-7	eadfe464-720b-4dcd-a0d8-45dba706bd33	21
Changes in blood pressure must be carefully monitored when LASIX is used with other antihypertensive drugs , especially during initial therapy .
1	0	6	B-EFF	Changes
2	8	9	I-EFF	in
3	11	15	I-EFF	blood
4	17	24	L-EFF	pressure
5	26	29	O	must
6	31	32	O	be
7	34	42	O	carefully
8	44	52	O	monitored
9	54	57	O	when
10	59	63	O	XXXXXXXX
11	65	66	O	is
12	68	71	O	used
13	73	76	O	with
14	78	82	O	other
15	84	99	B-DYN	antihypertensive
16	101	105	L-DYN	drugs
17	107	107	O	,
18	109	118	O	especially
19	120	125	O	during
20	127	133	O	initial
21	135	141	O	therapy
D/15:1:1

Lasix	473	34071-1	eadfe464-720b-4dcd-a0d8-45dba706bd33	39
Reports usually indicate that LASIX ototoxicity is associated with rapid injection , severe renal impairment , the use of higher than recommended doses , hypoproteinemia or concomitant therapy with aminoglycoside antibiotics , ethacrynic acid , or other ototoxic drugs .
1	0	6	O	Reports
2	8	14	O	usually
3	16	23	O	indicate
4	25	28	O	that
5	30	34	O	XXXXXXXX
6	36	46	U-EFF	ototoxicity
7	48	49	O	is
8	51	60	O	associated
9	62	65	O	with
10	67	71	O	rapid
11	73	81	O	injection
12	83	83	O	,
13	85	90	O	severe
14	92	96	O	renal
15	98	107	O	impairment
16	109	109	O	,
17	111	113	O	the
18	115	117	O	use
19	119	120	O	of
20	122	127	O	higher
21	129	132	O	than
22	134	144	O	recommended
23	146	150	O	doses
24	152	152	O	,
25	154	168	O	hypoproteinemia
26	170	171	O	or
27	173	183	O	concomitant
28	185	191	O	therapy
29	193	196	O	with
30	198	211	B-DYN	aminoglycoside
31	213	223	L-DYN	antibiotics
32	225	225	O	,
33	227	236	B-DYN	ethacrynic
34	238	241	L-DYN	acid
35	243	243	O	,
36	245	246	O	or
37	248	252	O	other
38	254	261	B-DYN	ototoxic
39	263	267	L-DYN	drugs
D/30:6:1 D/33:6:1 D/38:6:1

Lasix	474	34073-7	eadfe464-720b-4dcd-a0d8-45dba706bd33	9
Except in life-threatening situations, avoid this combination.
1	0	5	O	Except
2	7	8	O	in
3	10	13	O	life
4	15	25	O	threatening
5	27	36	O	situations
6	37	37	O	,
7	39	43	O	avoid
8	45	48	O	this
9	50	60	O	combination
NULL

Lasix	475	34073-7	eadfe464-720b-4dcd-a0d8-45dba706bd33	31
High-dose treatment of both LASIX and these other drugs may result in elevated serum levels of these drugs and may potentiate their toxicity as well as the toxicity of LASIX.
1	0	3	O	High
2	5	8	O	dose
3	10	18	O	treatment
4	20	21	O	of
5	23	26	O	both
6	28	32	O	XXXXXXXX
7	34	36	O	and
8	38	42	O	these
9	44	48	O	other
10	50	54	O	drugs
11	56	58	O	may
12	60	65	O	result
13	67	68	O	in
14	70	77	O	elevated
15	79	83	O	serum
16	85	90	O	levels
17	92	93	O	of
18	95	99	O	these
19	101	105	O	drugs
20	107	109	O	and
21	111	113	O	may
22	115	124	O	potentiate
23	126	130	O	their
24	132	139	O	toxicity
25	141	142	O	as
26	144	147	O	well
27	149	150	O	as
28	152	154	O	the
29	156	163	O	toxicity
30	165	166	O	of
31	168	172	O	XXXXXXXX
NULL

Lasix	476	34073-7	eadfe464-720b-4dcd-a0d8-45dba706bd33	8
However, norepinephrine may still be used effectively.
1	0	6	O	However
2	7	7	O	,
3	9	22	O	norepinephrine
4	24	26	O	may
5	28	32	O	still
6	34	35	O	be
7	37	40	O	used
8	42	52	O	effectively
NULL

Lasix	477	34073-7	eadfe464-720b-4dcd-a0d8-45dba706bd33	15
Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation.
1	0	11	O	Indomethacin
2	13	15	O	may
3	17	20	O	also
4	22	27	O	affect
5	29	34	O	plasma
6	36	40	O	renin
7	42	47	O	levels
8	48	48	O	,
9	50	60	O	aldosterone
10	62	70	O	excretion
11	71	71	O	,
12	73	75	O	and
13	77	81	O	renin
14	83	89	O	profile
15	91	100	O	evaluation
NULL

Lasix	478	34073-7	eadfe464-720b-4dcd-a0d8-45dba706bd33	22
Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of lithium toxicity.
1	0	6	U-KIN	Lithium
2	8	16	O	generally
3	18	23	O	should
4	25	27	O	not
5	29	30	O	be
6	32	36	O	given
7	38	41	O	with
8	43	51	O	GGGGGGGG
9	53	59	O	because
10	61	64	O	they
11	66	71	O	reduce
12	73	81	O	lithium's
13	83	87	O	renal
14	89	97	O	clearance
15	99	101	O	and
16	103	105	O	add
17	107	107	O	a
18	109	112	O	high
19	114	117	O	risk
20	119	120	O	of
21	122	128	O	lithium
22	130	137	O	toxicity
K/1:C54357

Lasix	479	34073-7	eadfe464-720b-4dcd-a0d8-45dba706bd33	9
Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
1	0	11	U-EFF	Potentiation
2	13	18	O	occurs
3	20	23	O	with
4	25	34	O	ganglionic
5	36	37	O	or
6	39	48	B-DYN	peripheral
7	50	59	I-DYN	adrenergic
8	61	68	I-DYN	blocking
9	70	74	L-DYN	drugs
D/6:1:1

Lasix	480	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	22
An interruption or reduction in the dosage of LASIX , angiotensin converting enzyme inhibitors , or angiotensin receptor blockers may be necessary .
1	0	1	O	An
2	3	14	O	interruption
3	16	17	O	or
4	19	27	O	reduction
5	29	30	O	in
6	32	34	O	the
7	36	41	O	dosage
8	43	44	O	of
9	46	50	O	XXXXXXXX
10	52	52	O	,
11	54	64	O	angiotensin
12	66	75	O	converting
13	77	82	O	enzyme
14	84	93	O	inhibitors
15	95	95	O	,
16	97	98	O	or
17	100	110	O	angiotensin
18	112	119	O	receptor
19	121	128	O	blockers
20	130	132	O	may
21	134	135	O	be
22	137	145	O	necessary
NULL

Lasix	481	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	25
As with any effective diuretic , electrolyte depletion may occur during LASIX therapy , especially in patients receiving higher doses and a restricted salt intake .
1	0	1	O	As
2	3	6	O	with
3	8	10	O	any
4	12	20	O	effective
5	22	29	O	diuretic
6	31	31	O	,
7	33	43	O	electrolyte
8	45	53	O	depletion
9	55	57	O	may
10	59	63	O	occur
11	65	70	O	during
12	72	76	O	XXXXXXXX
13	78	84	O	therapy
14	86	86	O	,
15	88	97	O	especially
16	99	100	O	in
17	102	109	O	patients
18	111	119	O	receiving
19	121	126	O	higher
20	128	132	O	doses
21	134	136	O	and
22	138	138	O	a
23	140	149	O	restricted
24	151	154	O	salt
25	156	161	O	intake
NULL

Lasix	482	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	26
Concomitant use of cyclosporine and LASIX is associated with increased risk of gouty arthritis secondary to LASIX-induced hyperurecemia and cyclosporine impairment of renal urate excretion .
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	30	U-DYN	cyclosporine
5	32	34	O	and
6	36	40	O	XXXXXXXX
7	42	43	O	is
8	45	54	O	associated
9	56	59	O	with
10	61	69	O	increased
11	71	74	O	risk
12	76	77	O	of
13	79	83	B-EFF	gouty
14	85	93	L-EFF	arthritis
15	95	103	O	secondary
16	105	106	O	to
17	108	112	O	XXXXXXXX
18	114	120	O	induced
19	122	134	U-EFF	hyperurecemia
20	136	138	O	and
21	140	151	O	cyclosporine
22	153	162	B-EFF	impairment
23	164	165	I-EFF	of
24	167	171	I-EFF	renal
25	173	177	I-EFF	urate
26	179	187	L-EFF	excretion
D/4:13:1 D/4:19:1 D/4:22:1

Lasix	483	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	14
Conversely , LASIX may decrease renal elimination of other drugs that undergo tubular secretion .
1	0	9	O	Conversely
2	11	11	O	,
3	13	17	O	XXXXXXXX
4	19	21	O	may
5	23	30	O	decrease
6	32	36	O	renal
7	38	48	O	elimination
8	50	51	O	of
9	53	57	O	other
10	59	63	O	drugs
11	65	68	O	that
12	70	76	O	undergo
13	78	84	O	tubular
14	86	94	O	secretion
NULL

Lasix	484	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	40
Hypokalemia may develop with LASIX , especially with brisk diuresis , inadequate oral electrolyte intake , when cirrhosis is present , or during concomitant use of corticosteroids , ACTH , licorice in large amounts , or prolonged use of laxatives .
1	0	10	U-EFF	Hypokalemia
2	12	14	O	may
3	16	22	O	develop
4	24	27	O	with
5	29	33	O	XXXXXXXX
6	35	35	O	,
7	37	46	O	especially
8	48	51	O	with
9	53	57	O	brisk
10	59	66	O	diuresis
11	68	68	O	,
12	70	79	O	inadequate
13	81	84	O	oral
14	86	96	O	electrolyte
15	98	103	O	intake
16	105	105	O	,
17	107	110	O	when
18	112	120	O	cirrhosis
19	122	123	O	is
20	125	131	O	present
21	133	133	O	,
22	135	136	O	or
23	138	143	O	during
24	145	155	O	concomitant
25	157	159	O	use
26	161	162	O	of
27	164	178	U-DYN	corticosteroids
28	180	180	O	,
29	182	185	U-DYN	ACTH
30	187	187	O	,
31	189	196	U-DYN	licorice
32	198	199	O	in
33	201	205	O	large
34	207	213	O	amounts
35	215	215	O	,
36	217	218	O	or
37	220	228	O	prolonged
38	230	232	O	use
39	234	235	O	of
40	237	245	U-DYN	laxatives
D/27:1:1 D/29:1:1 D/31:1:1 D/40:1:1

Lasix	485	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	35
In addition , nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if LASIX is not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment .
1	0	1	O	In
2	3	10	O	addition
3	12	12	O	,
4	14	27	U-EFF	nephrotoxicity
5	29	30	O	of
6	32	42	B-DYN	nephrotoxic
7	44	48	L-DYN	drugs
8	50	53	O	such
9	55	56	O	as
10	58	66	U-DYN	cisplatin
11	68	70	O	may
12	72	73	O	be
13	75	82	O	enhanced
14	84	85	O	if
15	87	91	O	XXXXXXXX
16	93	94	O	is
17	96	98	O	not
18	100	104	O	given
19	106	107	O	in
20	109	113	O	lower
21	115	119	O	doses
22	121	123	O	and
23	125	128	O	with
24	130	137	O	positive
25	139	143	O	fluid
26	145	151	O	balance
27	153	156	O	when
28	158	161	O	used
29	163	164	O	to
30	166	172	O	achieve
31	174	179	O	forced
32	181	188	O	diuresis
33	190	195	O	during
34	197	205	O	cisplatin
35	207	215	O	treatment
D/10:4:1 D/6:4:1

Lasix	486	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	33
In isolated cases , intravenous administration of LASIX within 24 hours of taking chloral hydrate may lead to flushing , sweating attacks , restlessness , nausea , increase in blood pressure and tachycardia .
1	0	1	O	In
2	3	10	O	isolated
3	12	16	O	cases
4	18	18	O	,
5	20	30	O	intravenous
6	32	45	O	administration
7	47	48	O	of
8	50	54	O	XXXXXXXX
9	56	61	O	within
10	63	64	O	24
11	66	70	O	hours
12	72	73	O	of
13	75	80	O	taking
14	82	88	B-DYN	chloral
15	90	96	L-DYN	hydrate
16	98	100	O	may
17	102	105	O	lead
18	107	108	O	to
19	110	117	U-EFF	flushing
20	119	119	O	,
21	121	128	B-EFF	sweating
22	130	136	L-EFF	attacks
23	138	138	O	,
24	140	151	U-EFF	restlessness
25	153	153	O	,
26	155	160	U-EFF	nausea
27	162	162	O	,
28	164	171	B-EFF	increase
29	173	174	I-EFF	in
30	176	180	I-EFF	blood
31	182	189	L-EFF	pressure
32	191	193	O	and
33	195	205	U-EFF	tachycardia
D/14:19:1 D/14:21:1 D/14:24:1 D/14:26:1 D/14:28:1 D/14:33:1

Lasix	487	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	40
LASIX ( furosemide ) produced no impairment of fertility in male or female rats , at 100 mg/kg/day ( the maximum effective diuretic dose in the rat and 8 times the maximal human dose of 600 mg/day ) .
1	0	4	O	XXXXXXXX
2	8	17	O	XXXXXXXX
3	21	28	O	produced
4	30	31	O	no
5	33	42	O	impairment
6	44	45	O	of
7	47	55	O	fertility
8	57	58	O	in
9	60	63	O	male
10	65	66	O	or
11	68	73	O	female
12	75	78	O	rats
13	80	80	O	,
14	82	83	O	at
15	85	87	O	100
16	89	90	O	mg
17	91	91	O	/
18	92	93	O	kg
19	94	94	O	/
20	95	97	O	day
21	101	103	O	the
22	105	111	O	maximum
23	113	121	O	effective
24	123	130	O	diuretic
25	132	135	O	dose
26	137	138	O	in
27	140	142	O	the
28	144	146	O	rat
29	148	150	O	and
30	152	152	O	8
31	154	158	O	times
32	160	162	O	the
33	164	170	O	maximal
34	172	176	O	human
35	178	181	O	dose
36	183	184	O	of
37	186	188	O	600
38	190	191	O	mg
39	192	192	O	/
40	193	195	O	day
NULL

Lasix	488	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	19
LASIX can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment .
1	0	4	O	XXXXXXXX
2	6	8	O	can
3	10	17	O	increase
4	19	21	O	the
5	23	26	O	risk
6	28	29	O	of
7	31	43	U-DYN	cephalosporin
8	45	51	O	induced
9	53	66	U-EFF	nephrotoxicity
10	68	71	O	even
11	73	74	O	in
12	76	78	O	the
13	80	86	O	setting
14	88	89	O	of
15	91	95	O	minor
16	97	98	O	or
17	100	108	O	transient
18	110	114	O	renal
19	116	125	O	impairment
D/7:9:1

Lasix	489	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	26
LASIX combined with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe hypotension and deterioration in renal function , including renal failure .
1	0	4	O	XXXXXXXX
2	6	13	O	combined
3	15	18	O	with
4	20	30	B-DYN	angiotensin
5	32	41	I-DYN	converting
6	43	48	I-DYN	enzyme
7	50	59	L-DYN	inhibitors
8	61	62	O	or
9	64	74	B-DYN	angiotensin
10	76	77	I-DYN	II
11	79	86	I-DYN	receptor
12	88	95	L-DYN	blockers
13	97	99	O	may
14	101	104	O	lead
15	106	107	O	to
16	109	114	O	severe
17	116	126	U-EFF	hypotension
18	128	130	O	and
19	132	144	B-EFF	deterioration
20	146	147	I-EFF	in
21	149	153	I-EFF	renal
22	155	162	L-EFF	function
23	164	164	O	,
24	166	174	O	including
25	176	180	B-EFF	renal
26	182	188	L-EFF	failure
D/4:17:1 D/4:19:1 D/4:25:1 D/9:17:1 D/9:19:1 D/9:25:1

Lasix	490	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	20
LASIX has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine .
1	0	4	O	XXXXXXXX
2	6	8	O	has
3	10	10	O	a
4	12	19	O	tendency
5	21	22	O	to
6	24	33	B-EFF	antagonize
7	35	37	I-EFF	the
8	39	46	I-EFF	skeletal
9	48	53	I-EFF	muscle
10	55	62	I-EFF	relaxing
11	64	69	L-EFF	effect
12	71	72	O	of
13	74	85	U-DYN	tubocurarine
14	87	89	O	and
15	91	93	O	may
16	95	104	B-EFF	potentiate
17	106	108	I-EFF	the
18	110	115	I-EFF	action
19	117	118	I-EFF	of
20	120	134	L-EFF	succinylcholine
D/13:16:0 D/13:6:1

Lasix	491	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	7
LASIX may decrease arterial responsiveness to norepinephrine .
1	0	4	O	XXXXXXXX
2	6	8	O	may
3	10	17	B-EFF	decrease
4	19	26	I-EFF	arterial
5	28	41	L-EFF	responsiveness
6	43	44	O	to
7	46	59	U-DYN	norepinephrine
D/7:3:1

Lasix	492	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	18
LASIX may increase the ototoxic potential of aminoglycoside antibiotics , especially in the presence of impaired renal function .
1	0	4	O	XXXXXXXX
2	6	8	O	may
3	10	17	O	increase
4	19	21	O	the
5	23	30	B-EFF	ototoxic
6	32	40	L-EFF	potential
7	42	43	O	of
8	45	58	B-DYN	aminoglycoside
9	60	70	L-DYN	antibiotics
10	72	72	O	,
11	74	83	O	especially
12	85	86	O	in
13	88	90	O	the
14	92	99	O	presence
15	101	102	O	of
16	104	111	O	impaired
17	113	117	O	renal
18	119	126	O	function
D/8:5:1

Lasix	493	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	16
LASIX may lower serum levels of calcium ( rarely cases of tetany have been reported ) and magnesium .
1	0	4	O	XXXXXXXX
2	6	8	O	may
3	10	14	O	lower
4	16	20	O	serum
5	22	27	O	levels
6	29	30	O	of
7	32	38	O	calcium
8	42	47	O	rarely
9	49	53	O	cases
10	55	56	O	of
11	58	63	O	tetany
12	65	68	O	have
13	70	73	O	been
14	75	82	O	reported
15	86	88	O	and
16	90	98	O	magnesium
NULL

Lasix	494	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	15
LASIX should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity .
1	0	4	O	XXXXXXXX
2	6	11	O	should
3	13	15	O	not
4	17	18	O	be
5	20	23	O	used
6	25	37	O	concomitantly
7	39	42	O	with
8	44	53	B-DYN	ethacrynic
9	55	58	L-DYN	acid
10	60	66	O	because
11	68	69	O	of
12	71	73	O	the
13	75	85	O	possibility
14	87	88	O	of
15	90	100	U-EFF	ototoxicity
D/8:15:1

Lasix	495	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	24
Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of LASIX ( furosemide ) in some patients by inhibiting prostaglandin synthesis .
1	0	9	O	Literature
2	11	17	O	reports
3	19	26	O	indicate
4	28	31	O	that
5	33	48	O	coadministration
6	50	51	O	of
7	53	64	U-DYN	indomethacin
8	66	68	O	may
9	70	75	O	reduce
10	77	79	O	the
11	81	91	O	natriuretic
12	93	95	O	and
13	97	112	O	antihypertensive
14	114	120	O	effects
15	122	123	O	of
16	125	129	O	XXXXXXXX
17	133	142	O	XXXXXXXX
18	146	147	O	in
19	149	152	O	some
20	154	161	O	patients
21	163	164	O	by
22	166	175	O	inhibiting
23	177	189	O	prostaglandin
24	191	199	O	synthesis
NULL

Lasix	496	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	20
Methotrexate and other drugs that , like LASIX , undergo significant renal tubular secretion may reduce the effect of LASIX .
1	0	11	U-DYN	Methotrexate
2	13	15	O	and
3	17	21	O	other
4	23	27	O	drugs
5	29	32	O	that
6	34	34	O	,
7	36	39	O	like
8	41	45	O	XXXXXXXX
9	47	47	O	,
10	49	55	O	undergo
11	57	67	O	significant
12	69	73	O	renal
13	75	81	O	tubular
14	83	91	O	secretion
15	93	95	O	may
16	97	102	B-EFF	reduce
17	104	106	I-EFF	the
18	108	113	I-EFF	effect
19	115	116	I-EFF	of
20	118	122	L-EFF	XXXXXXXX
D/1:16:1

Lasix	497	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	24
One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency .
1	0	2	O	One
2	4	8	O	study
3	10	11	O	in
4	13	15	O	six
5	17	24	O	subjects
6	26	37	O	demonstrated
7	39	42	O	that
8	44	46	O	the
9	48	58	O	combination
10	60	61	O	of
11	63	72	O	XXXXXXXX
12	74	76	O	and
13	78	92	B-DYN	acetylsalicylic
14	94	97	L-DYN	acid
15	99	109	O	temporarily
16	111	117	B-EFF	reduced
17	119	128	I-EFF	creatinine
18	130	138	L-EFF	clearance
19	140	141	O	in
20	143	150	O	patients
21	152	155	O	with
22	157	163	O	chronic
23	165	169	O	renal
24	171	183	O	insufficiency
D/13:16:1

Lasix	498	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	10
Patients allergic to sulfonamides may also be allergic to LASIX .
1	0	7	O	Patients
2	9	16	O	allergic
3	18	19	O	to
4	21	32	O	sulfonamides
5	34	36	O	may
6	38	41	O	also
7	43	44	O	be
8	46	53	O	allergic
9	55	56	O	to
10	58	62	O	XXXXXXXX
NULL

Lasix	499	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	23
Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of LASIX is achieved .
1	0	7	O	Patients
2	9	17	O	receiving
3	19	22	O	both
4	24	28	O	drugs
5	30	35	O	should
6	37	38	O	be
7	40	47	O	observed
8	49	55	O	closely
9	57	58	O	to
10	60	68	O	determine
11	70	71	O	if
12	73	75	O	the
13	77	83	O	desired
14	85	92	O	diuretic
15	94	96	O	and
16	97	97	O	/
17	98	99	O	or
18	101	116	O	antihypertensive
19	118	123	O	effect
20	125	126	O	of
21	128	132	O	XXXXXXXX
22	134	135	O	is
23	137	144	O	achieved
NULL

Lasix	500	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	25
Patients receiving both indomethacin and LASIX should be observed closely to determine if the desired diuretic and/or antihypertensive effect of LASIX is achieved .
1	0	7	O	Patients
2	9	17	O	receiving
3	19	22	O	both
4	24	35	U-UNK	indomethacin
5	37	39	O	and
6	41	45	O	XXXXXXXX
7	47	52	O	should
8	54	55	O	be
9	57	64	O	observed
10	66	72	O	closely
11	74	75	O	to
12	77	85	O	determine
13	87	88	O	if
14	90	92	O	the
15	94	100	O	desired
16	102	109	O	diuretic
17	111	113	O	and
18	114	114	O	/
19	115	116	O	or
20	118	133	O	antihypertensive
21	135	140	O	effect
22	142	143	O	of
23	145	149	O	XXXXXXXX
24	151	152	O	is
25	154	161	O	achieved
NULL

Lasix	501	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	28
Patients receiving high doses of salicylates concomitantly with LASIX , as in rheumatic disease , may experience salicylate toxicity at lower doses because of competitive renal excretory sites .
1	0	7	O	Patients
2	9	17	O	receiving
3	19	22	O	high
4	24	28	O	doses
5	30	31	O	of
6	33	43	U-KIN	salicylates
7	45	57	O	concomitantly
8	59	62	O	with
9	64	68	O	XXXXXXXX
10	70	70	O	,
11	72	73	O	as
12	75	76	O	in
13	78	86	O	rheumatic
14	88	94	O	disease
15	96	96	O	,
16	98	100	O	may
17	102	111	O	experience
18	113	122	O	salicylate
19	124	131	O	toxicity
20	133	134	O	at
21	136	140	O	lower
22	142	146	O	doses
23	148	154	O	because
24	156	157	O	of
25	159	169	O	competitive
26	171	175	O	renal
27	177	185	O	excretory
28	187	191	O	sites
K/6:C54357

Lasix	502	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	19
Patients receiving LASIX should be advised that they may experience symptoms from excessive fluid and/or electrolyte losses .
1	0	7	O	Patients
2	9	17	O	receiving
3	19	23	O	XXXXXXXX
4	25	30	O	should
5	32	33	O	be
6	35	41	O	advised
7	43	46	O	that
8	48	51	O	they
9	53	55	O	may
10	57	66	O	experience
11	68	75	O	symptoms
12	77	80	O	from
13	82	90	O	excessive
14	92	96	O	fluid
15	98	100	O	and
16	101	101	O	/
17	102	103	O	or
18	105	115	O	electrolyte
19	117	122	O	losses
NULL

Lasix	503	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	8
Phenytoin interferes directly with renal action of LASIX .
1	0	8	U-DYN	Phenytoin
2	10	19	B-EFF	interferes
3	21	28	I-EFF	directly
4	30	33	I-EFF	with
5	35	39	I-EFF	renal
6	41	46	I-EFF	action
7	48	49	I-EFF	of
8	51	55	L-EFF	XXXXXXXX
D/1:2:1

Lasix	504	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	25
Serum electrolytes ( particularly potassium ) , CO2 , creatinine and BUN should be determined frequently during the first few months of LASIX therapy and periodically thereafter .
1	0	4	O	Serum
2	6	17	O	electrolytes
3	21	32	O	particularly
4	34	42	O	potassium
5	46	46	O	,
6	48	50	O	CO2
7	52	52	O	,
8	54	63	O	creatinine
9	65	67	O	and
10	69	71	O	BUN
11	73	78	O	should
12	80	81	O	be
13	83	92	O	determined
14	94	103	O	frequently
15	105	110	O	during
16	112	114	O	the
17	116	120	O	first
18	122	124	O	few
19	126	131	O	months
20	133	134	O	of
21	136	140	O	XXXXXXXX
22	142	148	O	therapy
23	150	152	O	and
24	154	165	O	periodically
25	167	176	O	thereafter
NULL

Lasix	505	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	16
Simultaneous administration of sucralfate and LASIX tablets may reduce the natriuretic and antihypertensive effects of LASIX .
1	0	11	O	Simultaneous
2	13	26	O	administration
3	28	29	O	of
4	31	40	U-DYN	sucralfate
5	42	44	O	and
6	46	50	O	XXXXXXXX
7	52	58	O	tablets
8	60	62	O	may
9	64	69	O	reduce
10	71	73	O	the
11	75	85	O	natriuretic
12	87	89	O	and
13	91	106	O	antihypertensive
14	108	114	O	effects
15	116	117	O	of
16	119	123	O	XXXXXXXX
NULL

Lasix	506	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	14
The intake of LASIX and sucralfate should be separated by at least two hours .
1	0	2	O	The
2	4	9	O	intake
3	11	12	O	of
4	14	18	O	XXXXXXXX
5	20	22	O	and
6	24	33	U-UNK	sucralfate
7	35	40	O	should
8	42	43	O	be
9	45	53	O	separated
10	55	56	O	by
11	58	59	O	at
12	61	65	O	least
13	67	69	O	two
14	71	75	O	hours
NULL

Lasix	507	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	29
There are case reports of patients who developed increased BUN , serum creatinine and serum potassium levels , and weight gain when furosemide was used in conjunction with NSAIDs .
1	0	4	O	There
2	6	8	O	are
3	10	13	O	case
4	15	21	O	reports
5	23	24	O	of
6	26	33	O	patients
7	35	37	O	who
8	39	47	O	developed
9	49	57	B-EFF	increased
10	59	61	L-EFF	BUN
11	63	63	O	,
12	65	69	O	serum
13	71	80	O	creatinine
14	82	84	O	and
15	86	90	O	serum
16	92	100	O	potassium
17	102	107	O	levels
18	109	109	O	,
19	111	113	O	and
20	115	120	B-EFF	weight
21	122	125	L-EFF	gain
22	127	130	O	when
23	132	141	O	XXXXXXXX
24	143	145	O	was
25	147	150	O	used
26	152	153	O	in
27	155	165	O	conjunction
28	167	170	O	with
29	172	177	U-DYN	NSAIDs
D/29:20:1 D/29:9:1

Lasix	508	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	14
There is a risk of ototoxic effects if cisplatin and LASIX are given concomitantly .
1	0	4	O	There
2	6	7	O	is
3	9	9	O	a
4	11	14	O	risk
5	16	17	O	of
6	19	26	B-EFF	ototoxic
7	28	34	L-EFF	effects
8	36	37	O	if
9	39	47	U-DYN	cisplatin
10	49	51	O	and
11	53	57	O	XXXXXXXX
12	59	61	O	are
13	63	67	O	given
14	69	81	O	concomitantly
D/9:6:1

Lasix	509	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	23
There is evidence that treatment with phenytoin leads to decrease intestinal absorption of LASIX , and consequently to lower peak serum furosemide concentrations .
1	0	4	O	There
2	6	7	O	is
3	9	16	O	evidence
4	18	21	O	that
5	23	31	O	treatment
6	33	36	O	with
7	38	46	U-KIN	phenytoin
8	48	52	O	leads
9	54	55	O	to
10	57	64	O	decrease
11	66	75	O	intestinal
12	77	86	O	absorption
13	88	89	O	of
14	91	95	O	XXXXXXXX
15	97	97	O	,
16	99	101	O	and
17	103	114	O	consequently
18	116	117	O	to
19	119	123	B-TRI	lower
20	125	128	I-TRI	peak
21	130	134	I-TRI	serum
22	136	145	I-TRI	XXXXXXXX
23	147	160	L-TRI	concentrations
K/7:C54615

Lasix	510	42232-9	eadfe464-720b-4dcd-a0d8-45dba706bd33	13
Use of LASIX concomitantly with chloral hydrate is , therefore , not recommended .
1	0	2	O	Use
2	4	5	O	of
3	7	11	O	XXXXXXXX
4	13	25	O	concomitantly
5	27	30	O	with
6	32	38	B-UNK	chloral
7	40	46	L-UNK	hydrate
8	48	49	O	is
9	51	51	O	,
10	53	61	O	therefore
11	63	63	O	,
12	65	67	B-TRI	not
13	69	79	L-TRI	recommended
NULL

Nexterone	426	34068-7	e9108958-b8d7-4fba-87c3-9a32990de551	25
NEXTERONE Premixed Injection is available in GALAXY containers as a single-use , ready-to-use , iso-osmotic solution in dextrose for intravenous administration .
1	0	8	O	XXXXXXXX
2	10	17	O	Premixed
3	19	27	O	Injection
4	29	30	O	is
5	32	40	O	available
6	42	43	O	in
7	45	50	O	GALAXY
8	52	61	O	containers
9	63	64	O	as
10	66	66	O	a
11	68	73	O	single
12	75	77	O	use
13	79	79	O	,
14	81	85	O	ready
15	87	88	O	to
16	90	92	O	use
17	94	94	O	,
18	96	98	O	iso
19	100	106	O	osmotic
20	108	115	O	solution
21	117	118	O	in
22	120	127	O	dextrose
23	129	131	O	for
24	133	143	O	intravenous
25	145	158	O	administration
NULL

Nexterone	427	34070-3	e9108958-b8d7-4fba-87c3-9a32990de551	12
Known hypersensitivity to any of the components of NEXTERONE , including iodine .
1	0	4	O	Known
2	6	21	O	hypersensitivity
3	23	24	O	to
4	26	28	O	any
5	30	31	O	of
6	33	35	O	the
7	37	46	O	components
8	48	49	O	of
9	51	59	O	XXXXXXXX
10	61	61	O	,
11	63	71	O	including
12	73	78	O	iodine
NULL

Nexterone	428	34070-3	e9108958-b8d7-4fba-87c3-9a32990de551	14
Known hypersensitivity to any of the components of NEXTERONE Premixed Injection , including iodine .
1	0	4	O	Known
2	6	21	O	hypersensitivity
3	23	24	O	to
4	26	28	O	any
5	30	31	O	of
6	33	35	O	the
7	37	46	O	components
8	48	49	O	of
9	51	59	O	XXXXXXXX
10	61	68	O	Premixed
11	70	78	O	Injection
12	80	80	O	,
13	82	90	O	including
14	92	97	O	iodine
NULL

Nexterone	429	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	25
Amiodarone and DEA are inhibitors of P-glycoprotein and certain CYP450 enzymes , including CYP1A2 , CYP2C9 , CYP2D6 and CYP3A see Clinical Pharmacology ( 12.3 ) .
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	17	O	DEA
4	19	21	O	are
5	23	32	O	inhibitors
6	34	35	O	of
7	37	37	O	P
8	39	50	O	glycoprotein
9	52	54	O	and
10	56	62	O	certain
11	64	69	O	CYP450
12	71	77	O	enzymes
13	79	79	O	,
14	81	89	O	including
15	91	96	O	CYP1A2
16	98	98	O	,
17	100	105	O	CYP2C9
18	107	107	O	,
19	109	114	O	CYP2D6
20	116	118	O	and
21	120	124	O	CYP3A
22	126	128	O	see
23	130	137	O	Clinical
24	139	150	O	Pharmacology
25	154	157	O	12.3
NULL

Nexterone	430	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	51
Amiodarone has the potential for interactions with drugs or substances that may be substrates , inhibitors or inducers of CYP450 enzymes ( e.g. , inhibitors such as protease inhibitors , grapefruit juice , certain fluoroquinolone and macrolide antibiotics , azole antifungals and inducers such as St.   John s Wort ) or P-glycoprotein .
1	0	9	O	XXXXXXXX
2	11	13	O	has
3	15	17	O	the
4	19	27	B-TRI	potential
5	29	31	I-TRI	for
6	33	44	L-TRI	interactions
7	46	49	O	with
8	51	55	O	drugs
9	57	58	O	or
10	60	69	O	substances
11	71	74	O	that
12	76	78	O	may
13	80	81	O	be
14	83	92	O	substrates
15	94	94	O	,
16	96	105	O	inhibitors
17	107	108	O	or
18	110	117	B-UNK	inducers
19	119	120	I-UNK	of
20	122	127	I-UNK	CYP450
21	129	135	L-UNK	enzymes
22	139	141	O	e.g
23	144	144	O	,
24	146	155	O	inhibitors
25	157	160	O	such
26	162	163	O	as
27	165	172	B-UNK	protease
28	174	183	L-UNK	inhibitors
29	185	185	O	,
30	187	196	B-UNK	grapefruit
31	198	202	L-UNK	juice
32	204	204	O	,
33	206	212	O	certain
34	214	228	O	fluoroquinolone
35	230	232	O	and
36	234	242	B-UNK	macrolide
37	244	254	L-UNK	antibiotics
38	256	256	O	,
39	258	262	B-UNK	azole
40	264	274	L-UNK	antifungals
41	276	278	O	and
42	280	287	O	inducers
43	289	292	O	such
44	294	295	O	as
45	297	298	B-UNK	St
46	303	306	I-UNK	John
47	308	308	I-UNK	s
48	310	313	L-UNK	Wort
49	317	318	O	or
50	320	320	B-UNK	P
51	322	333	L-UNK	glycoprotein
NULL

Nexterone	431	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	87
Amiodarone is a substrate for CYP3A and CYP2C8, so inhibitors and inducers affect amiodarone exposure (7) Amiodarone inhibits p-glycoprotein and CYP1A2, CYP2C9, CYP2D6, and CYP3A, increasing exposure to other drugs (7) Drugs prolonging the QT interval: Co-administration of drugs prolonging the QT interval (such as class I and III antiarrhythmics, lithium, certain phenothiazines, tricyclic antidepressants, certain fluoroquinolone and macrolide antibiotics, azole antifungals, halogenated inhalation anesthetic agents) increases the risk of Torsade de Pointes.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	14	O	a
4	16	24	O	substrate
5	26	28	O	for
6	30	34	O	CYP3A
7	36	38	O	and
8	40	45	O	CYP2C8
9	46	46	O	,
10	48	49	O	so
11	51	60	O	inhibitors
12	62	64	O	and
13	66	73	O	inducers
14	75	80	B-TRI	affect
15	82	91	I-TRI	XXXXXXXX
16	93	100	L-TRI	exposure
17	103	103	O	7
18	106	115	O	XXXXXXXX
19	117	124	O	inhibits
20	126	126	O	p
21	128	139	O	glycoprotein
22	141	143	O	and
23	145	150	O	CYP1A2
24	151	151	O	,
25	153	158	O	CYP2C9
26	159	159	O	,
27	161	166	O	CYP2D6
28	167	167	O	,
29	169	171	O	and
30	173	177	O	CYP3A
31	178	178	O	,
32	180	189	O	increasing
33	191	198	O	exposure
34	200	201	O	to
35	203	207	O	other
36	209	213	O	drugs
37	216	216	O	7
38	219	223	O	Drugs
39	225	234	O	prolonging
40	236	238	O	the
41	240	241	O	QT
42	243	250	O	interval
43	251	251	O	:
44	253	254	O	Co
45	256	269	O	administration
46	271	272	O	of
47	274	278	B-DYN	drugs
48	280	289	I-DYN	prolonging
49	291	293	I-DYN	the
50	295	296	I-DYN	QT
51	298	305	L-DYN	interval
52	308	311	O	such
53	313	314	O	as
54	316	320	O	class
55	322	322	O	I
56	324	326	O	and
57	328	330	O	III
58	332	346	U-DYN	antiarrhythmics
59	347	347	O	,
60	349	355	U-DYN	lithium
61	356	356	O	,
62	358	364	O	certain
63	366	379	U-DYN	phenothiazines
64	380	380	O	,
65	382	390	B-DYN	tricyclic
66	392	406	L-DYN	antidepressants
67	407	407	O	,
68	409	415	O	certain
69	417	431	O	fluoroquinolone
70	433	435	O	and
71	437	445	B-DYN	macrolide
72	447	457	L-DYN	antibiotics
73	458	458	O	,
74	460	464	B-DYN	azole
75	466	476	L-DYN	antifungals
76	477	477	O	,
77	479	489	B-DYN	halogenated
78	491	500	I-DYN	inhalation
79	502	511	I-DYN	anesthetic
80	513	518	L-DYN	agents
81	521	529	O	increases
82	531	533	O	the
83	535	538	O	risk
84	540	541	O	of
85	543	549	B-EFF	Torsade
86	551	552	I-EFF	de
87	554	560	L-EFF	Pointes
D/47:85:1 D/58:85:1 D/60:85:1 D/63:85:1 D/65:85:1 D/71:85:1 D/74:85:1 D/77:85:1

Nexterone	432	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	22
Amiodarone is metabolized to the active metabolite desethylamiodarone ( DEA ) by the cytochrome P450 ( CYP450 ) enzyme group , specifically CYP3A and CYP2C8 .
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	27	O	to
5	29	31	O	the
6	33	38	O	active
7	40	49	O	metabolite
8	51	58	O	desethyl
9	59	68	O	XXXXXXXX
10	72	74	O	DEA
11	78	79	O	by
12	81	83	O	the
13	85	94	O	cytochrome
14	96	99	O	P450
15	103	108	O	CYP450
16	112	117	O	enzyme
17	119	123	O	group
18	125	125	O	,
19	127	138	O	specifically
20	140	144	O	CYP3A
21	146	148	O	and
22	150	155	O	CYP2C8
NULL

Nexterone	433	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	15
Antiarrhythmics : The metabolism of quinidine , procainamide , flecainide can be inhibited by amiodarone .
1	0	14	O	Antiarrhythmics
2	16	16	O	:
3	18	20	O	The
4	22	31	O	metabolism
5	33	34	O	of
6	36	44	U-KIN	quinidine
7	46	46	O	,
8	48	59	U-KIN	procainamide
9	61	61	O	,
10	63	72	U-KIN	flecainide
11	74	76	O	can
12	78	79	O	be
13	81	89	O	inhibited
14	91	92	O	by
15	94	103	O	XXXXXXXX
K/10:C54357 K/6:C54357 K/8:C54357

Nexterone	434	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	28
Anticoagulants : Potentiation of warfarin - type ( CYP2C9 and CYP3A substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .
1	0	13	O	Anticoagulants
2	15	15	O	:
3	17	28	O	Potentiation
4	30	31	O	of
5	33	40	U-DYN	warfarin
6	44	47	O	type
7	51	56	O	CYP2C9
8	58	60	O	and
9	62	66	B-DYN	CYP3A
10	68	76	L-DYN	substrate
11	80	92	O	anticoagulant
12	94	101	O	response
13	103	104	O	is
14	106	111	O	almost
15	113	118	O	always
16	120	123	O	seen
17	125	126	O	in
18	128	135	O	patients
19	137	145	O	receiving
20	147	156	O	XXXXXXXX
21	158	160	O	and
22	162	164	O	can
23	166	171	O	result
24	173	174	O	in
25	176	182	O	serious
26	184	185	O	or
27	187	191	O	fatal
28	193	200	U-EFF	bleeding
D/5:28:1 D/9:28:1

Nexterone	435	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	28
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.
1	0	13	O	Anticoagulants
2	14	14	O	:
3	16	27	O	Potentiation
4	29	30	O	of
5	32	39	U-DYN	warfarin
6	41	44	O	type
7	47	52	O	CYP2C9
8	54	56	O	and
9	58	62	O	CYP3A
10	64	72	O	substrate
11	75	87	O	anticoagulant
12	89	96	O	response
13	98	99	O	is
14	101	106	O	almost
15	108	113	O	always
16	115	118	O	seen
17	120	121	O	in
18	123	130	O	patients
19	132	140	O	receiving
20	142	151	O	XXXXXXXX
21	153	155	O	and
22	157	159	O	can
23	161	166	O	result
24	168	169	O	in
25	171	177	O	serious
26	179	180	O	or
27	182	186	O	fatal
28	188	195	U-EFF	bleeding
D/5:28:1

Nexterone	436	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	20
Bradycardia generally occurred within hours to days, but in some cases up to 2 weeks after initiating antiviral treatment.
1	0	10	O	Bradycardia
2	12	20	O	generally
3	22	29	O	occurred
4	31	36	O	within
5	38	42	O	hours
6	44	45	O	to
7	47	50	O	days
8	51	51	O	,
9	53	55	O	but
10	57	58	O	in
11	60	63	O	some
12	65	69	O	cases
13	71	72	O	up
14	74	75	O	to
15	77	77	O	2
16	79	83	O	weeks
17	85	89	O	after
18	91	100	O	initiating
19	102	110	O	antiviral
20	112	120	O	treatment
NULL

Nexterone	437	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	8
Bradycardia generally resolved after discontinuation of antiviral treatment.
1	0	10	O	Bradycardia
2	12	20	O	generally
3	22	29	O	resolved
4	31	35	O	after
5	37	51	O	discontinuation
6	53	54	O	of
7	56	64	O	antiviral
8	66	74	O	treatment
NULL

Nexterone	438	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	31
Cyclosporine ( CYP3A substrate ) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine , despite reduction in dose of cyclosporine .
1	0	11	U-DYN	Cyclosporine
2	15	19	B-DYN	CYP3A
3	21	29	L-DYN	substrate
4	33	44	O	administered
5	46	47	O	in
6	49	59	O	combination
7	61	64	O	with
8	66	69	O	oral
9	71	80	O	XXXXXXXX
10	82	84	O	has
11	86	89	O	been
12	91	98	O	reported
13	100	101	O	to
14	103	109	O	produce
15	111	122	O	persistently
16	124	131	B-TRI	elevated
17	133	138	I-TRI	plasma
18	140	153	L-TRI	concentrations
19	155	156	O	of
20	158	169	O	cyclosporine
21	171	179	O	resulting
22	181	182	O	in
23	184	191	B-EFF	elevated
24	193	202	L-EFF	creatinine
25	204	204	O	,
26	206	212	O	despite
27	214	222	O	reduction
28	224	225	O	in
29	227	230	O	dose
30	232	233	O	of
31	235	246	O	cyclosporine
D/1:23:1 D/2:23:1

Nexterone	439	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	31
Cyclosporine (CYP3A substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.
1	0	11	U-DYN	Cyclosporine
2	14	18	B-DYN	CYP3A
3	20	28	L-DYN	substrate
4	31	42	O	administered
5	44	45	O	in
6	47	57	O	combination
7	59	62	O	with
8	64	67	O	oral
9	69	78	O	XXXXXXXX
10	80	82	O	has
11	84	87	O	been
12	89	96	O	reported
13	98	99	O	to
14	101	107	O	produce
15	109	120	O	persistently
16	122	129	B-TRI	elevated
17	131	136	I-TRI	plasma
18	138	151	L-TRI	concentrations
19	153	154	O	of
20	156	167	O	cyclosporine
21	169	177	O	resulting
22	179	180	O	in
23	182	189	B-EFF	elevated
24	191	200	L-EFF	creatinine
25	201	201	O	,
26	203	209	O	despite
27	211	219	O	reduction
28	221	222	O	in
29	224	227	O	dose
30	229	230	O	of
31	232	243	O	cyclosporine
D/1:23:1 D/2:23:1

Nexterone	440	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	20
Digoxin : In patients receiving digoxin therapy , administration of oral amiodarone results in an increase in serum digoxin concentration .
1	0	6	O	Digoxin
2	8	8	O	:
3	10	11	O	In
4	13	20	O	patients
5	22	30	O	receiving
6	32	38	U-KIN	digoxin
7	40	46	O	therapy
8	48	48	O	,
9	50	63	O	administration
10	65	66	O	of
11	68	71	O	oral
12	73	82	O	XXXXXXXX
13	84	90	O	results
14	92	93	O	in
15	95	96	O	an
16	98	105	O	increase
17	107	108	O	in
18	110	114	O	serum
19	116	122	O	digoxin
20	124	136	O	concentration
K/6:C54357

Nexterone	441	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	53
Drugs that slow heart rate : Concomitant use of drugs with depressant effects on the sinus and AV node ( e.g. , digoxin , beta blockers , verapamil , diltiazem , ivabradine , clonidine ) can potentiate the electrophysiologic and hemodynamic effects of amiodarone , resulting in bradycardia , sinus arrest , and AV block .
1	0	4	O	Drugs
2	6	9	O	that
3	11	14	O	slow
4	16	20	O	heart
5	22	25	O	rate
6	27	27	O	:
7	29	39	O	Concomitant
8	41	43	O	use
9	45	46	O	of
10	48	52	B-DYN	drugs
11	54	57	I-DYN	with
12	59	68	I-DYN	depressant
13	70	76	I-DYN	effects
14	78	79	I-DYN	on
15	81	83	I-DYN	the
16	85	89	I-DYN	sinus
17	91	93	I-DYN	and
18	95	96	I-DYN	AV
19	98	101	L-DYN	node
20	105	107	O	e.g
21	110	110	O	,
22	112	118	U-DYN	digoxin
23	120	120	O	,
24	122	125	B-DYN	beta
25	127	134	L-DYN	blockers
26	136	136	O	,
27	138	146	U-DYN	verapamil
28	148	148	O	,
29	150	158	U-DYN	diltiazem
30	160	160	O	,
31	162	171	U-DYN	ivabradine
32	173	173	O	,
33	175	183	U-DYN	clonidine
34	187	189	O	can
35	191	200	O	potentiate
36	202	204	O	the
37	206	223	O	electrophysiologic
38	225	227	O	and
39	229	239	B-EFF	hemodynamic
40	241	247	L-EFF	effects
41	249	250	O	of
42	252	261	O	XXXXXXXX
43	263	263	O	,
44	265	273	O	resulting
45	275	276	O	in
46	278	288	U-EFF	bradycardia
47	290	290	O	,
48	292	296	B-EFF	sinus
49	298	303	L-EFF	arrest
50	305	305	O	,
51	307	309	O	and
52	311	312	B-EFF	AV
53	314	318	L-EFF	block
D/10:39:1 D/10:46:1 D/10:48:1 D/10:52:1 D/22:39:1 D/22:46:1 D/22:48:1 D/22:52:1 D/24:39:1 D/24:46:1 D/24:48:1 D/24:52:1 D/27:39:1 D/27:46:1 D/27:48:1 D/27:52:1 D/29:39:1 D/29:46:1 D/29:48:1 D/29:52:1 D/31:39:1 D/31:46:1 D/31:48:1 D/31:52:1 D/33:39:1 D/33:46:1 D/33:48:1 D/33:52:1

Nexterone	442	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	26
During transfer to oral amiodarone, reduce the dose levels of previously administered agents by 30 to 50% several days after the addition of oral amiodarone.
1	0	5	O	During
2	7	14	O	transfer
3	16	17	O	to
4	19	22	O	oral
5	24	33	U-KIN	XXXXXXXX
6	34	34	O	,
7	36	41	B-TRI	reduce
8	43	45	I-TRI	the
9	47	50	L-TRI	dose
10	52	57	O	levels
11	59	60	O	of
12	62	71	O	previously
13	73	84	O	administered
14	86	91	O	agents
15	93	94	O	by
16	96	97	O	30
17	99	100	O	to
18	102	104	O	50%
19	106	112	O	several
20	114	117	O	days
21	119	123	O	after
22	125	127	O	the
23	129	136	O	addition
24	138	139	O	of
25	141	144	O	oral
26	146	155	O	XXXXXXXX
K/5:C54355

Nexterone	443	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	31
Effect of amiodarone on other drugs Amiodarone and DEA are inhibitors of P-glycoprotein and certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6 and CYP3A [see Clinical Pharmacology (12.3)].
1	0	5	O	Effect
2	7	8	O	of
3	10	19	O	XXXXXXXX
4	21	22	O	on
5	24	28	O	other
6	30	34	O	drugs
7	36	45	O	XXXXXXXX
8	47	49	O	and
9	51	53	O	DEA
10	55	57	O	are
11	59	68	O	inhibitors
12	70	71	O	of
13	73	73	O	P
14	75	86	O	glycoprotein
15	88	90	O	and
16	92	98	O	certain
17	100	105	O	CYP450
18	107	113	O	enzymes
19	114	114	O	,
20	116	124	O	including
21	126	131	O	CYP1A2
22	132	132	O	,
23	134	139	O	CYP2C9
24	140	140	O	,
25	142	147	O	CYP2D6
26	149	151	O	and
27	153	157	O	CYP3A
28	160	162	O	see
29	164	171	O	Clinical
30	173	184	O	Pharmacology
31	187	190	O	12.3
NULL

Nexterone	444	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	28
Effect of other drugs on amiodarone Amiodarone is metabolized to the active metabolite desethylamiodarone (DEA) by the cytochrome P450 (CYP450) enzyme group, specifically CYP3A and CYP2C8.
1	0	5	O	Effect
2	7	8	O	of
3	10	14	O	other
4	16	20	O	drugs
5	22	23	O	on
6	25	34	O	XXXXXXXX
7	36	45	O	XXXXXXXX
8	47	48	O	is
9	50	60	O	metabolized
10	62	63	O	to
11	65	67	O	the
12	69	74	O	active
13	76	85	O	metabolite
14	87	94	O	desethyl
15	95	104	O	XXXXXXXX
16	107	109	O	DEA
17	112	113	O	by
18	115	117	O	the
19	119	128	O	cytochrome
20	130	133	O	P450
21	136	141	O	CYP450
22	144	149	O	enzyme
23	151	155	O	group
24	156	156	O	,
25	158	169	O	specifically
26	171	175	O	CYP3A
27	177	179	O	and
28	181	186	O	CYP2C8
NULL

Nexterone	445	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	18
HMG-CoA Reductase Inhibitors : Limit the dose of simvastatin in patients on amiodarone to 20 mg daily .
1	0	2	B-UNK	HMG
2	4	6	I-UNK	CoA
3	8	16	I-UNK	Reductase
4	18	27	L-UNK	Inhibitors
5	29	29	O	:
6	31	35	B-TRI	Limit
7	37	39	I-TRI	the
8	41	44	L-TRI	dose
9	46	47	O	of
10	49	59	U-UNK	simvastatin
11	61	62	O	in
12	64	71	O	patients
13	73	74	O	on
14	76	85	O	XXXXXXXX
15	87	88	O	to
16	90	91	O	20
17	93	94	O	mg
18	96	100	O	daily
NULL

Nexterone	446	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	22
If digitalis treatment is continued, monitor serum levels closely and observe patients for clinical evidence of toxicity [see Clinical Pharmacology (12.3)].
1	0	1	O	If
2	3	11	O	digitalis
3	13	21	O	treatment
4	23	24	O	is
5	26	34	O	continued
6	35	35	O	,
7	37	43	O	monitor
8	45	49	O	serum
9	51	56	O	levels
10	58	64	O	closely
11	66	68	O	and
12	70	76	O	observe
13	78	85	O	patients
14	87	89	O	for
15	91	98	O	clinical
16	100	107	O	evidence
17	109	110	O	of
18	112	119	O	toxicity
19	122	124	O	see
20	126	133	O	Clinical
21	135	146	O	Pharmacology
22	149	152	O	12.3
NULL

Nexterone	447	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	18
In general, avoid concomitant use of drugs that prolong the QT interval [see Warnings and Precautions (5.4)].
1	0	1	O	In
2	3	9	O	general
3	10	10	O	,
4	12	16	U-TRI	avoid
5	18	28	O	concomitant
6	30	32	O	use
7	34	35	O	of
8	37	41	B-UNK	drugs
9	43	46	I-UNK	that
10	48	54	I-UNK	prolong
11	56	58	I-UNK	the
12	60	61	I-UNK	QT
13	63	70	L-UNK	interval
14	73	75	O	see
15	77	84	O	Warnings
16	86	88	O	and
17	90	100	O	Precautions
18	103	105	O	5.4
NULL

Nexterone	448	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	19
In general, initiate any added antiarrhythmic drug at a lower than usual dose and monitor the patient carefully.
1	0	1	O	In
2	3	9	O	general
3	10	10	O	,
4	12	19	O	initiate
5	21	23	O	any
6	25	29	O	added
7	31	44	B-UNK	antiarrhythmic
8	46	49	L-UNK	drug
9	51	52	O	at
10	54	54	O	a
11	56	60	O	lower
12	62	65	O	than
13	67	71	O	usual
14	73	76	O	dose
15	78	80	O	and
16	82	88	U-TRI	monitor
17	90	92	O	the
18	94	100	O	patient
19	102	110	O	carefully
NULL

Nexterone	449	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	35
In view of the long and variable half-life of amiodarone, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of amiodarone [see Clinical Pharmacology (12.3)].
1	0	1	O	In
2	3	6	O	view
3	8	9	O	of
4	11	13	O	the
5	15	18	O	long
6	20	22	O	and
7	24	31	O	variable
8	33	36	O	half
9	38	41	O	life
10	43	44	O	of
11	46	55	O	XXXXXXXX
12	56	56	O	,
13	58	66	O	potential
14	68	70	O	for
15	72	75	O	drug
16	77	88	O	interactions
17	90	95	O	exists
18	97	99	O	not
19	101	104	O	only
20	106	109	O	with
21	111	121	O	concomitant
22	123	132	O	medication
23	134	136	O	but
24	138	141	O	also
25	143	146	O	with
26	148	152	O	drugs
27	154	165	O	administered
28	167	171	O	after
29	173	187	O	discontinuation
30	189	190	O	of
31	192	201	O	XXXXXXXX
32	204	206	O	see
33	208	215	O	Clinical
34	217	228	O	Pharmacology
35	231	234	O	12.3
NULL

Nexterone	450	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	14
Increased steady-state levels of phenytoin during concomitant therapy with amiodarone have been reported.
1	0	8	B-TRI	Increased
2	10	15	I-TRI	steady
3	17	21	I-TRI	state
4	23	28	L-TRI	levels
5	30	31	O	of
6	33	41	U-KIN	phenytoin
7	43	48	O	during
8	50	60	O	concomitant
9	62	68	O	therapy
10	70	73	O	with
11	75	84	O	XXXXXXXX
12	86	89	O	have
13	91	94	O	been
14	96	103	O	reported
K/6:C54611

Nexterone	451	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	34
Limit the daily dose of lovastatin to 40 mg. Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as amiodarone may increase the plasma concentration of these drugs.
1	0	4	B-TRI	Limit
2	6	8	I-TRI	the
3	10	14	I-TRI	daily
4	16	19	L-TRI	dose
5	21	22	O	of
6	24	33	U-KIN	lovastatin
7	35	36	O	to
8	38	39	O	40
9	41	42	O	mg
10	45	49	O	Lower
11	51	58	O	starting
12	60	62	O	and
13	64	74	O	maintenance
14	76	80	O	doses
15	82	83	O	of
16	85	89	O	other
17	91	96	B-KIN	CYP3A4
18	98	107	L-KIN	substrates
19	110	112	O	e.g
20	114	114	O	,
21	116	127	U-KIN	atorvastatin
22	130	132	O	may
23	134	135	O	be
24	137	144	O	required
25	146	147	O	as
26	149	158	O	XXXXXXXX
27	160	162	O	may
28	164	171	O	increase
29	173	175	O	the
30	177	182	O	plasma
31	184	196	O	concentration
32	198	199	O	of
33	201	205	O	these
34	207	211	O	drugs
K/17:C54357 K/21:C54357 K/6:C54357

Nexterone	452	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	25
Lower starting and maintenance doses of other CYP3A4 substrates ( e.g. , atorvastatin ) may be required as amiodarone may increase the plasma concentration of these drugs .
1	0	4	O	Lower
2	6	13	O	starting
3	15	17	O	and
4	19	29	O	maintenance
5	31	35	O	doses
6	37	38	O	of
7	40	44	O	other
8	46	51	B-KIN	CYP3A4
9	53	62	L-KIN	substrates
10	66	68	O	e.g
11	71	71	O	,
12	73	84	U-KIN	atorvastatin
13	88	90	O	may
14	92	93	O	be
15	95	102	O	required
16	104	105	O	as
17	107	116	O	XXXXXXXX
18	118	120	B-TRI	may
19	122	129	I-TRI	increase
20	131	133	I-TRI	the
21	135	140	I-TRI	plasma
22	142	154	L-TRI	concentration
23	156	157	O	of
24	159	163	O	these
25	165	169	O	drugs
K/12:C54357 K/8:C54357

Nexterone	453	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	12
Monitor cyclosporine drug levels and renal function in patients taking both drugs.
1	0	6	O	Monitor
2	8	19	U-UNK	cyclosporine
3	21	24	O	drug
4	26	31	O	levels
5	33	35	O	and
6	37	41	O	renal
7	43	50	O	function
8	52	53	O	in
9	55	62	O	patients
10	64	69	O	taking
11	71	74	O	both
12	76	80	O	drugs
NULL

Nexterone	454	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	14
Monitor heart rate in patients on amiodarone and concomitant drugs that slow heart rate.
1	0	6	O	Monitor
2	8	12	O	heart
3	14	17	O	rate
4	19	20	O	in
5	22	29	O	patients
6	31	32	O	on
7	34	43	U-DYN	XXXXXXXX
8	45	47	O	and
9	49	59	O	concomitant
10	61	65	B-DYN	drugs
11	67	70	I-DYN	that
12	72	75	I-DYN	slow
13	77	81	I-DYN	heart
14	83	86	L-DYN	rate
NULL

Nexterone	455	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	14
Monitor heart rate in patients taking or recently discontinuing amiodarone when starting antiviral treatment .
1	0	6	O	Monitor
2	8	12	O	heart
3	14	17	O	rate
4	19	20	O	in
5	22	29	O	patients
6	31	36	O	taking
7	38	39	O	or
8	41	48	O	recently
9	50	62	O	discontinuing
10	64	73	O	XXXXXXXX
11	75	78	O	when
12	80	87	O	starting
13	89	97	U-UNK	antiviral
14	99	107	O	treatment
NULL

Nexterone	456	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	8
Monitor phenytoin levels in patients taking both drugs.
1	0	6	O	Monitor
2	8	16	O	phenytoin
3	18	23	O	levels
4	25	26	O	in
5	28	35	O	patients
6	37	42	O	taking
7	44	47	O	both
8	49	53	O	drugs
NULL

Nexterone	457	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	20
Patients should avoid grapefruit juice beverages while taking amiodarone because exposure to amiodarone is significantly increased [see Clinical Pharmacology (12.3)].
1	0	7	O	Patients
2	9	14	O	should
3	16	20	O	avoid
4	22	31	B-KIN	grapefruit
5	33	37	L-KIN	juice
6	39	47	O	beverages
7	49	53	O	while
8	55	60	O	taking
9	62	71	O	XXXXXXXX
10	73	79	O	because
11	81	88	O	exposure
12	90	91	O	to
13	93	102	O	XXXXXXXX
14	104	105	O	is
15	107	119	O	significantly
16	121	129	O	increased
17	132	134	O	see
18	136	143	O	Clinical
19	145	156	O	Pharmacology
20	159	162	O	12.3
K/4:C54355

Nexterone	458	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	33
Postmarketing cases of symptomatic bradycardia , some requiring pacemaker insertion and at least one fatal , have been reported when ledipasvir/sofosbuvir or sofosbuvir with simeprevir were initiated in patients on amiodarone .
1	0	12	O	Postmarketing
2	14	18	O	cases
3	20	21	O	of
4	23	33	O	symptomatic
5	35	45	U-EFF	bradycardia
6	47	47	O	,
7	49	52	O	some
8	54	62	O	requiring
9	64	72	O	pacemaker
10	74	82	O	insertion
11	84	86	O	and
12	88	89	O	at
13	91	95	O	least
14	97	99	O	one
15	101	105	O	fatal
16	107	107	O	,
17	109	112	O	have
18	114	117	O	been
19	119	126	O	reported
20	128	131	O	when
21	133	142	U-DYN	ledipasvir
22	143	143	O	/
23	144	153	U-DYN	sofosbuvir
24	155	156	O	or
25	158	167	O	sofosbuvir
26	169	172	O	with
27	174	183	U-DYN	simeprevir
28	185	188	O	were
29	190	198	O	initiated
30	200	201	O	in
31	203	210	O	patients
32	212	213	O	on
33	215	224	O	XXXXXXXX
D/21:5:1 D/23:5:1 D/27:5:1

Nexterone	459	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	9
Reduce dose of digoxin by half or discontinue digoxin.
1	0	5	O	Reduce
2	7	10	O	dose
3	12	13	O	of
4	15	21	U-UNK	digoxin
5	23	24	O	by
6	26	29	O	half
7	31	32	O	or
8	34	44	O	discontinue
9	46	52	O	digoxin
NULL

Nexterone	460	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	25
Review the continued need for the other antiarrhythmic agent after the effects of amiodarone have been established , and attempt discontinuation see Clinical Pharmacology ( 12.3 ) .
1	0	5	O	Review
2	7	9	O	the
3	11	19	O	continued
4	21	24	O	need
5	26	28	O	for
6	30	32	O	the
7	34	38	O	other
8	40	53	O	antiarrhythmic
9	55	59	O	agent
10	61	65	O	after
11	67	69	O	the
12	71	77	O	effects
13	79	80	O	of
14	82	91	O	XXXXXXXX
15	93	96	O	have
16	98	101	O	been
17	103	113	O	established
18	115	115	O	,
19	117	119	O	and
20	121	127	O	attempt
21	129	143	O	discontinuation
22	145	147	O	see
23	149	156	O	Clinical
24	158	169	O	Pharmacology
25	173	176	O	12.3
NULL

Nexterone	461	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	37
Since the concomitant administration of warfarin with amiodarone increases the INR by 100 % after 3 to 4 days , reduce the dose of the anticoagulant by one-third to one-half , and monitor INR closely .
1	0	4	O	Since
2	6	8	O	the
3	10	20	O	concomitant
4	22	35	O	administration
5	37	38	O	of
6	40	47	U-DYN	warfarin
7	49	52	O	with
8	54	63	O	XXXXXXXX
9	65	73	B-EFF	increases
10	75	77	I-EFF	the
11	79	81	L-EFF	INR
12	83	84	O	by
13	86	88	O	100
14	90	90	O	%
15	92	96	O	after
16	98	98	O	3
17	100	101	O	to
18	103	103	O	4
19	105	108	O	days
20	110	110	O	,
21	112	117	O	reduce
22	119	121	O	the
23	123	126	O	dose
24	128	129	O	of
25	131	133	O	the
26	135	147	O	anticoagulant
27	149	150	O	by
28	152	154	O	one
29	156	160	O	third
30	162	163	O	to
31	165	167	O	one
32	169	172	O	half
33	174	174	O	,
34	176	178	O	and
35	180	186	O	monitor
36	188	190	O	INR
37	192	198	O	closely
D/6:9:1

Nexterone	462	34073-7	e9108958-b8d7-4fba-87c3-9a32990de551	7
The mechanism for this effect is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	16	O	for
4	18	21	O	this
5	23	28	O	effect
6	30	31	O	is
7	33	39	O	unknown
NULL

Nexterone	463	43685-7	e9108958-b8d7-4fba-87c3-9a32990de551	33
Amiodarone inhibits peripheral conversion of thyroxine ( T4 ) to triiodothyronine ( T3 ) and may cause increased T4 levels , decreased T3 levels , and increased levels of inactive reverse T3 ( rT3 ) in clinically euthyroid patients .
1	0	9	O	XXXXXXXX
2	11	18	O	inhibits
3	20	29	O	peripheral
4	31	40	O	conversion
5	42	43	O	of
6	45	53	B-KIN	thyroxine
7	57	58	L-KIN	T4
8	62	63	O	to
9	65	80	B-KIN	triiodothyronine
10	84	85	L-KIN	T3
11	89	91	O	and
12	93	95	O	may
13	97	101	O	cause
14	103	111	O	increased
15	113	114	O	T4
16	116	121	O	levels
17	123	123	O	,
18	125	133	O	decreased
19	135	136	O	T3
20	138	143	O	levels
21	145	145	O	,
22	147	149	O	and
23	151	159	O	increased
24	161	166	O	levels
25	168	169	O	of
26	171	178	O	inactive
27	180	186	O	reverse
28	188	189	O	T3
29	193	195	O	rT3
30	199	200	O	in
31	202	211	O	clinically
32	213	221	O	euthyroid
33	223	230	O	patients
K/6:C54357 K/9:C54358

Nexterone	464	43685-7	e9108958-b8d7-4fba-87c3-9a32990de551	19
Amiodarone is also a potential source of large amounts of inorganic iodine and can cause either hypothyroidism or hyperthyroidism .
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	17	O	also
4	19	19	O	a
5	21	29	O	potential
6	31	36	O	source
7	38	39	O	of
8	41	45	O	large
9	47	53	O	amounts
10	55	56	O	of
11	58	66	O	inorganic
12	68	73	O	iodine
13	75	77	O	and
14	79	81	O	can
15	83	87	O	cause
16	89	94	O	either
17	96	109	O	hypothyroidism
18	111	112	O	or
19	114	128	O	hyperthyroidism
NULL

Nexterone	465	43685-7	e9108958-b8d7-4fba-87c3-9a32990de551	34
Because of the long half-life of amiodarone and its metabolite desethylamiodarone , the potential for adverse reactions or interactions , as well as observed adverse effects , can persist following amiodarone withdrawal .
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	18	O	long
5	20	23	O	half
6	25	28	O	life
7	30	31	O	of
8	33	42	O	XXXXXXXX
9	44	46	O	and
10	48	50	O	its
11	52	61	O	metabolite
12	63	70	O	desethyl
13	71	80	O	XXXXXXXX
14	82	82	O	,
15	84	86	O	the
16	88	96	O	potential
17	98	100	O	for
18	102	108	O	adverse
19	110	118	O	reactions
20	120	121	O	or
21	123	134	O	interactions
22	136	136	O	,
23	138	139	O	as
24	141	144	O	well
25	146	147	O	as
26	149	156	O	observed
27	158	164	O	adverse
28	166	172	O	effects
29	174	174	O	,
30	176	178	O	can
31	180	186	O	persist
32	188	196	O	following
33	198	207	O	XXXXXXXX
34	209	218	O	withdrawal
NULL

Nexterone	466	43685-7	e9108958-b8d7-4fba-87c3-9a32990de551	28
Like all antiarrhythmic agents , NEXTERONE may cause a worsening of existing arrhythmias or precipitate a new arrhythmia , sometimes leading to fatal outcomes see Adverse Reactions ( 6.2 ) .
1	0	3	O	Like
2	5	7	O	all
3	9	22	O	antiarrhythmic
4	24	29	O	agents
5	31	31	O	,
6	33	41	O	XXXXXXXX
7	43	45	O	may
8	47	51	O	cause
9	53	53	O	a
10	55	63	O	worsening
11	65	66	O	of
12	68	75	O	existing
13	77	87	O	arrhythmias
14	89	90	O	or
15	92	102	O	precipitate
16	104	104	O	a
17	106	108	O	new
18	110	119	O	arrhythmia
19	121	121	O	,
20	123	131	O	sometimes
21	133	139	O	leading
22	141	142	O	to
23	144	148	O	fatal
24	150	157	O	outcomes
25	159	161	O	see
26	163	169	O	Adverse
27	171	179	O	Reactions
28	183	185	O	6.2
NULL

Nexterone	467	43685-7	e9108958-b8d7-4fba-87c3-9a32990de551	18
Manage hypothyroidism by reducing the dose of or discontinuing NEXTERONE and considering the need for thyroid hormone supplement .
1	0	5	O	Manage
2	7	20	O	hypothyroidism
3	22	23	O	by
4	25	32	O	reducing
5	34	36	O	the
6	38	41	O	dose
7	43	44	O	of
8	46	47	O	or
9	49	61	O	discontinuing
10	63	71	O	XXXXXXXX
11	73	75	O	and
12	77	87	O	considering
13	89	91	O	the
14	93	96	O	need
15	98	100	O	for
16	102	108	O	thyroid
17	110	116	O	hormone
18	118	127	O	supplement
NULL

Nexterone	468	43685-7	e9108958-b8d7-4fba-87c3-9a32990de551	31
Perform close perioperative monitoring in patients undergoing general anesthesia who are on amiodarone therapy as they may be more sensitive to the myocardial depressant and conduction defects of halogenated inhalational anesthetics .
1	0	6	O	Perform
2	8	12	O	close
3	14	26	O	perioperative
4	28	37	O	monitoring
5	39	40	O	in
6	42	49	O	patients
7	51	60	O	undergoing
8	62	68	O	general
9	70	79	O	anesthesia
10	81	83	O	who
11	85	87	O	are
12	89	90	O	on
13	92	101	O	XXXXXXXX
14	103	109	O	therapy
15	111	112	O	as
16	114	117	O	they
17	119	121	O	may
18	123	124	O	be
19	126	129	O	more
20	131	139	O	sensitive
21	141	142	O	to
22	144	146	O	the
23	148	157	B-EFF	myocardial
24	159	168	L-EFF	depressant
25	170	172	O	and
26	174	183	B-EFF	conduction
27	185	191	L-EFF	defects
28	193	194	O	of
29	196	206	B-DYN	halogenated
30	208	219	I-DYN	inhalational
31	221	231	L-DYN	anesthetics
D/29:23:1 D/29:26:1

Nexterone	469	43685-7	e9108958-b8d7-4fba-87c3-9a32990de551	28
Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent .
1	0	6	O	Reserve
2	8	10	O	the
3	12	22	O	combination
4	24	25	O	of
5	27	36	O	XXXXXXXX
6	38	41	O	with
7	43	47	O	other
8	49	62	O	antiarrhythmic
9	64	72	O	therapies
10	74	77	O	that
11	79	85	O	prolong
12	87	89	O	the
13	91	93	O	QTc
14	95	96	O	to
15	98	105	O	patients
16	107	110	O	with
17	112	115	O	life
18	117	127	O	threatening
19	129	139	O	ventricular
20	141	151	O	arrhythmias
21	153	155	O	who
22	157	159	O	are
23	161	172	O	incompletely
24	174	183	O	responsive
25	185	186	O	to
26	188	188	O	a
27	190	195	O	single
28	197	201	O	agent
NULL

Nexterone	470	43685-7	e9108958-b8d7-4fba-87c3-9a32990de551	19
Since NEXTERONE contains dextrose , patients with allergy to corn or corn products are at risk for allergic reaction .
1	0	4	O	Since
2	6	14	O	XXXXXXXX
3	16	23	O	contains
4	25	32	O	dextrose
5	34	34	O	,
6	36	43	O	patients
7	45	48	O	with
8	50	56	O	allergy
9	58	59	O	to
10	61	64	O	corn
11	66	67	O	or
12	69	72	O	corn
13	74	81	O	products
14	83	85	O	are
15	87	88	O	at
16	90	93	O	risk
17	95	97	O	for
18	99	106	O	allergic
19	108	115	O	reaction
NULL

NitroMist	67	34068-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	23
After an initial priming of 10 sprays , each metered spray of NitroMist delivers 33 mg of solution containing 400 mcg of nitroglycerin .
1	0	4	O	After
2	6	7	O	an
3	9	15	O	initial
4	17	23	O	priming
5	25	26	O	of
6	28	29	O	10
7	31	36	O	sprays
8	38	38	O	,
9	40	43	O	each
10	45	51	O	metered
11	53	57	O	spray
12	59	60	O	of
13	62	70	O	XXXXXXXX
14	72	79	O	delivers
15	81	82	O	33
16	84	85	O	mg
17	87	88	O	of
18	90	97	O	solution
19	99	108	O	containing
20	110	112	O	400
21	114	116	O	mcg
22	118	119	O	of
23	121	133	O	XXXXXXXX
NULL

NitroMist	68	34070-3	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	50
Administration of NitroMist is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate ( cGMP ) - specific phosphodiesterase type 5 ( PDE5 ) , as PDE5 inhibitors such as sildenafil , vardenafil , and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates see DRUG INTERACTIONS ( 7.1 ) .
1	0	13	O	Administration
2	15	16	O	of
3	18	26	O	XXXXXXXX
4	28	29	O	is
5	31	45	O	contraindicated
6	47	48	O	in
7	50	57	O	patients
8	59	61	O	who
9	63	65	O	are
10	67	71	O	using
11	73	73	O	a
12	75	83	O	selective
13	85	93	O	inhibitor
14	95	96	O	of
15	98	103	O	cyclic
16	105	113	O	guanosine
17	115	127	O	monophosphate
18	131	134	O	cGMP
19	140	147	O	specific
20	149	165	O	phosphodiesterase
21	167	170	O	type
22	172	172	O	5
23	176	179	O	PDE5
24	183	183	O	,
25	185	186	O	as
26	188	191	B-DYN	PDE5
27	193	202	L-DYN	inhibitors
28	204	207	O	such
29	209	210	O	as
30	212	221	U-DYN	sildenafil
31	223	223	O	,
32	225	234	U-DYN	vardenafil
33	236	236	O	,
34	238	240	O	and
35	242	250	U-DYN	tadalafil
36	252	255	O	have
37	257	260	O	been
38	262	266	O	shown
39	268	269	O	to
40	271	280	O	potentiate
41	282	284	O	the
42	286	296	B-EFF	hypotensive
43	298	304	L-EFF	effects
44	306	307	O	of
45	309	315	O	organic
46	317	324	O	nitrates
47	326	328	O	see
48	330	333	O	DRUG
49	335	346	O	INTERACTIONS
50	350	352	O	7.1
D/26:42:1 D/30:42:1 D/32:42:1 D/35:42:1

NitroMist	69	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	7
(7.5) Ergotamine: increased bioavailability of ergotamine.
1	1	3	O	7.5
2	6	15	U-KIN	Ergotamine
3	16	16	O	:
4	18	26	B-TRI	increased
5	28	42	L-TRI	bioavailability
6	44	45	O	of
7	47	56	O	ergotamine
K/2:C54357

NitroMist	70	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	23
(7.6) Administration of NitroMist is contraindicated in patients who are using a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type5 (PDE5).
1	1	3	O	7.6
2	6	19	O	Administration
3	21	22	O	of
4	24	32	O	XXXXXXXX
5	34	35	O	is
6	37	51	U-TRI	contraindicated
7	53	54	O	in
8	56	63	O	patients
9	65	67	O	who
10	69	71	O	are
11	73	77	O	using
12	79	79	O	a
13	81	89	B-UNK	selective
14	91	99	I-UNK	inhibitor
15	101	102	I-UNK	of
16	104	109	I-UNK	cyclic
17	111	119	I-UNK	guanosine
18	121	133	I-UNK	monophosphate
19	136	139	I-UNK	cGMP
20	142	149	I-UNK	specific
21	151	167	I-UNK	phosphodiesterase
22	169	173	I-UNK	type5
23	176	179	L-UNK	PDE5
NULL

NitroMist	71	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	15
Activated partial thromboplastin times ( APTT ) should be monitored in patients receiving heparin and intravenous nitroglycerin .
1	0	8	O	Activated
2	10	16	O	partial
3	18	31	O	thromboplastin
4	33	37	O	times
5	41	44	O	APTT
6	48	53	B-TRI	should
7	55	56	I-TRI	be
8	58	66	L-TRI	monitored
9	68	69	O	in
10	71	78	O	patients
11	80	88	O	receiving
12	90	96	U-UNK	heparin
13	98	100	O	and
14	102	112	O	intravenous
15	114	126	O	XXXXXXXX
NULL

NitroMist	72	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	15
Activated partial thromboplastin times (APTT) should be monitored in patients receiving heparin and intravenous nitroglycerin.
1	0	8	O	Activated
2	10	16	O	partial
3	18	31	O	thromboplastin
4	33	37	O	times
5	40	43	O	APTT
6	46	51	B-TRI	should
7	53	54	I-TRI	be
8	56	64	L-TRI	monitored
9	66	67	O	in
10	69	76	O	patients
11	78	86	O	receiving
12	88	94	U-UNK	heparin
13	96	98	O	and
14	100	110	O	intravenous
15	112	124	O	XXXXXXXX
NULL

NitroMist	73	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	34
Appropriate supportive care for the severe hypotension has not been studied, but it seems reasonable to treat this as a nitrate overdose, with elevation of the extremities and with central volume expansion.
1	0	10	O	Appropriate
2	12	21	O	supportive
3	23	26	O	care
4	28	30	O	for
5	32	34	O	the
6	36	41	O	severe
7	43	53	O	hypotension
8	55	57	O	has
9	59	61	O	not
10	63	66	O	been
11	68	74	O	studied
12	75	75	O	,
13	77	79	O	but
14	81	82	O	it
15	84	88	O	seems
16	90	99	O	reasonable
17	101	102	O	to
18	104	108	O	treat
19	110	113	O	this
20	115	116	O	as
21	118	118	O	a
22	120	126	O	nitrate
23	128	135	O	overdose
24	136	136	O	,
25	138	141	O	with
26	143	151	O	elevation
27	153	154	O	of
28	156	158	O	the
29	160	170	O	extremities
30	172	174	O	and
31	176	179	O	with
32	181	187	O	central
33	189	194	O	volume
34	196	204	O	expansion
NULL

NitroMist	74	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	6
Aspirin : increased nitroglycerin levels ( 7.3 ) .
1	0	6	U-KIN	Aspirin
2	8	8	O	:
3	10	18	B-TRI	increased
4	20	32	I-TRI	XXXXXXXX
5	34	39	L-TRI	levels
6	43	45	O	7.3
K/1:C54355

NitroMist	75	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	32
Coadministration of aspirin and nitroglycerin has been reported to result in increased nitroglycerin maximum concentrations by as much as 67 % and AUC by 73 % when administered as a single dose .
1	0	15	O	Coadministration
2	17	18	O	of
3	20	26	U-KIN	aspirin
4	28	30	O	and
5	32	44	O	XXXXXXXX
6	46	48	O	has
7	50	53	O	been
8	55	62	O	reported
9	64	65	O	to
10	67	72	O	result
11	74	75	O	in
12	77	85	O	increased
13	87	99	O	XXXXXXXX
14	101	107	O	maximum
15	109	122	O	concentrations
16	124	125	O	by
17	127	128	O	as
18	130	133	O	much
19	135	136	O	as
20	138	139	O	67
21	141	141	O	%
22	143	145	O	and
23	147	149	O	AUC
24	151	152	O	by
25	154	155	O	73
26	157	157	O	%
27	159	162	O	when
28	164	175	O	administered
29	177	178	O	as
30	180	180	O	a
31	182	187	O	single
32	189	192	O	dose
K/3:C54605

NitroMist	76	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	7
Ergotamine is known to precipitate angina pectoris.
1	0	9	O	Ergotamine
2	11	12	O	is
3	14	18	O	known
4	20	21	O	to
5	23	33	O	precipitate
6	35	40	O	angina
7	42	49	O	pectoris
NULL

NitroMist	77	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	17
If labetolol is used with nitroglycerin in patients with angina pectoris , additional hypotensive effects may occur .
1	0	1	O	If
2	3	11	U-DYN	labetolol
3	13	14	O	is
4	16	19	O	used
5	21	24	O	with
6	26	38	O	XXXXXXXX
7	40	41	O	in
8	43	50	O	patients
9	52	55	O	with
10	57	62	O	angina
11	64	71	O	pectoris
12	73	73	O	,
13	75	84	O	additional
14	86	96	B-EFF	hypotensive
15	98	104	L-EFF	effects
16	106	108	O	may
17	110	114	O	occur
D/2:14:1

NitroMist	78	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	15
Intravenous administration of nitroglycerin decreases the thrombolytic effect of tissue-type plasminogen activator ( t-PA ) .
1	0	10	O	Intravenous
2	12	25	O	administration
3	27	28	O	of
4	30	42	O	XXXXXXXX
5	44	52	O	decreases
6	54	56	O	the
7	58	69	O	thrombolytic
8	71	76	O	effect
9	78	79	O	of
10	81	86	B-DYN	tissue
11	88	91	I-DYN	type
12	93	103	I-DYN	plasminogen
13	105	113	I-DYN	activator
14	117	117	I-DYN	t
15	119	120	L-DYN	PA
NULL

NitroMist	79	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	8
Intravenous nitroglycerin reduces the anticoagulant effect of heparin .
1	0	10	O	Intravenous
2	12	24	O	XXXXXXXX
3	26	32	B-EFF	reduces
4	34	36	I-EFF	the
5	38	50	I-EFF	anticoagulant
6	52	57	L-EFF	effect
7	59	60	O	of
8	62	68	U-DYN	heparin
D/8:3:1

NitroMist	80	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	12
It is not known if this effect occurs following single nitroglycerin doses.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	14	O	known
5	16	17	O	if
6	19	22	O	this
7	24	29	O	effect
8	31	36	O	occurs
9	38	46	O	following
10	48	53	O	single
11	55	67	O	XXXXXXXX
12	69	73	O	doses
NULL

NitroMist	81	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	13
Labetolol blunts the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effects .
1	0	8	O	Labetolol
2	10	15	O	blunts
3	17	19	O	the
4	21	26	O	reflex
5	28	38	O	tachycardia
6	40	47	O	produced
7	49	50	O	by
8	52	64	O	XXXXXXXX
9	66	72	O	without
10	74	83	O	preventing
11	85	87	O	its
12	89	99	O	hypotensive
13	101	107	O	effects
NULL

NitroMist	82	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	16
Marked orthostatic hypotension has been reported when calcium channel blockers and organic nitrates were used concomitantly.
1	0	5	B-EFF	Marked
2	7	17	I-EFF	orthostatic
3	19	29	L-EFF	hypotension
4	31	33	O	has
5	35	38	O	been
6	40	47	O	reported
7	49	52	O	when
8	54	60	B-DYN	calcium
9	62	68	I-DYN	channel
10	70	77	L-DYN	blockers
11	79	81	O	and
12	83	89	O	organic
13	91	98	O	nitrates
14	100	103	O	were
15	105	108	O	used
16	110	122	O	concomitantly
D/8:1:1

NitroMist	83	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	18
Oral administration of nitroglycerin markedly decreases the first-pass metabolism of dihydroergotamine and subsequently increases its oral bioavailability .
1	0	3	O	Oral
2	5	18	O	administration
3	20	21	O	of
4	23	35	O	XXXXXXXX
5	37	44	O	markedly
6	46	54	O	decreases
7	56	58	O	the
8	60	64	O	first
9	66	69	O	pass
10	71	80	O	metabolism
11	82	83	O	of
12	85	101	U-KIN	dihydroergotamine
13	103	105	O	and
14	107	118	O	subsequently
15	120	128	O	increases
16	130	132	O	its
17	134	137	O	oral
18	139	153	O	bioavailability
K/12:C54357

NitroMist	84	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	19
Patients receiving antihypertensive drugs, beta-adrenergic blockers, and nitrates should be observed for possible additive hypotensive effects.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	34	B-DYN	antihypertensive
4	36	40	L-DYN	drugs
5	41	41	O	,
6	43	46	B-DYN	beta
7	48	57	I-DYN	adrenergic
8	59	66	L-DYN	blockers
9	67	67	O	,
10	69	71	O	and
11	73	80	U-DYN	nitrates
12	82	87	O	should
13	89	90	O	be
14	92	99	O	observed
15	101	103	O	for
16	105	112	O	possible
17	114	121	O	additive
18	123	133	B-EFF	hypotensive
19	135	141	L-EFF	effects
D/11:18:1 D/3:18:1 D/6:18:1

NitroMist	85	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	21
PDE5 inhibitors such as sildenafil, vardenafil, and tadalafil have been shown to potentiate the hypotensive effects of organic nitrates.
1	0	3	B-DYN	PDE5
2	5	14	L-DYN	inhibitors
3	16	19	O	such
4	21	22	O	as
5	24	33	U-DYN	sildenafil
6	34	34	O	,
7	36	45	U-DYN	vardenafil
8	46	46	O	,
9	48	50	O	and
10	52	60	U-DYN	tadalafil
11	62	65	O	have
12	67	70	O	been
13	72	76	O	shown
14	78	79	O	to
15	81	90	O	potentiate
16	92	94	O	the
17	96	106	B-EFF	hypotensive
18	108	114	L-EFF	effects
19	116	117	O	of
20	119	125	O	organic
21	127	134	O	nitrates
D/1:17:1 D/10:17:1 D/5:17:1 D/7:17:1

NitroMist	86	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	42
PDE5 inhibitors: Concomitant use contraindicated (4.1, 7.1) Antihypertensives: Possible additive hypotensive effects (7.2) Aspirin: increased nitroglycerin levels (7.3) Tissue-type plasminogen activator (t-PA): decreased thrombolytic effect (7.4) Heparin: anticoagulant effect of heparin may be reduced.
1	0	3	B-UNK	PDE5
2	5	14	L-UNK	inhibitors
3	15	15	O	:
4	17	27	O	Concomitant
5	29	31	O	use
6	33	47	U-TRI	contraindicated
7	50	52	O	4.1
8	53	53	O	,
9	55	57	O	7.1
10	60	76	U-DYN	Antihypertensives
11	77	77	O	:
12	79	86	O	Possible
13	88	95	B-EFF	additive
14	97	107	I-EFF	hypotensive
15	109	115	L-EFF	effects
16	118	120	O	7.2
17	123	129	U-KIN	Aspirin
18	130	130	O	:
19	132	140	B-TRI	increased
20	142	154	I-TRI	XXXXXXXX
21	156	161	L-TRI	levels
22	164	166	O	7.3
23	169	174	B-DYN	Tissue
24	176	179	I-DYN	type
25	181	191	I-DYN	plasminogen
26	193	201	I-DYN	activator
27	204	204	I-DYN	t
28	206	207	L-DYN	PA
29	209	209	O	:
30	211	219	B-EFF	decreased
31	221	232	I-EFF	thrombolytic
32	234	239	L-EFF	effect
33	242	244	O	7.4
34	247	253	U-DYN	Heparin
35	254	254	O	:
36	256	268	O	anticoagulant
37	270	275	O	effect
38	277	278	O	of
39	280	286	O	heparin
40	288	290	O	may
41	292	293	O	be
42	295	301	O	reduced
D/10:13:1 D/10:30:0 D/23:13:0 D/23:30:1 D/34:13:0 D/34:30:0K/17:C54355

NitroMist	87	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	11
Plasma levels of t-PA are reduced when coadministered with nitroglycerin .
1	0	5	O	Plasma
2	7	12	O	levels
3	14	15	O	of
4	17	17	B-KIN	t
5	19	20	L-KIN	PA
6	22	24	O	are
7	26	32	O	reduced
8	34	37	O	when
9	39	52	O	coadministered
10	54	57	O	with
11	59	71	O	XXXXXXXX
K/4:C54358

NitroMist	88	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	26
The time course and dose dependence of this interaction have not been studied, and use within a few days of one another cannot be recommended.
1	0	2	O	The
2	4	7	O	time
3	9	14	O	course
4	16	18	O	and
5	20	23	O	dose
6	25	34	O	dependence
7	36	37	O	of
8	39	42	O	this
9	44	54	O	interaction
10	56	59	O	have
11	61	63	O	not
12	65	68	O	been
13	70	76	O	studied
14	77	77	O	,
15	79	81	O	and
16	83	85	O	use
17	87	92	O	within
18	94	94	O	a
19	96	98	O	few
20	100	103	O	days
21	105	106	O	of
22	108	110	O	one
23	112	118	O	another
24	120	125	O	cannot
25	127	128	O	be
26	130	140	O	recommended
NULL

NitroMist	89	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	24
The use of any form of nitroglycerin during the early days of acute myocardial infarction requires particular attention to hemodynamic monitoring and clinical status.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	13	O	any
5	15	18	O	form
6	20	21	O	of
7	23	35	O	XXXXXXXX
8	37	42	O	during
9	44	46	O	the
10	48	52	O	early
11	54	57	O	days
12	59	60	O	of
13	62	66	O	acute
14	68	77	O	myocardial
15	79	88	O	infarction
16	90	97	O	requires
17	99	108	O	particular
18	110	118	O	attention
19	120	121	O	to
20	123	133	O	hemodynamic
21	135	144	O	monitoring
22	146	148	O	and
23	150	157	O	clinical
24	159	164	O	status
NULL

NitroMist	90	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	15
The vasodilatory and hemodynamic effects of nitroglycerin may be enhanced by concomitant administration of aspirin.
1	0	2	O	The
2	4	15	O	vasodilatory
3	17	19	O	and
4	21	31	O	hemodynamic
5	33	39	O	effects
6	41	42	O	of
7	44	56	O	XXXXXXXX
8	58	60	O	may
9	62	63	O	be
10	65	72	O	enhanced
11	74	75	O	by
12	77	87	O	concomitant
13	89	102	O	administration
14	104	105	O	of
15	107	113	U-DYN	aspirin
NULL

NitroMist	91	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	14
Therefore , caution should be observed in patients receiving nitroglycerin during t-PA therapy .
1	0	8	O	Therefore
2	10	10	O	,
3	12	18	B-TRI	caution
4	20	25	I-TRI	should
5	27	28	I-TRI	be
6	30	37	L-TRI	observed
7	39	40	O	in
8	42	49	O	patients
9	51	59	O	receiving
10	61	73	O	XXXXXXXX
11	75	80	O	during
12	82	82	B-UNK	t
13	84	85	L-UNK	PA
14	87	93	O	therapy
NULL

NitroMist	92	34073-7	1dfb2a25-abbd-4fe2-9531-8c76a7b2efa6	24
Therefore , patients receiving sublingual nitroglycerin should avoid ergotamine and related drugs or be monitored for symptoms of ergotism if this is not possible .
1	0	8	O	Therefore
2	10	10	O	,
3	12	19	O	patients
4	21	29	O	receiving
5	31	40	O	sublingual
6	42	54	O	XXXXXXXX
7	56	61	O	should
8	63	67	O	avoid
9	69	78	U-DYN	ergotamine
10	80	82	O	and
11	84	90	O	related
12	92	96	O	drugs
13	98	99	O	or
14	101	102	O	be
15	104	112	O	monitored
16	114	116	O	for
17	118	125	B-EFF	symptoms
18	127	128	I-EFF	of
19	130	137	L-EFF	ergotism
20	139	140	O	if
21	142	145	O	this
22	147	148	O	is
23	150	152	O	not
24	154	161	O	possible
D/9:17:1

Remodulin	290	34068-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	36
Diluted Remodulin has been shown to be stable at ambient temperature when stored for up to 14 days using high-pH glycine diluent at concentrations as low as 0.004 mg/mL ( 4,000 ng/mL ) .
1	0	6	O	Diluted
2	8	16	O	XXXXXXXX
3	18	20	O	has
4	22	25	O	been
5	27	31	O	shown
6	33	34	O	to
7	36	37	O	be
8	39	44	O	stable
9	46	47	O	at
10	49	55	O	ambient
11	57	67	O	temperature
12	69	72	O	when
13	74	79	O	stored
14	81	83	O	for
15	85	86	O	up
16	88	89	O	to
17	91	92	O	14
18	94	97	O	days
19	99	103	O	using
20	105	108	O	high
21	110	111	O	pH
22	113	119	O	glycine
23	121	127	O	diluent
24	129	130	O	at
25	132	145	O	concentrations
26	147	148	O	as
27	150	152	O	low
28	154	155	O	as
29	157	161	O	0.004
30	163	164	O	mg
31	165	165	O	/
32	166	167	O	mL
33	171	175	O	4,000
34	177	178	O	ng
35	179	179	O	/
36	180	181	O	mL
NULL

Remodulin	291	34068-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	18
Increase the Remodulin dose gradually as the Flolan dose is decreased , based on constant observation of response .
1	0	7	O	Increase
2	9	11	O	the
3	13	21	O	XXXXXXXX
4	23	26	O	dose
5	28	36	O	gradually
6	38	39	O	as
7	41	43	O	the
8	45	50	O	Flolan
9	52	55	O	dose
10	57	58	O	is
11	60	68	O	decreased
12	70	70	O	,
13	72	76	O	based
14	78	79	O	on
15	81	88	O	constant
16	90	100	O	observation
17	102	103	O	of
18	105	112	O	response
NULL

Remodulin	292	34068-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	31
Initiate Remodulin at a recommended dose of 10 % of the current Flolan dose , and then escalate as the Flolan dose is decreased ( see Table 2 for recommended dose titrations ) .
1	0	7	O	Initiate
2	9	17	O	XXXXXXXX
3	19	20	O	at
4	22	22	O	a
5	24	34	O	recommended
6	36	39	O	dose
7	41	42	O	of
8	44	45	O	10
9	47	47	O	%
10	49	50	O	of
11	52	54	O	the
12	56	62	O	current
13	64	69	O	Flolan
14	71	74	O	dose
15	76	76	O	,
16	78	80	O	and
17	82	85	O	then
18	87	94	O	escalate
19	96	97	O	as
20	99	101	O	the
21	103	108	O	Flolan
22	110	113	O	dose
23	115	116	O	is
24	118	126	O	decreased
25	130	132	O	see
26	134	138	O	Table
27	140	140	O	2
28	142	144	O	for
29	146	156	O	recommended
30	158	161	O	dose
31	163	172	O	titrations
NULL

Remodulin	293	34068-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	21
Patients are individually titrated to a dose that allows transition from Flolan therapy to Remodulin while balancing prostacyclin-limiting adverse events .
1	0	7	O	Patients
2	9	11	O	are
3	13	24	O	individually
4	26	33	O	titrated
5	35	36	O	to
6	38	38	O	a
7	40	43	O	dose
8	45	48	O	that
9	50	55	O	allows
10	57	66	O	transition
11	68	71	O	from
12	73	78	O	Flolan
13	80	86	O	therapy
14	88	89	O	to
15	91	99	O	XXXXXXXX
16	101	105	O	while
17	107	115	O	balancing
18	117	128	O	prostacyclin
19	130	137	O	limiting
20	139	145	O	adverse
21	147	152	O	events
NULL

Remodulin	294	34068-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	54
Remodulin can be administered without further dilution for subcutaneous administration , or diluted for intravenous infusion with Sterile Diluent for Remodulin or similar approved high-pH glycine diluent ( e.g. Sterile Diluent for Flolan or Sterile Diluent for Epoprostenol Sodium ) , Sterile Water for Injection , or 0.9 %   Sodium Chloride Injection prior to administration .
1	0	8	O	XXXXXXXX
2	10	12	O	can
3	14	15	O	be
4	17	28	O	administered
5	30	36	O	without
6	38	44	O	further
7	46	53	O	dilution
8	55	57	O	for
9	59	70	O	subcutaneous
10	72	85	O	administration
11	87	87	O	,
12	89	90	O	or
13	92	98	O	diluted
14	100	102	O	for
15	104	114	O	intravenous
16	116	123	O	infusion
17	125	128	O	with
18	130	136	O	Sterile
19	138	144	O	Diluent
20	146	148	O	for
21	150	158	O	XXXXXXXX
22	160	161	O	or
23	163	169	O	similar
24	171	178	O	approved
25	180	183	O	high
26	185	186	O	pH
27	188	194	O	glycine
28	196	202	O	diluent
29	206	208	O	e.g
30	211	217	O	Sterile
31	219	225	O	Diluent
32	227	229	O	for
33	231	236	O	Flolan
34	238	239	O	or
35	241	247	O	Sterile
36	249	255	O	Diluent
37	257	259	O	for
38	261	272	O	Epoprostenol
39	274	279	O	Sodium
40	283	283	O	,
41	285	291	O	Sterile
42	293	297	O	Water
43	299	301	O	for
44	303	311	O	Injection
45	313	313	O	,
46	315	316	O	or
47	318	320	O	0.9
48	322	322	O	%
49	326	331	O	Sodium
50	333	340	O	Chloride
51	342	350	O	Injection
52	352	356	O	prior
53	358	359	O	to
54	361	374	O	administration
NULL

Remodulin	295	34068-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	25
Transition from Flolan to Remodulin is accomplished by initiating the infusion of Remodulin and increasing it , while simultaneously reducing the dose of intravenous Flolan .
1	0	9	O	Transition
2	11	14	O	from
3	16	21	O	Flolan
4	23	24	O	to
5	26	34	O	XXXXXXXX
6	36	37	O	is
7	39	50	O	accomplished
8	52	53	O	by
9	55	64	O	initiating
10	66	68	O	the
11	70	77	O	infusion
12	79	80	O	of
13	82	90	O	XXXXXXXX
14	92	94	O	and
15	96	105	O	increasing
16	107	108	O	it
17	110	110	O	,
18	112	116	O	while
19	118	131	O	simultaneously
20	133	140	O	reducing
21	142	144	O	the
22	146	149	O	dose
23	151	152	O	of
24	154	164	O	intravenous
25	166	171	O	Flolan
NULL

Remodulin	296	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	17
(7.2) Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.
1	1	3	O	7.2
2	6	14	O	XXXXXXXX
3	16	21	O	dosage
4	23	32	O	adjustment
5	34	36	O	may
6	38	39	O	be
7	41	49	O	necessary
8	51	52	O	if
9	54	63	O	inhibitors
10	65	66	O	or
11	68	75	B-UNK	inducers
12	77	78	I-UNK	of
13	80	85	L-UNK	CYP2C8
14	87	89	O	are
15	91	95	O	added
16	97	98	O	or
17	100	108	O	withdrawn
NULL

Remodulin	297	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	20
(7.6) Concomitant administration of Remodulin with diuretics, antihypertensive agents or other vasodilators may increase the risk of symptomatic hypotension.
1	1	3	O	7.6
2	6	16	O	Concomitant
3	18	31	O	administration
4	33	34	O	of
5	36	44	O	XXXXXXXX
6	46	49	O	with
7	51	59	U-DYN	diuretics
8	60	60	O	,
9	62	77	B-DYN	antihypertensive
10	79	84	L-DYN	agents
11	86	87	O	or
12	89	93	O	other
13	95	106	U-DYN	GGGGGGGG
14	108	110	O	may
15	112	119	O	increase
16	121	123	O	the
17	125	128	O	risk
18	130	131	O	of
19	133	143	B-EFF	symptomatic
20	145	155	L-EFF	hypotension
D/13:19:1 D/7:19:1 D/9:19:1

Remodulin	298	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	10
7.6 Effect of Cytochrome P450 Inhibitors and Inducers on Treprostinil .
1	0	2	O	7.6
2	4	9	O	Effect
3	11	12	O	of
4	14	23	O	Cytochrome
5	25	28	O	P450
6	30	39	O	Inhibitors
7	41	43	O	and
8	45	52	O	Inducers
9	54	55	O	on
10	57	68	O	XXXXXXXX
NULL

Remodulin	299	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	19
Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A.
1	0	11	O	Additionally
2	12	12	O	,
3	14	25	O	XXXXXXXX
4	27	30	O	does
5	32	34	O	not
6	36	41	O	induce
7	43	52	O	cytochrome
8	54	57	O	P450
9	59	68	O	isoenzymes
10	70	75	O	CYP1A2
11	76	76	O	,
12	78	83	O	CYP2B6
13	84	84	O	,
14	86	91	O	CYP2C9
15	92	92	O	,
16	94	100	O	CYP2C19
17	101	101	O	,
18	103	105	O	and
19	107	111	O	CYP3A
NULL

Remodulin	300	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	12
Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	23	O	the
5	25	30	O	CYP2C8
6	32	37	O	enzyme
7	39	45	O	inducer
8	47	54	U-KIN	rifampin
9	56	64	B-TRI	decreases
10	66	73	L-TRI	exposure
11	75	76	O	to
12	78	89	O	XXXXXXXX
K/8:C54356

Remodulin	301	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	19
Concomitant administration of Remodulin with diuretics , antihypertensive agents or other vasodilators may increase the risk of symptomatic hypotension .
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	38	O	XXXXXXXX
5	40	43	O	with
6	45	53	U-DYN	diuretics
7	55	55	O	,
8	57	72	B-DYN	antihypertensive
9	74	79	L-DYN	agents
10	81	82	O	or
11	84	88	O	other
12	90	101	U-DYN	GGGGGGGG
13	103	105	O	may
14	107	114	O	increase
15	116	118	O	the
16	120	123	O	risk
17	125	126	O	of
18	128	138	B-EFF	symptomatic
19	140	150	L-EFF	hypotension
D/12:18:1 D/6:18:1 D/8:18:1

Remodulin	302	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	38
Drug interaction studies have been carried out with treprostinil ( oral or subcutaneous ) co-administered with acetaminophen ( 4 g/day ) , warfarin ( 25 mg/day ) , and fluconazole ( 200 mg/day ) , respectively in healthy volunteers .
1	0	3	O	Drug
2	5	15	O	interaction
3	17	23	O	studies
4	25	28	O	have
5	30	33	O	been
6	35	41	O	carried
7	43	45	O	out
8	47	50	O	with
9	52	63	O	XXXXXXXX
10	67	70	O	oral
11	72	73	O	or
12	75	86	O	subcutaneous
13	90	91	O	co
14	93	104	O	administered
15	106	109	O	with
16	111	123	O	acetaminophen
17	127	127	O	4
18	129	129	O	g
19	130	130	O	/
20	131	133	O	day
21	137	137	O	,
22	139	146	O	warfarin
23	150	151	O	25
24	153	154	O	mg
25	155	155	O	/
26	156	158	O	day
27	162	162	O	,
28	164	166	O	and
29	168	178	O	fluconazole
30	182	184	O	200
31	186	187	O	mg
32	188	188	O	/
33	189	191	O	day
34	195	195	O	,
35	197	208	O	respectively
36	210	211	O	in
37	213	219	O	healthy
38	221	230	O	volunteers
NULL

Remodulin	303	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	32
Human pharmacokinetic studies with an oral formulation of treprostinil ( treprostinil diethanolamine ) indicated that co-administration of the cytochrome P450 ( CYP ) 2C8 enzyme inhibitor gemfibrozil increases exposure ( both Cmax and AUC ) to treprostinil .
1	0	4	O	Human
2	6	20	O	pharmacokinetic
3	22	28	O	studies
4	30	33	O	with
5	35	36	O	an
6	38	41	O	oral
7	43	53	O	formulation
8	55	56	O	of
9	58	69	O	XXXXXXXX
10	73	84	O	XXXXXXXX
11	86	99	O	diethanolamine
12	103	111	O	indicated
13	113	116	O	that
14	118	119	O	co
15	121	134	O	administration
16	136	137	O	of
17	139	141	O	the
18	143	152	B-KIN	cytochrome
19	154	157	I-KIN	P450
20	161	163	I-KIN	CYP
21	167	169	I-KIN	2C8
22	171	176	I-KIN	enzyme
23	178	186	L-KIN	inhibitor
24	188	198	U-KIN	gemfibrozil
25	200	208	B-TRI	increases
26	210	217	L-TRI	exposure
27	221	224	O	both
28	226	229	O	Cmax
29	231	233	O	and
30	235	237	O	AUC
31	241	242	O	to
32	244	255	O	XXXXXXXX
K/18:C54605 K/24:C54605

Remodulin	304	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	30
In a human pharmacokinetic study conducted with bosentan ( 250 mg/day ) and an oral formulation of treprostinil ( treprostinil diethanolamine ) , no pharmacokinetic interactions between treprostinil and bosentan were observed .
1	0	1	O	In
2	3	3	O	a
3	5	9	O	human
4	11	25	O	pharmacokinetic
5	27	31	O	study
6	33	41	O	conducted
7	43	46	O	with
8	48	55	O	bosentan
9	59	61	O	250
10	63	64	O	mg
11	65	65	O	/
12	66	68	O	day
13	72	74	O	and
14	76	77	O	an
15	79	82	O	oral
16	84	94	O	formulation
17	96	97	O	of
18	99	110	O	XXXXXXXX
19	114	125	O	XXXXXXXX
20	127	140	O	diethanolamine
21	144	144	O	,
22	146	147	O	no
23	149	163	O	pharmacokinetic
24	165	176	O	interactions
25	178	184	O	between
26	186	197	O	XXXXXXXX
27	199	201	O	and
28	203	210	O	bosentan
29	212	215	O	were
30	217	224	O	observed
NULL

Remodulin	305	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	30
In a human pharmacokinetic study conducted with sildenafil ( 60 mg/day ) and an oral formulation of treprostinil ( treprostinil diethanolamine ) , no pharmacokinetic interactions between treprostinil and sildenafil were observed .
1	0	1	O	In
2	3	3	O	a
3	5	9	O	human
4	11	25	O	pharmacokinetic
5	27	31	O	study
6	33	41	O	conducted
7	43	46	O	with
8	48	57	O	sildenafil
9	61	62	O	60
10	64	65	O	mg
11	66	66	O	/
12	67	69	O	day
13	73	75	O	and
14	77	78	O	an
15	80	83	O	oral
16	85	95	O	formulation
17	97	98	O	of
18	100	111	O	XXXXXXXX
19	115	126	O	XXXXXXXX
20	128	141	O	diethanolamine
21	145	145	O	,
22	147	148	O	no
23	150	164	O	pharmacokinetic
24	166	177	O	interactions
25	179	185	O	between
26	187	198	O	XXXXXXXX
27	200	202	O	and
28	204	213	O	sildenafil
29	215	218	O	were
30	220	227	O	observed
NULL

Remodulin	306	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	32
In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	18	O	of
5	20	24	O	human
6	26	32	O	hepatic
7	34	43	O	microsomes
8	45	50	O	showed
9	52	55	O	that
10	57	68	O	XXXXXXXX
11	70	73	O	does
12	75	77	O	not
13	79	85	O	inhibit
14	87	96	O	cytochrome
15	98	101	O	P450
16	104	106	O	CYP
17	109	118	O	isoenzymes
18	120	125	O	CYP1A2
19	126	126	O	,
20	128	133	O	CYP2A6
21	134	134	O	,
22	136	141	O	CYP2C8
23	142	142	O	,
24	144	149	O	CYP2C9
25	150	150	O	,
26	152	158	O	CYP2C19
27	159	159	O	,
28	161	166	O	CYP2D6
29	167	167	O	,
30	169	174	O	CYP2E1
31	176	178	O	and
32	180	184	O	CYP3A
NULL

Remodulin	307	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	32
It has not been determined if the safety and efficacy of treprostinil by the parenteral ( subcutaneously or intravenously ) route are altered by inhibitors or inducers of CYP2C8 see Warnings and Precautions ( 5.4 ) .
1	0	1	O	It
2	3	5	O	has
3	7	9	O	not
4	11	14	O	been
5	16	25	O	determined
6	27	28	O	if
7	30	32	O	the
8	34	39	O	safety
9	41	43	O	and
10	45	52	O	efficacy
11	54	55	O	of
12	57	68	O	XXXXXXXX
13	70	71	O	by
14	73	75	O	the
15	77	86	O	parenteral
16	90	103	O	subcutaneously
17	105	106	O	or
18	108	120	O	intravenously
19	124	128	O	route
20	130	132	O	are
21	134	140	O	altered
22	142	143	O	by
23	145	154	O	inhibitors
24	156	157	O	or
25	159	166	O	inducers
26	168	169	O	of
27	171	176	O	CYP2C8
28	178	180	O	see
29	182	189	O	Warnings
30	191	193	O	and
31	195	205	O	Precautions
32	209	211	O	5.4
NULL

Remodulin	308	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	27
Pharmacodynamics Blood pressure lowering drugs (e.g., diuretics, antihypertensive agents, or vasodilators): Risk of increased reduction in blood pressure (7.1) Remodulin inhibits platelet aggregation.
1	0	15	O	Pharmacodynamics
2	17	21	B-DYN	Blood
3	23	30	I-DYN	pressure
4	32	39	I-DYN	lowering
5	41	45	L-DYN	drugs
6	48	50	O	e.g
7	52	52	O	,
8	54	62	U-DYN	diuretics
9	63	63	O	,
10	65	80	B-DYN	antihypertensive
11	82	87	L-DYN	agents
12	88	88	O	,
13	90	91	O	or
14	93	104	U-DYN	GGGGGGGG
15	106	106	O	:
16	108	111	O	Risk
17	113	114	O	of
18	116	124	B-EFF	increased
19	126	134	I-EFF	reduction
20	136	137	I-EFF	in
21	139	143	I-EFF	blood
22	145	152	L-EFF	pressure
23	155	157	O	7.1
24	160	168	O	XXXXXXXX
25	170	177	O	inhibits
26	179	186	O	platelet
27	188	198	O	aggregation
D/10:18:1 D/14:18:1 D/2:18:1 D/8:18:1

Remodulin	309	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	17
Pharmacokinetic/pharmacodynamic interaction studies have been conducted with treprostinil administered subcutaneously (Remodulin) and orally (treprostinil diethanolamine).
1	0	14	O	Pharmacokinetic
2	15	15	O	/
3	16	30	O	pharmacodynamic
4	32	42	O	interaction
5	44	50	O	studies
6	52	55	O	have
7	57	60	O	been
8	62	70	O	conducted
9	72	75	O	with
10	77	88	O	XXXXXXXX
11	90	101	O	administered
12	103	116	O	subcutaneously
13	119	127	O	XXXXXXXX
14	130	132	O	and
15	134	139	O	orally
16	142	153	O	XXXXXXXX
17	155	168	O	diethanolamine
NULL

Remodulin	310	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	31
Pharmacokinetics In a human pharmacokinetic study conducted with bosentan (250 mg/day) and an oral formulation of treprostinil (treprostinil diethanolamine), no pharmacokinetic interactions between treprostinil and bosentan were observed.
1	0	15	O	Pharmacokinetics
2	17	18	O	In
3	20	20	O	a
4	22	26	O	human
5	28	42	O	pharmacokinetic
6	44	48	O	study
7	50	58	O	conducted
8	60	63	O	with
9	65	72	O	bosentan
10	75	77	O	250
11	79	80	O	mg
12	81	81	O	/
13	82	84	O	day
14	87	89	O	and
15	91	92	O	an
16	94	97	O	oral
17	99	109	O	formulation
18	111	112	O	of
19	114	125	O	XXXXXXXX
20	128	139	O	XXXXXXXX
21	141	154	O	diethanolamine
22	156	156	O	,
23	158	159	O	no
24	161	175	O	pharmacokinetic
25	177	188	O	interactions
26	190	196	O	between
27	198	209	O	XXXXXXXX
28	211	213	O	and
29	215	222	O	bosentan
30	224	227	O	were
31	229	236	O	observed
NULL

Remodulin	311	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	12
Potential for increased risk of bleeding, particularly among patients on anticoagulants.
1	0	8	O	Potential
2	10	12	O	for
3	14	22	O	increased
4	24	27	O	risk
5	29	30	O	of
6	32	39	U-EFF	bleeding
7	40	40	O	,
8	42	53	O	particularly
9	55	59	O	among
10	61	68	O	patients
11	70	71	O	on
12	73	86	U-DYN	anticoagulants
D/12:6:1

Remodulin	312	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	16
Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn .
1	0	8	O	XXXXXXXX
2	10	15	O	dosage
3	17	26	O	adjustment
4	28	30	O	may
5	32	33	O	be
6	35	43	O	necessary
7	45	46	O	if
8	48	57	O	inhibitors
9	59	60	O	or
10	62	69	B-UNK	inducers
11	71	72	I-UNK	of
12	74	79	L-UNK	CYP2C8
13	81	83	O	are
14	85	89	O	added
15	91	92	O	or
16	94	102	O	withdrawn
NULL

Remodulin	313	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	12
Remodulin has not been studied in conjunction with Flolan or Tracleer ( bosentan ) .
1	0	8	O	XXXXXXXX
2	10	12	O	has
3	14	16	O	not
4	18	21	O	been
5	23	29	O	studied
6	31	32	O	in
7	34	44	O	conjunction
8	46	49	O	with
9	51	56	O	Flolan
10	58	59	O	or
11	61	68	O	Tracleer
12	72	79	O	bosentan
NULL

Remodulin	314	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	20
Since treprostinil inhibits platelet aggregation , there may be an increased risk of bleeding , particularly among patients receiving anticoagulants .
1	0	4	O	Since
2	6	17	O	XXXXXXXX
3	19	26	O	inhibits
4	28	35	O	platelet
5	37	47	O	aggregation
6	49	49	O	,
7	51	55	O	there
8	57	59	O	may
9	61	62	O	be
10	64	65	O	an
11	67	75	O	increased
12	77	80	O	risk
13	82	83	O	of
14	85	92	U-EFF	bleeding
15	94	94	O	,
16	96	107	O	particularly
17	109	113	O	among
18	115	122	O	patients
19	124	132	O	receiving
20	134	147	U-DYN	anticoagulants
D/20:14:1

Remodulin	315	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	40
The pharmacokinetics of R - and S - warfarin and the INR in healthy subjects given a single 25 mg dose of warfarin were unaffected by continuous subcutaneous infusion of treprostinil at an infusion rate of 10 ng/kg/min .
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	24	O	R
5	28	30	O	and
6	32	32	O	S
7	36	43	O	warfarin
8	45	47	O	and
9	49	51	O	the
10	53	55	O	INR
11	57	58	O	in
12	60	66	O	healthy
13	68	75	O	subjects
14	77	81	O	given
15	83	83	O	a
16	85	90	O	single
17	92	93	O	25
18	95	96	O	mg
19	98	101	O	dose
20	103	104	O	of
21	106	113	O	warfarin
22	115	118	O	were
23	120	129	O	unaffected
24	131	132	O	by
25	134	143	O	continuous
26	145	156	O	subcutaneous
27	158	165	O	infusion
28	167	168	O	of
29	170	181	O	XXXXXXXX
30	183	184	O	at
31	186	187	O	an
32	189	196	O	infusion
33	198	201	O	rate
34	203	204	O	of
35	206	207	O	10
36	209	210	O	ng
37	211	211	O	/
38	212	213	O	kg
39	214	214	O	/
40	215	217	O	min
NULL

Remodulin	316	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	40
The pharmacokinetics of R- and S- warfarin and the INR in healthy subjects given a single 25 mg dose of warfarin were unaffected by continuous subcutaneous infusion of treprostinil at an infusion rate of 10 ng/kg/min.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	24	O	R
5	27	29	O	and
6	31	31	O	S
7	34	41	O	warfarin
8	43	45	O	and
9	47	49	O	the
10	51	53	O	INR
11	55	56	O	in
12	58	64	O	healthy
13	66	73	O	subjects
14	75	79	O	given
15	81	81	O	a
16	83	88	O	single
17	90	91	O	25
18	93	94	O	mg
19	96	99	O	dose
20	101	102	O	of
21	104	111	O	warfarin
22	113	116	O	were
23	118	127	O	unaffected
24	129	130	O	by
25	132	141	O	continuous
26	143	154	O	subcutaneous
27	156	163	O	infusion
28	165	166	O	of
29	168	179	O	XXXXXXXX
30	181	182	O	at
31	184	185	O	an
32	187	194	O	infusion
33	196	199	O	rate
34	201	202	O	of
35	204	205	O	10
36	207	208	O	ng
37	209	209	O	/
38	210	211	O	kg
39	212	212	O	/
40	213	215	O	min
NULL

Remodulin	317	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	14
These studies did not show a clinically significant effect on the pharmacokinetics of treprostinil.
1	0	4	O	These
2	6	12	O	studies
3	14	16	O	did
4	18	20	O	not
5	22	25	O	show
6	27	27	O	a
7	29	38	O	clinically
8	40	50	O	significant
9	52	57	O	effect
10	59	60	O	on
11	62	64	O	the
12	66	81	O	pharmacokinetics
13	83	84	O	of
14	86	97	O	XXXXXXXX
NULL

Remodulin	318	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	15
Thus Remodulin is not expected to alter the pharmacokinetics of compounds metabolized by CYP enzymes.
1	0	3	O	Thus
2	5	13	O	XXXXXXXX
3	15	16	O	is
4	18	20	O	not
5	22	29	O	expected
6	31	32	O	to
7	34	38	O	alter
8	40	42	O	the
9	44	59	O	pharmacokinetics
10	61	62	O	of
11	64	72	O	compounds
12	74	84	O	metabolized
13	86	87	O	by
14	89	91	O	CYP
15	93	99	O	enzymes
NULL

Remodulin	319	34073-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	10
Treprostinil does not affect the pharmacokinetics or pharmacodynamics of warfarin .
1	0	11	O	XXXXXXXX
2	13	16	O	does
3	18	20	O	not
4	22	27	O	affect
5	29	31	O	the
6	33	48	O	pharmacokinetics
7	50	51	O	or
8	53	68	O	pharmacodynamics
9	70	71	O	of
10	73	80	O	warfarin
NULL

Remodulin	320	43685-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	38
Administration of IV Remodulin with a high pH glycine diluent has been associated with a lower incidence of BSIs when compared to neutral diluents ( sterile water , 0.9 %   sodium chloride ) when used along with catheter care guidelines .
1	0	13	O	Administration
2	15	16	O	of
3	18	19	O	IV
4	21	29	O	XXXXXXXX
5	31	34	O	with
6	36	36	O	a
7	38	41	O	high
8	43	44	O	pH
9	46	52	O	glycine
10	54	60	O	diluent
11	62	64	O	has
12	66	69	O	been
13	71	80	O	associated
14	82	85	O	with
15	87	87	O	a
16	89	93	O	lower
17	95	103	O	incidence
18	105	106	O	of
19	108	111	O	BSIs
20	113	116	O	when
21	118	125	O	compared
22	127	128	O	to
23	130	136	O	neutral
24	138	145	O	diluents
25	149	155	O	sterile
26	157	161	O	water
27	163	163	O	,
28	165	167	O	0.9
29	169	169	O	%
30	173	178	O	sodium
31	180	187	O	chloride
32	191	194	O	when
33	196	199	O	used
34	201	205	O	along
35	207	210	O	with
36	212	219	O	catheter
37	221	224	O	care
38	226	235	O	guidelines
NULL

Remodulin	321	43685-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	22
Co-administration of a CYP2C8 enzyme inducer ( e.g. , rifampin ) decreases exposure to treprostinil see Drug Interactions ( 7.5 ) and Clinical Pharmacology ( 12.3 ) .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	21	O	a
5	23	28	B-KIN	CYP2C8
6	30	35	I-KIN	enzyme
7	37	43	L-KIN	inducer
8	47	49	O	e.g
9	52	52	O	,
10	54	61	U-KIN	rifampin
11	65	73	B-TRI	decreases
12	75	82	L-TRI	exposure
13	84	85	O	to
14	87	98	O	XXXXXXXX
15	100	102	O	see
16	104	107	O	Drug
17	109	120	O	Interactions
18	124	126	O	7.5
19	130	132	O	and
20	134	141	O	Clinical
21	143	154	O	Pharmacology
22	158	161	O	12.3
K/10:C54356 K/5:C54356

Remodulin	322	43685-7	6c80bb38-e8db-4138-9f0d-dbbf9c673185	21
Co-administration of a cytochrome P450 ( CYP ) 2C8 enzyme inhibitor ( e.g. , gemfibrozil ) increases exposure ( both Cmax and AUC ) to treprostinil .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	21	O	a
5	23	32	B-KIN	cytochrome
6	34	37	I-KIN	P450
7	41	43	I-KIN	CYP
8	47	49	I-KIN	2C8
9	51	56	I-KIN	enzyme
10	58	66	L-KIN	inhibitor
11	70	72	O	e.g
12	75	75	O	,
13	77	87	U-KIN	gemfibrozil
14	91	99	B-TRI	increases
15	101	108	L-TRI	exposure
16	112	115	O	both
17	117	120	O	Cmax
18	122	124	O	and
19	126	128	O	AUC
20	132	133	O	to
21	135	146	O	XXXXXXXX
K/13:C54355 K/5:C54605

SAMSCA	157	34068-7	5526617c-c7b9-4556-886d-729bbabbc566	28
Co-administration of SAMSCA with inhibitors of P-gp ( e.g. , cyclosporine ) may necessitate a decrease in SAMSCA dose see Warnings and Precautions ( 5.5 ) , Drug Interactions ( 7.1 ) .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	XXXXXXXX
5	28	31	O	with
6	33	42	B-UNK	inhibitors
7	44	45	I-UNK	of
8	47	47	I-UNK	P
9	49	50	L-UNK	gp
10	54	56	O	e.g
11	59	59	O	,
12	61	72	U-UNK	cyclosporine
13	76	78	O	may
14	80	90	O	necessitate
15	92	92	O	a
16	94	101	O	decrease
17	103	104	O	in
18	106	111	O	XXXXXXXX
19	113	116	O	dose
20	118	120	O	see
21	122	129	O	Warnings
22	131	133	O	and
23	135	145	O	Precautions
24	149	151	O	5.5
25	155	155	O	,
26	157	160	O	Drug
27	162	173	O	Interactions
28	177	179	O	7.1
NULL

SAMSCA	158	34068-7	5526617c-c7b9-4556-886d-729bbabbc566	19
Co-administration of SAMSCA with potent CYP 3A inducers ( e.g. , rifampin ) reduces tolvaptan plasma concentrations by 85 % .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	XXXXXXXX
5	28	31	O	with
6	33	38	B-KIN	potent
7	40	42	I-KIN	CYP
8	44	45	I-KIN	3A
9	47	54	L-KIN	inducers
10	58	60	O	e.g
11	63	63	O	,
12	65	72	U-KIN	rifampin
13	76	82	B-TRI	reduces
14	84	92	I-TRI	XXXXXXXX
15	94	99	I-TRI	plasma
16	101	114	L-TRI	concentrations
17	116	117	O	by
18	119	120	O	85
19	122	122	O	%
K/12:C54356 K/6:C54356

SAMSCA	159	34070-3	5526617c-c7b9-4556-886d-729bbabbc566	12
Ketoconazole 200 mg administered with tolvaptan increased tolvaptan exposure by 5-fold .
1	0	11	U-KIN	Ketoconazole
2	13	15	O	200
3	17	18	O	mg
4	20	31	O	administered
5	33	36	O	with
6	38	46	O	XXXXXXXX
7	48	56	B-TRI	increased
8	58	66	I-TRI	XXXXXXXX
9	68	75	L-TRI	exposure
10	77	78	O	by
11	80	80	O	5
12	82	85	O	fold
K/1:C54355

SAMSCA	160	34070-3	5526617c-c7b9-4556-886d-729bbabbc566	45
There is not adequate experience to define the dose adjustment that would be needed to allow safe use of tolvaptan with strong CYP 3A inhibitors such as clarithromycin , ketoconazole , itraconazole , ritonavir , indinavir , nelfinavir , saquinavir , nefazodone , and telithromycin .
1	0	4	O	There
2	6	7	O	is
3	9	11	O	not
4	13	20	O	adequate
5	22	31	O	experience
6	33	34	O	to
7	36	41	O	define
8	43	45	O	the
9	47	50	O	dose
10	52	61	O	adjustment
11	63	66	O	that
12	68	72	O	would
13	74	75	O	be
14	77	82	O	needed
15	84	85	O	to
16	87	91	O	allow
17	93	96	O	safe
18	98	100	O	use
19	102	103	O	of
20	105	113	O	XXXXXXXX
21	115	118	O	with
22	120	125	O	strong
23	127	129	O	CYP
24	131	132	O	3A
25	134	143	O	inhibitors
26	145	148	O	such
27	150	151	O	as
28	153	166	O	clarithromycin
29	168	168	O	,
30	170	181	O	ketoconazole
31	183	183	O	,
32	185	196	O	itraconazole
33	198	198	O	,
34	200	208	O	ritonavir
35	210	210	O	,
36	212	220	O	indinavir
37	222	222	O	,
38	224	233	O	nelfinavir
39	235	235	O	,
40	237	246	O	saquinavir
41	248	248	O	,
42	250	259	O	nefazodone
43	261	261	O	,
44	263	265	O	and
45	267	279	O	telithromycin
NULL

SAMSCA	161	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	21
A substantial increase in the exposure to tolvaptan would be expected when SAMSCA is co-administered with moderate CYP 3A inhibitors.
1	0	0	O	A
2	2	12	O	substantial
3	14	21	O	increase
4	23	24	O	in
5	26	28	O	the
6	30	37	O	exposure
7	39	40	O	to
8	42	50	O	XXXXXXXX
9	52	56	O	would
10	58	59	O	be
11	61	68	O	expected
12	70	73	O	when
13	75	80	O	XXXXXXXX
14	82	83	O	is
15	85	86	O	co
16	88	99	O	administered
17	101	104	O	with
18	106	113	B-KIN	moderate
19	115	117	I-KIN	CYP
20	119	120	I-KIN	3A
21	122	131	L-KIN	inhibitors
K/18:C54355

SAMSCA	162	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	35
Adverse reactions of hyperkalemia were approximately 1-2 % higher when tolvaptan was administered with angiotensin receptor blockers , angiotensin converting enzyme inhibitors and potassium sparing diuretics compared to administration of these medications with placebo .
1	0	6	O	Adverse
2	8	16	O	reactions
3	18	19	O	of
4	21	32	U-EFF	hyperkalemia
5	34	37	O	were
6	39	51	O	approximately
7	53	53	O	1
8	55	55	O	2
9	57	57	O	%
10	59	64	O	higher
11	66	69	O	when
12	71	79	O	XXXXXXXX
13	81	83	O	was
14	85	96	O	administered
15	98	101	O	with
16	103	113	B-DYN	angiotensin
17	115	122	I-DYN	receptor
18	124	131	L-DYN	blockers
19	133	133	O	,
20	135	145	B-DYN	angiotensin
21	147	156	I-DYN	converting
22	158	163	I-DYN	enzyme
23	165	174	L-DYN	inhibitors
24	176	178	O	and
25	180	188	B-DYN	potassium
26	190	196	I-DYN	sparing
27	198	206	L-DYN	diuretics
28	208	215	O	compared
29	217	218	O	to
30	220	233	O	administration
31	235	236	O	of
32	238	242	O	these
33	244	254	O	medications
34	256	259	O	with
35	261	267	O	placebo
D/16:4:1 D/20:4:1 D/25:4:1

SAMSCA	163	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	31
Although specific interaction studies were not performed , in clinical studies tolvaptan was used concomitantly with beta-blockers , angiotensin receptor blockers , angiotensin converting enzyme inhibitors and potassium sparing diuretics .
1	0	7	O	Although
2	9	16	O	specific
3	18	28	O	interaction
4	30	36	O	studies
5	38	41	O	were
6	43	45	O	not
7	47	55	O	performed
8	57	57	O	,
9	59	60	O	in
10	62	69	O	clinical
11	71	77	O	studies
12	79	87	O	XXXXXXXX
13	89	91	O	was
14	93	96	O	used
15	98	110	O	concomitantly
16	112	115	O	with
17	117	120	O	beta
18	122	129	O	blockers
19	131	131	O	,
20	133	143	O	angiotensin
21	145	152	O	receptor
22	154	161	O	blockers
23	163	163	O	,
24	165	175	O	angiotensin
25	177	186	O	converting
26	188	193	O	enzyme
27	195	204	O	inhibitors
28	206	208	O	and
29	210	218	O	potassium
30	220	226	O	sparing
31	228	236	O	diuretics
NULL

SAMSCA	164	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	17
As a V2-receptor antagonist , tolvaptan may interfere with the V2-agonist activity of desmopressin ( dDAVP ) .
1	0	1	O	As
2	3	3	O	a
3	5	6	O	V2
4	8	15	O	receptor
5	17	26	O	antagonist
6	28	28	O	,
7	30	38	O	XXXXXXXX
8	40	42	O	may
9	44	52	O	interfere
10	54	57	O	with
11	59	61	O	the
12	63	64	O	V2
13	66	72	O	agonist
14	74	81	O	activity
15	83	84	O	of
16	86	97	U-DYN	desmopressin
17	101	105	O	dDAVP
NULL

SAMSCA	165	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	23
Co-administration of lovastatin , digoxin , furosemide , and hydrochlorothiazide with SAMSCA has no clinically relevant impact on the exposure to tolvaptan .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	30	O	lovastatin
5	32	32	O	,
6	34	40	O	digoxin
7	42	42	O	,
8	44	53	O	furosemide
9	55	55	O	,
10	57	59	O	and
11	61	79	O	hydrochlorothiazide
12	81	84	O	with
13	86	91	O	XXXXXXXX
14	93	95	O	has
15	97	98	O	no
16	100	109	O	clinically
17	111	118	O	relevant
18	120	125	O	impact
19	127	128	O	on
20	130	132	O	the
21	134	141	O	exposure
22	143	144	O	to
23	146	154	O	XXXXXXXX
NULL

SAMSCA	166	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	25
Co-administration of lovastatin and SAMSCA increases the exposure to lovastatin and its active metabolite lovastatin - hydroxyacid by factors of 1.4 and 1.3 , respectively .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	30	U-KIN	lovastatin
5	32	34	O	and
6	36	41	O	XXXXXXXX
7	43	51	O	increases
8	53	55	O	the
9	57	64	O	exposure
10	66	67	O	to
11	69	78	O	lovastatin
12	80	82	O	and
13	84	86	O	its
14	88	93	O	active
15	95	104	O	metabolite
16	106	115	O	lovastatin
17	119	129	O	hydroxyacid
18	131	132	O	by
19	134	140	O	factors
20	142	143	O	of
21	145	147	O	1.4
22	149	151	O	and
23	153	155	O	1.3
24	157	157	O	,
25	159	170	O	respectively
K/4:C54357

SAMSCA	167	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	13
Co-administration of rifampin and SAMSCA reduces exposure to tolvaptan by 85 % .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	28	U-KIN	rifampin
5	30	32	O	and
6	34	39	O	XXXXXXXX
7	41	47	B-TRI	reduces
8	49	56	L-TRI	exposure
9	58	59	O	to
10	61	69	O	XXXXXXXX
11	71	72	O	by
12	74	75	O	85
13	77	77	O	%
K/4:C54356

SAMSCA	168	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	19
Co-administration of SAMSCA and ketoconazole 200 mg daily results in a 5-fold increase in exposure to tolvaptan .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	XXXXXXXX
5	28	30	O	and
6	32	43	U-KIN	ketoconazole
7	45	47	O	200
8	49	50	O	mg
9	52	56	O	daily
10	58	64	O	results
11	66	67	O	in
12	69	69	O	a
13	71	71	O	5
14	73	76	O	fold
15	78	85	O	increase
16	87	88	O	in
17	90	97	O	exposure
18	99	100	O	to
19	102	110	O	XXXXXXXX
K/6:C54355

SAMSCA	169	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	18
Co-administration of SAMSCA and ketoconazole 200mg daily results in a 5-fold increase in exposure to tolvaptan.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	XXXXXXXX
5	28	30	O	and
6	32	43	U-KIN	ketoconazole
7	45	49	O	200mg
8	51	55	O	daily
9	57	63	O	results
10	65	66	O	in
11	68	68	O	a
12	70	70	O	5
13	72	75	O	fold
14	77	84	O	increase
15	86	87	O	in
16	89	96	O	exposure
17	98	99	O	to
18	101	109	O	XXXXXXXX
K/6:C54355

SAMSCA	170	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	48
Co-administration of SAMSCA with 400 mg ketoconazole daily or with other strong CYP 3A inhibitors ( e.g. , clarithromycin , itraconazole , telithromycin , saquinavir , nelfinavir , ritonavir and nefazodone ) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	XXXXXXXX
5	28	31	O	with
6	33	35	O	400
7	37	38	O	mg
8	40	51	U-KIN	ketoconazole
9	53	57	O	daily
10	59	60	O	or
11	62	65	O	with
12	67	71	O	other
13	73	78	O	strong
14	80	82	B-KIN	CYP
15	84	85	I-KIN	3A
16	87	96	L-KIN	inhibitors
17	100	102	O	e.g
18	105	105	O	,
19	107	120	U-KIN	clarithromycin
20	122	122	O	,
21	124	135	U-KIN	itraconazole
22	137	137	O	,
23	139	151	U-KIN	telithromycin
24	153	153	O	,
25	155	164	U-KIN	saquinavir
26	166	166	O	,
27	168	177	U-KIN	nelfinavir
28	179	179	O	,
29	181	189	U-KIN	ritonavir
30	191	193	O	and
31	195	204	U-KIN	nefazodone
32	208	209	O	at
33	211	213	O	the
34	215	221	O	highest
35	223	229	O	labeled
36	231	234	O	dose
37	236	240	O	would
38	242	243	O	be
39	245	252	O	expected
40	254	255	O	to
41	257	261	O	cause
42	263	264	O	an
43	266	269	O	even
44	271	277	O	greater
45	279	286	O	increase
46	288	289	O	in
47	291	299	O	XXXXXXXX
48	301	308	O	exposure
K/14:C54355 K/19:C54355 K/21:C54355 K/23:C54355 K/25:C54355 K/27:C54355 K/29:C54355 K/31:C54355 K/8:C54355

SAMSCA	171	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	47
Co-administration of SAMSCA with 400mg ketoconazole daily or with other strong CYP 3A inhibitors (e.g., clarithromycin, itraconazole, telithromycin, saquinavir, nelfinavir, ritonavir and nefazodone) at the highest labeled dose would be expected to cause an even greater increase in tolvaptan exposure.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	XXXXXXXX
5	28	31	O	with
6	33	37	O	400mg
7	39	50	U-KIN	ketoconazole
8	52	56	O	daily
9	58	59	O	or
10	61	64	O	with
11	66	70	O	other
12	72	77	O	strong
13	79	81	B-KIN	CYP
14	83	84	I-KIN	3A
15	86	95	L-KIN	inhibitors
16	98	100	O	e.g
17	102	102	O	,
18	104	117	U-KIN	clarithromycin
19	118	118	O	,
20	120	131	U-KIN	itraconazole
21	132	132	O	,
22	134	146	U-KIN	telithromycin
23	147	147	O	,
24	149	158	U-KIN	saquinavir
25	159	159	O	,
26	161	170	U-KIN	nelfinavir
27	171	171	O	,
28	173	181	U-KIN	ritonavir
29	183	185	O	and
30	187	196	U-KIN	nefazodone
31	199	200	O	at
32	202	204	O	the
33	206	212	O	highest
34	214	220	O	labeled
35	222	225	O	dose
36	227	231	O	would
37	233	234	O	be
38	236	243	O	expected
39	245	246	O	to
40	248	252	O	cause
41	254	255	O	an
42	257	260	O	even
43	262	268	O	greater
44	270	277	O	increase
45	279	280	O	in
46	282	290	O	XXXXXXXX
47	292	299	O	exposure
K/13:C54355 K/18:C54355 K/20:C54355 K/22:C54355 K/24:C54355 K/26:C54355 K/28:C54355 K/30:C54355 K/7:C54355

SAMSCA	172	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	17
Co-administration of SAMSCA with digoxin increased digoxin AUC by 20 % and Cmax by 30 % .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	XXXXXXXX
5	28	31	O	with
6	33	39	U-KIN	digoxin
7	41	49	O	increased
8	51	57	O	digoxin
9	59	61	O	AUC
10	63	64	O	by
11	66	67	O	20
12	69	69	O	%
13	71	73	O	and
14	75	78	O	Cmax
15	80	81	O	by
16	83	84	O	30
17	86	86	O	%
K/6:C54613

SAMSCA	173	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	23
Co-administration of SAMSCA with moderate CYP3A inhibitors should therefore generally be avoided see Dosage and Administration ( 2.3 ) and Warnings and Precautions ( 5.5 ) .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	XXXXXXXX
5	28	31	O	with
6	33	40	B-UNK	moderate
7	42	46	I-UNK	CYP3A
8	48	57	L-UNK	inhibitors
9	59	64	O	should
10	66	74	O	therefore
11	76	84	O	generally
12	86	87	O	be
13	89	95	O	avoided
14	97	99	O	see
15	101	106	O	Dosage
16	108	110	O	and
17	112	125	O	Administration
18	129	131	O	2.3
19	135	137	O	and
20	139	146	O	Warnings
21	148	150	O	and
22	152	162	O	Precautions
23	166	168	O	5.5
NULL

SAMSCA	174	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	31
Co-administration of tolvaptan does not appear to alter the pharmacokinetics of warfarin , furosemide , hydrochlorothiazide , or amiodarone ( or its active metabolite , desethylamiodarone ) to a clinically significant degree .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	29	O	XXXXXXXX
5	31	34	O	does
6	36	38	O	not
7	40	45	O	appear
8	47	48	O	to
9	50	54	O	alter
10	56	58	O	the
11	60	75	O	pharmacokinetics
12	77	78	O	of
13	80	87	O	warfarin
14	89	89	O	,
15	91	100	O	furosemide
16	102	102	O	,
17	104	122	O	hydrochlorothiazide
18	124	124	O	,
19	126	127	O	or
20	129	138	O	amiodarone
21	142	143	O	or
22	145	147	O	its
23	149	154	O	active
24	156	165	O	metabolite
25	167	167	O	,
26	169	186	O	desethylamiodarone
27	190	191	O	to
28	193	193	O	a
29	195	204	O	clinically
30	206	216	O	significant
31	218	223	O	degree
NULL

SAMSCA	175	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	28
Concomitant administration of tolvaptan with furosemide or hydrochlorothiazide results in a 24 hour urine volume/excretion rate that is similar to the rate after tolvaptan administration alone .
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	38	O	XXXXXXXX
5	40	43	O	with
6	45	54	O	furosemide
7	56	57	O	or
8	59	77	O	hydrochlorothiazide
9	79	85	O	results
10	87	88	O	in
11	90	90	O	a
12	92	93	O	24
13	95	98	O	hour
14	100	104	O	urine
15	106	111	O	volume
16	112	112	O	/
17	113	121	O	excretion
18	123	126	O	rate
19	128	131	O	that
20	133	134	O	is
21	136	142	O	similar
22	144	145	O	to
23	147	149	O	the
24	151	154	O	rate
25	156	160	O	after
26	162	170	O	XXXXXXXX
27	172	185	O	administration
28	187	191	O	alone
NULL

SAMSCA	176	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	49
CYP 3A Inducers Avoid co-administration of CYP 3A inducers (e.g., rifampin, rifabutin, rifapentin, barbiturates, phenytoin, carbamazepine, St. John's Wort) with SAMSCA, as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment.
1	0	2	O	CYP
2	4	5	O	3A
3	7	14	O	Inducers
4	16	20	O	Avoid
5	22	23	O	co
6	25	38	O	administration
7	40	41	O	of
8	43	45	B-KIN	CYP
9	47	48	I-KIN	3A
10	50	57	L-KIN	inducers
11	60	62	O	e.g
12	64	64	O	,
13	66	73	U-KIN	rifampin
14	74	74	O	,
15	76	84	U-KIN	rifabutin
16	85	85	O	,
17	87	96	U-KIN	rifapentin
18	97	97	O	,
19	99	110	U-KIN	barbiturates
20	111	111	O	,
21	113	121	U-KIN	phenytoin
22	122	122	O	,
23	124	136	U-KIN	carbamazepine
24	137	137	O	,
25	139	140	B-KIN	St
26	143	148	I-KIN	John's
27	150	153	L-KIN	Wort
28	156	159	O	with
29	161	166	O	XXXXXXXX
30	167	167	O	,
31	169	170	O	as
32	172	175	O	this
33	177	179	O	can
34	181	184	O	lead
35	186	187	O	to
36	189	189	O	a
37	191	199	O	reduction
38	201	202	O	in
39	204	206	O	the
40	208	213	O	plasma
41	215	227	O	concentration
42	229	230	O	of
43	232	240	O	XXXXXXXX
44	242	244	O	and
45	246	254	O	decreased
46	256	268	O	effectiveness
47	270	271	O	of
48	273	278	O	XXXXXXXX
49	280	288	O	treatment
K/13:C54356 K/15:C54356 K/17:C54356 K/19:C54356 K/21:C54356 K/23:C54356 K/25:C54356 K/8:C54356

SAMSCA	177	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	21
CYP 3A inhibitors can lead to a marked increase in tolvaptan concentrations [see Dosage and Administration (2.3), Drug Interactions (7.1)].
1	0	2	B-KIN	CYP
2	4	5	I-KIN	3A
3	7	16	L-KIN	inhibitors
4	18	20	O	can
5	22	25	O	lead
6	27	28	O	to
7	30	30	O	a
8	32	37	O	marked
9	39	46	O	increase
10	48	49	O	in
11	51	59	O	XXXXXXXX
12	61	74	O	concentrations
13	77	79	O	see
14	81	86	O	Dosage
15	88	90	O	and
16	92	105	O	Administration
17	108	110	O	2.3
18	112	112	O	,
19	114	117	O	Drug
20	119	130	O	Interactions
21	133	135	O	7.1
K/1:C54355

SAMSCA	178	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	22
Do not use SAMSCA with strong inhibitors of CYP 3A [see Contraindications (4.4)] and avoid concomitant use with moderate CYP 3A inhibitors.
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	9	L-TRI	use
4	11	16	O	XXXXXXXX
5	18	21	O	with
6	23	28	B-UNK	strong
7	30	39	I-UNK	inhibitors
8	41	42	I-UNK	of
9	44	46	I-UNK	CYP
10	48	49	L-UNK	3A
11	52	54	O	see
12	56	72	O	Contraindications
13	75	77	O	4.4
14	81	83	O	and
15	85	89	U-TRI	avoid
16	91	101	O	concomitant
17	103	105	O	use
18	107	110	O	with
19	112	119	B-UNK	moderate
20	121	123	I-UNK	CYP
21	125	126	I-UNK	3A
22	128	137	L-UNK	inhibitors
NULL

SAMSCA	179	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	29
Grapefruit Juice Co-administration of grapefruit juice and SAMSCA results in a 1.8-fold increase in exposure to tolvaptan [see Dose and Administration (2.3) and Warnings and Precautions (5.5)].
1	0	9	O	Grapefruit
2	11	15	O	Juice
3	17	18	O	Co
4	20	33	O	administration
5	35	36	O	of
6	38	47	O	grapefruit
7	49	53	O	juice
8	55	57	O	and
9	59	64	O	XXXXXXXX
10	66	72	O	results
11	74	75	O	in
12	77	77	O	a
13	79	81	O	1.8
14	83	86	O	fold
15	88	95	O	increase
16	97	98	O	in
17	100	107	O	exposure
18	109	110	O	to
19	112	120	O	XXXXXXXX
20	123	125	O	see
21	127	130	O	Dose
22	132	134	O	and
23	136	149	O	Administration
24	152	154	O	2.3
25	157	159	O	and
26	161	168	O	Warnings
27	170	172	O	and
28	174	184	O	Precautions
29	187	189	O	5.5
NULL

SAMSCA	180	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	26
If co-administered with CYP 3A inducers, the dose of SAMSCA may need to be increased [see Dosage and Administration (2.3), Drug Interactions (7.1)].
1	0	1	O	If
2	3	4	O	co
3	6	17	O	administered
4	19	22	O	with
5	24	26	B-UNK	CYP
6	28	29	I-UNK	3A
7	31	38	L-UNK	inducers
8	39	39	O	,
9	41	43	O	the
10	45	48	O	dose
11	50	51	O	of
12	53	58	O	XXXXXXXX
13	60	62	O	may
14	64	67	O	need
15	69	70	O	to
16	72	73	O	be
17	75	83	O	increased
18	86	88	O	see
19	90	95	O	Dosage
20	97	99	O	and
21	101	114	O	Administration
22	117	119	O	2.3
23	121	121	O	,
24	123	126	O	Drug
25	128	139	O	Interactions
26	142	144	O	7.1
NULL

SAMSCA	181	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	36
In a male subject with mild Von Willebrand ( vW ) disease , intravenous infusion of dDAVP 2 hours after administration of oral tolvaptan did not produce the expected increases in vW Factor Antigen or Factor VIII activity .
1	0	1	O	In
2	3	3	O	a
3	5	8	O	male
4	10	16	O	subject
5	18	21	O	with
6	23	26	O	mild
7	28	30	O	Von
8	32	41	O	Willebrand
9	45	46	O	vW
10	50	56	O	disease
11	58	58	O	,
12	60	70	O	intravenous
13	72	79	O	infusion
14	81	82	O	of
15	84	88	O	dDAVP
16	90	90	O	2
17	92	96	O	hours
18	98	102	O	after
19	104	117	O	administration
20	119	120	O	of
21	122	125	O	oral
22	127	135	O	XXXXXXXX
23	137	139	O	did
24	141	143	O	not
25	145	151	O	produce
26	153	155	O	the
27	157	164	O	expected
28	166	174	O	increases
29	176	177	O	in
30	179	180	O	vW
31	182	187	O	Factor
32	189	195	O	Antigen
33	197	198	O	or
34	200	205	O	Factor
35	207	210	O	VIII
36	212	219	O	activity
NULL

SAMSCA	182	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	36
In a male subject with mild Von Willebrand (vW) disease, intravenous infusion of dDAVP 2 hours after administration of oral tolvaptan did not produce the expected increases in vW Factor Antigen or Factor VIII activity.
1	0	1	O	In
2	3	3	O	a
3	5	8	O	male
4	10	16	O	subject
5	18	21	O	with
6	23	26	O	mild
7	28	30	O	Von
8	32	41	O	Willebrand
9	44	45	O	vW
10	48	54	O	disease
11	55	55	O	,
12	57	67	O	intravenous
13	69	76	O	infusion
14	78	79	O	of
15	81	85	O	dDAVP
16	87	87	O	2
17	89	93	O	hours
18	95	99	O	after
19	101	114	O	administration
20	116	117	O	of
21	119	122	O	oral
22	124	132	O	XXXXXXXX
23	134	136	O	did
24	138	140	O	not
25	142	148	O	produce
26	150	152	O	the
27	154	161	O	expected
28	163	171	O	increases
29	173	174	O	in
30	176	177	O	vW
31	179	184	O	Factor
32	186	192	O	Antigen
33	194	195	O	or
34	197	202	O	Factor
35	204	207	O	VIII
36	209	216	O	activity
NULL

SAMSCA	183	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	11
It is not recommended to administer SAMSCA with a V2-agonist.
1	0	1	O	It
2	3	4	O	is
3	6	8	B-TRI	not
4	10	20	L-TRI	recommended
5	22	23	O	to
6	25	34	O	administer
7	36	41	O	XXXXXXXX
8	43	46	O	with
9	48	48	O	a
10	50	51	B-UNK	V2
11	53	59	L-UNK	agonist
NULL

SAMSCA	184	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	14
Ketoconazole and Other Strong CYP 3A Inhibitors SAMSCA is metabolized primarily by CYP 3A.
1	0	11	O	Ketoconazole
2	13	15	O	and
3	17	21	O	Other
4	23	28	O	Strong
5	30	32	O	CYP
6	34	35	O	3A
7	37	46	O	Inhibitors
8	48	53	O	XXXXXXXX
9	55	56	O	is
10	58	68	O	metabolized
11	70	78	O	primarily
12	80	81	O	by
13	83	85	O	CYP
14	87	88	O	3A
NULL

SAMSCA	185	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	15
Ketoconazole is a strong inhibitor of CYP 3A and also an inhibitor of P-gp.
1	0	11	O	Ketoconazole
2	13	14	O	is
3	16	16	O	a
4	18	23	O	strong
5	25	33	O	inhibitor
6	35	36	O	of
7	38	40	O	CYP
8	42	43	O	3A
9	45	47	O	and
10	49	52	O	also
11	54	55	O	an
12	57	65	O	inhibitor
13	67	68	O	of
14	70	70	O	P
15	72	73	O	gp
NULL

SAMSCA	186	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	9
Lovastatin SAMSCA is a weak inhibitor of CYP 3A.
1	0	9	O	Lovastatin
2	11	16	O	XXXXXXXX
3	18	19	O	is
4	21	21	O	a
5	23	26	O	weak
6	28	36	O	inhibitor
7	38	39	O	of
8	41	43	O	CYP
9	45	46	O	3A
NULL

SAMSCA	187	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	31
Lovastatin, Digoxin, Furosemide, and Hydrochlorothiazide Co-administration of lovastatin, digoxin, furosemide, and hydrochlorothiazide with SAMSCA has no clinically relevant impact on the exposure to tolvaptan.
1	0	9	O	Lovastatin
2	10	10	O	,
3	12	18	O	Digoxin
4	19	19	O	,
5	21	30	O	Furosemide
6	31	31	O	,
7	33	35	O	and
8	37	55	O	Hydrochlorothiazide
9	57	58	O	Co
10	60	73	O	administration
11	75	76	O	of
12	78	87	O	lovastatin
13	88	88	O	,
14	90	96	O	digoxin
15	97	97	O	,
16	99	108	O	furosemide
17	109	109	O	,
18	111	113	O	and
19	115	133	O	hydrochlorothiazide
20	135	138	O	with
21	140	145	O	XXXXXXXX
22	147	149	O	has
23	151	152	O	no
24	154	163	O	clinically
25	165	172	O	relevant
26	174	179	O	impact
27	181	182	O	on
28	184	186	O	the
29	188	195	O	exposure
30	197	198	O	to
31	200	208	O	XXXXXXXX
NULL

SAMSCA	188	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	33
Moderate CYP 3A Inhibitors The impact of moderate CYP 3A inhibitors (e.g., erythromycin, fluconazole, aprepitant, diltiazem and verapamil) on the exposure to co-administered tolvaptan has not been assessed.
1	0	7	O	Moderate
2	9	11	O	CYP
3	13	14	O	3A
4	16	25	O	Inhibitors
5	27	29	O	The
6	31	36	O	impact
7	38	39	O	of
8	41	48	O	moderate
9	50	52	O	CYP
10	54	55	O	3A
11	57	66	O	inhibitors
12	69	71	O	e.g
13	73	73	O	,
14	75	86	O	erythromycin
15	87	87	O	,
16	89	99	O	fluconazole
17	100	100	O	,
18	102	111	O	aprepitant
19	112	112	O	,
20	114	122	O	diltiazem
21	124	126	O	and
22	128	136	O	verapamil
23	139	140	O	on
24	142	144	O	the
25	146	153	O	exposure
26	155	156	O	to
27	158	159	O	co
28	161	172	O	administered
29	174	182	O	XXXXXXXX
30	184	186	O	has
31	188	190	O	not
32	192	195	O	been
33	197	204	O	assessed
NULL

SAMSCA	189	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	16
Other Drugs Affecting Exposure to Tolvaptan CYP 3A Inhibitors Tolvaptan is a substrate of CYP 3A.
1	0	4	O	Other
2	6	10	O	Drugs
3	12	20	O	Affecting
4	22	29	O	Exposure
5	31	32	O	to
6	34	42	O	XXXXXXXX
7	44	46	O	CYP
8	48	49	O	3A
9	51	60	O	Inhibitors
10	62	70	O	XXXXXXXX
11	72	73	O	is
12	75	75	O	a
13	77	85	O	substrate
14	87	88	O	of
15	90	92	O	CYP
16	94	95	O	3A
NULL

SAMSCA	190	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	41
P-gp Inhibitors Reduction in the dose of SAMSCA may be required in patients concomitantly treated with P-gp inhibitors, such as e.g., cyclosporine, based on clinical response [see Dose and Administration (2.3) and Warnings and Precautions (5.5)].
1	0	0	O	P
2	2	3	O	gp
3	5	14	O	Inhibitors
4	16	24	O	Reduction
5	26	27	O	in
6	29	31	O	the
7	33	36	O	dose
8	38	39	O	of
9	41	46	O	XXXXXXXX
10	48	50	O	may
11	52	53	O	be
12	55	62	O	required
13	64	65	O	in
14	67	74	O	patients
15	76	88	O	concomitantly
16	90	96	O	treated
17	98	101	O	with
18	103	103	B-UNK	P
19	105	106	I-UNK	gp
20	108	117	L-UNK	inhibitors
21	118	118	O	,
22	120	123	O	such
23	125	126	O	as
24	128	130	O	e.g
25	132	132	O	,
26	134	145	U-UNK	cyclosporine
27	146	146	O	,
28	148	152	O	based
29	154	155	O	on
30	157	164	O	clinical
31	166	173	O	response
32	176	178	O	see
33	180	183	O	Dose
34	185	187	O	and
35	189	202	O	Administration
36	205	207	O	2.3
37	210	212	O	and
38	214	221	O	Warnings
39	223	225	O	and
40	227	237	O	Precautions
41	240	242	O	5.5
NULL

SAMSCA	191	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	34
P-gp Inhibitors The dose of SAMSCA may have to be reduced when SAMSCA is co-administered with P-gp inhibitors, e.g., cyclosporine [see Dosage and Administration (2.3), Drug Interactions (7.1)].
1	0	0	O	P
2	2	3	O	gp
3	5	14	O	Inhibitors
4	16	18	O	The
5	20	23	O	dose
6	25	26	O	of
7	28	33	O	XXXXXXXX
8	35	37	O	may
9	39	42	O	have
10	44	45	O	to
11	47	48	O	be
12	50	56	O	reduced
13	58	61	O	when
14	63	68	O	XXXXXXXX
15	70	71	O	is
16	73	74	O	co
17	76	87	O	administered
18	89	92	O	with
19	94	94	B-UNK	P
20	96	97	I-UNK	gp
21	99	108	L-UNK	inhibitors
22	109	109	O	,
23	111	113	O	e.g
24	115	115	O	,
25	117	128	U-UNK	cyclosporine
26	131	133	O	see
27	135	140	O	Dosage
28	142	144	O	and
29	146	159	O	Administration
30	162	164	O	2.3
31	166	166	O	,
32	168	171	O	Drug
33	173	184	O	Interactions
34	187	189	O	7.1
NULL

SAMSCA	192	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	17
Pharmacodynamic Interactions Tolvaptan produces a greater 24hour urine volume/excretion rate than does furosemide or hydrochlorothiazide.
1	0	14	O	Pharmacodynamic
2	16	27	O	Interactions
3	29	37	O	XXXXXXXX
4	39	46	O	produces
5	48	48	O	a
6	50	56	O	greater
7	58	63	O	24hour
8	65	69	O	urine
9	71	76	O	volume
10	77	77	O	/
11	78	86	O	excretion
12	88	91	O	rate
13	93	96	O	than
14	98	101	O	does
15	103	112	O	furosemide
16	114	115	O	or
17	117	135	O	hydrochlorothiazide
NULL

SAMSCA	193	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	38
Reduction in the dose of SAMSCA may be required in patients concomitantly treated with P-gp inhibitors , such as e.g. , cyclosporine , based on clinical response see Dose and Administration ( 2.3 ) and Warnings and Precautions ( 5.5 ) .
1	0	8	O	Reduction
2	10	11	O	in
3	13	15	O	the
4	17	20	O	dose
5	22	23	O	of
6	25	30	O	XXXXXXXX
7	32	34	O	may
8	36	37	O	be
9	39	46	O	required
10	48	49	O	in
11	51	58	O	patients
12	60	72	O	concomitantly
13	74	80	O	treated
14	82	85	O	with
15	87	87	B-UNK	P
16	89	90	I-UNK	gp
17	92	101	L-UNK	inhibitors
18	103	103	O	,
19	105	108	O	such
20	110	111	O	as
21	113	115	O	e.g
22	118	118	O	,
23	120	131	U-UNK	cyclosporine
24	133	133	O	,
25	135	139	O	based
26	141	142	O	on
27	144	151	O	clinical
28	153	160	O	response
29	162	164	O	see
30	166	169	O	Dose
31	171	173	O	and
32	175	188	O	Administration
33	192	194	O	2.3
34	198	200	O	and
35	202	209	O	Warnings
36	211	213	O	and
37	215	225	O	Precautions
38	229	231	O	5.5
NULL

SAMSCA	194	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	16
Rifampin and Other CYP 3A Inducers Rifampin is an inducer of CYP 3A and P-gp.
1	0	7	O	Rifampin
2	9	11	O	and
3	13	17	O	Other
4	19	21	O	CYP
5	23	24	O	3A
6	26	33	O	Inducers
7	35	42	O	Rifampin
8	44	45	O	is
9	47	48	O	an
10	50	56	O	inducer
11	58	59	O	of
12	61	63	O	CYP
13	65	66	O	3A
14	68	70	O	and
15	72	72	O	P
16	74	75	O	gp
NULL

SAMSCA	195	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	10
Serum potassium levels should be monitored during concomitant drug therapy.
1	0	4	O	Serum
2	6	14	O	potassium
3	16	21	O	levels
4	23	28	O	should
5	30	31	O	be
6	33	41	O	monitored
7	43	48	O	during
8	50	60	O	concomitant
9	62	65	O	drug
10	67	73	O	therapy
NULL

SAMSCA	196	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	18
The dose of SAMSCA may have to be increased [Dosage and Administration (2.3) and Warnings and Precautions (5.5)].
1	0	2	O	The
2	4	7	O	dose
3	9	10	O	of
4	12	17	O	XXXXXXXX
5	19	21	O	may
6	23	26	O	have
7	28	29	O	to
8	31	32	O	be
9	34	42	O	increased
10	45	50	O	Dosage
11	52	54	O	and
12	56	69	O	Administration
13	72	74	O	2.3
14	77	79	O	and
15	81	88	O	Warnings
16	90	92	O	and
17	94	104	O	Precautions
18	107	109	O	5.5
NULL

SAMSCA	197	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	29
The impact of moderate CYP 3A inhibitors ( e.g. , erythromycin , fluconazole , aprepitant , diltiazem and verapamil ) on the exposure to co-administered tolvaptan has not been assessed .
1	0	2	O	The
2	4	9	O	impact
3	11	12	O	of
4	14	21	O	moderate
5	23	25	O	CYP
6	27	28	O	3A
7	30	39	O	inhibitors
8	43	45	O	e.g
9	48	48	O	,
10	50	61	O	erythromycin
11	63	63	O	,
12	65	75	O	fluconazole
13	77	77	O	,
14	79	88	O	aprepitant
15	90	90	O	,
16	92	100	O	diltiazem
17	102	104	O	and
18	106	114	O	verapamil
19	118	119	O	on
20	121	123	O	the
21	125	132	O	exposure
22	134	135	O	to
23	137	138	O	co
24	140	151	O	administered
25	153	161	O	XXXXXXXX
26	163	165	O	has
27	167	169	O	not
28	171	174	O	been
29	176	183	O	assessed
NULL

SAMSCA	198	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	43
Therefore , the expected clinical effects of SAMSCA in the presence of rifampin and other inducers ( e.g. , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine and St.   John 's   Wort ) may not be observed at the usual dose levels of SAMSCA .
1	0	8	O	Therefore
2	10	10	O	,
3	12	14	O	the
4	16	23	O	expected
5	25	32	O	clinical
6	34	40	O	effects
7	42	43	O	of
8	45	50	O	XXXXXXXX
9	52	53	O	in
10	55	57	O	the
11	59	66	O	presence
12	68	69	O	of
13	71	78	U-UNK	rifampin
14	80	82	O	and
15	84	88	O	other
16	90	97	U-UNK	inducers
17	101	103	O	e.g
18	106	106	O	,
19	108	116	U-UNK	rifabutin
20	118	118	O	,
21	120	129	U-UNK	rifapentin
22	131	131	O	,
23	133	144	U-UNK	barbiturates
24	146	146	O	,
25	148	156	U-UNK	phenytoin
26	158	158	O	,
27	160	172	U-UNK	carbamazepine
28	174	176	O	and
29	178	179	B-UNK	St
30	184	187	I-UNK	John
31	189	190	I-UNK	's
32	194	197	L-UNK	Wort
33	201	203	O	may
34	205	207	O	not
35	209	210	O	be
36	212	219	O	observed
37	221	222	O	at
38	224	226	O	the
39	228	232	O	usual
40	234	237	O	dose
41	239	244	O	levels
42	246	247	O	of
43	249	254	O	XXXXXXXX
NULL

SAMSCA	199	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	7
This is not a clinically relevant change.
1	0	3	O	This
2	5	6	O	is
3	8	10	O	not
4	12	12	O	a
5	14	23	O	clinically
6	25	32	O	relevant
7	34	39	O	change
NULL

SAMSCA	200	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	21
Thus, SAMSCA and strong CYP 3A inhibitors should not be co-administered [see Dosage and Administration (2.3) and Contraindications (4.4)].
1	0	3	O	Thus
2	4	4	O	,
3	6	11	O	XXXXXXXX
4	13	15	O	and
5	17	22	B-UNK	strong
6	24	26	I-UNK	CYP
7	28	29	I-UNK	3A
8	31	40	L-UNK	inhibitors
9	42	47	B-TRI	should
10	49	51	I-TRI	not
11	53	54	I-TRI	be
12	56	57	I-TRI	co
13	59	70	L-TRI	administered
14	73	75	O	see
15	77	82	O	Dosage
16	84	86	O	and
17	88	101	O	Administration
18	104	106	O	2.3
19	109	111	O	and
20	113	129	O	Contraindications
21	132	134	O	4.4
NULL

SAMSCA	201	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	16
Tolvaptan produces a greater 24 hour urine volume/excretion rate than does furosemide or hydrochlorothiazide .
1	0	8	O	XXXXXXXX
2	10	17	O	produces
3	19	19	O	a
4	21	27	O	greater
5	29	30	O	24
6	32	35	O	hour
7	37	41	O	urine
8	43	48	O	volume
9	49	49	O	/
10	50	58	O	excretion
11	60	63	O	rate
12	65	68	O	than
13	70	73	O	does
14	75	84	O	furosemide
15	86	87	O	or
16	89	107	O	hydrochlorothiazide
NULL

SAMSCA	202	34073-7	5526617c-c7b9-4556-886d-729bbabbc566	39
Warfarin, Amiodarone, Furosemide, and Hydrochlorothiazide Co-administration of tolvaptan does not appear to alter the pharmacokinetics of warfarin, furosemide, hydrochlorothiazide, or amiodarone (or its active metabolite, desethylamiodarone) to a clinically significant degree.
1	0	7	O	Warfarin
2	8	8	O	,
3	10	19	O	Amiodarone
4	20	20	O	,
5	22	31	O	Furosemide
6	32	32	O	,
7	34	36	O	and
8	38	56	O	Hydrochlorothiazide
9	58	59	O	Co
10	61	74	O	administration
11	76	77	O	of
12	79	87	O	XXXXXXXX
13	89	92	O	does
14	94	96	O	not
15	98	103	O	appear
16	105	106	O	to
17	108	112	O	alter
18	114	116	O	the
19	118	133	O	pharmacokinetics
20	135	136	O	of
21	138	145	O	warfarin
22	146	146	O	,
23	148	157	O	furosemide
24	158	158	O	,
25	160	178	O	hydrochlorothiazide
26	179	179	O	,
27	181	182	O	or
28	184	193	O	amiodarone
29	196	197	O	or
30	199	201	O	its
31	203	208	O	active
32	210	219	O	metabolite
33	220	220	O	,
34	222	239	O	desethylamiodarone
35	242	243	O	to
36	245	245	O	a
37	247	256	O	clinically
38	258	268	O	significant
39	270	275	O	degree
NULL

SAMSCA	203	43685-7	5526617c-c7b9-4556-886d-729bbabbc566	47
Avoid co-administration of CYP 3A inducers ( e.g. , rifampin , rifabutin , rifapentin , barbiturates , phenytoin , carbamazepine , St.   John 's   Wort ) with SAMSCA , as this can lead to a reduction in the plasma concentration of tolvaptan and decreased effectiveness of SAMSCA treatment .
1	0	4	O	Avoid
2	6	7	O	co
3	9	22	O	administration
4	24	25	O	of
5	27	29	B-KIN	CYP
6	31	32	I-KIN	3A
7	34	41	L-KIN	inducers
8	45	47	O	e.g
9	50	50	O	,
10	52	59	U-KIN	rifampin
11	61	61	O	,
12	63	71	U-KIN	rifabutin
13	73	73	O	,
14	75	84	U-KIN	rifapentin
15	86	86	O	,
16	88	99	U-KIN	barbiturates
17	101	101	O	,
18	103	111	U-KIN	phenytoin
19	113	113	O	,
20	115	127	U-KIN	carbamazepine
21	129	129	O	,
22	131	132	B-KIN	St
23	137	140	I-KIN	John
24	142	143	I-KIN	's
25	147	150	L-KIN	Wort
26	154	157	O	with
27	159	164	O	XXXXXXXX
28	166	166	O	,
29	168	169	O	as
30	171	174	O	this
31	176	178	O	can
32	180	183	O	lead
33	185	186	O	to
34	188	188	O	a
35	190	198	O	reduction
36	200	201	O	in
37	203	205	O	the
38	207	212	O	plasma
39	214	226	O	concentration
40	228	229	O	of
41	231	239	O	XXXXXXXX
42	241	243	O	and
43	245	253	O	decreased
44	255	267	O	effectiveness
45	269	270	O	of
46	272	277	O	XXXXXXXX
47	279	287	O	treatment
K/10:C54356 K/12:C54356 K/14:C54356 K/16:C54356 K/18:C54356 K/20:C54356 K/22:C54356 K/5:C54356

SAMSCA	204	43685-7	5526617c-c7b9-4556-886d-729bbabbc566	34
In patients receiving SAMSCA who develop medically significant signs or symptoms of hypovolemia , interrupt or discontinue SAMSCA therapy and provide supportive care with careful management of vital signs , fluid balance and electrolytes .
1	0	1	O	In
2	3	10	O	patients
3	12	20	O	receiving
4	22	27	O	XXXXXXXX
5	29	31	O	who
6	33	39	O	develop
7	41	49	O	medically
8	51	61	O	significant
9	63	67	O	signs
10	69	70	O	or
11	72	79	O	symptoms
12	81	82	O	of
13	84	94	O	hypovolemia
14	96	96	O	,
15	98	106	O	interrupt
16	108	109	O	or
17	111	121	O	discontinue
18	123	128	O	XXXXXXXX
19	130	136	O	therapy
20	138	140	O	and
21	142	148	O	provide
22	150	159	O	supportive
23	161	164	O	care
24	166	169	O	with
25	171	177	O	careful
26	179	188	O	management
27	190	191	O	of
28	193	197	O	vital
29	199	203	O	signs
30	205	205	O	,
31	207	211	O	fluid
32	213	219	O	balance
33	221	223	O	and
34	225	236	O	electrolytes
NULL

SAMSCA	205	43685-7	5526617c-c7b9-4556-886d-729bbabbc566	31
The dose of SAMSCA may have to be reduced when SAMSCA is co-administered with P-gp inhibitors , e.g. , cyclosporine see Dosage and Administration ( 2.3 ) , Drug Interactions ( 7.1 ) .
1	0	2	O	The
2	4	7	O	dose
3	9	10	O	of
4	12	17	O	XXXXXXXX
5	19	21	B-TRI	may
6	23	26	I-TRI	have
7	28	29	I-TRI	to
8	31	32	I-TRI	be
9	34	40	L-TRI	reduced
10	42	45	O	when
11	47	52	O	XXXXXXXX
12	54	55	O	is
13	57	58	O	co
14	60	71	O	administered
15	73	76	O	with
16	78	78	B-UNK	P
17	80	81	I-UNK	gp
18	83	92	L-UNK	inhibitors
19	94	94	O	,
20	96	98	O	e.g
21	101	101	O	,
22	103	114	U-UNK	cyclosporine
23	116	118	O	see
24	120	125	O	Dosage
25	127	129	O	and
26	131	144	O	Administration
27	148	150	O	2.3
28	154	154	O	,
29	156	159	O	Drug
30	161	172	O	Interactions
31	176	178	O	7.1
NULL

TENEX	386	34068-7	886e050c-dd22-4f35-ac3b-243f091125c3	27
The recommended initial dose of Tenex ( guanfacine hydrochloride ) when given alone or in combination with another antihypertensive drug is 1 mg daily given at bedtime to minimize somnolence .
1	0	2	O	The
2	4	14	O	recommended
3	16	22	O	initial
4	24	27	O	dose
5	29	30	O	of
6	32	36	O	XXXXXXXX
7	40	63	O	XXXXXXXX
8	67	70	O	when
9	72	76	O	given
10	78	82	O	alone
11	84	85	O	or
12	87	88	O	in
13	90	100	O	combination
14	102	105	O	with
15	107	113	O	another
16	115	130	O	antihypertensive
17	132	135	O	drug
18	137	138	O	is
19	140	140	O	1
20	142	143	O	mg
21	145	149	O	daily
22	151	155	O	given
23	157	158	O	at
24	160	166	O	bedtime
25	168	169	O	to
26	171	178	O	minimize
27	180	189	O	somnolence
NULL

TENEX	387	34073-7	886e050c-dd22-4f35-ac3b-243f091125c3	22
Anticoagulants Ten patients who were stabilized on oral anticoagulants were given guanfacine, 1 - 2 mg/day, for 4 weeks.
1	0	13	O	Anticoagulants
2	15	17	O	Ten
3	19	26	O	patients
4	28	30	O	who
5	32	35	O	were
6	37	46	O	stabilized
7	48	49	O	on
8	51	54	O	oral
9	56	69	O	anticoagulants
10	71	74	O	were
11	76	80	O	given
12	82	91	O	XXXXXXXX
13	92	92	O	,
14	94	94	O	1
15	98	98	O	2
16	100	101	O	mg
17	102	102	O	/
18	103	105	O	day
19	106	106	O	,
20	108	110	O	for
21	112	112	O	4
22	114	118	O	weeks
NULL

TENEX	388	34073-7	886e050c-dd22-4f35-ac3b-243f091125c3	29
Further, if guanfacine is to be discontinued in such patients, careful tapering of the dosage may be necessary in order to avoid rebound phenomena (see Rebound above).
1	0	6	O	Further
2	7	7	O	,
3	9	10	O	if
4	12	21	O	XXXXXXXX
5	23	24	O	is
6	26	27	O	to
7	29	30	O	be
8	32	43	O	discontinued
9	45	46	O	in
10	48	51	O	such
11	53	60	O	patients
12	61	61	O	,
13	63	69	O	careful
14	71	78	O	tapering
15	80	81	O	of
16	83	85	O	the
17	87	92	O	dosage
18	94	96	O	may
19	98	99	O	be
20	101	109	O	necessary
21	111	112	O	in
22	114	118	O	order
23	120	121	O	to
24	123	127	O	avoid
25	129	135	O	rebound
26	137	145	O	phenomena
27	148	150	O	see
28	152	158	O	Rebound
29	160	164	O	above
NULL

TENEX	389	34073-7	886e050c-dd22-4f35-ac3b-243f091125c3	17
In several well-controlled studies , guanfacine was administered together with diuretics with no drug interactions reported .
1	0	1	O	In
2	3	9	O	several
3	11	14	O	well
4	16	25	O	controlled
5	27	33	O	studies
6	35	35	O	,
7	37	46	O	XXXXXXXX
8	48	50	O	was
9	52	63	O	administered
10	65	72	O	together
11	74	77	O	with
12	79	87	O	diuretics
13	89	92	O	with
14	94	95	O	no
15	97	100	O	drug
16	102	113	O	interactions
17	115	122	O	reported
NULL

TENEX	390	34073-7	886e050c-dd22-4f35-ac3b-243f091125c3	20
In such cases, therefore, more frequent dosing may be required to achieve or maintain the desired hypotensive response.
1	0	1	O	In
2	3	6	O	such
3	8	12	O	cases
4	13	13	O	,
5	15	23	O	therefore
6	24	24	O	,
7	26	29	O	more
8	31	38	O	frequent
9	40	45	O	dosing
10	47	49	O	may
11	51	52	O	be
12	54	61	O	required
13	63	64	O	to
14	66	72	O	achieve
15	74	75	O	or
16	77	84	O	maintain
17	86	88	O	the
18	90	96	O	desired
19	98	108	O	hypotensive
20	110	117	O	response
NULL

TENEX	391	34073-7	886e050c-dd22-4f35-ac3b-243f091125c3	19
In the long-term safety studies, Tenex was given concomitantly with many drugs without evidence of any interactions.
1	0	1	O	In
2	3	5	O	the
3	7	10	O	long
4	12	15	O	term
5	17	22	O	safety
6	24	30	O	studies
7	31	31	O	,
8	33	37	O	XXXXXXXX
9	39	41	O	was
10	43	47	O	given
11	49	61	O	concomitantly
12	63	66	O	with
13	68	71	O	many
14	73	77	O	drugs
15	79	85	O	without
16	87	94	O	evidence
17	96	97	O	of
18	99	101	O	any
19	103	114	O	interactions
NULL

TENEX	392	34073-7	886e050c-dd22-4f35-ac3b-243f091125c3	9
No changes were observed in the degree of anticoagulation.
1	0	1	O	No
2	3	9	O	changes
3	11	14	O	were
4	16	23	O	observed
5	25	26	O	in
6	28	30	O	the
7	32	37	O	degree
8	39	40	O	of
9	42	56	O	anticoagulation
NULL

TENEX	393	34073-7	886e050c-dd22-4f35-ac3b-243f091125c3	21
Ten patients who were stabilized on oral anticoagulants were given guanfacine , 1 - 2 mg/day , for 4 weeks .
1	0	2	O	Ten
2	4	11	O	patients
3	13	15	O	who
4	17	20	O	were
5	22	31	O	stabilized
6	33	34	O	on
7	36	39	O	oral
8	41	54	O	anticoagulants
9	56	59	O	were
10	61	65	O	given
11	67	76	O	XXXXXXXX
12	78	78	O	,
13	80	80	O	1
14	84	84	O	2
15	86	87	O	mg
16	88	88	O	/
17	89	91	O	day
18	93	93	O	,
19	95	97	O	for
20	99	99	O	4
21	101	105	O	weeks
NULL

TENEX	394	34073-7	886e050c-dd22-4f35-ac3b-243f091125c3	32
The administration of guanfacine concomitantly with a known microsomal enzyme inducer ( phenobarbital or phenytoin ) to two patients with renal impairment reportedly resulted in significant reductions in elimination half-life and plasma concentration .
1	0	2	O	The
2	4	17	O	administration
3	19	20	O	of
4	22	31	O	XXXXXXXX
5	33	45	O	concomitantly
6	47	50	O	with
7	52	52	O	a
8	54	58	O	known
9	60	69	B-KIN	microsomal
10	71	76	I-KIN	enzyme
11	78	84	L-KIN	inducer
12	88	100	U-KIN	phenobarbital
13	102	103	O	or
14	105	113	U-KIN	phenytoin
15	117	118	O	to
16	120	122	O	two
17	124	131	O	patients
18	133	136	O	with
19	138	142	O	renal
20	144	153	O	impairment
21	155	164	O	reportedly
22	166	173	O	resulted
23	175	176	O	in
24	178	188	O	significant
25	190	199	B-TRI	reductions
26	201	202	I-TRI	in
27	204	214	I-TRI	elimination
28	216	219	I-TRI	half
29	221	224	L-TRI	life
30	226	228	O	and
31	230	235	O	plasma
32	237	249	O	concentration
K/12:C54356 K/14:C54356 K/9:C54356

TENEX	395	34073-7	886e050c-dd22-4f35-ac3b-243f091125c3	17
The potential for increased sedation when Tenex is given with other CNS-depressant drugs should be appreciated .
1	0	2	O	The
2	4	12	O	potential
3	14	16	O	for
4	18	26	B-EFF	increased
5	28	35	L-EFF	sedation
6	37	40	O	when
7	42	46	O	XXXXXXXX
8	48	49	O	is
9	51	55	O	given
10	57	60	O	with
11	62	66	O	other
12	68	70	B-DYN	CNS
13	72	81	I-DYN	depressant
14	83	87	L-DYN	drugs
15	89	94	O	should
16	96	97	O	be
17	99	109	O	appreciated
D/12:4:1

TENEX	396	34073-7	886e050c-dd22-4f35-ac3b-243f091125c3	58
The principal drugs given (number of patients in parentheses) were: cardiac glycosides (115), sedatives and hypnotics (103), coronary vasodilators (52), oral hypoglycemics (45), cough and cold preparations (45), NSAIDs (38), antihyperlipidemics (29), antigout drugs (24), oral contraceptives (18), bronchodilators (13), insulin (10), and beta blockers (10).
1	0	2	O	The
2	4	12	O	principal
3	14	18	O	drugs
4	20	24	O	given
5	27	32	O	number
6	34	35	O	of
7	37	44	O	patients
8	46	47	O	in
9	49	59	O	parentheses
10	62	65	O	were
11	66	66	O	:
12	68	74	O	cardiac
13	76	85	O	glycosides
14	88	90	O	115
15	92	92	O	,
16	94	102	O	sedatives
17	104	106	O	and
18	108	116	O	hypnotics
19	119	121	O	103
20	123	123	O	,
21	125	132	O	coronary
22	134	145	O	vasodilators
23	148	149	O	52
24	151	151	O	,
25	153	156	O	oral
26	158	170	O	hypoglycemics
27	173	174	O	45
28	176	176	O	,
29	178	182	O	cough
30	184	186	O	and
31	188	191	O	cold
32	193	204	O	preparations
33	207	208	O	45
34	210	210	O	,
35	212	217	O	NSAIDs
36	220	221	O	38
37	223	223	O	,
38	225	243	O	antihyperlipidemics
39	246	247	O	29
40	249	249	O	,
41	251	258	O	antigout
42	260	264	O	drugs
43	267	268	O	24
44	270	270	O	,
45	272	275	O	oral
46	277	290	O	contraceptives
47	293	294	O	18
48	296	296	O	,
49	298	312	O	bronchodilators
50	315	316	O	13
51	318	318	O	,
52	320	326	O	insulin
53	329	330	O	10
54	332	332	O	,
55	334	336	O	and
56	338	341	O	beta
57	343	350	O	blockers
58	353	354	O	10
NULL

TENEX	397	42232-9	886e050c-dd22-4f35-ac3b-243f091125c3	31
Like other antihypertensive agents , Tenex ( guanfacine hydrochloride ) should be used with caution in patients with severe coronary insufficiency , recent myocardial infarction , cerebrovascular disease , or chronic renal or hepatic failure .
1	0	3	O	Like
2	5	9	O	other
3	11	33	O	GGGGGGGG
4	35	35	O	,
5	37	41	O	XXXXXXXX
6	45	68	O	XXXXXXXX
7	72	77	O	should
8	79	80	O	be
9	82	85	O	used
10	87	90	O	with
11	92	98	O	caution
12	100	101	O	in
13	103	110	O	patients
14	112	115	O	with
15	117	122	O	severe
16	124	131	O	coronary
17	133	145	O	insufficiency
18	147	147	O	,
19	149	154	O	recent
20	156	165	O	myocardial
21	167	176	O	infarction
22	178	178	O	,
23	180	194	O	cerebrovascular
24	196	202	O	disease
25	204	204	O	,
26	206	207	O	or
27	209	215	O	chronic
28	217	221	O	renal
29	223	224	O	or
30	226	232	O	hepatic
31	234	240	O	failure
NULL

TENEX	398	42232-9	886e050c-dd22-4f35-ac3b-243f091125c3	20
Tenex , like other orally active central 2-adrenergic agonists , causes sedation or drowsiness , especially when beginning therapy .
1	0	4	O	XXXXXXXX
2	6	6	O	,
3	8	11	O	like
4	13	17	O	other
5	19	24	O	orally
6	26	31	O	active
7	33	39	O	central
8	41	41	O	2
9	43	52	O	adrenergic
10	54	61	O	agonists
11	63	63	O	,
12	65	70	O	causes
13	72	79	O	sedation
14	81	82	O	or
15	84	93	O	drowsiness
16	95	95	O	,
17	97	106	O	especially
18	108	111	O	when
19	113	121	O	beginning
20	123	129	O	therapy
NULL

TENEX	399	42232-9	886e050c-dd22-4f35-ac3b-243f091125c3	27
When Tenex is used with other centrally active depressants ( such as phenothiazines , barbiturates , or benzodiazepines ) , the potential for additive sedative effects should be considered .
1	0	3	O	When
2	5	9	O	XXXXXXXX
3	11	12	O	is
4	14	17	O	used
5	19	22	O	with
6	24	28	O	other
7	30	38	B-DYN	centrally
8	40	45	I-DYN	active
9	47	57	L-DYN	depressants
10	61	64	O	such
11	66	67	O	as
12	69	82	U-DYN	phenothiazines
13	84	84	O	,
14	86	97	U-DYN	barbiturates
15	99	99	O	,
16	101	102	O	or
17	104	118	U-DYN	benzodiazepines
18	122	122	O	,
19	124	126	O	the
20	128	136	O	potential
21	138	140	O	for
22	142	149	B-EFF	additive
23	151	158	I-EFF	sedative
24	160	166	L-EFF	effects
25	168	173	O	should
26	175	176	O	be
27	178	187	O	considered
D/12:22:1 D/14:22:1 D/17:22:1 D/7:22:1

Tekturna	366	34070-3	833c7a0b-5f64-4363-94d5-9a179049113a	21
Do not use aliskiren with ARBs or ACEIs in patients with diabetes see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.3 ) .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	9	L-TRI	use
4	11	19	O	XXXXXXXX
5	21	24	O	with
6	26	29	U-UNK	ARBs
7	31	32	O	or
8	34	38	U-UNK	ACEIs
9	40	41	O	in
10	43	50	O	patients
11	52	55	O	with
12	57	64	O	diabetes
13	66	68	O	see
14	70	77	O	Warnings
15	79	81	O	and
16	83	93	O	Precautions
17	97	99	O	5.2
18	103	105	O	and
19	107	114	O	Clinical
20	116	122	O	Studies
21	126	129	O	14.3
NULL

Tekturna	367	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	20
(5.7, 7, 12.3) Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Increased risk of renal impairment and loss of antihypertensive effect.
1	1	3	O	5.7
2	4	4	O	,
3	6	6	O	7
4	7	7	O	,
5	9	12	O	12.3
6	15	26	O	Nonsteroidal
7	28	31	O	Anti
8	33	44	O	Inflammatory
9	46	50	O	Drugs
10	53	58	O	NSAIDs
11	61	69	O	Increased
12	71	74	O	risk
13	76	77	O	of
14	79	83	O	renal
15	85	94	O	impairment
16	96	98	O	and
17	100	103	O	loss
18	105	106	O	of
19	108	123	O	antihypertensive
20	125	130	O	effect
NULL

Tekturna	368	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	17
Cyclosporine : Avoid coadministration of cyclosporine with aliskiren see Warnings and Precautions ( 5.7 ) and Clinical Pharmacology ( 12.3 ) .
1	0	11	U-UNK	Cyclosporine
2	13	13	O	:
3	15	19	U-TRI	Avoid
4	21	36	O	coadministration
5	38	39	O	of
6	41	52	O	cyclosporine
7	54	57	O	with
8	59	67	O	XXXXXXXX
9	69	71	O	see
10	73	80	O	Warnings
11	82	84	O	and
12	86	96	O	Precautions
13	100	102	O	5.7
14	106	108	O	and
15	110	117	O	Clinical
16	119	130	O	Pharmacology
17	134	137	O	12.3
NULL

Tekturna	369	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	7
Cyclosporine or Itraconazole: Avoid concomitant use.
1	0	11	U-UNK	Cyclosporine
2	13	14	O	or
3	16	27	U-UNK	Itraconazole
4	28	28	O	:
5	30	34	U-TRI	Avoid
6	36	46	O	concomitant
7	48	50	O	use
NULL

Tekturna	370	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	50
Dual Blockade of the Renin-Angiotensin-Aldosterone System (RAAS): The concomitant use of aliskiren with other agents acting on the RAAS such as ACEIs or ARBs is associated with an increased risk of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
1	0	3	O	Dual
2	5	12	O	Blockade
3	14	15	O	of
4	17	19	O	the
5	21	25	O	Renin
6	27	37	O	Angiotensin
7	39	49	O	Aldosterone
8	51	56	O	System
9	59	62	O	RAAS
10	64	64	O	:
11	66	68	O	The
12	70	80	O	concomitant
13	82	84	O	use
14	86	87	O	of
15	89	97	O	XXXXXXXX
16	99	102	O	with
17	104	108	O	other
18	110	115	B-DYN	agents
19	117	122	I-DYN	acting
20	124	125	I-DYN	on
21	127	129	I-DYN	the
22	131	134	L-DYN	RAAS
23	136	139	O	such
24	141	142	O	as
25	144	148	U-DYN	ACEIs
26	150	151	O	or
27	153	156	U-DYN	ARBs
28	158	159	O	is
29	161	170	O	associated
30	172	175	O	with
31	177	178	O	an
32	180	188	O	increased
33	190	193	O	risk
34	195	196	O	of
35	198	208	U-EFF	hypotension
36	209	209	O	,
37	211	222	U-EFF	hyperkalemia
38	223	223	O	,
39	225	227	O	and
40	229	235	B-EFF	changes
41	237	238	I-EFF	in
42	240	244	I-EFF	renal
43	246	253	L-EFF	function
44	256	264	O	including
45	266	270	B-EFF	acute
46	272	276	I-EFF	renal
47	278	284	L-EFF	failure
48	287	294	O	compared
49	296	297	O	to
50	299	309	O	monotherapy
D/18:35:1 D/18:37:1 D/18:40:1 D/18:45:1 D/25:35:1 D/25:37:1 D/25:40:1 D/25:45:1 D/27:35:1 D/27:37:1 D/27:40:1 D/27:45:1

Tekturna	371	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	12
Furosemide : Oral coadministration of aliskiren and furosemide reduced exposure to furosemide .
1	0	9	O	Furosemide
2	11	11	O	:
3	13	16	O	Oral
4	18	33	O	coadministration
5	35	36	O	of
6	38	46	O	XXXXXXXX
7	48	50	O	and
8	52	61	U-KIN	furosemide
9	63	69	B-TRI	reduced
10	71	78	I-TRI	exposure
11	80	81	L-TRI	to
12	83	92	O	furosemide
K/8:C54358

Tekturna	372	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	25
In general , avoid combined use of aliskiren with ACE inhibitors or ARBs , particularly in patients with CrCl less than 60 mL/min .
1	0	1	O	In
2	3	9	O	general
3	11	11	O	,
4	13	17	U-TRI	avoid
5	19	26	O	combined
6	28	30	O	use
7	32	33	O	of
8	35	43	O	XXXXXXXX
9	45	48	O	with
10	50	52	B-UNK	ACE
11	54	63	L-UNK	inhibitors
12	65	66	O	or
13	68	71	U-UNK	ARBs
14	73	73	O	,
15	75	86	O	particularly
16	88	89	O	in
17	91	98	O	patients
18	100	103	O	with
19	105	108	O	CrCl
20	110	113	O	less
21	115	118	O	than
22	120	121	O	60
23	123	124	O	mL
24	125	125	O	/
25	126	128	O	min
NULL

Tekturna	373	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	17
Itraconazole : Avoid coadministration of itraconazole with aliskiren see Warnings and Precautions ( 5.7 ) and Clinical Pharmacology ( 12.3 ) .
1	0	11	O	Itraconazole
2	13	13	O	:
3	15	19	U-TRI	Avoid
4	21	36	O	coadministration
5	38	39	O	of
6	41	52	U-UNK	itraconazole
7	54	57	O	with
8	59	67	O	XXXXXXXX
9	69	71	O	see
10	73	80	O	Warnings
11	82	84	O	and
12	86	96	O	Precautions
13	100	102	O	5.7
14	106	108	O	and
15	110	117	O	Clinical
16	119	130	O	Pharmacology
17	134	137	O	12.3
NULL

Tekturna	374	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	29
Monitor blood pressure , renal function , and electrolytes in patients taking aliskiren and other agents that affect the RAAS see Warnings and Precautions ( 5.4 , 5.5 , 5.6 ) .
1	0	6	O	Monitor
2	8	12	O	blood
3	14	21	O	pressure
4	23	23	O	,
5	25	29	O	renal
6	31	38	O	function
7	40	40	O	,
8	42	44	O	and
9	46	57	O	electrolytes
10	59	60	O	in
11	62	69	O	patients
12	71	76	O	taking
13	78	86	O	XXXXXXXX
14	88	90	O	and
15	92	96	O	other
16	98	103	O	agents
17	105	108	O	that
18	110	115	O	affect
19	117	119	O	the
20	121	124	O	RAAS
21	126	128	O	see
22	130	137	O	Warnings
23	139	141	O	and
24	143	153	O	Precautions
25	157	159	O	5.4
26	161	161	O	,
27	163	165	O	5.5
28	167	167	O	,
29	169	171	O	5.6
NULL

Tekturna	375	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	9
Monitor diuretic effects when furosemide is coadministered with aliskiren .
1	0	6	U-TRI	Monitor
2	8	15	O	diuretic
3	17	23	O	effects
4	25	28	O	when
5	30	39	U-UNK	furosemide
6	41	42	O	is
7	44	57	O	coadministered
8	59	62	O	with
9	64	72	O	XXXXXXXX
NULL

Tekturna	376	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	11
Monitor renal function periodically in patients receiving aliskiren and NSAID therapy .
1	0	6	U-TRI	Monitor
2	8	12	O	renal
3	14	21	O	function
4	23	34	O	periodically
5	36	37	O	in
6	39	46	O	patients
7	48	56	O	receiving
8	58	66	O	XXXXXXXX
9	68	70	O	and
10	72	76	U-UNK	NSAID
11	78	84	O	therapy
NULL

Tekturna	377	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	23
Most patients receiving the combination of two drugs that inhibit the renin-angiotensin system do not obtain any additional benefit compared to monotherapy.
1	0	3	O	Most
2	5	12	O	patients
3	14	22	O	receiving
4	24	26	O	the
5	28	38	O	combination
6	40	41	O	of
7	43	45	O	two
8	47	51	O	drugs
9	53	56	O	that
10	58	64	O	inhibit
11	66	68	O	the
12	70	74	O	renin
13	76	86	O	angiotensin
14	88	93	O	system
15	95	96	O	do
16	98	100	O	not
17	102	107	O	obtain
18	109	111	O	any
19	113	122	O	additional
20	124	130	O	benefit
21	132	139	O	compared
22	141	142	O	to
23	144	154	O	monotherapy
NULL

Tekturna	378	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	66
Nonsteroidal Anti-Inflammatory Drugs ( NSAIDs ) including selective Cyclooxygenase-2 inhibitors ( COX-2 inhibitors ) : In patients who are elderly , volume-depleted ( including those on diuretic therapy ) , or with compromised renal function , coadministration of NSAIDs , including selective COX-2 inhibitors with agents that affect the RAAS , including aliskiren , may result in deterioration of renal function , including possible acute renal failure .
1	0	11	O	Nonsteroidal
2	13	16	O	Anti
3	18	29	O	Inflammatory
4	31	35	O	Drugs
5	39	44	U-DYN	NSAIDs
6	48	56	O	including
7	58	66	O	selective
8	68	81	O	Cyclooxygenase
9	83	83	O	2
10	85	94	O	inhibitors
11	98	100	O	COX
12	102	102	O	2
13	104	113	O	inhibitors
14	117	117	O	:
15	119	120	O	In
16	122	129	O	patients
17	131	133	O	who
18	135	137	O	are
19	139	145	O	elderly
20	147	147	O	,
21	149	154	O	volume
22	156	163	O	depleted
23	167	175	O	including
24	177	181	O	those
25	183	184	O	on
26	186	193	O	diuretic
27	195	201	O	therapy
28	205	205	O	,
29	207	208	O	or
30	210	213	O	with
31	215	225	O	compromised
32	227	231	O	renal
33	233	240	O	function
34	242	242	O	,
35	244	259	O	coadministration
36	261	262	O	of
37	264	269	O	NSAIDs
38	271	271	O	,
39	273	281	O	including
40	283	291	B-DYN	selective
41	293	295	I-DYN	COX
42	297	297	I-DYN	2
43	299	308	L-DYN	inhibitors
44	310	313	O	with
45	315	320	O	agents
46	322	325	O	that
47	327	332	O	affect
48	334	336	O	the
49	338	341	O	RAAS
50	343	343	O	,
51	345	353	O	including
52	355	363	O	XXXXXXXX
53	365	365	O	,
54	367	369	O	may
55	371	376	O	result
56	378	379	O	in
57	381	393	B-EFF	deterioration
58	395	396	I-EFF	of
59	398	402	I-EFF	renal
60	404	411	L-EFF	function
61	413	413	O	,
62	415	423	O	including
63	425	432	O	possible
64	434	438	B-EFF	acute
65	440	444	I-EFF	renal
66	446	452	L-EFF	failure
D/40:57:1 D/40:64:1 D/5:57:1 D/5:64:1

Tekturna	379	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	66
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) including selective Cyclooxygenase-2 inhibitors (COX-2 inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors with agents that affect the RAAS, including aliskiren, may result in deterioration of renal function, including possible acute renal failure.
1	0	11	B-DYN	Nonsteroidal
2	13	16	I-DYN	Anti
3	18	29	I-DYN	Inflammatory
4	31	35	L-DYN	Drugs
5	38	43	U-DYN	NSAIDs
6	46	54	O	including
7	56	64	O	selective
8	66	79	B-DYN	Cyclooxygenase
9	81	81	I-DYN	2
10	83	92	L-DYN	inhibitors
11	95	97	B-DYN	COX
12	99	99	I-DYN	2
13	101	110	L-DYN	inhibitors
14	112	112	O	:
15	114	115	O	In
16	117	124	O	patients
17	126	128	O	who
18	130	132	O	are
19	134	140	O	elderly
20	141	141	O	,
21	143	148	O	volume
22	150	157	O	depleted
23	160	168	O	including
24	170	174	O	those
25	176	177	O	on
26	179	186	O	diuretic
27	188	194	O	therapy
28	196	196	O	,
29	198	199	O	or
30	201	204	O	with
31	206	216	O	compromised
32	218	222	O	renal
33	224	231	O	function
34	232	232	O	,
35	234	249	O	coadministration
36	251	252	O	of
37	254	259	O	NSAIDs
38	260	260	O	,
39	262	270	O	including
40	272	280	O	selective
41	282	284	O	COX
42	286	286	O	2
43	288	297	O	inhibitors
44	299	302	O	with
45	304	309	O	agents
46	311	314	O	that
47	316	321	O	affect
48	323	325	O	the
49	327	330	O	RAAS
50	331	331	O	,
51	333	341	O	including
52	343	351	O	XXXXXXXX
53	352	352	O	,
54	354	356	O	may
55	358	363	O	result
56	365	366	O	in
57	368	380	B-EFF	deterioration
58	382	383	I-EFF	of
59	385	389	I-EFF	renal
60	391	398	L-EFF	function
61	399	399	O	,
62	401	409	O	including
63	411	418	O	possible
64	420	424	B-EFF	acute
65	426	430	I-EFF	renal
66	432	438	L-EFF	failure
D/1:57:1 D/1:64:1 D/11:57:1 D/11:64:1 D/5:57:1 D/5:64:1 D/8:57:1 D/8:64:1

Tekturna	380	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	10
The antihypertensive effect of aliskiren may be attenuated by NSAIDs .
1	0	2	O	The
2	4	19	O	antihypertensive
3	21	26	O	effect
4	28	29	O	of
5	31	39	O	XXXXXXXX
6	41	43	O	may
7	45	46	O	be
8	48	57	O	attenuated
9	59	60	O	by
10	62	67	U-DYN	NSAIDs
NULL

Tekturna	381	34073-7	833c7a0b-5f64-4363-94d5-9a179049113a	19
The concomitant use of aliskiren with an ARB or an ACEI in diabetic patients is contraindicated [see Contraindications (4)].
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	31	O	XXXXXXXX
6	33	36	O	with
7	38	39	O	an
8	41	43	U-UNK	ARB
9	45	46	O	or
10	48	49	O	an
11	51	54	U-UNK	ACEI
12	56	57	O	in
13	59	66	O	diabetic
14	68	75	O	patients
15	77	78	O	is
16	80	94	U-TRI	contraindicated
17	97	99	O	see
18	101	117	O	Contraindications
19	120	120	O	4
NULL

Tekturna	382	43685-7	833c7a0b-5f64-4363-94d5-9a179049113a	13
Avoid concomitant use of aliskiren with cyclosporine or itraconazole see Drug Interactions ( 7 ) .
1	0	4	U-TRI	Avoid
2	6	16	O	concomitant
3	18	20	O	use
4	22	23	O	of
5	25	33	O	XXXXXXXX
6	35	38	O	with
7	40	51	U-UNK	cyclosporine
8	53	54	O	or
9	56	67	U-UNK	itraconazole
10	69	71	O	see
11	73	76	O	Drug
12	78	89	O	Interactions
13	93	93	O	7
NULL

Tekturna	383	43685-7	833c7a0b-5f64-4363-94d5-9a179049113a	38
In general , avoid combined use of aliskiren with ACE inhibitors or ARBs , particularly in patients with creatinine clearance ( CrCl ) less than 60 mL/min see Contraindications ( 4 ) , Drug Interactions ( 7 ) and Clinical Studies ( 14.3 ) .
1	0	1	O	In
2	3	9	O	general
3	11	11	O	,
4	13	17	U-TRI	avoid
5	19	26	O	combined
6	28	30	O	use
7	32	33	O	of
8	35	43	O	XXXXXXXX
9	45	48	O	with
10	50	52	B-UNK	ACE
11	54	63	L-UNK	inhibitors
12	65	66	O	or
13	68	71	U-UNK	ARBs
14	73	73	O	,
15	75	86	O	particularly
16	88	89	O	in
17	91	98	O	patients
18	100	103	O	with
19	105	114	O	creatinine
20	116	124	O	clearance
21	128	131	O	CrCl
22	135	138	O	less
23	140	143	O	than
24	145	146	O	60
25	148	149	O	mL
26	150	150	O	/
27	151	153	O	min
28	155	157	O	see
29	159	175	O	Contraindications
30	179	179	O	4
31	183	183	O	,
32	185	188	O	Drug
33	190	201	O	Interactions
34	205	205	O	7
35	209	211	O	and
36	213	220	O	Clinical
37	222	228	O	Studies
38	232	235	O	14.3
NULL

Tekturna	384	43685-7	833c7a0b-5f64-4363-94d5-9a179049113a	86
Patients whose renal function may depend in part on the activity of the RAAS ( e.g. , patients with renal artery stenosis , severe heart failure , post-myocardial infarction or volume depletion ) or patients receiving ARB , ACEI or nonsteroidal anti-inflammatory drug ( NSAID ) , including selective Cyclooxygenase-2 inhibitors ( COX-2 inhibitors ) , therapy may be at particular risk for developing acute renal failure on Tekturna see Warnings and Precautions ( 5.2 Drug Interactions ( 7 ) , and Use in Specific Populations ( 8.7 ) and Clinical Studies ( 14.3 ) .
1	0	7	O	Patients
2	9	13	O	whose
3	15	19	O	renal
4	21	28	O	function
5	30	32	O	may
6	34	39	O	depend
7	41	42	O	in
8	44	47	O	part
9	49	50	O	on
10	52	54	O	the
11	56	63	O	activity
12	65	66	O	of
13	68	70	O	the
14	72	75	O	RAAS
15	79	81	O	e.g
16	84	84	O	,
17	86	93	O	patients
18	95	98	O	with
19	100	104	O	renal
20	106	111	O	artery
21	113	120	O	stenosis
22	122	122	O	,
23	124	129	O	severe
24	131	135	O	heart
25	137	143	O	failure
26	145	145	O	,
27	147	150	O	post
28	152	161	O	myocardial
29	163	172	O	infarction
30	174	175	O	or
31	177	182	O	volume
32	184	192	O	depletion
33	196	197	O	or
34	199	206	O	patients
35	208	216	O	receiving
36	218	220	U-DYN	ARB
37	222	222	O	,
38	224	227	U-DYN	ACEI
39	229	230	O	or
40	232	243	B-DYN	nonsteroidal
41	245	248	I-DYN	anti
42	250	261	I-DYN	inflammatory
43	263	266	L-DYN	drug
44	270	274	U-DYN	NSAID
45	278	278	O	,
46	280	288	O	including
47	290	298	O	selective
48	300	313	B-DYN	Cyclooxygenase
49	315	315	I-DYN	2
50	317	326	L-DYN	inhibitors
51	330	332	B-DYN	COX
52	334	334	I-DYN	2
53	336	345	L-DYN	inhibitors
54	349	349	O	,
55	351	357	O	therapy
56	359	361	O	may
57	363	364	O	be
58	366	367	O	at
59	369	378	O	particular
60	380	383	O	risk
61	385	387	O	for
62	389	398	O	developing
63	400	404	B-EFF	acute
64	406	410	I-EFF	renal
65	412	418	L-EFF	failure
66	420	421	O	on
67	423	430	O	XXXXXXXX
68	432	434	O	see
69	436	443	O	Warnings
70	445	447	O	and
71	449	459	O	Precautions
72	463	465	O	5.2
73	467	470	O	Drug
74	472	483	O	Interactions
75	487	487	O	7
76	491	491	O	,
77	493	495	O	and
78	497	499	O	Use
79	501	502	O	in
80	504	511	O	Specific
81	513	523	O	Populations
82	527	529	O	8.7
83	533	535	O	and
84	537	544	O	Clinical
85	546	552	O	Studies
86	556	559	O	14.3
D/36:63:1 D/38:63:1 D/40:63:1 D/44:63:1 D/48:63:1 D/51:63:1

Tekturna	385	43685-7	833c7a0b-5f64-4363-94d5-9a179049113a	17
When aliskiren was given with cyclosporine or itraconazole , the blood concentrations of aliskiren were significantly increased .
1	0	3	O	When
2	5	13	O	XXXXXXXX
3	15	17	O	was
4	19	23	O	given
5	25	28	O	with
6	30	41	U-KIN	cyclosporine
7	43	44	O	or
8	46	57	U-KIN	itraconazole
9	59	59	O	,
10	61	63	O	the
11	65	69	O	blood
12	71	84	O	concentrations
13	86	87	O	of
14	89	97	O	XXXXXXXX
15	99	102	O	were
16	104	116	O	significantly
17	118	126	O	increased
K/6:C54355 K/8:C54355

Tracleer	323	34066-1	749e42fb-2fe0-45dd-9268-b43bb3f4081c	37
Hormonal contraceptives , including oral , injectable , transdermal , and implantable contraceptives should not be used as the sole means of contraception because these may not be effective in patients receiving Tracleer see Drug Interactions ( 7.2 ) .
1	0	7	B-UNK	Hormonal
2	9	22	L-UNK	contraceptives
3	24	24	O	,
4	26	34	O	including
5	36	39	O	oral
6	41	41	O	,
7	43	52	O	injectable
8	54	54	O	,
9	56	66	O	transdermal
10	68	68	O	,
11	70	72	O	and
12	74	84	O	implantable
13	86	99	O	contraceptives
14	101	106	B-TRI	should
15	108	110	I-TRI	not
16	112	113	I-TRI	be
17	115	118	L-TRI	used
18	120	121	O	as
19	123	125	O	the
20	127	130	O	sole
21	132	136	O	means
22	138	139	O	of
23	141	153	O	contraception
24	155	161	O	because
25	163	167	O	these
26	169	171	O	may
27	173	175	O	not
28	177	178	O	be
29	180	188	O	effective
30	190	191	O	in
31	193	200	O	patients
32	202	210	O	receiving
33	212	219	O	XXXXXXXX
34	221	223	O	see
35	225	228	O	Drug
36	230	241	O	Interactions
37	245	247	O	7.2
NULL

Tracleer	324	34068-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	34
After at least 10 days following the initiation of ritonavir , resume Tracleer at the recommended initial dose once daily or every other day based upon individual tolerability see Cytochrome P450 Drug Interactions ( 7.1 ) .
1	0	4	O	After
2	6	7	O	at
3	9	13	O	least
4	15	16	O	10
5	18	21	O	days
6	23	31	O	following
7	33	35	O	the
8	37	46	O	initiation
9	48	49	O	of
10	51	59	O	ritonavir
11	61	61	O	,
12	63	68	O	resume
13	70	77	O	XXXXXXXX
14	79	80	O	at
15	82	84	O	the
16	86	96	O	recommended
17	98	104	O	initial
18	106	109	O	dose
19	111	114	O	once
20	116	120	O	daily
21	122	123	O	or
22	125	129	O	every
23	131	135	O	other
24	137	139	O	day
25	141	145	O	based
26	147	150	O	upon
27	152	161	O	individual
28	163	174	O	tolerability
29	176	178	O	see
30	180	189	O	Cytochrome
31	191	194	O	P450
32	196	199	O	Drug
33	201	212	O	Interactions
34	216	218	O	7.1
NULL

Tracleer	325	34068-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	8
Co-administration of Ritonavir in Patients on Tracleer .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	29	O	Ritonavir
5	31	32	O	in
6	34	41	O	Patients
7	43	44	O	on
8	46	53	O	XXXXXXXX
NULL

Tracleer	326	34068-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	8
Co-administration of Tracleer in Patients on Ritonavir .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	28	O	XXXXXXXX
5	30	31	O	in
6	33	40	O	Patients
7	42	43	O	on
8	45	53	O	Ritonavir
NULL

Tracleer	327	34068-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	13
Discontinue use of Tracleer at least 36 hours prior to initiation of ritonavir .
1	0	10	B-TRI	Discontinue
2	12	14	L-TRI	use
3	16	17	O	of
4	19	26	O	XXXXXXXX
5	28	29	O	at
6	31	35	O	least
7	37	38	O	36
8	40	44	O	hours
9	46	50	O	prior
10	52	53	O	to
11	55	64	O	initiation
12	66	67	O	of
13	69	77	U-UNK	ritonavir
NULL

Tracleer	328	34068-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	36
In patients who have been receiving ritonavir for at least 10 days , start Tracleer at the recommended initial dose once daily or every other day based upon individual tolerability see Cytochrome P450 Drug Interactions ( 7.1 ) .
1	0	1	O	In
2	3	10	O	patients
3	12	14	O	who
4	16	19	O	have
5	21	24	O	been
6	26	34	O	receiving
7	36	44	O	ritonavir
8	46	48	O	for
9	50	51	O	at
10	53	57	O	least
11	59	60	O	10
12	62	65	O	days
13	67	67	O	,
14	69	73	O	start
15	75	82	O	XXXXXXXX
16	84	85	O	at
17	87	89	O	the
18	91	101	O	recommended
19	103	109	O	initial
20	111	114	O	dose
21	116	119	O	once
22	121	125	O	daily
23	127	128	O	or
24	130	134	O	every
25	136	140	O	other
26	142	144	O	day
27	146	150	O	based
28	152	155	O	upon
29	157	166	O	individual
30	168	179	O	tolerability
31	181	183	O	see
32	185	194	O	Cytochrome
33	196	199	O	P450
34	201	204	O	Drug
35	206	217	O	Interactions
36	221	223	O	7.1
NULL

Tracleer	329	34070-3	749e42fb-2fe0-45dd-9268-b43bb3f4081c	16
An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan .
1	0	1	O	An
2	3	11	O	increased
3	13	16	O	risk
4	18	19	O	of
5	21	25	B-EFF	liver
6	27	32	I-EFF	enzyme
7	34	43	L-EFF	elevations
8	45	47	O	was
9	49	56	O	observed
10	58	59	O	in
11	61	68	O	patients
12	70	78	O	receiving
13	80	88	U-DYN	glyburide
14	90	102	O	concomitantly
15	104	107	O	with
16	109	116	O	XXXXXXXX
D/13:5:1

Tracleer	330	34070-3	749e42fb-2fe0-45dd-9268-b43bb3f4081c	15
Co-administration of cyclosporine A and bosentan resulted in markedly increased plasma concentrations of bosentan .
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	32	B-KIN	cyclosporine
5	34	34	L-KIN	A
6	36	38	O	and
7	40	47	O	XXXXXXXX
8	49	56	O	resulted
9	58	59	O	in
10	61	68	O	markedly
11	70	78	B-TRI	increased
12	80	85	I-TRI	plasma
13	87	100	L-TRI	concentrations
14	102	103	O	of
15	105	112	O	XXXXXXXX
K/4:C54355

Tracleer	331	34070-3	749e42fb-2fe0-45dd-9268-b43bb3f4081c	17
Therefore , concomitant use of Tracleer and cyclosporine A is contraindicated see Cytochrome P450 Drug Interactions ( 7.1 ) .
1	0	8	O	Therefore
2	10	10	O	,
3	12	22	O	concomitant
4	24	26	O	use
5	28	29	O	of
6	31	38	O	XXXXXXXX
7	40	42	O	and
8	44	55	B-UNK	cyclosporine
9	57	57	L-UNK	A
10	59	60	O	is
11	62	76	U-TRI	contraindicated
12	78	80	O	see
13	82	91	O	Cytochrome
14	93	96	O	P450
15	98	101	O	Drug
16	103	114	O	Interactions
17	118	120	O	7.1
NULL

Tracleer	332	34070-3	749e42fb-2fe0-45dd-9268-b43bb3f4081c	15
Therefore co-administration of glyburide and Tracleer is contraindicated see Cytochrome P450 Drug Interactions ( 7.1 ) .
1	0	8	O	Therefore
2	10	11	O	co
3	13	26	O	administration
4	28	29	O	of
5	31	39	U-UNK	glyburide
6	41	43	O	and
7	45	52	O	XXXXXXXX
8	54	55	O	is
9	57	71	U-TRI	contraindicated
10	73	75	O	see
11	77	86	O	Cytochrome
12	88	91	O	P450
13	93	96	O	Drug
14	98	109	O	Interactions
15	113	115	O	7.1
NULL

Tracleer	333	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	32
An interaction study demonstrated that co-administration of bosentan and a combination oral hormonal contraceptive produced average decreases of norethindrone and ethinyl estradiol levels of 14 % and 31 % , respectively .
1	0	1	O	An
2	3	13	O	interaction
3	15	19	O	study
4	21	32	O	demonstrated
5	34	37	O	that
6	39	40	O	co
7	42	55	O	administration
8	57	58	O	of
9	60	67	O	XXXXXXXX
10	69	71	O	and
11	73	73	O	a
12	75	85	B-KIN	combination
13	87	90	I-KIN	oral
14	92	99	I-KIN	hormonal
15	101	113	L-KIN	contraceptive
16	115	122	O	produced
17	124	130	O	average
18	132	140	O	decreases
19	142	143	O	of
20	145	157	O	norethindrone
21	159	161	O	and
22	163	169	O	ethinyl
23	171	179	O	estradiol
24	181	186	O	levels
25	188	189	O	of
26	191	192	O	14
27	194	194	O	%
28	196	198	O	and
29	200	201	O	31
30	203	203	O	%
31	205	205	O	,
32	207	218	O	respectively
K/12:C54358

Tracleer	334	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	21
Bosentan had no relevant inhibitory effect on any CYP isozyme in vitro (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A).
1	0	7	O	XXXXXXXX
2	9	11	O	had
3	13	14	O	no
4	16	23	O	relevant
5	25	34	O	inhibitory
6	36	41	O	effect
7	43	44	O	on
8	46	48	O	any
9	50	52	O	CYP
10	54	60	O	isozyme
11	62	63	O	in
12	65	69	O	vitro
13	72	77	O	CYP1A2
14	78	78	O	,
15	80	85	O	CYP2C9
16	86	86	O	,
17	88	94	O	CYP2C19
18	95	95	O	,
19	97	102	O	CYP2D6
20	103	103	O	,
21	105	109	O	CYP3A
NULL

Tracleer	335	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	8
Bosentan is an inducer of CYP3A and CYP2C9.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	13	O	an
4	15	21	O	inducer
5	23	24	O	of
6	26	30	O	CYP3A
7	32	34	O	and
8	36	41	O	CYP2C9
NULL

Tracleer	336	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	7
Bosentan is metabolized by CYP2C9 and CYP3A.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	22	O	metabolized
4	24	25	O	by
5	27	32	O	CYP2C9
6	34	36	O	and
7	38	42	O	CYP3A
NULL

Tracleer	337	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	21
Co-administration of such combinations of a CYP2C9 inhibitor plus a strong or moderate CYP3A inhibitor with Tracleer is not recommended.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	24	O	such
5	26	37	O	combinations
6	39	40	O	of
7	42	42	O	a
8	44	49	O	CYP2C9
9	51	59	O	inhibitor
10	61	64	O	plus
11	66	66	O	a
12	68	73	O	strong
13	75	76	O	or
14	78	85	O	moderate
15	87	91	O	CYP3A
16	93	101	O	inhibitor
17	103	106	O	with
18	108	115	O	XXXXXXXX
19	117	118	O	is
20	120	122	B-TRI	not
21	124	134	L-TRI	recommended
NULL

Tracleer	338	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	49
Concomitant administration of both a CYP2C9 inhibitor ( such as fluconazole or amiodarone ) and a strong CYP3A inhibitor ( e.g. , ketoconazole , itraconazole ) or a moderate CYP3A inhibitor ( e.g. , amprenavir , erythromycin , fluconazole , diltiazem ) with Tracleer will likely lead to large increases in plasma concentrations of bosentan .
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	33	O	both
5	35	35	O	a
6	37	42	B-KIN	CYP2C9
7	44	52	L-KIN	inhibitor
8	56	59	O	such
9	61	62	O	as
10	64	74	U-KIN	fluconazole
11	76	77	O	or
12	79	88	U-KIN	amiodarone
13	92	94	O	and
14	96	96	O	a
15	98	103	B-KIN	strong
16	105	109	I-KIN	CYP3A
17	111	119	L-KIN	inhibitor
18	123	125	O	e.g
19	128	128	O	,
20	130	141	U-KIN	ketoconazole
21	143	143	O	,
22	145	156	U-KIN	itraconazole
23	160	161	O	or
24	163	163	O	a
25	165	172	B-KIN	moderate
26	174	178	I-KIN	CYP3A
27	180	188	L-KIN	inhibitor
28	192	194	O	e.g
29	197	197	O	,
30	199	208	U-KIN	amprenavir
31	210	210	O	,
32	212	223	U-KIN	erythromycin
33	225	225	O	,
34	227	237	O	fluconazole
35	239	239	O	,
36	241	249	U-KIN	diltiazem
37	253	256	O	with
38	258	265	O	XXXXXXXX
39	267	270	O	will
40	272	277	O	likely
41	279	282	O	lead
42	284	285	O	to
43	287	291	O	large
44	293	301	O	increases
45	303	304	O	in
46	306	311	O	plasma
47	313	326	O	concentrations
48	328	329	O	of
49	331	338	O	XXXXXXXX
K/10:C54355 K/12:C54355 K/15:C54355 K/20:C54355 K/22:C54355 K/25:C54355 K/30:C54355 K/32:C54355 K/36:C54355 K/6:C54355

Tracleer	339	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	18
Consequently plasma concentrations of drugs metabolized by these two isozymes will be decreased when Tracleer is co-administered.
1	0	11	O	Consequently
2	13	18	O	plasma
3	20	33	O	concentrations
4	35	36	O	of
5	38	42	O	drugs
6	44	54	O	metabolized
7	56	57	O	by
8	59	63	O	these
9	65	67	O	two
10	69	76	O	isozymes
11	78	81	O	will
12	83	84	O	be
13	86	94	O	decreased
14	96	99	O	when
15	101	108	O	XXXXXXXX
16	110	111	O	is
17	113	114	O	co
18	116	127	O	administered
NULL

Tracleer	340	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	17
Consequently, Tracleer is not expected to increase the plasma concentrations of drugs metabolized by these enzymes.
1	0	11	O	Consequently
2	12	12	O	,
3	14	21	O	XXXXXXXX
4	23	24	O	is
5	26	28	O	not
6	30	37	O	expected
7	39	40	O	to
8	42	49	O	increase
9	51	53	O	the
10	55	60	O	plasma
11	62	75	O	concentrations
12	77	78	O	of
13	80	84	O	drugs
14	86	96	O	metabolized
15	98	99	O	by
16	101	105	O	these
17	107	113	O	enzymes
NULL

Tracleer	341	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	9
CYP3A induction-mediated effect of bosentan on other drugs .
1	0	4	O	CYP3A
2	6	14	O	induction
3	16	23	O	mediated
4	25	30	O	effect
5	32	33	O	of
6	35	42	O	XXXXXXXX
7	44	45	O	on
8	47	51	O	other
9	53	57	O	drugs
NULL

Tracleer	342	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	41
Cytochrome P450: Coadministration of Tracleer with drugs metabolized by CYP2C9 and CYP3A can increase exposure to Tracleer and/or the coadministered drug (4.2, 4.3, 7.1) Hormonal contraceptives: Tracleer use decreases contraceptive exposure and reduces effectiveness (7.2).
1	0	9	O	Cytochrome
2	11	14	O	P450
3	15	15	O	:
4	17	32	O	Coadministration
5	34	35	O	of
6	37	44	O	XXXXXXXX
7	46	49	O	with
8	51	55	B-KIN	drugs
9	57	67	I-KIN	metabolized
10	69	70	I-KIN	by
11	72	77	L-KIN	CYP2C9
12	79	81	O	and
13	83	87	O	CYP3A
14	89	91	O	can
15	93	100	B-TRI	increase
16	102	109	L-TRI	exposure
17	111	112	O	to
18	114	121	O	XXXXXXXX
19	123	125	O	and
20	126	126	O	/
21	127	128	O	or
22	130	132	O	the
23	134	147	O	coadministered
24	149	152	O	drug
25	155	157	O	4.2
26	158	158	O	,
27	160	162	O	4.3
28	163	163	O	,
29	165	167	O	7.1
30	170	177	B-KIN	Hormonal
31	179	192	L-KIN	contraceptives
32	193	193	O	:
33	195	202	O	XXXXXXXX
34	204	206	O	use
35	208	216	O	decreases
36	218	230	O	contraceptive
37	232	239	O	exposure
38	241	243	O	and
39	245	251	O	reduces
40	253	265	O	effectiveness
41	268	270	O	7.2
K/30:C54358 K/8:C54357

Tracleer	343	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	33
Effect of other drugs on bosentan Figure 1 Figure 2 Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when Tracleer is co-administered.
1	0	5	O	Effect
2	7	8	O	of
3	10	14	O	other
4	16	20	O	drugs
5	22	23	O	on
6	25	32	O	XXXXXXXX
7	34	39	O	Figure
8	41	41	O	1
9	43	48	O	Figure
10	50	50	O	2
11	52	59	O	Hormonal
12	61	74	O	contraceptives
13	75	75	O	,
14	77	85	O	including
15	87	90	O	oral
16	91	91	O	,
17	93	102	O	injectable
18	103	103	O	,
19	105	115	O	transdermal
20	116	116	O	,
21	118	120	O	and
22	122	132	O	implantable
23	134	138	O	forms
24	139	139	O	,
25	141	143	O	may
26	145	147	O	not
27	149	150	O	be
28	152	159	O	reliable
29	161	164	O	when
30	166	173	O	XXXXXXXX
31	175	176	O	is
32	178	179	O	co
33	181	192	O	administered
NULL

Tracleer	344	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	23
Females should practice additional methods of contraception and not rely on hormonal contraception alone when taking Tracleer [see Use in Specific Populations (8.3)].
1	0	6	O	Females
2	8	13	O	should
3	15	22	O	practice
4	24	33	O	additional
5	35	41	O	methods
6	43	44	O	of
7	46	58	O	contraception
8	60	62	O	and
9	64	66	O	not
10	68	71	O	rely
11	73	74	O	on
12	76	83	O	hormonal
13	85	97	O	contraception
14	99	103	O	alone
15	105	108	O	when
16	110	115	O	taking
17	117	124	O	XXXXXXXX
18	127	129	O	see
19	131	133	O	Use
20	135	136	O	in
21	138	145	O	Specific
22	147	157	O	Populations
23	160	162	O	8.3
NULL

Tracleer	345	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	23
Hormonal contraceptives , including oral , injectable , transdermal , and implantable forms , may not be reliable when Tracleer is co-administered .
1	0	7	O	Hormonal
2	9	22	O	contraceptives
3	24	24	O	,
4	26	34	O	including
5	36	39	O	oral
6	41	41	O	,
7	43	52	O	injectable
8	54	54	O	,
9	56	66	O	transdermal
10	68	68	O	,
11	70	72	O	and
12	74	84	O	implantable
13	86	90	O	forms
14	92	92	O	,
15	94	96	O	may
16	98	100	O	not
17	102	103	O	be
18	105	112	O	reliable
19	114	117	O	when
20	119	126	O	XXXXXXXX
21	128	129	O	is
22	131	132	O	co
23	134	145	O	administered
NULL

Tracleer	346	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	12
Hormonal contraceptives : Tracleer use decreases contraceptive exposure and reduces effectiveness ( 7.2 ) .
1	0	7	B-KIN	Hormonal
2	9	22	L-KIN	contraceptives
3	24	24	O	:
4	26	33	O	XXXXXXXX
5	35	37	O	use
6	39	47	O	decreases
7	49	61	O	contraceptive
8	63	70	O	exposure
9	72	74	O	and
10	76	82	O	reduces
11	84	96	O	effectiveness
12	100	102	O	7.2
K/1:C54358

Tracleer	347	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	18
However, decreases in exposure were as much as 56% and 66%, respectively, in individual subjects.
1	0	6	O	However
2	7	7	O	,
3	9	17	O	decreases
4	19	20	O	in
5	22	29	O	exposure
6	31	34	O	were
7	36	37	O	as
8	39	42	O	much
9	44	45	O	as
10	47	49	O	56%
11	51	53	O	and
12	55	57	O	66%
13	58	58	O	,
14	60	71	O	respectively
15	72	72	O	,
16	74	75	O	in
17	77	86	O	individual
18	88	95	O	subjects
NULL

Tracleer	348	34073-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	14
Inhibition of these enzymes may increase the plasma concentration of bosentan [see Pharmacokinetics (12.3)].
1	0	9	O	Inhibition
2	11	12	O	of
3	14	18	O	these
4	20	26	O	enzymes
5	28	30	O	may
6	32	39	O	increase
7	41	43	O	the
8	45	50	O	plasma
9	52	64	O	concentration
10	66	67	O	of
11	69	76	O	XXXXXXXX
12	79	81	O	see
13	83	98	O	Pharmacokinetics
14	101	104	O	12.3
NULL

Tracleer	349	43685-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	25
Peripheral edema is a known clinical consequence of PAH and worsening PAH and is also a known effect of Tracleer and other endothelin receptor antagonists .
1	0	9	O	Peripheral
2	11	15	O	edema
3	17	18	O	is
4	20	20	O	a
5	22	26	O	known
6	28	35	O	clinical
7	37	47	O	consequence
8	49	50	O	of
9	52	54	O	PAH
10	56	58	O	and
11	60	68	O	worsening
12	70	72	O	PAH
13	74	76	O	and
14	78	79	O	is
15	81	84	O	also
16	86	86	O	a
17	88	92	O	known
18	94	99	O	effect
19	101	102	O	of
20	104	111	O	XXXXXXXX
21	113	115	O	and
22	117	121	O	other
23	123	132	O	endothelin
24	134	141	O	receptor
25	143	153	O	antagonists
NULL

Tracleer	350	43685-7	749e42fb-2fe0-45dd-9268-b43bb3f4081c	29
Preclinical data also suggest that Tracleer , similar to other endothelin receptor antagonists , may have an adverse effect on spermatogenesis see Adverse Reactions ( 6.1 ) , Nonclinical Toxicology ( 13.1 ) .
1	0	10	O	Preclinical
2	12	15	O	data
3	17	20	O	also
4	22	28	O	suggest
5	30	33	O	that
6	35	42	O	XXXXXXXX
7	44	44	O	,
8	46	52	O	similar
9	54	55	O	to
10	57	61	O	other
11	63	72	O	endothelin
12	74	81	O	receptor
13	83	93	O	antagonists
14	95	95	O	,
15	97	99	O	may
16	101	104	O	have
17	106	107	O	an
18	109	115	O	adverse
19	117	122	O	effect
20	124	125	O	on
21	127	141	O	spermatogenesis
22	143	145	O	see
23	147	153	O	Adverse
24	155	163	O	Reactions
25	167	169	O	6.1
26	173	173	O	,
27	175	185	O	Nonclinical
28	187	196	O	Toxicology
29	200	203	O	13.1
NULL

Vasotec	102	34068-7	39631f1f-5d19-43c1-b504-bf56d991ed97	30
Add 50 mL of Bicitra Registered trademark of Alza Corporation to a polyethylene terephthalate ( PET ) bottle containing ten 20 mg tablets of VASOTEC and shake for at least 2 minutes .
1	0	2	O	Add
2	4	5	O	50
3	7	8	O	mL
4	10	11	O	of
5	13	19	O	Bicitra
6	21	30	O	Registered
7	32	40	O	trademark
8	42	43	O	of
9	45	48	O	Alza
10	50	60	O	Corporation
11	62	63	O	to
12	65	65	O	a
13	67	78	O	polyethylene
14	80	92	O	terephthalate
15	96	98	O	PET
16	102	107	O	bottle
17	109	118	O	containing
18	120	122	O	ten
19	124	125	O	20
20	127	128	O	mg
21	130	136	O	tablets
22	138	139	O	of
23	141	147	O	XXXXXXXX
24	149	151	O	and
25	153	157	O	shake
26	159	161	O	for
27	163	164	O	at
28	166	170	O	least
29	172	172	O	2
30	174	180	O	minutes
NULL

Vasotec	103	34068-7	39631f1f-5d19-43c1-b504-bf56d991ed97	25
Concomitant administration of VASOTEC with potassium supplements , potassium salt substitutes , or potassium-sparing diuretics may lead to increases of serum potassium ( see PRECAUTIONS ) .
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	36	O	XXXXXXXX
5	38	41	O	with
6	43	51	B-DYN	potassium
7	53	63	L-DYN	supplements
8	65	65	O	,
9	67	75	B-DYN	potassium
10	77	80	I-DYN	salt
11	82	92	L-DYN	substitutes
12	94	94	O	,
13	96	97	O	or
14	99	107	B-DYN	potassium
15	109	115	I-DYN	sparing
16	117	125	L-DYN	diuretics
17	127	129	O	may
18	131	134	O	lead
19	136	137	O	to
20	139	147	B-EFF	increases
21	149	150	I-EFF	of
22	152	156	I-EFF	serum
23	158	166	L-EFF	potassium
24	170	172	O	see
25	174	184	O	PRECAUTIONS
D/14:20:1 D/6:20:1 D/9:20:1

Vasotec	104	34068-7	39631f1f-5d19-43c1-b504-bf56d991ed97	15
If blood pressure is not controlled with VASOTEC alone , a diuretic may be added .
1	0	1	O	If
2	3	7	O	blood
3	9	16	O	pressure
4	18	19	O	is
5	21	23	O	not
6	25	34	O	controlled
7	36	39	O	with
8	41	47	O	XXXXXXXX
9	49	53	O	alone
10	55	55	O	,
11	57	57	O	a
12	59	66	O	diuretic
13	68	70	O	may
14	72	73	O	be
15	75	79	O	added
NULL

Vasotec	105	34068-7	39631f1f-5d19-43c1-b504-bf56d991ed97	22
In patients who are currently being treated with a diuretic , symptomatic hypotension occasionally may occur following the initial dose of VASOTEC .
1	0	1	O	In
2	3	10	O	patients
3	12	14	O	who
4	16	18	O	are
5	20	28	O	currently
6	30	34	O	being
7	36	42	O	treated
8	44	47	O	with
9	49	49	O	a
10	51	58	U-DYN	diuretic
11	60	60	O	,
12	62	72	B-EFF	symptomatic
13	74	84	L-EFF	hypotension
14	86	97	O	occasionally
15	99	101	O	may
16	103	107	O	occur
17	109	117	O	following
18	119	121	O	the
19	123	129	O	initial
20	131	134	O	dose
21	136	137	O	of
22	139	145	O	XXXXXXXX
D/10:12:1

Vasotec	106	34068-7	39631f1f-5d19-43c1-b504-bf56d991ed97	27
The diuretic should , if possible , be discontinued for two to three days before beginning therapy with VASOTEC to reduce the likelihood of hypotension ( see WARNINGS ) .
1	0	2	O	The
2	4	11	U-DYN	diuretic
3	13	18	O	should
4	20	20	O	,
5	22	23	O	if
6	25	32	O	possible
7	34	34	O	,
8	36	37	O	be
9	39	50	O	discontinued
10	52	54	O	for
11	56	58	O	two
12	60	61	O	to
13	63	67	O	three
14	69	72	O	days
15	74	79	O	before
16	81	89	O	beginning
17	91	97	O	therapy
18	99	102	O	with
19	104	110	O	XXXXXXXX
20	112	113	O	to
21	115	120	O	reduce
22	122	124	O	the
23	126	135	O	likelihood
24	137	138	O	of
25	140	150	U-EFF	hypotension
26	154	156	O	see
27	158	165	O	WARNINGS
D/2:25:1

Vasotec	107	34068-7	39631f1f-5d19-43c1-b504-bf56d991ed97	18
VASOTEC is indicated for the treatment of symptomatic heart failure , usually in combination with diuretics and digitalis .
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	19	O	indicated
4	21	23	O	for
5	25	27	O	the
6	29	37	O	treatment
7	39	40	O	of
8	42	52	O	symptomatic
9	54	58	O	heart
10	60	66	O	failure
11	68	68	O	,
12	70	76	O	usually
13	78	79	O	in
14	81	91	O	combination
15	93	96	O	with
16	98	106	O	diuretics
17	108	110	O	and
18	112	120	O	digitalis
NULL

Vasotec	108	34070-3	39631f1f-5d19-43c1-b504-bf56d991ed97	21
Do not administer VASOTEC within 36 hours of switching to or from sacubitril/valsartan , a neprilysin inhibitor ( see WARNINGS ) .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	16	L-TRI	administer
4	18	24	O	XXXXXXXX
5	26	31	O	within
6	33	34	O	36
7	36	40	O	hours
8	42	43	O	of
9	45	53	O	switching
10	55	56	O	to
11	58	59	O	or
12	61	64	O	from
13	66	75	B-UNK	sacubitril
14	76	76	I-UNK	/
15	77	85	L-UNK	valsartan
16	87	87	O	,
17	89	89	O	a
18	91	100	B-UNK	neprilysin
19	102	110	L-UNK	inhibitor
20	114	116	O	see
21	118	125	O	WARNINGS
NULL

Vasotec	109	34070-3	39631f1f-5d19-43c1-b504-bf56d991ed97	15
Do not coadminister aliskiren with VASOTEC in patients with diabetes ( see PRECAUTIONS , Drug Interactions ) .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	18	L-TRI	coadminister
4	20	28	U-UNK	aliskiren
5	30	33	O	with
6	35	41	O	XXXXXXXX
7	43	44	O	in
8	46	53	O	patients
9	55	58	O	with
10	60	67	O	diabetes
11	71	73	O	see
12	75	85	O	PRECAUTIONS
13	87	87	O	,
14	89	92	O	Drug
15	94	105	O	Interactions
NULL

Vasotec	110	34070-3	39631f1f-5d19-43c1-b504-bf56d991ed97	12
VASOTEC is contraindicated in combination with a neprilysin inhibitor ( e.g. , sacubitril ) .
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	25	U-TRI	contraindicated
4	27	28	O	in
5	30	40	O	combination
6	42	45	O	with
7	47	47	O	a
8	49	58	B-UNK	neprilysin
9	60	68	L-UNK	inhibitor
10	72	74	O	e.g
11	77	77	O	,
12	79	88	U-UNK	sacubitril
NULL

Vasotec	111	34070-3	39631f1f-5d19-43c1-b504-bf56d991ed97	37
VASOTEC is contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an angiotensin converting enzyme inhibitor and in patients with hereditary or idiopathic angioedema .
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	25	O	contraindicated
4	27	28	O	in
5	30	37	O	patients
6	39	41	O	who
7	43	45	O	are
8	47	60	O	hypersensitive
9	62	63	O	to
10	65	68	O	this
11	70	76	O	product
12	78	80	O	and
13	82	83	O	in
14	85	92	O	patients
15	94	97	O	with
16	99	99	O	a
17	101	107	O	history
18	109	110	O	of
19	112	121	O	angioedema
20	123	129	O	related
21	131	132	O	to
22	134	141	O	previous
23	143	151	O	treatment
24	153	156	O	with
25	158	159	O	an
26	161	171	O	angiotensin
27	173	182	O	converting
28	184	189	O	enzyme
29	191	199	O	inhibitor
30	201	203	O	and
31	205	206	O	in
32	208	215	O	patients
33	217	220	O	with
34	222	231	O	hereditary
35	233	234	O	or
36	236	245	O	idiopathic
37	247	256	O	angioedema
NULL

Vasotec	112	34071-1	39631f1f-5d19-43c1-b504-bf56d991ed97	30
Angioedema of the face , extremities , lips , tongue , glottis and/or larynx has been reported in patients treated with angiotensin converting enzyme inhibitors , including VASOTEC .
1	0	9	O	Angioedema
2	11	12	O	of
3	14	16	O	the
4	18	21	O	face
5	23	23	O	,
6	25	35	O	extremities
7	37	37	O	,
8	39	42	O	lips
9	44	44	O	,
10	46	51	O	tongue
11	53	53	O	,
12	55	61	O	glottis
13	63	65	O	and
14	66	66	O	/
15	67	68	O	or
16	70	75	O	larynx
17	77	79	O	has
18	81	84	O	been
19	86	93	O	reported
20	95	96	O	in
21	98	105	O	patients
22	107	113	O	treated
23	115	118	O	with
24	120	130	O	angiotensin
25	132	141	O	converting
26	143	148	O	enzyme
27	150	159	O	inhibitors
28	161	161	O	,
29	163	171	O	including
30	173	179	O	XXXXXXXX
NULL

Vasotec	113	34071-1	39631f1f-5d19-43c1-b504-bf56d991ed97	18
If symptomatic hypotension develops , a dose reduction or discontinuation of VASOTEC or concomitant diuretic may be necessary .
1	0	1	O	If
2	3	13	B-EFF	symptomatic
3	15	25	L-EFF	hypotension
4	27	34	O	develops
5	36	36	O	,
6	38	38	O	a
7	40	43	O	dose
8	45	53	O	reduction
9	55	56	O	or
10	58	72	O	discontinuation
11	74	75	O	of
12	77	83	O	XXXXXXXX
13	85	86	O	or
14	88	98	O	concomitant
15	100	107	U-DYN	diuretic
16	109	111	O	may
17	113	114	O	be
18	116	124	O	necessary
D/15:2:1

Vasotec	114	34071-1	39631f1f-5d19-43c1-b504-bf56d991ed97	43
In patients at risk for excessive hypotension , therapy should be started under very close medical supervision and such patients should be followed closely for the first two weeks of treatment and whenever the dose of enalapril and/or diuretic is increased .
1	0	1	O	In
2	3	10	O	patients
3	12	13	O	at
4	15	18	O	risk
5	20	22	O	for
6	24	32	O	excessive
7	34	44	O	hypotension
8	46	46	O	,
9	48	54	O	therapy
10	56	61	O	should
11	63	64	O	be
12	66	72	O	started
13	74	78	O	under
14	80	83	O	very
15	85	89	O	close
16	91	97	O	medical
17	99	109	O	supervision
18	111	113	O	and
19	115	118	O	such
20	120	127	O	patients
21	129	134	O	should
22	136	137	O	be
23	139	146	O	followed
24	148	154	O	closely
25	156	158	O	for
26	160	162	O	the
27	164	168	O	first
28	170	172	O	two
29	174	178	O	weeks
30	180	181	O	of
31	183	191	O	treatment
32	193	195	O	and
33	197	204	O	whenever
34	206	208	O	the
35	210	213	O	dose
36	215	216	O	of
37	218	226	O	XXXXXXXX
38	228	230	O	and
39	231	231	O	/
40	232	233	O	or
41	235	242	U-UNK	diuretic
42	244	245	O	is
43	247	255	O	increased
NULL

Vasotec	115	34071-1	39631f1f-5d19-43c1-b504-bf56d991ed97	51
It may be advisable to eliminate the diuretic ( except in patients with heart failure ) , reduce the diuretic dose or increase salt intake cautiously before initiating therapy with VASOTEC in patients at risk for excessive hypotension who are able to tolerate such adjustments ( see PRECAUTIONS , Drug Interactions and ADVERSE REACTIONS ) .
1	0	1	O	It
2	3	5	O	may
3	7	8	O	be
4	10	18	O	advisable
5	20	21	O	to
6	23	31	U-TRI	eliminate
7	33	35	O	the
8	37	44	U-UNK	diuretic
9	48	53	O	except
10	55	56	O	in
11	58	65	O	patients
12	67	70	O	with
13	72	76	O	heart
14	78	84	O	failure
15	88	88	O	,
16	90	95	O	reduce
17	97	99	O	the
18	101	108	O	diuretic
19	110	113	O	dose
20	115	116	O	or
21	118	125	O	increase
22	127	130	O	salt
23	132	137	O	intake
24	139	148	O	cautiously
25	150	155	O	before
26	157	166	O	initiating
27	168	174	O	therapy
28	176	179	O	with
29	181	187	O	XXXXXXXX
30	189	190	O	in
31	192	199	O	patients
32	201	202	O	at
33	204	207	O	risk
34	209	211	O	for
35	213	221	O	excessive
36	223	233	O	hypotension
37	235	237	O	who
38	239	241	O	are
39	243	246	O	able
40	248	249	O	to
41	251	258	O	tolerate
42	260	263	O	such
43	265	275	O	adjustments
44	279	281	O	see
45	283	293	O	PRECAUTIONS
46	295	295	O	,
47	297	300	O	Drug
48	302	313	O	Interactions
49	315	317	O	and
50	319	325	O	ADVERSE
51	327	335	O	REACTIONS
NULL

Vasotec	116	34071-1	39631f1f-5d19-43c1-b504-bf56d991ed97	34
Presumably because angiotensin-converting enzyme inhibitors affect the metabolism of eicosanoids and polypeptides , including endogenous bradykinin , patients receiving ACE inhibitors ( including VASOTEC ) may be subject to a variety of adverse reactions , some of them serious .
1	0	9	O	Presumably
2	11	17	O	because
3	19	58	O	GGGGGGGG
4	60	65	O	affect
5	67	69	O	the
6	71	80	O	metabolism
7	82	83	O	of
8	85	95	U-UNK	eicosanoids
9	97	99	O	and
10	101	112	U-UNK	polypeptides
11	114	114	O	,
12	116	124	O	including
13	126	135	B-UNK	endogenous
14	137	146	L-UNK	bradykinin
15	148	148	O	,
16	150	157	O	patients
17	159	167	O	receiving
18	169	182	O	GGGGGGGG
19	186	194	O	including
20	196	202	O	XXXXXXXX
21	206	208	O	may
22	210	211	O	be
23	213	219	O	subject
24	221	222	O	to
25	224	224	O	a
26	226	232	O	variety
27	234	235	O	of
28	237	243	O	adverse
29	245	253	O	reactions
30	255	255	O	,
31	257	260	O	some
32	262	263	O	of
33	265	268	O	them
34	270	276	O	serious
NULL

Vasotec	117	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	38
(see WARNINGS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
1	1	3	O	see
2	5	12	O	WARNINGS
3	15	18	O	Dual
4	20	27	O	blockade
5	29	30	O	of
6	32	34	O	the
7	36	38	O	RAS
8	40	43	O	with
9	45	55	B-DYN	angiotensin
10	57	64	I-DYN	receptor
11	66	73	L-DYN	blockers
12	74	74	O	,
13	76	89	U-DYN	GGGGGGGG
14	90	90	O	,
15	92	93	O	or
16	95	103	U-DYN	aliskiren
17	105	106	O	is
18	108	117	O	associated
19	119	122	O	with
20	124	132	O	increased
21	134	138	O	risks
22	140	141	O	of
23	143	153	U-EFF	hypotension
24	154	154	O	,
25	156	167	U-EFF	hyperkalemia
26	168	168	O	,
27	170	172	O	and
28	174	180	B-EFF	changes
29	182	183	I-EFF	in
30	185	189	I-EFF	renal
31	191	198	I-EFF	function
32	201	209	I-EFF	including
33	211	215	I-EFF	acute
34	217	221	I-EFF	renal
35	223	229	L-EFF	failure
36	232	239	O	compared
37	241	242	O	to
38	244	254	O	monotherapy
D/13:23:1 D/13:25:1 D/13:28:1 D/16:23:1 D/16:25:1 D/16:28:1 D/9:23:1 D/9:25:1 D/9:28:1

Vasotec	118	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	21
Agents Causing Renin Release: The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
1	0	5	B-DYN	Agents
2	7	13	I-DYN	Causing
3	15	19	I-DYN	Renin
4	21	27	L-DYN	Release
5	28	28	O	:
6	30	32	O	The
7	34	49	B-EFF	antihypertensive
8	51	56	L-EFF	effect
9	58	59	O	of
10	61	67	O	XXXXXXXX
11	69	70	O	is
12	72	80	O	augmented
13	82	83	O	by
14	85	107	B-DYN	GGGGGGGG
15	109	112	I-DYN	that
16	114	118	I-DYN	cause
17	120	124	I-DYN	renin
18	126	132	L-DYN	release
19	135	137	O	e.g
20	139	139	O	,
21	141	149	U-DYN	diuretics
D/1:7:1 D/14:7:1 D/21:7:1

Vasotec	119	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	14
Agents Increasing Serum Potassium: VASOTEC attenuates potassium loss caused by thiazide-type diuretics.
1	0	5	O	Agents
2	7	16	O	Increasing
3	18	22	O	Serum
4	24	32	O	Potassium
5	33	33	O	:
6	35	41	O	XXXXXXXX
7	43	52	B-EFF	attenuates
8	54	62	I-EFF	potassium
9	64	67	L-EFF	loss
10	69	74	O	caused
11	76	77	O	by
12	79	86	B-DYN	thiazide
13	88	91	I-DYN	type
14	93	101	L-DYN	diuretics
D/12:7:1

Vasotec	120	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	17
Drug Interactions Neprilysin Inhibitors: Patients taking concomitant neprilysin inhibitors may be at increased risk for angioedema.
1	0	3	O	Drug
2	5	16	O	Interactions
3	18	27	O	Neprilysin
4	29	38	O	Inhibitors
5	39	39	O	:
6	41	48	O	Patients
7	50	55	O	taking
8	57	67	O	concomitant
9	69	78	B-DYN	neprilysin
10	80	89	L-DYN	inhibitors
11	91	93	O	may
12	95	96	O	be
13	98	99	O	at
14	101	109	O	increased
15	111	114	O	risk
16	116	118	O	for
17	120	129	U-EFF	angioedema
D/9:17:1

Vasotec	121	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	67
Gold: Nitritoid reactions (symptoms include facial flushing, nausea, vomiting and hypotension) have been reported rarely in patients on therapy with injectable gold (sodium aurothiomalate) and concomitant ACE inhibitor therapy including VASOTEC. mTOR (mammalian target of rapamycin) inhibitors: Patients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema (see WARNINGS).
1	0	3	O	Gold
2	4	4	O	:
3	6	14	B-EFF	Nitritoid
4	16	24	L-EFF	reactions
5	27	34	O	symptoms
6	36	42	O	include
7	44	49	B-EFF	facial
8	51	58	L-EFF	flushing
9	59	59	O	,
10	61	66	U-EFF	nausea
11	67	67	O	,
12	69	76	U-EFF	vomiting
13	78	80	O	and
14	82	92	U-EFF	hypotension
15	95	98	O	have
16	100	103	O	been
17	105	112	O	reported
18	114	119	O	rarely
19	121	122	O	in
20	124	131	O	patients
21	133	134	O	on
22	136	142	O	therapy
23	144	147	O	with
24	149	158	O	injectable
25	160	163	O	gold
26	166	171	B-DYN	sodium
27	173	186	L-DYN	aurothiomalate
28	189	191	O	and
29	193	203	O	concomitant
30	205	207	O	ACE
31	209	217	O	inhibitor
32	219	225	O	therapy
33	227	235	O	including
34	237	243	O	XXXXXXXX
35	246	249	O	mTOR
36	252	260	O	mammalian
37	262	267	O	target
38	269	270	O	of
39	272	280	O	rapamycin
40	283	292	O	inhibitors
41	293	293	O	:
42	295	302	O	Patients
43	304	312	O	receiving
44	314	329	O	coadministration
45	331	332	O	of
46	334	336	O	ACE
47	338	346	O	inhibitor
48	348	350	O	and
49	352	355	O	mTOR
50	357	365	O	inhibitor
51	368	370	O	e.g
52	372	372	O	,
53	374	385	U-DYN	temsirolimus
54	386	386	O	,
55	388	396	O	sirolimus
56	397	397	O	,
57	399	408	U-DYN	everolimus
58	411	417	O	therapy
59	419	421	O	may
60	423	424	O	be
61	426	427	O	at
62	429	437	O	increased
63	439	442	O	risk
64	444	446	O	for
65	448	457	U-EFF	angioedema
66	460	462	O	see
67	464	471	O	WARNINGS
D/26:10:1 D/26:12:1 D/26:14:1 D/26:3:1 D/26:65:0 D/26:7:1 D/53:10:0 D/53:12:0 D/53:14:0 D/53:3:0 D/53:65:1 D/53:7:0 D/57:10:0 D/57:12:0 D/57:14:0 D/57:3:0 D/57:65:1 D/57:7:0

Vasotec	122	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	13
However, reports suggest that NSAIDs may diminish the antihypertensive effect of ACE inhibitors.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	reports
4	17	23	O	suggest
5	25	28	O	that
6	30	35	U-DYN	NSAIDs
7	37	39	O	may
8	41	48	O	diminish
9	50	52	O	the
10	54	69	O	antihypertensive
11	71	76	O	effect
12	78	79	O	of
13	81	94	O	GGGGGGGG
NULL

Vasotec	123	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	35
Hypotension  Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril.
1	0	10	O	Hypotension
2	13	20	O	Patients
3	22	23	O	on
4	25	32	O	Diuretic
5	34	40	O	Therapy
6	41	41	O	:
7	43	50	O	Patients
8	52	53	O	on
9	55	63	U-DYN	diuretics
10	65	67	O	and
11	69	78	O	especially
12	80	84	O	those
13	86	87	O	in
14	89	92	O	whom
15	94	101	O	diuretic
16	103	109	O	therapy
17	111	113	O	was
18	115	122	O	recently
19	124	133	O	instituted
20	134	134	O	,
21	136	138	O	may
22	140	151	O	occasionally
23	153	162	O	experience
24	164	165	O	an
25	167	175	B-EFF	excessive
26	177	185	I-EFF	reduction
27	187	188	I-EFF	of
28	190	194	I-EFF	blood
29	196	203	L-EFF	pressure
30	205	209	O	after
31	211	220	O	initiation
32	222	223	O	of
33	225	231	O	therapy
34	233	236	O	with
35	238	246	O	XXXXXXXX
D/9:25:1

Vasotec	124	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	40
If it is necessary to continue the diuretic, provide close medical supervision after the initial dose for at least two hours and until blood pressure has stabilized for at least an additional hour (see WARNINGS and DOSAGE AND ADMINISTRATION ).
1	0	1	O	If
2	3	4	O	it
3	6	7	O	is
4	9	17	O	necessary
5	19	20	O	to
6	22	29	O	continue
7	31	33	O	the
8	35	42	U-UNK	diuretic
9	43	43	O	,
10	45	51	O	provide
11	53	57	O	close
12	59	65	O	medical
13	67	77	U-TRI	supervision
14	79	83	O	after
15	85	87	O	the
16	89	95	O	initial
17	97	100	O	dose
18	102	104	O	for
19	106	107	O	at
20	109	113	O	least
21	115	117	O	two
22	119	123	O	hours
23	125	127	O	and
24	129	133	O	until
25	135	139	O	blood
26	141	148	O	pressure
27	150	152	O	has
28	154	163	O	stabilized
29	165	167	O	for
30	169	170	O	at
31	172	176	O	least
32	178	179	O	an
33	181	190	O	additional
34	192	195	O	hour
35	198	200	O	see
36	202	209	O	WARNINGS
37	211	213	O	and
38	215	220	O	DOSAGE
39	222	224	O	AND
40	226	239	O	ADMINISTRATION
NULL

Vasotec	125	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	9
In general, avoid combined use of RAS inhibitors.
1	0	1	O	In
2	3	9	O	general
3	10	10	O	,
4	12	16	U-TRI	avoid
5	18	25	O	combined
6	27	29	O	use
7	31	32	O	of
8	34	36	B-UNK	RAS
9	38	47	L-UNK	inhibitors
NULL

Vasotec	126	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	22
Lithium: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.
1	0	6	O	Lithium
2	7	7	O	:
3	9	15	O	Lithium
4	17	24	U-TRI	toxicity
5	26	28	O	has
6	30	33	O	been
7	35	42	O	reported
8	44	45	O	in
9	47	54	O	patients
10	56	64	O	receiving
11	66	72	U-KIN	lithium
12	74	86	O	concomitantly
13	88	91	O	with
14	93	97	O	drugs
15	99	103	O	which
16	105	109	O	cause
17	111	121	O	elimination
18	123	124	O	of
19	126	131	O	sodium
20	132	132	O	,
21	134	142	O	including
22	144	157	O	GGGGGGGG
K/11:C54357

Vasotec	127	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	18
Most patients receiving the combination of two RAS inhibitors do not obtain any additional benefit compared to monotherapy.
1	0	3	O	Most
2	5	12	O	patients
3	14	22	O	receiving
4	24	26	O	the
5	28	38	O	combination
6	40	41	O	of
7	43	45	O	two
8	47	49	O	RAS
9	51	60	O	inhibitors
10	62	63	O	do
11	65	67	O	not
12	69	74	O	obtain
13	76	78	O	any
14	80	89	O	additional
15	91	97	O	benefit
16	99	106	O	compared
17	108	109	O	to
18	111	121	O	monotherapy
NULL

Vasotec	128	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	63
Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including enalapril, may result in deterioration of renal function, including possible acute renal failure.
1	0	2	O	Non
2	4	12	O	Steroidal
3	14	17	O	Anti
4	19	30	O	Inflammatory
5	32	37	O	Agents
6	39	47	O	including
7	49	57	O	Selective
8	59	72	O	Cyclooxygenase
9	74	74	O	2
10	76	85	O	Inhibitors
11	88	90	O	COX
12	92	92	O	2
13	94	103	O	Inhibitors
14	105	105	O	:
15	107	108	O	In
16	110	117	O	patients
17	119	121	O	who
18	123	125	O	are
19	127	133	O	elderly
20	134	134	O	,
21	136	141	O	volume
22	143	150	O	depleted
23	153	161	O	including
24	163	167	O	those
25	169	170	O	on
26	172	179	O	diuretic
27	181	187	O	therapy
28	189	189	O	,
29	191	192	O	or
30	194	197	O	with
31	199	209	O	compromised
32	211	215	O	renal
33	217	224	O	function
34	225	225	O	,
35	227	242	O	coadministration
36	244	245	O	of
37	247	252	U-DYN	NSAIDs
38	253	253	O	,
39	255	263	O	including
40	265	273	B-DYN	selective
41	275	277	I-DYN	COX
42	279	279	I-DYN	2
43	281	290	L-DYN	inhibitors
44	291	291	O	,
45	293	296	O	with
46	298	311	O	GGGGGGGG
47	312	312	O	,
48	314	322	O	including
49	324	332	O	XXXXXXXX
50	333	333	O	,
51	335	337	O	may
52	339	344	O	result
53	346	347	O	in
54	349	361	B-EFF	deterioration
55	363	364	I-EFF	of
56	366	370	I-EFF	renal
57	372	379	L-EFF	function
58	380	380	O	,
59	382	390	O	including
60	392	399	O	possible
61	401	405	B-EFF	acute
62	407	411	I-EFF	renal
63	413	419	L-EFF	failure
D/37:54:1 D/37:61:1 D/40:54:1 D/40:61:1

Vasotec	129	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	35
Other Cardiovascular Agents: VASOTEC has been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.
1	0	4	O	Other
2	6	19	O	Cardiovascular
3	21	26	O	Agents
4	27	27	O	:
5	29	35	O	XXXXXXXX
6	37	39	O	has
7	41	44	O	been
8	46	49	O	used
9	51	63	O	concomitantly
10	65	68	O	with
11	70	73	O	beta
12	75	84	O	adrenergic
13	86	93	O	blocking
14	95	100	O	agents
15	101	101	O	,
16	103	112	O	methyldopa
17	113	113	O	,
18	115	122	O	nitrates
19	123	123	O	,
20	125	131	O	calcium
21	133	140	O	blocking
22	142	147	O	agents
23	148	148	O	,
24	150	160	O	hydralazine
25	161	161	O	,
26	163	170	O	prazosin
27	172	174	O	and
28	176	182	O	digoxin
29	184	190	O	without
30	192	199	O	evidence
31	201	202	O	of
32	204	213	O	clinically
33	215	225	O	significant
34	227	233	O	adverse
35	235	246	O	interactions
NULL

Vasotec	130	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	28
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
1	0	8	B-DYN	Potassium
2	10	16	I-DYN	sparing
3	18	26	L-DYN	diuretics
4	29	31	O	e.g
5	33	33	O	,
6	35	48	U-DYN	spironolactone
7	49	49	O	,
8	51	61	U-DYN	triamterene
9	62	62	O	,
10	64	65	O	or
11	67	75	U-DYN	amiloride
12	77	77	O	,
13	79	87	B-DYN	potassium
14	89	99	L-DYN	supplements
15	100	100	O	,
16	102	103	O	or
17	105	113	B-DYN	potassium
18	115	124	I-DYN	containing
19	126	129	I-DYN	salt
20	131	141	L-DYN	substitutes
21	143	145	O	may
22	147	150	O	lead
23	152	153	O	to
24	155	165	O	significant
25	167	175	B-EFF	increases
26	177	178	I-EFF	in
27	180	184	I-EFF	serum
28	186	194	L-EFF	potassium
D/1:25:1 D/11:25:1 D/13:25:1 D/17:25:1 D/6:25:1 D/8:25:1

Vasotec	131	34073-7	39631f1f-5d19-43c1-b504-bf56d991ed97	28
Therefore, if concomitant use of these agents is indicated because of demonstrated hypokalemia, they should be used with caution and with frequent monitoring of serum potassium.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	if
4	14	24	O	concomitant
5	26	28	O	use
6	30	31	O	of
7	33	37	O	these
8	39	44	O	agents
9	46	47	O	is
10	49	57	O	indicated
11	59	65	O	because
12	67	68	O	of
13	70	81	O	demonstrated
14	83	93	O	hypokalemia
15	94	94	O	,
16	96	99	O	they
17	101	106	O	should
18	108	109	O	be
19	111	114	O	used
20	116	119	O	with
21	121	127	O	caution
22	129	131	O	and
23	133	136	O	with
24	138	145	O	frequent
25	147	156	O	monitoring
26	158	159	O	of
27	161	165	O	serum
28	167	175	O	potassium
NULL

Vasotec	132	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	24
A few cases of lithium toxicity have been reported in patients receiving concomitant VASOTEC and lithium and were reversible upon discontinuation of both drugs .
1	0	0	O	A
2	2	4	O	few
3	6	10	O	cases
4	12	13	O	of
5	15	21	U-KIN	lithium
6	23	30	U-TRI	toxicity
7	32	35	O	have
8	37	40	O	been
9	42	49	O	reported
10	51	52	O	in
11	54	61	O	patients
12	63	71	O	receiving
13	73	83	O	concomitant
14	85	91	O	XXXXXXXX
15	93	95	O	and
16	97	103	O	lithium
17	105	107	O	and
18	109	112	O	were
19	114	123	O	reversible
20	125	128	O	upon
21	130	144	O	discontinuation
22	146	147	O	of
23	149	152	O	both
24	154	158	O	drugs
K/5:C54357

Vasotec	133	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	21
Angioedema , including laryngeal edema , may occur at any time during treatment with angiotensin converting enzyme inhibitors , including enalapril .
1	0	9	O	Angioedema
2	11	11	O	,
3	13	21	O	including
4	23	31	O	laryngeal
5	33	37	O	edema
6	39	39	O	,
7	41	43	O	may
8	45	49	O	occur
9	51	52	O	at
10	54	56	O	any
11	58	61	O	time
12	63	68	O	during
13	70	78	O	treatment
14	80	83	O	with
15	85	95	O	angiotensin
16	97	106	O	converting
17	108	113	O	enzyme
18	115	124	O	inhibitors
19	126	126	O	,
20	128	136	O	including
21	138	146	O	XXXXXXXX
NULL

Vasotec	134	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	17
Antihypertensive effects of VASOTEC have been established in hypertensive pediatric patients age 1 month to 16 years .
1	0	15	O	Antihypertensive
2	17	23	O	effects
3	25	26	O	of
4	28	34	O	XXXXXXXX
5	36	39	O	have
6	41	44	O	been
7	46	56	O	established
8	58	59	O	in
9	61	72	O	hypertensive
10	74	82	O	pediatric
11	84	91	O	patients
12	93	95	O	age
13	97	97	O	1
14	99	103	O	month
15	105	106	O	to
16	108	109	O	16
17	111	115	O	years
NULL

Vasotec	135	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	23
As with all vasodilators , enalapril should be given with caution to patients with obstruction in the outflow tract of the left ventricle .
1	0	1	O	As
2	3	6	O	with
3	8	10	O	all
4	12	23	O	vasodilators
5	25	25	O	,
6	27	35	O	XXXXXXXX
7	37	42	O	should
8	44	45	O	be
9	47	51	O	given
10	53	56	O	with
11	58	64	O	caution
12	66	67	O	to
13	69	76	O	patients
14	78	81	O	with
15	83	93	O	obstruction
16	95	96	O	in
17	98	100	O	the
18	102	108	O	outflow
19	110	114	O	tract
20	116	117	O	of
21	119	121	O	the
22	123	126	O	left
23	128	136	O	ventricle
NULL

Vasotec	136	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	16
Avoid use of aliskiren with VASOTEC in patients with renal impairment ( GFR 60 mL/min ) .
1	0	4	U-TRI	Avoid
2	6	8	O	use
3	10	11	O	of
4	13	21	U-UNK	aliskiren
5	23	26	O	with
6	28	34	O	XXXXXXXX
7	36	37	O	in
8	39	46	O	patients
9	48	51	O	with
10	53	57	O	renal
11	59	68	O	impairment
12	72	74	O	GFR
13	76	77	O	60
14	79	80	O	mL
15	81	81	O	/
16	82	84	O	min
NULL

Vasotec	137	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	21
Closely monitor blood pressure , renal function , and electrolytes in patients on VASOTEC and other agents that affect the RAS .
1	0	6	O	Closely
2	8	14	O	monitor
3	16	20	O	blood
4	22	29	O	pressure
5	31	31	O	,
6	33	37	O	renal
7	39	46	O	function
8	48	48	O	,
9	50	52	O	and
10	54	65	O	electrolytes
11	67	68	O	in
12	70	77	O	patients
13	79	80	O	on
14	82	88	O	XXXXXXXX
15	90	92	O	and
16	94	98	O	other
17	100	105	O	agents
18	107	110	O	that
19	112	117	O	affect
20	119	121	O	the
21	123	125	O	RAS
NULL

Vasotec	138	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	10
Do not coadminister aliskiren with VASOTEC in patients with diabetes .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	18	L-TRI	coadminister
4	20	28	U-UNK	aliskiren
5	30	33	O	with
6	35	41	O	XXXXXXXX
7	43	44	O	in
8	46	53	O	patients
9	55	58	O	with
10	60	67	O	diabetes
NULL

Vasotec	139	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	16
Dosage reduction and/or discontinuation of the diuretic and/or VASOTEC may be required .
1	0	5	B-TRI	Dosage
2	7	15	L-TRI	reduction
3	17	19	O	and
4	20	20	O	/
5	21	22	O	or
6	24	38	O	discontinuation
7	40	41	O	of
8	43	45	O	the
9	47	54	U-UNK	diuretic
10	56	58	O	and
11	59	59	O	/
12	60	61	O	or
13	63	69	O	XXXXXXXX
14	71	73	O	may
15	75	76	O	be
16	78	85	O	required
NULL

Vasotec	140	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	11
Enalapril and enalaprilat have been detected in human breast milk .
1	0	8	O	XXXXXXXX
2	10	12	O	and
3	14	22	O	XXXXXXXX
4	23	24	O	at
5	26	29	O	have
6	31	34	O	been
7	36	43	O	detected
8	45	46	O	in
9	48	52	O	human
10	54	59	O	breast
11	61	64	O	milk
NULL

Vasotec	141	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	16
In a clinical pharmacology study , indomethacin or sulindac was administered to hypertensive patients receiving VASOTEC .
1	0	1	O	In
2	3	3	O	a
3	5	12	O	clinical
4	14	25	O	pharmacology
5	27	31	O	study
6	33	33	O	,
7	35	46	O	indomethacin
8	48	49	O	or
9	51	58	O	sulindac
10	60	62	O	was
11	64	75	O	administered
12	77	78	O	to
13	80	91	O	hypertensive
14	93	100	O	patients
15	102	110	O	receiving
16	112	118	O	XXXXXXXX
NULL

Vasotec	142	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	25
In patients undergoing major surgery or during anesthesia with agents that produce hypotension , enalapril may block angiotensin II formation secondary to compensatory renin release .
1	0	1	O	In
2	3	10	O	patients
3	12	21	O	undergoing
4	23	27	O	major
5	29	35	O	surgery
6	37	38	O	or
7	40	45	O	during
8	47	56	O	anesthesia
9	58	61	O	with
10	63	68	O	agents
11	70	73	O	that
12	75	81	O	produce
13	83	93	O	hypotension
14	95	95	O	,
15	97	105	O	XXXXXXXX
16	107	109	O	may
17	111	115	O	block
18	117	127	O	angiotensin
19	129	130	O	II
20	132	140	O	formation
21	142	150	O	secondary
22	152	153	O	to
23	155	166	O	compensatory
24	168	172	O	renin
25	174	180	O	release
NULL

Vasotec	143	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	49
In patients who are elderly , volume-depleted ( including those on diuretic therapy ) , or with compromised renal function , coadministration of NSAIDs , including selective COX-2 inhibitors , with ACE inhibitors , including enalapril , may result in deterioration of renal function , including possible acute renal failure .
1	0	1	O	In
2	3	10	O	patients
3	12	14	O	who
4	16	18	O	are
5	20	26	O	elderly
6	28	28	O	,
7	30	35	O	volume
8	37	44	O	depleted
9	48	56	O	including
10	58	62	O	those
11	64	65	O	on
12	67	74	O	diuretic
13	76	82	O	therapy
14	86	86	O	,
15	88	89	O	or
16	91	94	O	with
17	96	106	O	compromised
18	108	112	O	renal
19	114	121	O	function
20	123	123	O	,
21	125	140	O	coadministration
22	142	143	O	of
23	145	150	U-DYN	NSAIDs
24	152	152	O	,
25	154	162	O	including
26	164	172	B-DYN	selective
27	174	176	I-DYN	COX
28	178	178	I-DYN	2
29	180	189	L-DYN	inhibitors
30	191	191	O	,
31	193	196	O	with
32	198	211	O	GGGGGGGG
33	213	213	O	,
34	215	223	O	including
35	225	233	O	XXXXXXXX
36	235	235	O	,
37	237	239	O	may
38	241	246	O	result
39	248	249	O	in
40	251	263	B-EFF	deterioration
41	265	266	I-EFF	of
42	268	272	I-EFF	renal
43	274	281	L-EFF	function
44	283	283	O	,
45	285	293	O	including
46	295	302	O	possible
47	304	308	B-EFF	acute
48	310	314	I-EFF	renal
49	316	322	L-EFF	failure
D/23:40:1 D/23:47:1 D/26:40:1 D/26:47:1

Vasotec	144	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	56
In patients with severe heart failure whose renal function may depend on the activity of the renin-angiotensin-aldosterone system , treatment with angiotensin converting enzyme inhibitors , including VASOTEC , may be associated with oliguria and/or progressive azotemia and rarely with acute renal failure and/or death ( see PRECAUTIONS , Drug Interactions ) .
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	22	O	severe
5	24	28	O	heart
6	30	36	O	failure
7	38	42	O	whose
8	44	48	O	renal
9	50	57	O	function
10	59	61	O	may
11	63	68	O	depend
12	70	71	O	on
13	73	75	O	the
14	77	84	O	activity
15	86	87	O	of
16	89	91	O	the
17	93	97	O	renin
18	99	109	O	angiotensin
19	111	121	O	aldosterone
20	123	128	O	system
21	130	130	O	,
22	132	140	O	treatment
23	142	145	O	with
24	147	157	O	angiotensin
25	159	168	O	converting
26	170	175	O	enzyme
27	177	186	O	inhibitors
28	188	188	O	,
29	190	198	O	including
30	200	206	O	XXXXXXXX
31	208	208	O	,
32	210	212	O	may
33	214	215	O	be
34	217	226	O	associated
35	228	231	O	with
36	233	240	O	oliguria
37	242	244	O	and
38	245	245	O	/
39	246	247	O	or
40	249	259	O	progressive
41	261	268	O	azotemia
42	270	272	O	and
43	274	279	O	rarely
44	281	284	O	with
45	286	290	O	acute
46	292	296	O	renal
47	298	304	O	failure
48	306	308	O	and
49	309	309	O	/
50	310	311	O	or
51	313	317	O	death
52	321	323	O	see
53	325	335	O	PRECAUTIONS
54	337	337	O	,
55	339	342	O	Drug
56	344	355	O	Interactions
NULL

Vasotec	145	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	16
In this study there was no evidence of a blunting of the antihypertensive action of VASOTEC .
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	14	18	O	there
5	20	22	O	was
6	24	25	O	no
7	27	34	O	evidence
8	36	37	O	of
9	39	39	O	a
10	41	48	O	blunting
11	50	51	O	of
12	53	55	O	the
13	57	72	O	antihypertensive
14	74	79	O	action
15	81	82	O	of
16	84	90	O	XXXXXXXX
NULL

Vasotec	146	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	17
It is recommended that serum lithium levels be monitored frequently if enalapril is administered concomitantly with lithium .
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	27	O	serum
6	29	35	U-UNK	lithium
7	37	42	O	levels
8	44	45	O	be
9	47	55	U-TRI	monitored
10	57	66	O	frequently
11	68	69	O	if
12	71	79	O	XXXXXXXX
13	81	82	O	is
14	84	95	O	administered
15	97	109	O	concomitantly
16	111	114	O	with
17	116	122	O	lithium
NULL

Vasotec	147	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	11
Monitor renal function periodically in patients receiving enalapril and NSAID therapy .
1	0	6	B-TRI	Monitor
2	8	12	I-TRI	renal
3	14	21	L-TRI	function
4	23	34	O	periodically
5	36	37	O	in
6	39	46	O	patients
7	48	56	O	receiving
8	58	66	O	XXXXXXXX
9	68	70	O	and
10	72	76	U-UNK	NSAID
11	78	84	O	therapy
NULL

Vasotec	148	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	32
Nitritoid reactions ( symptoms include facial flushing , nausea , vomiting and hypotension ) have been reported rarely in patients on therapy with injectable gold ( sodium aurothiomalate ) and concomitant ACE inhibitor therapy including VASOTEC .
1	0	8	B-EFF	Nitritoid
2	10	18	L-EFF	reactions
3	22	29	O	symptoms
4	31	37	O	include
5	39	44	B-EFF	facial
6	46	53	L-EFF	flushing
7	55	55	O	,
8	57	62	U-EFF	nausea
9	64	64	O	,
10	66	73	U-EFF	vomiting
11	75	77	O	and
12	79	89	U-EFF	hypotension
13	93	96	O	have
14	98	101	O	been
15	103	110	O	reported
16	112	117	O	rarely
17	119	120	O	in
18	122	129	O	patients
19	131	132	O	on
20	134	140	O	therapy
21	142	145	O	with
22	147	156	B-DYN	injectable
23	158	161	L-DYN	gold
24	165	170	B-DYN	sodium
25	172	185	L-DYN	aurothiomalate
26	189	191	O	and
27	193	203	O	concomitant
28	205	207	O	ACE
29	209	217	O	inhibitor
30	219	225	O	therapy
31	227	235	O	including
32	237	243	O	XXXXXXXX
D/22:1:1 D/22:10:1 D/22:12:1 D/22:5:1 D/22:8:1 D/24:1:1 D/24:10:1 D/24:12:1 D/24:5:1 D/24:8:1

Vasotec	149	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	29
Patients on diuretics and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril .
1	0	7	O	Patients
2	9	10	O	on
3	12	20	U-DYN	diuretics
4	22	24	O	and
5	26	35	O	especially
6	37	41	O	those
7	43	44	O	in
8	46	49	O	whom
9	51	58	O	diuretic
10	60	66	O	therapy
11	68	70	O	was
12	72	79	O	recently
13	81	90	O	instituted
14	92	92	O	,
15	94	96	O	may
16	98	109	O	occasionally
17	111	120	O	experience
18	122	123	O	an
19	125	133	O	excessive
20	135	143	B-EFF	reduction
21	145	146	I-EFF	of
22	148	152	I-EFF	blood
23	154	161	L-EFF	pressure
24	163	167	O	after
25	169	178	O	initiation
26	180	181	O	of
27	183	189	O	therapy
28	191	194	O	with
29	196	204	O	XXXXXXXX
D/3:20:1

Vasotec	150	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	15
Potassium-sparing agents should generally not be used in patients with heart failure receiving VASOTEC .
1	0	8	B-UNK	Potassium
2	10	16	I-UNK	sparing
3	18	23	L-UNK	agents
4	25	30	O	should
5	32	40	O	generally
6	42	44	O	not
7	46	47	O	be
8	49	52	O	used
9	54	55	O	in
10	57	64	O	patients
11	66	69	O	with
12	71	75	O	heart
13	77	83	O	failure
14	85	93	O	receiving
15	95	101	O	XXXXXXXX
NULL

Vasotec	151	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	48
Risk factors for the development of hyperkalemia include renal insufficiency , diabetes mellitus , and the concomitant use of potassium-sparing diuretics , potassium supplements and/or potassium-containing salt substitutes , which should be used cautiously , if at all , with VASOTEC ( see Drug Interactions ) .
1	0	3	O	Risk
2	5	11	O	factors
3	13	15	O	for
4	17	19	O	the
5	21	31	O	development
6	33	34	O	of
7	36	47	U-EFF	hyperkalemia
8	49	55	O	include
9	57	61	O	renal
10	63	75	O	insufficiency
11	77	77	O	,
12	79	86	O	diabetes
13	88	95	O	mellitus
14	97	97	O	,
15	99	101	O	and
16	103	105	O	the
17	107	117	O	concomitant
18	119	121	O	use
19	123	124	O	of
20	126	134	B-DYN	potassium
21	136	142	I-DYN	sparing
22	144	152	L-DYN	diuretics
23	154	154	O	,
24	156	164	B-DYN	potassium
25	166	176	L-DYN	supplements
26	178	180	O	and
27	181	181	O	/
28	182	183	O	or
29	185	193	B-DYN	potassium
30	195	204	I-DYN	containing
31	206	209	I-DYN	salt
32	211	221	L-DYN	substitutes
33	223	223	O	,
34	225	229	O	which
35	231	236	O	should
36	238	239	O	be
37	241	244	O	used
38	246	255	O	cautiously
39	257	257	O	,
40	259	260	O	if
41	262	263	O	at
42	265	267	O	all
43	269	269	O	,
44	271	274	O	with
45	276	282	O	XXXXXXXX
46	286	288	O	see
47	290	293	O	Drug
48	295	306	O	Interactions
D/20:7:1 D/24:7:1 D/29:7:1

Vasotec	152	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	40
Some patients with hypertension or heart failure with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine , usually minor and transient , especially when VASOTEC has been given concomitantly with a diuretic .
1	0	3	O	Some
2	5	12	O	patients
3	14	17	O	with
4	19	30	O	hypertension
5	32	33	O	or
6	35	39	O	heart
7	41	47	O	failure
8	49	52	O	with
9	54	55	O	no
10	57	64	O	apparent
11	66	68	O	pre
12	70	77	O	existing
13	79	83	O	renal
14	85	92	O	vascular
15	94	100	O	disease
16	102	105	O	have
17	107	115	O	developed
18	117	125	O	increases
19	127	128	O	in
20	130	134	O	blood
21	136	139	O	urea
22	141	143	O	and
23	145	149	O	serum
24	151	160	O	creatinine
25	162	162	O	,
26	164	170	O	usually
27	172	176	O	minor
28	178	180	O	and
29	182	190	O	transient
30	192	192	O	,
31	194	203	O	especially
32	205	208	O	when
33	210	216	O	XXXXXXXX
34	218	220	O	has
35	222	225	O	been
36	227	231	O	given
37	233	245	O	concomitantly
38	247	250	O	with
39	252	252	O	a
40	254	261	U-DYN	diuretic
NULL

Vasotec	153	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	16
The antihypertensive effect of VASOTEC is augmented by antihypertensive agents that cause renin release ( e.g. , diuretics ) .
1	0	2	O	The
2	4	19	O	antihypertensive
3	21	26	O	effect
4	28	29	O	of
5	31	37	O	XXXXXXXX
6	39	40	O	is
7	42	50	O	augmented
8	52	53	O	by
9	55	77	B-DYN	GGGGGGGG
10	79	82	I-DYN	that
11	84	88	I-DYN	cause
12	90	94	I-DYN	renin
13	96	102	L-DYN	release
14	106	108	O	e.g
15	111	111	O	,
16	113	121	U-DYN	diuretics
NULL

Vasotec	154	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	27
The possibility of hypotensive effects with enalapril can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril .
1	0	2	O	The
2	4	14	O	possibility
3	16	17	O	of
4	19	29	B-EFF	hypotensive
5	31	37	L-EFF	effects
6	39	42	O	with
7	44	52	O	XXXXXXXX
8	54	56	O	can
9	58	59	O	be
10	61	69	O	minimized
11	71	72	O	by
12	74	79	O	either
13	81	93	O	discontinuing
14	95	97	O	the
15	99	106	U-DYN	diuretic
16	108	109	O	or
17	111	120	O	increasing
18	122	124	O	the
19	126	129	O	salt
20	131	136	O	intake
21	138	142	O	prior
22	144	145	O	to
23	147	156	O	initiation
24	158	159	O	of
25	161	169	O	treatment
26	171	174	O	with
27	176	184	O	XXXXXXXX
D/15:4:1

Vasotec	155	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	9
VASOTEC attenuates potassium loss caused by thiazide-type diuretics .
1	0	6	O	XXXXXXXX
2	8	17	B-EFF	attenuates
3	19	27	I-EFF	potassium
4	29	32	L-EFF	loss
5	34	39	O	caused
6	41	42	O	by
7	44	51	B-DYN	thiazide
8	53	56	I-DYN	type
9	58	66	L-DYN	diuretics
D/7:2:1

Vasotec	156	42232-9	39631f1f-5d19-43c1-b504-bf56d991ed97	31
VASOTEC has been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , calcium-blocking agents , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .
1	0	6	O	XXXXXXXX
2	8	10	O	has
3	12	15	O	been
4	17	20	O	used
5	22	34	O	concomitantly
6	36	39	O	with
7	41	44	O	beta
8	46	55	O	adrenergic
9	57	64	O	blocking
10	66	71	O	agents
11	73	73	O	,
12	75	84	O	methyldopa
13	86	86	O	,
14	88	95	O	nitrates
15	97	97	O	,
16	99	105	O	calcium
17	107	114	O	blocking
18	116	121	O	agents
19	123	123	O	,
20	125	135	O	hydralazine
21	137	137	O	,
22	139	146	O	prazosin
23	148	150	O	and
24	152	158	O	digoxin
25	160	166	O	without
26	168	175	O	evidence
27	177	178	O	of
28	180	189	O	clinically
29	191	201	O	significant
30	203	209	O	adverse
31	211	222	O	interactions
NULL

Ventavis	417	34073-7	d3bebc1c-f032-402a-bbc9-aff024276ed1	10
Acetylsalicylic acid did not alter the clearance ( pharmacokinetics ) of iloprost .
1	0	14	O	Acetylsalicylic
2	16	19	O	acid
3	21	23	O	did
4	25	27	O	not
5	29	33	O	alter
6	35	37	O	the
7	39	47	O	clearance
8	51	66	O	pharmacokinetics
9	70	71	O	of
10	73	80	O	XXXXXXXX
NULL

Ventavis	418	34073-7	d3bebc1c-f032-402a-bbc9-aff024276ed1	30
Although clinical studies have not been conducted with Ventavis (inhaled iloprost), in vitro studies of iloprost indicate that no relevant inhibition of cytochrome P450 drug metabolism would be expected.
1	0	7	O	Although
2	9	16	O	clinical
3	18	24	O	studies
4	26	29	O	have
5	31	33	O	not
6	35	38	O	been
7	40	48	O	conducted
8	50	53	O	with
9	55	62	O	XXXXXXXX
10	65	71	O	inhaled
11	73	80	O	XXXXXXXX
12	82	82	O	,
13	84	85	O	in
14	87	91	O	vitro
15	93	99	O	studies
16	101	102	O	of
17	104	111	O	XXXXXXXX
18	113	120	O	indicate
19	122	125	O	that
20	127	128	O	no
21	130	137	O	relevant
22	139	148	O	inhibition
23	150	151	O	of
24	153	162	O	cytochrome
25	164	167	O	P450
26	169	172	O	drug
27	174	183	O	metabolism
28	185	189	O	would
29	191	192	O	be
30	194	201	O	expected
NULL

Ventavis	419	34073-7	d3bebc1c-f032-402a-bbc9-aff024276ed1	34
During clinical trials , iloprost was used concurrently with anticoagulants , diuretics , cardiac glycosides , calcium channel blockers , analgesics , antipyretics , nonsteroidal anti-inflammatory drugs , corticosteroids , and other medications .
1	0	5	O	During
2	7	14	O	clinical
3	16	21	O	trials
4	23	23	O	,
5	25	32	O	XXXXXXXX
6	34	36	O	was
7	38	41	O	used
8	43	54	O	concurrently
9	56	59	O	with
10	61	74	O	anticoagulants
11	76	76	O	,
12	78	86	O	diuretics
13	88	88	O	,
14	90	96	O	cardiac
15	98	107	O	glycosides
16	109	109	O	,
17	111	117	O	calcium
18	119	125	O	channel
19	127	134	O	blockers
20	136	136	O	,
21	138	147	O	analgesics
22	149	149	O	,
23	151	162	O	antipyretics
24	164	164	O	,
25	166	177	O	nonsteroidal
26	179	182	O	anti
27	184	195	O	inflammatory
28	197	201	O	drugs
29	203	203	O	,
30	205	219	O	corticosteroids
31	221	221	O	,
32	223	225	O	and
33	227	231	O	other
34	233	243	O	medications
NULL

Ventavis	420	34073-7	d3bebc1c-f032-402a-bbc9-aff024276ed1	16
However , Ventavis has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents .
1	0	6	O	However
2	8	8	O	,
3	10	17	O	XXXXXXXX
4	19	21	O	has
5	23	25	O	the
6	27	35	O	potential
7	37	38	O	to
8	40	47	B-EFF	increase
9	49	51	I-EFF	the
10	53	63	I-EFF	hypotensive
11	65	70	L-EFF	effect
12	72	73	O	of
13	75	86	U-DYN	GGGGGGGG
14	88	90	O	and
15	92	107	B-DYN	antihypertensive
16	109	114	L-DYN	agents
D/13:8:1 D/15:8:1

Ventavis	421	34073-7	d3bebc1c-f032-402a-bbc9-aff024276ed1	22
In studies in normal subjects , there was no pharmacodynamic interaction between intravenous iloprost and either nifedipine , diltiazem , or captopril .
1	0	1	O	In
2	3	9	O	studies
3	11	12	O	in
4	14	19	O	normal
5	21	28	O	subjects
6	30	30	O	,
7	32	36	O	there
8	38	40	O	was
9	42	43	O	no
10	45	59	O	pharmacodynamic
11	61	71	O	interaction
12	73	79	O	between
13	81	91	O	intravenous
14	93	100	O	XXXXXXXX
15	102	104	O	and
16	106	111	O	either
17	113	122	O	nifedipine
18	124	124	O	,
19	126	134	O	diltiazem
20	136	136	O	,
21	138	139	O	or
22	141	149	O	captopril
NULL

Ventavis	422	34073-7	d3bebc1c-f032-402a-bbc9-aff024276ed1	12
Intravenous infusion of iloprost had no effect on the pharmacokinetics of digoxin.
1	0	10	O	Intravenous
2	12	19	O	infusion
3	21	22	O	of
4	24	31	O	XXXXXXXX
5	33	35	O	had
6	37	38	O	no
7	40	45	O	effect
8	47	48	O	on
9	50	52	O	the
10	54	69	O	pharmacokinetics
11	71	72	O	of
12	74	80	O	digoxin
NULL

Ventavis	423	34073-7	d3bebc1c-f032-402a-bbc9-aff024276ed1	25
Since Ventavis inhibits platelet function , there is a potential for increased risk of bleeding , particularly in patients maintained on anticoagulants or platelet inhibitors .
1	0	4	O	Since
2	6	13	O	XXXXXXXX
3	15	22	O	inhibits
4	24	31	O	platelet
5	33	40	O	function
6	42	42	O	,
7	44	48	O	there
8	50	51	O	is
9	53	53	O	a
10	55	63	O	potential
11	65	67	O	for
12	69	77	O	increased
13	79	82	O	risk
14	84	85	O	of
15	87	94	U-EFF	bleeding
16	96	96	O	,
17	98	109	O	particularly
18	111	112	O	in
19	114	121	O	patients
20	123	132	O	maintained
21	134	135	O	on
22	137	150	U-DYN	anticoagulants
23	152	153	O	or
24	155	162	B-DYN	platelet
25	164	173	L-DYN	inhibitors
D/22:15:1 D/24:15:1

Ventavis	424	34073-7	d3bebc1c-f032-402a-bbc9-aff024276ed1	17
There is a potential for increased risk of bleeding, particularly in patients maintained on anticoagulants (7.3).
1	0	4	O	There
2	6	7	O	is
3	9	9	O	a
4	11	19	O	potential
5	21	23	O	for
6	25	33	O	increased
7	35	38	O	risk
8	40	41	O	of
9	43	50	U-EFF	bleeding
10	51	51	O	,
11	53	64	O	particularly
12	66	67	O	in
13	69	76	O	patients
14	78	87	O	maintained
15	89	90	O	on
16	92	105	U-DYN	anticoagulants
17	108	110	O	7.3
D/16:9:1

Ventavis	425	34073-7	d3bebc1c-f032-402a-bbc9-aff024276ed1	15
Ventavis has the potential to increase the hypotensive effect of vasodilators and antihypertensive agents ( 7.2 ) .
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	15	O	the
4	17	25	O	potential
5	27	28	O	to
6	30	37	B-EFF	increase
7	39	41	I-EFF	the
8	43	53	I-EFF	hypotensive
9	55	60	L-EFF	effect
10	62	63	O	of
11	65	76	U-DYN	GGGGGGGG
12	78	80	O	and
13	82	97	B-DYN	antihypertensive
14	99	104	L-DYN	agents
15	108	110	O	7.2
D/11:6:1 D/13:6:1

Xarelto	36	34066-1	10db92f9-2300-4a80-836b-673e1ae91610	20
Epidural or spinal hematomas have occurred in patients treated with XARELTO who are receiving neuraxial anesthesia or undergoing spinal puncture .
1	0	7	O	Epidural
2	9	10	O	or
3	12	17	O	spinal
4	19	27	O	hematomas
5	29	32	O	have
6	34	41	O	occurred
7	43	44	O	in
8	46	53	O	patients
9	55	61	O	treated
10	63	66	O	with
11	68	74	O	XXXXXXXX
12	76	78	O	who
13	80	82	O	are
14	84	92	O	receiving
15	94	102	O	neuraxial
16	104	113	O	anesthesia
17	115	116	O	or
18	118	127	O	undergoing
19	129	134	O	spinal
20	136	143	O	puncture
NULL

Xarelto	37	34066-1	10db92f9-2300-4a80-836b-673e1ae91610	16
Premature discontinuation of any oral anticoagulant , including XARELTO , increases the risk of thrombotic events .
1	0	8	O	Premature
2	10	24	O	discontinuation
3	26	27	O	of
4	29	31	O	any
5	33	36	O	oral
6	38	50	O	anticoagulant
7	52	52	O	,
8	54	62	O	including
9	64	70	O	XXXXXXXX
10	72	72	O	,
11	74	82	O	increases
12	84	86	O	the
13	88	91	O	risk
14	93	94	O	of
15	96	105	O	thrombotic
16	107	112	O	events
NULL

Xarelto	38	34066-1	10db92f9-2300-4a80-836b-673e1ae91610	69
use of indwelling epiduralcatheters . concomitant use of other drugs that affect hemostasis , such as nnon-steroidal anti-inflammatory drugs ( NSAIDs ) , platelet inhibitors , other anticoagulants . a history of traumatic or repeated epidural or spinal punctures . a history of spinal deformity or spinal surgery . optimal timing between the administration of XXARELTOand neuraxial procedures is not known . see Warnings and Precautions ( 5.2 , 5.3 ) and Adverse Reactions ( 6.2 ) .
1	0	2	O	use
2	4	5	O	of
3	7	16	O	indwelling
4	18	34	O	epiduralcatheters
5	38	48	O	concomitant
6	50	52	O	use
7	54	55	O	of
8	57	61	O	other
9	63	67	O	drugs
10	69	72	O	that
11	74	79	O	affect
12	81	90	O	hemostasis
13	92	92	O	,
14	94	97	O	such
15	99	100	O	as
16	102	105	O	nnon
17	107	115	O	steroidal
18	117	120	O	anti
19	122	133	O	inflammatory
20	135	139	O	drugs
21	143	148	O	NSAIDs
22	152	152	O	,
23	154	161	O	platelet
24	163	172	O	inhibitors
25	174	174	O	,
26	176	180	O	other
27	182	195	O	anticoagulants
28	199	199	O	a
29	201	207	O	history
30	209	210	O	of
31	212	220	O	traumatic
32	222	223	O	or
33	225	232	O	repeated
34	234	241	O	epidural
35	243	244	O	or
36	246	251	O	spinal
37	253	261	O	punctures
38	265	265	O	a
39	267	273	O	history
40	275	276	O	of
41	278	283	O	spinal
42	285	293	O	deformity
43	295	296	O	or
44	298	303	O	spinal
45	305	311	O	surgery
46	315	321	O	optimal
47	323	328	O	timing
48	330	336	O	between
49	338	340	O	the
50	342	355	O	administration
51	357	358	O	of
52	360	367	O	XXXXXXXX
53	368	370	O	and
54	372	380	O	neuraxial
55	382	391	O	procedures
56	393	394	O	is
57	396	398	O	not
58	400	404	O	known
59	408	410	O	see
60	412	419	O	Warnings
61	421	423	O	and
62	425	435	O	Precautions
63	439	441	O	5.2
64	443	443	O	,
65	445	447	O	5.3
66	451	453	O	and
67	455	461	O	Adverse
68	463	471	O	Reactions
69	475	477	O	6.2
NULL

Xarelto	39	34068-7	10db92f9-2300-4a80-836b-673e1ae91610	19
For unfractionated heparin being administered by continuous infusion , stop the infusion and start XARELTO at the same time .
1	0	2	O	For
2	4	17	O	unfractionated
3	19	25	O	heparin
4	27	31	O	being
5	33	44	O	administered
6	46	47	O	by
7	49	58	O	continuous
8	60	67	O	infusion
9	69	69	O	,
10	71	74	O	stop
11	76	78	O	the
12	80	87	O	infusion
13	89	91	O	and
14	93	97	O	start
15	99	105	O	XXXXXXXX
16	107	108	O	at
17	110	112	O	the
18	114	117	O	same
19	119	122	O	time
NULL

Xarelto	40	34068-7	10db92f9-2300-4a80-836b-673e1ae91610	26
One approach is to discontinue XARELTO and begin both a parenteral anticoagulant and warfarin at the time the next dose of XARELTO would have been taken .
1	0	2	O	One
2	4	11	O	approach
3	13	14	O	is
4	16	17	O	to
5	19	29	O	discontinue
6	31	37	O	XXXXXXXX
7	39	41	O	and
8	43	47	O	begin
9	49	52	O	both
10	54	54	O	a
11	56	65	O	parenteral
12	67	79	O	anticoagulant
13	81	83	O	and
14	85	92	O	warfarin
15	94	95	O	at
16	97	99	O	the
17	101	104	O	time
18	106	108	O	the
19	110	113	O	next
20	115	118	O	dose
21	120	121	O	of
22	123	129	O	XXXXXXXX
23	131	135	O	would
24	137	140	O	have
25	142	145	O	been
26	147	151	O	taken
NULL

Xarelto	41	34068-7	10db92f9-2300-4a80-836b-673e1ae91610	52
Switching from Anticoagulants other than Warfarin to XARELTO - For patients currently receiving an anticoagulant other than warfarin , start XARELTO 0 to 2 hours prior to the next scheduled evening administration of the drug ( e.g. , low molecular weight heparin or non-warfarin oral anticoagulant ) and omit administration of the other anticoagulant .
1	0	8	O	Switching
2	10	13	O	from
3	15	28	O	Anticoagulants
4	30	34	O	other
5	36	39	O	than
6	41	48	O	Warfarin
7	50	51	O	to
8	53	59	O	XXXXXXXX
9	63	65	O	For
10	67	74	O	patients
11	76	84	O	currently
12	86	94	O	receiving
13	96	97	O	an
14	99	111	O	anticoagulant
15	113	117	O	other
16	119	122	O	than
17	124	131	O	warfarin
18	133	133	O	,
19	135	139	O	start
20	141	147	O	XXXXXXXX
21	149	149	O	0
22	151	152	O	to
23	154	154	O	2
24	156	160	O	hours
25	162	166	O	prior
26	168	169	O	to
27	171	173	O	the
28	175	178	O	next
29	180	188	O	scheduled
30	190	196	O	evening
31	198	211	O	administration
32	213	214	O	of
33	216	218	O	the
34	220	223	O	drug
35	227	229	O	e.g
36	232	232	O	,
37	234	236	O	low
38	238	246	O	molecular
39	248	253	O	weight
40	255	261	O	heparin
41	263	264	O	or
42	266	268	O	non
43	270	277	O	warfarin
44	279	282	O	oral
45	284	296	O	anticoagulant
46	300	302	O	and
47	304	307	O	omit
48	309	322	O	administration
49	324	325	O	of
50	327	329	O	the
51	331	335	O	other
52	337	349	O	anticoagulant
NULL

Xarelto	42	34068-7	10db92f9-2300-4a80-836b-673e1ae91610	35
Switching from Warfarin to XARELTO - When switching patients from warfarin to XARELTO , discontinue warfarin and start XARELTO as soon as the International Normalized Ratio ( INR ) is below 3.0 to avoid periods of inadequate anticoagulation .
1	0	8	O	Switching
2	10	13	O	from
3	15	22	O	Warfarin
4	24	25	O	to
5	27	33	O	XXXXXXXX
6	37	40	O	When
7	42	50	O	switching
8	52	59	O	patients
9	61	64	O	from
10	66	73	O	warfarin
11	75	76	O	to
12	78	84	O	XXXXXXXX
13	86	86	O	,
14	88	98	O	discontinue
15	100	107	O	warfarin
16	109	111	O	and
17	113	117	O	start
18	119	125	O	XXXXXXXX
19	127	128	O	as
20	130	133	O	soon
21	135	136	O	as
22	138	140	O	the
23	142	154	O	International
24	156	165	O	Normalized
25	167	171	O	Ratio
26	175	177	O	INR
27	181	182	O	is
28	184	188	O	below
29	190	192	O	3.0
30	194	195	O	to
31	197	201	O	avoid
32	203	209	O	periods
33	211	212	O	of
34	214	223	O	inadequate
35	225	239	O	anticoagulation
NULL

Xarelto	43	34068-7	10db92f9-2300-4a80-836b-673e1ae91610	52
Switching from XARELTO to Anticoagulants other than Warfarin - For patients currently taking XARELTO and transitioning to an anticoagulant with rapid onset , discontinue XARELTO and give the first dose of the other anticoagulant ( oral or parenteral ) at the time that the next XARELTO dose would have been taken see Drug Interactions ( 7.4 ) .
1	0	8	O	Switching
2	10	13	O	from
3	15	21	O	XXXXXXXX
4	23	24	O	to
5	26	39	O	Anticoagulants
6	41	45	O	other
7	47	50	O	than
8	52	59	O	Warfarin
9	63	65	O	For
10	67	74	O	patients
11	76	84	O	currently
12	86	91	O	taking
13	93	99	O	XXXXXXXX
14	101	103	O	and
15	105	117	O	transitioning
16	119	120	O	to
17	122	123	O	an
18	125	137	O	anticoagulant
19	139	142	O	with
20	144	148	O	rapid
21	150	154	O	onset
22	156	156	O	,
23	158	168	O	discontinue
24	170	176	O	XXXXXXXX
25	178	180	O	and
26	182	185	O	give
27	187	189	O	the
28	191	195	O	first
29	197	200	O	dose
30	202	203	O	of
31	205	207	O	the
32	209	213	O	other
33	215	227	O	anticoagulant
34	231	234	O	oral
35	236	237	O	or
36	239	248	O	parenteral
37	252	253	O	at
38	255	257	O	the
39	259	262	O	time
40	264	267	O	that
41	269	271	O	the
42	273	276	O	next
43	278	284	O	XXXXXXXX
44	286	289	O	dose
45	291	295	O	would
46	297	300	O	have
47	302	305	O	been
48	307	311	O	taken
49	313	315	O	see
50	317	320	O	Drug
51	322	333	O	Interactions
52	337	339	O	7.4
NULL

Xarelto	44	34068-7	10db92f9-2300-4a80-836b-673e1ae91610	19
Switching from XARELTO to Warfarin - No clinical trial data are available to guide converting patients from XARELTO to warfarin .
1	0	8	O	Switching
2	10	13	O	from
3	15	21	O	XXXXXXXX
4	23	24	O	to
5	26	33	O	Warfarin
6	37	38	O	No
7	40	47	O	clinical
8	49	53	O	trial
9	55	58	O	data
10	60	62	O	are
11	64	72	O	available
12	74	75	O	to
13	77	81	O	guide
14	83	92	O	converting
15	94	101	O	patients
16	103	106	O	from
17	108	114	O	XXXXXXXX
18	116	117	O	to
19	119	126	O	warfarin
NULL

Xarelto	45	34068-7	10db92f9-2300-4a80-836b-673e1ae91610	54
The recommended dose of XARELTO for the reduction in the risk of recurrence of DVT and/or PE after at least 6 months of standard anticoagulant treatment in patients at continued risk of DVT and/or PE is 10 mg taken orally once daily with or without food see Clinical Studies ( 14.3 ) .
1	0	2	O	The
2	4	14	O	recommended
3	16	19	O	dose
4	21	22	O	of
5	24	30	O	XXXXXXXX
6	32	34	O	for
7	36	38	O	the
8	40	48	O	reduction
9	50	51	O	in
10	53	55	O	the
11	57	60	O	risk
12	62	63	O	of
13	65	74	O	recurrence
14	76	77	O	of
15	79	81	O	DVT
16	83	85	O	and
17	86	86	O	/
18	87	88	O	or
19	90	91	O	PE
20	93	97	O	after
21	99	100	O	at
22	102	106	O	least
23	108	108	O	6
24	110	115	O	months
25	117	118	O	of
26	120	127	O	standard
27	129	141	O	anticoagulant
28	143	151	O	treatment
29	153	154	O	in
30	156	163	O	patients
31	165	166	O	at
32	168	176	O	continued
33	178	181	O	risk
34	183	184	O	of
35	186	188	O	DVT
36	190	192	O	and
37	193	193	O	/
38	194	195	O	or
39	197	198	O	PE
40	200	201	O	is
41	203	204	O	10
42	206	207	O	mg
43	209	213	O	taken
44	215	220	O	orally
45	222	225	O	once
46	227	231	O	daily
47	233	236	O	with
48	238	239	O	or
49	241	247	O	without
50	249	252	O	food
51	254	256	O	see
52	258	265	O	Clinical
53	267	273	O	Studies
54	277	280	O	14.3
NULL

Xarelto	46	34068-7	10db92f9-2300-4a80-836b-673e1ae91610	23
XARELTO affects INR , so INR measurements made during coadministration with warfarin may not be useful for determining the appropriate dose of warfarin .
1	0	6	O	XXXXXXXX
2	8	14	O	affects
3	16	18	O	INR
4	20	20	O	,
5	22	23	O	so
6	25	27	O	INR
7	29	40	O	measurements
8	42	45	O	made
9	47	52	O	during
10	54	69	O	coadministration
11	71	74	O	with
12	76	83	O	warfarin
13	85	87	O	may
14	89	91	O	not
15	93	94	O	be
16	96	101	O	useful
17	103	105	O	for
18	107	117	O	determining
19	119	121	O	the
20	123	133	O	appropriate
21	135	138	O	dose
22	140	141	O	of
23	143	150	O	warfarin
NULL

Xarelto	47	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	41
Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor , pharmacokinetic data suggests that no precautions are necessary with concomitant administration with XARELTO as the change in exposure is unlikely to affect the bleeding risk see Clinical Pharmacology ( 12.3 ) .
1	0	7	O	Although
2	9	22	O	clarithromycin
3	24	25	O	is
4	27	27	O	a
5	29	36	O	combined
6	38	38	O	P
7	40	41	O	gp
8	43	45	O	and
9	47	52	O	strong
10	54	59	O	CYP3A4
11	61	69	O	inhibitor
12	71	71	O	,
13	73	87	O	pharmacokinetic
14	89	92	O	data
15	94	101	O	suggests
16	103	106	O	that
17	108	109	O	no
18	111	121	O	precautions
19	123	125	O	are
20	127	135	O	necessary
21	137	140	O	with
22	142	152	O	concomitant
23	154	167	O	administration
24	169	172	O	with
25	174	180	O	XXXXXXXX
26	182	183	O	as
27	185	187	O	the
28	189	194	O	change
29	196	197	O	in
30	199	206	O	exposure
31	208	209	O	is
32	211	218	O	unlikely
33	220	221	O	to
34	223	228	O	affect
35	230	232	O	the
36	234	241	O	bleeding
37	243	246	O	risk
38	248	250	O	see
39	252	259	O	Clinical
40	261	272	O	Pharmacology
41	276	279	O	12.3
NULL

Xarelto	48	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	28
Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A4 inhibitors ( e.g. , ketoconazole and ritonavir ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .
1	0	4	U-TRI	Avoid
2	6	16	O	concomitant
3	18	31	O	administration
4	33	34	O	of
5	36	42	O	XXXXXXXX
6	44	47	O	with
7	49	53	O	known
8	55	62	O	combined
9	64	64	O	P
10	66	67	O	gp
11	69	71	O	and
12	73	78	B-UNK	strong
13	80	85	I-UNK	CYP3A4
14	87	96	L-UNK	inhibitors
15	100	102	O	e.g
16	105	105	O	,
17	107	118	U-UNK	ketoconazole
18	120	122	O	and
19	124	132	U-UNK	ritonavir
20	136	138	O	see
21	140	147	O	Warnings
22	149	151	O	and
23	153	163	O	Precautions
24	167	169	O	5.6
25	173	175	O	and
26	177	184	O	Clinical
27	186	197	O	Pharmacology
28	201	204	O	12.3
NULL

Xarelto	49	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	37
Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A4 inducers ( e.g. , carbamazepine , phenytoin , rifampin , St.   John 's   wort ) see Warnings and Precautions ( 5.6 ) and Clinical Pharmacology ( 12.3 ) .
1	0	4	U-TRI	Avoid
2	6	16	O	concomitant
3	18	20	O	use
4	22	23	O	of
5	25	31	O	XXXXXXXX
6	33	36	O	with
7	38	42	O	drugs
8	44	47	O	that
9	49	51	O	are
10	53	60	O	combined
11	62	62	O	P
12	64	65	O	gp
13	67	69	O	and
14	71	76	B-UNK	strong
15	78	83	I-UNK	CYP3A4
16	85	92	L-UNK	inducers
17	96	98	O	e.g
18	101	101	O	,
19	103	115	U-UNK	carbamazepine
20	117	117	O	,
21	119	127	U-UNK	phenytoin
22	129	129	O	,
23	131	138	U-UNK	rifampin
24	140	140	O	,
25	142	143	B-UNK	St
26	148	151	I-UNK	John
27	153	154	I-UNK	's
28	158	161	L-UNK	wort
29	165	167	O	see
30	169	176	O	Warnings
31	178	180	O	and
32	182	192	O	Precautions
33	196	198	O	5.6
34	202	204	O	and
35	206	213	O	Clinical
36	215	226	O	Pharmacology
37	230	233	O	12.3
NULL

Xarelto	50	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	17
Avoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk .
1	0	4	O	Avoid
2	6	15	O	concurrent
3	17	19	O	use
4	21	22	O	of
5	24	30	O	XXXXXXXX
6	32	35	O	with
7	37	41	O	other
8	43	56	U-DYN	anticoagulants
9	58	60	O	due
10	62	63	O	to
11	65	73	B-EFF	increased
12	75	82	I-EFF	bleeding
13	84	87	L-EFF	risk
14	89	94	O	unless
15	96	102	O	benefit
16	104	112	O	outweighs
17	114	117	O	risk
D/8:11:1

Xarelto	51	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	23
Coadministration of enoxaparin, warfarin, aspirin, clopidogrel and chronic NSAID use may increase the risk of bleeding [see Clinical Pharmacology (12.3)].
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	U-DYN	enoxaparin
4	30	30	O	,
5	32	39	U-DYN	warfarin
6	40	40	O	,
7	42	48	U-DYN	aspirin
8	49	49	O	,
9	51	61	U-DYN	clopidogrel
10	63	65	O	and
11	67	73	B-DYN	chronic
12	75	79	L-DYN	NSAID
13	81	83	O	use
14	85	87	O	may
15	89	96	O	increase
16	98	100	O	the
17	102	105	O	risk
18	107	108	O	of
19	110	117	U-EFF	bleeding
20	120	122	O	see
21	124	131	O	Clinical
22	133	144	O	Pharmacology
23	147	150	O	12.3
D/11:19:1 D/3:19:1 D/5:19:1 D/7:19:1 D/9:19:1

Xarelto	52	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	19
Combined P-gp and strong CYP3A4 inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events .
1	0	7	O	Combined
2	9	9	O	P
3	11	12	O	gp
4	14	16	O	and
5	18	23	O	strong
6	25	30	B-DYN	CYP3A4
7	32	39	L-DYN	inducers
8	41	48	B-TRI	decrease
9	50	57	L-TRI	exposure
10	59	60	O	to
11	62	72	O	XXXXXXXX
12	74	76	O	and
13	78	80	O	may
14	82	89	O	increase
15	91	93	O	the
16	95	98	O	risk
17	100	101	O	of
18	103	116	B-EFF	thromboembolic
19	118	123	L-EFF	events
D/6:18:1

Xarelto	53	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	44
Combined P-gp and strong CYP3A4 inhibitors and inducers: Avoid concomitant use (7.2, 7.3) Anticoagulants: Avoid concomitant use (7.4) Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters.
1	0	7	O	Combined
2	9	9	O	P
3	11	12	O	gp
4	14	16	O	and
5	18	23	B-UNK	strong
6	25	30	I-UNK	CYP3A4
7	32	41	L-UNK	inhibitors
8	43	45	O	and
9	47	54	O	inducers
10	55	55	O	:
11	57	61	U-TRI	Avoid
12	63	73	O	concomitant
13	75	77	O	use
14	80	82	O	7.2
15	83	83	O	,
16	85	87	O	7.3
17	90	103	U-UNK	Anticoagulants
18	104	104	O	:
19	106	110	O	Avoid
20	112	122	O	concomitant
21	124	126	O	use
22	129	131	O	7.4
23	134	144	O	XXXXXXXX
24	146	147	O	is
25	149	149	O	a
26	151	159	O	substrate
27	161	162	O	of
28	164	169	O	CYP3A4
29	170	170	O	/
30	171	171	O	5
31	172	172	O	,
32	174	179	O	CYP2J2
33	180	180	O	,
34	182	184	O	and
35	186	188	O	the
36	190	190	O	P
37	192	193	O	gp
38	195	197	O	and
39	199	201	O	ATP
40	203	209	O	binding
41	211	218	O	cassette
42	220	221	O	G2
43	224	228	O	ABCG2
44	231	242	O	transporters
NULL

Xarelto	54	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	18
Combined P-gp and strong CYP3A4 inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding .
1	0	7	O	Combined
2	9	9	O	P
3	11	12	O	gp
4	14	16	O	and
5	18	23	B-DYN	strong
6	25	30	I-DYN	CYP3A4
7	32	41	L-DYN	inhibitors
8	43	50	B-TRI	increase
9	52	59	L-TRI	exposure
10	61	62	O	to
11	64	74	O	XXXXXXXX
12	76	78	O	and
13	80	82	O	may
14	84	91	O	increase
15	93	95	O	the
16	97	100	O	risk
17	102	103	O	of
18	105	112	U-EFF	bleeding
D/5:18:1

Xarelto	55	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	60
Interaction with Combined P-gp and Moderate CYP3A4 Inhibitors in Patients with Renal Impairment XARELTO should not be used in patients with CrCl 15 to <80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors (e.g., erythromycin) unless the potential benefit justifies the potential risk [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].
1	0	10	O	Interaction
2	12	15	O	with
3	17	24	O	Combined
4	26	26	O	P
5	28	29	O	gp
6	31	33	O	and
7	35	42	O	Moderate
8	44	49	O	CYP3A4
9	51	60	O	Inhibitors
10	62	63	O	in
11	65	72	O	Patients
12	74	77	O	with
13	79	83	O	Renal
14	85	94	O	Impairment
15	96	102	O	XXXXXXXX
16	104	109	B-TRI	should
17	111	113	I-TRI	not
18	115	116	I-TRI	be
19	118	121	L-TRI	used
20	123	124	O	in
21	126	133	O	patients
22	135	138	O	with
23	140	143	O	CrCl
24	145	146	O	15
25	148	149	O	to
26	151	153	O	<80
27	155	156	O	mL
28	157	157	O	/
29	158	160	O	min
30	162	164	O	who
31	166	168	O	are
32	170	178	O	receiving
33	180	190	O	concomitant
34	192	199	O	combined
35	201	201	O	P
36	203	204	O	gp
37	206	208	O	and
38	210	217	B-UNK	moderate
39	219	224	I-UNK	CYP3A4
40	226	235	L-UNK	inhibitors
41	238	240	O	e.g
42	242	242	O	,
43	244	255	U-UNK	erythromycin
44	258	263	O	unless
45	265	267	O	the
46	269	277	O	potential
47	279	285	O	benefit
48	287	295	O	justifies
49	297	299	O	the
50	301	309	O	potential
51	311	314	O	risk
52	317	319	O	see
53	321	328	O	Warnings
54	330	332	O	and
55	334	344	O	Precautions
56	347	349	O	5.4
57	352	354	O	and
58	356	363	O	Clinical
59	365	376	O	Pharmacology
60	379	382	O	12.3
NULL

Xarelto	56	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	37
Interaction with Combined P-gp and Strong CYP3A4 Inhibitors Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole and ritonavir) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].
1	0	10	O	Interaction
2	12	15	O	with
3	17	24	O	Combined
4	26	26	O	P
5	28	29	O	gp
6	31	33	O	and
7	35	40	O	Strong
8	42	47	O	CYP3A4
9	49	58	O	Inhibitors
10	60	64	U-TRI	Avoid
11	66	76	O	concomitant
12	78	91	O	administration
13	93	94	O	of
14	96	102	O	XXXXXXXX
15	104	107	O	with
16	109	113	O	known
17	115	122	O	combined
18	124	124	O	P
19	126	127	O	gp
20	129	131	O	and
21	133	138	B-UNK	strong
22	140	145	I-UNK	CYP3A4
23	147	156	L-UNK	inhibitors
24	159	161	O	e.g
25	163	163	O	,
26	165	176	U-UNK	ketoconazole
27	178	180	O	and
28	182	190	U-UNK	ritonavir
29	194	196	O	see
30	198	205	O	Warnings
31	207	209	O	and
32	211	221	O	Precautions
33	224	226	O	5.6
34	229	231	O	and
35	233	240	O	Clinical
36	242	253	O	Pharmacology
37	256	259	O	12.3
NULL

Xarelto	57	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	29
Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs [see Warnings and Precautions (5.2)].
1	0	7	O	Promptly
2	9	16	O	evaluate
3	18	20	O	any
4	22	26	O	signs
5	28	29	O	or
6	31	38	O	symptoms
7	40	41	O	of
8	43	47	B-EFF	blood
9	49	52	L-EFF	loss
10	54	55	O	if
11	57	64	O	patients
12	66	68	O	are
13	70	76	O	treated
14	78	90	O	concomitantly
15	92	95	O	with
16	97	103	U-DYN	aspirin
17	104	104	O	,
18	106	110	O	other
19	112	119	B-DYN	platelet
20	121	131	I-DYN	aggregation
21	133	142	L-DYN	inhibitors
22	143	143	O	,
23	145	146	O	or
24	148	153	U-DYN	NSAIDs
25	156	158	O	see
26	160	167	O	Warnings
27	169	171	O	and
28	173	183	O	Precautions
29	186	188	O	5.2
D/16:8:1 D/19:8:1 D/24:8:1

Xarelto	58	34073-7	10db92f9-2300-4a80-836b-673e1ae91610	46
XARELTO should not be used in patients with CrCl 15 to 80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A4 inhibitors ( e.g. , erythromycin ) unless the potential benefit justifies the potential risk see Warnings and Precautions ( 5.4 ) and Clinical Pharmacology ( 12.3 ) .
1	0	6	O	XXXXXXXX
2	8	13	B-TRI	should
3	15	17	I-TRI	not
4	19	20	I-TRI	be
5	22	25	L-TRI	used
6	27	28	O	in
7	30	37	O	patients
8	39	42	O	with
9	44	47	O	CrCl
10	49	50	O	15
11	52	53	O	to
12	55	56	O	80
13	58	59	O	mL
14	60	60	O	/
15	61	63	O	min
16	65	67	O	who
17	69	71	O	are
18	73	81	O	receiving
19	83	93	O	concomitant
20	95	102	O	combined
21	104	104	O	P
22	106	107	O	gp
23	109	111	O	and
24	113	120	B-UNK	moderate
25	122	127	I-UNK	CYP3A4
26	129	138	L-UNK	inhibitors
27	142	144	O	e.g
28	147	147	O	,
29	149	160	U-UNK	erythromycin
30	164	169	O	unless
31	171	173	O	the
32	175	183	O	potential
33	185	191	O	benefit
34	193	201	O	justifies
35	203	205	O	the
36	207	215	O	potential
37	217	220	O	risk
38	222	224	O	see
39	226	233	O	Warnings
40	235	237	O	and
41	239	249	O	Precautions
42	253	255	O	5.4
43	259	261	O	and
44	263	270	O	Clinical
45	272	283	O	Pharmacology
46	287	290	O	12.3
NULL

Xarelto	59	43685-7	10db92f9-2300-4a80-836b-673e1ae91610	8
A specific antidote for rivaroxaban is not available .
1	0	0	O	A
2	2	9	O	specific
3	11	18	O	antidote
4	20	22	O	for
5	24	34	O	XXXXXXXX
6	36	37	O	is
7	39	41	O	not
8	43	51	O	available
NULL

Xarelto	60	43685-7	10db92f9-2300-4a80-836b-673e1ae91610	21
An increased rate of stroke was observed during the transition from XARELTO to warfarin in clinical trials in atrial fibrillation patients .
1	0	1	O	An
2	3	11	O	increased
3	13	16	O	rate
4	18	19	O	of
5	21	26	O	stroke
6	28	30	O	was
7	32	39	O	observed
8	41	46	O	during
9	48	50	O	the
10	52	61	O	transition
11	63	66	O	from
12	68	74	O	XXXXXXXX
13	76	77	O	to
14	79	86	O	warfarin
15	88	89	O	in
16	91	98	O	clinical
17	100	105	O	trials
18	107	108	O	in
19	110	115	O	atrial
20	117	128	O	fibrillation
21	130	137	O	patients
NULL

Xarelto	61	43685-7	10db92f9-2300-4a80-836b-673e1ae91610	21
Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A4 inducers see Drug Interactions ( 7.3 ) .
1	0	4	U-TRI	Avoid
2	6	16	O	concomitant
3	18	20	O	use
4	22	23	O	of
5	25	31	O	XXXXXXXX
6	33	36	O	with
7	38	42	O	drugs
8	44	47	O	that
9	49	51	O	are
10	53	57	O	known
11	59	66	O	combined
12	68	68	O	P
13	70	71	O	gp
14	73	75	O	and
15	77	82	B-UNK	strong
16	84	89	I-UNK	CYP3A4
17	91	98	L-UNK	inducers
18	100	102	O	see
19	104	107	O	Drug
20	109	120	O	Interactions
21	124	126	O	7.3
NULL

Xarelto	62	43685-7	10db92f9-2300-4a80-836b-673e1ae91610	18
Avoid concomitant use of XARELTO with known combined P-gp and strong CYP3A4 inhibitors see Drug Interactions ( 7.2 ) .
1	0	4	U-TRI	Avoid
2	6	16	O	concomitant
3	18	20	O	use
4	22	23	O	of
5	25	31	O	XXXXXXXX
6	33	36	O	with
7	38	42	O	known
8	44	51	O	combined
9	53	53	O	P
10	55	56	O	gp
11	58	60	O	and
12	62	67	B-UNK	strong
13	69	74	I-UNK	CYP3A4
14	76	85	L-UNK	inhibitors
15	87	89	O	see
16	91	94	O	Drug
17	96	107	O	Interactions
18	111	113	O	7.2
NULL

Xarelto	63	43685-7	10db92f9-2300-4a80-836b-673e1ae91610	26
Concomitant use of drugs that are known combined P-gp and strong CYP3A4 inhibitors increases rivaroxaban exposure and may increase bleeding risk see Drug Interactions ( 7.2 ) .
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	23	O	drugs
5	25	28	O	that
6	30	32	O	are
7	34	38	O	known
8	40	47	O	combined
9	49	49	O	P
10	51	52	O	gp
11	54	56	O	and
12	58	63	B-KIN	strong
13	65	70	I-KIN	CYP3A4
14	72	81	L-KIN	inhibitors
15	83	91	B-TRI	increases
16	93	103	I-TRI	XXXXXXXX
17	105	112	L-TRI	exposure
18	114	116	O	and
19	118	120	O	may
20	122	129	O	increase
21	131	138	O	bleeding
22	140	143	O	risk
23	145	147	O	see
24	149	152	O	Drug
25	154	165	O	Interactions
26	169	171	O	7.2
K/12:C54355

Xarelto	64	43685-7	10db92f9-2300-4a80-836b-673e1ae91610	31
Initiation of XARELTO is not recommended acutely as an alternative to unfractionated heparin in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy .
1	0	9	O	Initiation
2	11	12	O	of
3	14	20	O	XXXXXXXX
4	22	23	O	is
5	25	27	O	not
6	29	39	O	recommended
7	41	47	O	acutely
8	49	50	O	as
9	52	53	O	an
10	55	65	O	alternative
11	67	68	O	to
12	70	83	O	unfractionated
13	85	91	O	heparin
14	93	94	O	in
15	96	103	O	patients
16	105	108	O	with
17	110	118	O	pulmonary
18	120	127	O	embolism
19	129	131	O	who
20	133	139	O	present
21	141	144	O	with
22	146	156	O	hemodynamic
23	158	168	O	instability
24	170	171	O	or
25	173	175	O	who
26	177	179	O	may
27	181	187	O	receive
28	189	200	O	thrombolysis
29	202	203	O	or
30	205	213	O	pulmonary
31	215	225	O	embolectomy
NULL

Xarelto	65	43685-7	10db92f9-2300-4a80-836b-673e1ae91610	23
Premature discontinuation of any oral anticoagulant , including XARELTO , in the absence of adequate alternative anticoagulation increases the risk of thrombotic events .
1	0	8	O	Premature
2	10	24	O	discontinuation
3	26	27	O	of
4	29	31	O	any
5	33	36	O	oral
6	38	50	O	anticoagulant
7	52	52	O	,
8	54	62	O	including
9	64	70	O	XXXXXXXX
10	72	72	O	,
11	74	75	O	in
12	77	79	O	the
13	81	87	O	absence
14	89	90	O	of
15	92	99	O	adequate
16	101	111	O	alternative
17	113	127	O	anticoagulation
18	129	137	O	increases
19	139	141	O	the
20	143	146	O	risk
21	148	149	O	of
22	151	160	O	thrombotic
23	162	167	O	events
NULL

Xarelto	66	43685-7	10db92f9-2300-4a80-836b-673e1ae91610	15
Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban .
1	0	8	O	Protamine
2	10	16	O	sulfate
3	18	20	O	and
4	22	28	O	vitamin
5	30	30	O	K
6	32	34	O	are
7	36	38	O	not
8	40	47	O	expected
9	49	50	O	to
10	52	57	O	affect
11	59	61	O	the
12	63	75	O	anticoagulant
13	77	84	O	activity
14	86	87	O	of
15	89	99	O	XXXXXXXX
NULL

edarbi	351	34068-7	75b16bfc-38c1-4133-bd7d-13258d54edec	8
Edarbi may be administered with other antihypertensive agents .
1	0	5	O	XXXXXXXX
2	7	9	O	may
3	11	12	O	be
4	14	25	O	administered
5	27	30	O	with
6	32	36	O	other
7	38	53	O	antihypertensive
8	55	60	O	agents
NULL

edarbi	352	34068-7	75b16bfc-38c1-4133-bd7d-13258d54edec	24
If blood pressure is not controlled with Edarbi alone , additional blood pressure reduction can be achieved by taking Edarbi with other antihypertensive agents .
1	0	1	O	If
2	3	7	O	blood
3	9	16	O	pressure
4	18	19	O	is
5	21	23	O	not
6	25	34	O	controlled
7	36	39	O	with
8	41	46	O	XXXXXXXX
9	48	52	O	alone
10	54	54	O	,
11	56	65	O	additional
12	67	71	O	blood
13	73	80	O	pressure
14	82	90	O	reduction
15	92	94	O	can
16	96	97	O	be
17	99	106	O	achieved
18	108	109	O	by
19	111	116	O	taking
20	118	123	O	XXXXXXXX
21	125	128	O	with
22	130	134	O	other
23	136	151	O	antihypertensive
24	153	158	O	agents
NULL

edarbi	353	34070-3	75b16bfc-38c1-4133-bd7d-13258d54edec	10
Do not coadminister aliskiren with Edarbi in patients with diabetes .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	18	L-TRI	coadminister
4	20	28	U-UNK	aliskiren
5	30	33	O	with
6	35	40	O	XXXXXXXX
7	42	43	O	in
8	45	52	O	patients
9	54	57	O	with
10	59	66	O	diabetes
NULL

edarbi	354	34070-3	75b16bfc-38c1-4133-bd7d-13258d54edec	14
Do not coadminister aliskiren with Edarbi in patients with diabetes see Drug Interactions ( 7 ) .
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	18	L-TRI	coadminister
4	20	28	U-UNK	aliskiren
5	30	33	O	with
6	35	40	O	XXXXXXXX
7	42	43	O	in
8	45	52	O	patients
9	54	57	O	with
10	59	66	O	diabetes
11	68	70	O	see
12	72	75	O	Drug
13	77	88	O	Interactions
14	92	92	O	7
NULL

edarbi	355	34073-7	75b16bfc-38c1-4133-bd7d-13258d54edec	16
Avoid use of aliskiren with Edarbi in patients with renal impairment ( GFR 60 mL/min ) .
1	0	4	U-TRI	Avoid
2	6	8	O	use
3	10	11	O	of
4	13	21	U-UNK	aliskiren
5	23	26	O	with
6	28	33	O	XXXXXXXX
7	35	36	O	in
8	38	45	O	patients
9	47	50	O	with
10	52	56	O	renal
11	58	67	O	impairment
12	71	73	O	GFR
13	75	76	O	60
14	78	79	O	mL
15	80	80	O	/
16	81	83	O	min
NULL

edarbi	356	34073-7	75b16bfc-38c1-4133-bd7d-13258d54edec	20
Closely monitor blood pressure , renal function and electrolytes in patients on Edarbi and other agents that affect the RAS .
1	0	6	O	Closely
2	8	14	U-TRI	monitor
3	16	20	O	blood
4	22	29	O	pressure
5	31	31	O	,
6	33	37	O	renal
7	39	46	O	function
8	48	50	O	and
9	52	63	O	electrolytes
10	65	66	O	in
11	68	75	O	patients
12	77	78	O	on
13	80	85	O	XXXXXXXX
14	87	89	O	and
15	91	95	O	other
16	97	102	B-UNK	agents
17	104	107	I-UNK	that
18	109	114	I-UNK	affect
19	116	118	I-UNK	the
20	120	122	L-UNK	RAS
NULL

edarbi	357	34073-7	75b16bfc-38c1-4133-bd7d-13258d54edec	45
Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
1	0	3	O	Dual
2	5	12	O	Blockade
3	14	15	O	of
4	17	19	O	the
5	21	25	O	Renin
6	27	37	O	Angiotensin
7	39	44	O	System
8	47	49	O	RAS
9	52	55	O	Dual
10	57	64	O	blockade
11	66	67	O	of
12	69	71	O	the
13	73	75	O	RAS
14	77	80	O	with
15	82	92	O	angiotensin
16	94	101	O	receptor
17	103	110	O	blockers
18	111	111	O	,
19	113	115	B-DYN	ACE
20	117	126	L-DYN	inhibitors
21	127	127	O	,
22	129	130	O	or
23	132	140	U-DYN	aliskiren
24	142	143	O	is
25	145	154	O	associated
26	156	159	O	with
27	161	169	O	increased
28	171	175	O	risks
29	177	178	O	of
30	180	190	U-EFF	hypotension
31	191	191	O	,
32	193	204	U-EFF	hyperkalemia
33	205	205	O	,
34	207	209	O	and
35	211	217	B-EFF	changes
36	219	220	I-EFF	in
37	222	226	I-EFF	renal
38	228	235	L-EFF	function
39	238	246	O	including
40	248	252	B-EFF	acute
41	254	258	I-EFF	renal
42	260	266	L-EFF	failure
43	269	276	O	compared
44	278	279	O	to
45	281	291	O	monotherapy
D/19:30:1 D/19:32:1 D/19:35:1 D/19:40:1 D/23:30:1 D/23:32:1 D/23:35:1 D/23:40:1

edarbi	358	34073-7	75b16bfc-38c1-4133-bd7d-13258d54edec	18
Dual inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia.
1	0	3	O	Dual
2	5	14	O	inhibition
3	16	17	O	of
4	19	21	O	the
5	23	27	O	renin
6	29	39	O	angiotensin
7	41	46	O	system
8	47	47	O	:
9	49	57	O	Increased
10	59	62	O	risk
11	64	65	O	of
12	67	71	O	renal
13	73	82	O	impairment
14	83	83	O	,
15	85	95	O	hypotension
16	96	96	O	,
17	98	100	O	and
18	102	113	O	hyperkalemia
NULL

edarbi	359	34073-7	75b16bfc-38c1-4133-bd7d-13258d54edec	53
In patients who are elderly , volume-depleted ( including those on diuretic therapy ) , or who have compromised renal function , coadministration of NSAIDs , including selective COX-2 inhibitors , with angiotensin II receptor antagonists , including azilsartan , may result in deterioration of renal function , including possible acute renal failure .
1	0	1	O	In
2	3	10	O	patients
3	12	14	O	who
4	16	18	O	are
5	20	26	O	elderly
6	28	28	O	,
7	30	35	O	volume
8	37	44	O	depleted
9	48	56	O	including
10	58	62	O	those
11	64	65	O	on
12	67	74	O	diuretic
13	76	82	O	therapy
14	86	86	O	,
15	88	89	O	or
16	91	93	O	who
17	95	98	O	have
18	100	110	O	compromised
19	112	116	O	renal
20	118	125	O	function
21	127	127	O	,
22	129	144	O	coadministration
23	146	147	O	of
24	149	154	U-DYN	NSAIDs
25	156	156	O	,
26	158	166	O	including
27	168	176	B-DYN	selective
28	178	180	I-DYN	COX
29	182	182	I-DYN	2
30	184	193	L-DYN	inhibitors
31	195	195	O	,
32	197	200	O	with
33	202	212	O	angiotensin
34	214	215	O	II
35	217	224	O	receptor
36	226	236	O	antagonists
37	238	238	O	,
38	240	248	O	including
39	250	259	O	XXXXXXXX
40	261	261	O	,
41	263	265	O	may
42	267	272	O	result
43	274	275	O	in
44	277	289	B-EFF	deterioration
45	291	292	I-EFF	of
46	294	298	I-EFF	renal
47	300	307	L-EFF	function
48	309	309	O	,
49	311	319	O	including
50	321	328	O	possible
51	330	334	B-EFF	acute
52	336	340	I-EFF	renal
53	342	348	L-EFF	failure
D/24:44:1 D/24:51:1 D/27:44:1 D/27:51:1

edarbi	360	34073-7	75b16bfc-38c1-4133-bd7d-13258d54edec	11
Monitor renal function periodically in patients receiving azilsartan and NSAID therapy .
1	0	6	U-TRI	Monitor
2	8	12	O	renal
3	14	21	O	function
4	23	34	O	periodically
5	36	37	O	in
6	39	46	O	patients
7	48	56	O	receiving
8	58	67	O	XXXXXXXX
9	69	71	O	and
10	73	77	U-UNK	NSAID
11	79	85	O	therapy
NULL

edarbi	361	34073-7	75b16bfc-38c1-4133-bd7d-13258d54edec	37
No clinically significant drug interactions have been observed in studies of azilsartan medoxomil or azilsartan given with amlodipine , antacids , chlorthalidone , digoxin , fluconazole , glyburide , ketoconazole , metformin , pioglitazone , and warfarin .
1	0	1	O	No
2	3	12	O	clinically
3	14	24	O	significant
4	26	29	O	drug
5	31	42	O	interactions
6	44	47	O	have
7	49	52	O	been
8	54	61	O	observed
9	63	64	O	in
10	66	72	O	studies
11	74	75	O	of
12	77	86	O	XXXXXXXX
13	88	96	O	medoxomil
14	98	99	O	or
15	101	110	O	XXXXXXXX
16	112	116	O	given
17	118	121	O	with
18	123	132	O	amlodipine
19	134	134	O	,
20	136	143	O	antacids
21	145	145	O	,
22	147	160	O	chlorthalidone
23	162	162	O	,
24	164	170	O	digoxin
25	172	172	O	,
26	174	184	O	fluconazole
27	186	186	O	,
28	188	196	O	glyburide
29	198	198	O	,
30	200	211	O	ketoconazole
31	213	213	O	,
32	215	223	O	metformin
33	225	225	O	,
34	227	238	O	pioglitazone
35	240	240	O	,
36	242	244	O	and
37	246	253	O	warfarin
NULL

edarbi	362	34073-7	75b16bfc-38c1-4133-bd7d-13258d54edec	67
Non-steroidal Anti-Inflammatory Agents, including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or who have compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists, including azilsartan, may result in deterioration of renal function, including possible acute renal failure.
1	0	2	B-DYN	Non
2	4	12	I-DYN	steroidal
3	14	17	I-DYN	Anti
4	19	30	I-DYN	Inflammatory
5	32	37	L-DYN	Agents
6	38	38	O	,
7	40	48	O	including
8	50	58	B-DYN	Selective
9	60	73	I-DYN	Cyclooxygenase
10	75	75	I-DYN	2
11	77	86	L-DYN	Inhibitors
12	89	91	B-DYN	COX
13	93	93	I-DYN	2
14	95	104	L-DYN	Inhibitors
15	107	108	O	In
16	110	117	O	patients
17	119	121	O	who
18	123	125	O	are
19	127	133	O	elderly
20	134	134	O	,
21	136	141	O	volume
22	143	150	O	depleted
23	153	161	O	including
24	163	167	O	those
25	169	170	O	on
26	172	179	O	diuretic
27	181	187	O	therapy
28	189	189	O	,
29	191	192	O	or
30	194	196	O	who
31	198	201	O	have
32	203	213	O	compromised
33	215	219	O	renal
34	221	228	O	function
35	229	229	O	,
36	231	246	O	coadministration
37	248	249	O	of
38	251	256	U-DYN	NSAIDs
39	257	257	O	,
40	259	267	O	including
41	269	277	O	selective
42	279	281	O	COX
43	283	283	O	2
44	285	294	O	inhibitors
45	295	295	O	,
46	297	300	O	with
47	302	312	O	angiotensin
48	314	315	O	II
49	317	324	O	receptor
50	326	336	O	antagonists
51	337	337	O	,
52	339	347	O	including
53	349	358	O	XXXXXXXX
54	359	359	O	,
55	361	363	O	may
56	365	370	O	result
57	372	373	O	in
58	375	387	B-EFF	deterioration
59	389	390	I-EFF	of
60	392	396	I-EFF	renal
61	398	405	L-EFF	function
62	406	406	O	,
63	408	416	O	including
64	418	425	O	possible
65	427	431	B-EFF	acute
66	433	437	I-EFF	renal
67	439	445	L-EFF	failure
D/1:58:1 D/1:65:1 D/12:58:1 D/12:65:1 D/38:58:1 D/38:65:1 D/8:58:1 D/8:65:1

edarbi	363	34073-7	75b16bfc-38c1-4133-bd7d-13258d54edec	23
The antihypertensive effect of angiotensin II receptor antagonists , including azilsartan , may be attenuated by NSAIDs , including selective COX-2 inhibitors .
1	0	2	O	The
2	4	19	O	antihypertensive
3	21	26	O	effect
4	28	29	O	of
5	31	41	O	angiotensin
6	43	44	O	II
7	46	53	O	receptor
8	55	65	O	antagonists
9	67	67	O	,
10	69	77	O	including
11	79	88	O	XXXXXXXX
12	90	90	O	,
13	92	94	O	may
14	96	97	O	be
15	99	108	O	attenuated
16	110	111	O	by
17	113	118	U-DYN	NSAIDs
18	120	120	O	,
19	122	130	O	including
20	132	140	B-DYN	selective
21	142	144	I-DYN	COX
22	146	146	I-DYN	2
23	148	157	L-DYN	inhibitors
NULL

edarbi	364	34073-7	75b16bfc-38c1-4133-bd7d-13258d54edec	10
Therefore, Edarbi may be used concomitantly with these medications.
1	0	8	O	Therefore
2	9	9	O	,
3	11	16	O	XXXXXXXX
4	18	20	O	may
5	22	23	O	be
6	25	28	O	used
7	30	42	O	concomitantly
8	44	47	O	with
9	49	53	O	these
10	55	65	O	medications
NULL

edarbi	365	43685-7	75b16bfc-38c1-4133-bd7d-13258d54edec	39
In patients with an activated renin-angiotensin system , such as volume - and/or salt-depleted patients ( e.g. , those being treated with high doses of diuretics ) , symptomatic hypotension may occur after initiation of treatment with Edarbi .
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	18	O	an
5	20	28	O	activated
6	30	34	O	renin
7	36	46	O	angiotensin
8	48	53	O	system
9	55	55	O	,
10	57	60	O	such
11	62	63	O	as
12	65	70	O	volume
13	74	76	O	and
14	77	77	O	/
15	78	79	O	or
16	81	84	O	salt
17	86	93	O	depleted
18	95	102	O	patients
19	106	108	O	e.g
20	111	111	O	,
21	113	117	O	those
22	119	123	O	being
23	125	131	O	treated
24	133	136	O	with
25	138	141	O	high
26	143	147	O	doses
27	149	150	O	of
28	152	160	O	diuretics
29	164	164	O	,
30	166	176	O	symptomatic
31	178	188	O	hypotension
32	190	192	O	may
33	194	198	O	occur
34	200	204	O	after
35	206	215	O	initiation
36	217	218	O	of
37	220	228	O	treatment
38	230	233	O	with
39	235	240	O	XXXXXXXX
NULL

